In O-ADR O-ADR
these O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
636 O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TUDORZA O-ADR O-ADR
PRESSAIR O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
400 O-ADR O-ADR
mcg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
resulted O-ADR O-ADR
in O-ADR O-ADR
interruption O-ADR O-ADR
or O-ADR O-ADR
discontinuation O-ADR O-ADR
for O-ADR O-ADR
78 O-ADR O-ADR
( O-ADR O-ADR
53 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
subjects O-ADR O-ADR
. O-ADR O-ADR
Renal O-ADR O-ADR
disorders O-ADR O-ADR
: O-ADR O-ADR
glycosuria B-ADR B-ADR
, O-ADR O-ADR
hemoglobinuria B-ADR B-ADR
. O-ADR O-ADR
In O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
for O-ADR O-ADR
these O-ADR O-ADR
two O-ADR O-ADR
indications O-ADR O-ADR
, O-ADR O-ADR
there O-ADR O-ADR
was O-ADR O-ADR
no O-ADR O-ADR
apparent O-ADR O-ADR
correlation O-ADR O-ADR
of O-ADR O-ADR
antibody O-ADR O-ADR
frequency O-ADR O-ADR
, O-ADR O-ADR
antibody O-ADR O-ADR
titers O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
neutralizing O-ADR O-ADR
status O-ADR O-ADR
to O-ADR O-ADR
clinical O-ADR O-ADR
response O-ADR O-ADR
or O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
. O-ADR O-ADR
Interrupt O-ADR O-ADR
and O-ADR O-ADR
then O-ADR O-ADR
reduce O-ADR O-ADR
or O-ADR O-ADR
discontinue O-ADR O-ADR
Zydelig O-ADR O-ADR
as O-ADR O-ADR
recommended O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
AdreView O-ADR O-ADR
safety O-ADR O-ADR
and O-ADR O-ADR
efficacy O-ADR O-ADR
have O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
established O-ADR O-ADR
in O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Pharmacology O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
In O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
severe O-ADR O-ADR
aplastic O-ADR O-ADR
anemia O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
or O-ADR O-ADR
equal O-ADR O-ADR
to O-ADR O-ADR
20 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
: O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
cough B-ADR B-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
headache B-ADR B-ADR
. O-ADR O-ADR
Of O-ADR O-ADR
the O-ADR O-ADR
372 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
immunogenicity O-ADR O-ADR
assessment O-ADR O-ADR
at O-ADR O-ADR
baseline O-ADR O-ADR
( O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
receiving O-ADR O-ADR
belatacept O-ADR O-ADR
treatment O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
29 O-ADR O-ADR
patients O-ADR O-ADR
tested O-ADR O-ADR
positive O-ADR O-ADR
for O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
belatacept O-ADR O-ADR
antibodies O-ADR O-ADR
; O-ADR O-ADR
13 O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
had O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
modified O-ADR O-ADR
cytotoxic O-ADR O-ADR
T O-ADR O-ADR
- O-ADR O-ADR
lymphocyte O-ADR O-ADR
- O-ADR O-ADR
associated O-ADR O-ADR
antigen O-ADR O-ADR
4 O-ADR O-ADR
( O-ADR O-ADR
CTLA O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Monitor O-ADR O-ADR
for O-ADR O-ADR
dizziness O-ADR O-ADR
and O-ADR O-ADR
somnolence O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
: O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Reported O-ADR O-ADR
by O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
Patients O-ADR O-ADR
Treated O-ADR O-ADR
with O-ADR O-ADR
CIMZIA O-ADR O-ADR
Dosed O-ADR O-ADR
Every O-ADR O-ADR
Other O-ADR O-ADR
Week O-ADR O-ADR
during O-ADR O-ADR
Placebo O-ADR O-ADR
- O-ADR O-ADR
Controlled O-ADR O-ADR
Period O-ADR O-ADR
of O-ADR O-ADR
Rheumatoid O-ADR O-ADR
Arthritis O-ADR O-ADR
Studies O-ADR O-ADR
, O-ADR O-ADR
with O-ADR O-ADR
Concomitant O-ADR O-ADR
Methotrexate O-ADR O-ADR
. O-ADR O-ADR
Signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
more O-ADR O-ADR
severe O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
acute O-ADR O-ADR
cases O-ADR O-ADR
have O-ADR O-ADR
included O-ADR O-ADR
hallucination B-ADR B-ADR
, O-ADR O-ADR
syncope B-ADR B-ADR
, O-ADR O-ADR
seizure B-ADR B-ADR
, O-ADR O-ADR
coma B-ADR B-ADR
, O-ADR O-ADR
respiratory B-ADR B-ADR
arrest I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
death B-ADR B-ADR
. O-ADR O-ADR
BOXED O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
RISK O-ADR O-ADR
OF O-ADR O-ADR
THYROID B-ADR B-ADR
C I-ADR I-ADR
- O-ADR O-ADR
CELL O-ADR O-ADR
TUMORS I-ADR I-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
RISK O-ADR O-ADR
OF O-ADR O-ADR
THYROID B-ADR B-ADR
C I-ADR I-ADR
- O-ADR O-ADR
CELL O-ADR O-ADR
TUMORS I-ADR I-ADR
* O-ADR O-ADR
In O-ADR O-ADR
male O-ADR O-ADR
and O-ADR O-ADR
female O-ADR O-ADR
rats O-ADR O-ADR
, O-ADR O-ADR
dulaglutide O-ADR O-ADR
causes O-ADR O-ADR
a O-ADR O-ADR
dose O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
and O-ADR O-ADR
treatment O-ADR O-ADR
- O-ADR O-ADR
duration O-ADR O-ADR
- O-ADR O-ADR
dependent O-ADR O-ADR
increase O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
thyroid B-ADR B-ADR
C I-ADR I-ADR
- O-ADR O-ADR
cell O-ADR O-ADR
tumors I-ADR I-ADR
) O-ADR O-ADR
after O-ADR O-ADR
lifetime O-ADR O-ADR
exposure O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
gradual O-ADR O-ADR
reduction O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
dose O-ADR O-ADR
rather O-ADR O-ADR
than O-ADR O-ADR
abrupt O-ADR O-ADR
cessation O-ADR O-ADR
is O-ADR O-ADR
recommended O-ADR O-ADR
whenever O-ADR O-ADR
possible O-ADR O-ADR
. O-ADR O-ADR
Changes O-ADR B-ADR
in O-ADR I-ADR
body O-ADR I-ADR
weight O-ADR I-ADR
( O-ADR O-ADR
kg O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
proportion O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
with O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
gain B-ADR B-ADR
in I-ADR I-ADR
body I-ADR I-ADR
weight I-ADR I-ADR
from O-ADR O-ADR
4 O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
, O-ADR O-ADR
4 O-ADR O-ADR
- O-ADR O-ADR
or O-ADR O-ADR
6 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
, O-ADR O-ADR
fixed O-ADR O-ADR
- O-ADR O-ADR
or O-ADR O-ADR
flexible O-ADR O-ADR
- O-ADR O-ADR
dose O-ADR O-ADR
studies O-ADR O-ADR
in O-ADR O-ADR
adult O-ADR O-ADR
subjects O-ADR O-ADR
are O-ADR O-ADR
presented O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
NESINA O-ADR O-ADR
25 O-ADR O-ADR
mg O-ADR O-ADR
and O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
than O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
placebo O-ADR O-ADR
are O-ADR O-ADR
summarized O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
data O-ADR O-ADR
described O-ADR O-ADR
below O-ADR O-ADR
reflect O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
Picato O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
gel O-ADR O-ADR
in O-ADR O-ADR
499 O-ADR O-ADR
subjects O-ADR O-ADR
with O-ADR O-ADR
actinic O-ADR O-ADR
keratosis O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
274 O-ADR O-ADR
subjects O-ADR O-ADR
exposed O-ADR O-ADR
to O-ADR O-ADR
Picato O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
gel O-ADR O-ADR
field O-ADR O-ADR
treatment O-ADR O-ADR
( O-ADR O-ADR
skin O-ADR O-ADR
area O-ADR O-ADR
of O-ADR O-ADR
25 O-ADR O-ADR
cm O-ADR O-ADR
2 O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
face O-ADR O-ADR
or O-ADR O-ADR
scalp O-ADR O-ADR
regions O-ADR O-ADR
) O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
concentration O-ADR O-ADR
of O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
015 O-ADR O-ADR
% O-ADR O-ADR
once O-ADR O-ADR
daily O-ADR O-ADR
for O-ADR O-ADR
3 O-ADR O-ADR
consecutive O-ADR O-ADR
days O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
225 O-ADR O-ADR
subjects O-ADR O-ADR
exposed O-ADR O-ADR
to O-ADR O-ADR
Picato O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
gel O-ADR O-ADR
field O-ADR O-ADR
treatment O-ADR O-ADR
( O-ADR O-ADR
skin O-ADR O-ADR
area O-ADR O-ADR
of O-ADR O-ADR
25 O-ADR O-ADR
cm O-ADR O-ADR
2 O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
trunk O-ADR O-ADR
or O-ADR O-ADR
extremities O-ADR O-ADR
regions O-ADR O-ADR
) O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
concentration O-ADR O-ADR
of O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
05 O-ADR O-ADR
% O-ADR O-ADR
once O-ADR O-ADR
daily O-ADR O-ADR
for O-ADR O-ADR
2 O-ADR O-ADR
consecutive O-ADR O-ADR
days O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
A O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
study O-ADR O-ADR
with O-ADR O-ADR
another O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
acting O-ADR O-ADR
beta2 O-ADR O-ADR
- O-ADR O-ADR
adrenergic O-ADR O-ADR
agonist O-ADR O-ADR
( O-ADR O-ADR
salmeterol O-ADR O-ADR
) O-ADR O-ADR
showed O-ADR O-ADR
an O-ADR O-ADR
increase O-ADR O-ADR
in O-ADR O-ADR
asthma O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
deaths B-ADR B-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
salmeterol O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Dyax O-ADR O-ADR
Corp O-ADR O-ADR
. O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
888 O-ADR O-ADR
- O-ADR O-ADR
452 O-ADR O-ADR
- O-ADR O-ADR
5248 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
Embryo O-ADR O-ADR
- O-ADR O-ADR
fetal O-ADR O-ADR
Toxicity O-ADR O-ADR
TREANDA O-ADR O-ADR
can O-ADR O-ADR
cause O-ADR O-ADR
fetal B-ADR B-ADR
harm I-ADR I-ADR
when O-ADR O-ADR
administered O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
pregnant O-ADR O-ADR
woman O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
Study O-ADR O-ADR
3 O-ADR O-ADR
, O-ADR O-ADR
22 O-ADR O-ADR
/ O-ADR O-ADR
230 O-ADR O-ADR
( O-ADR O-ADR
9 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
patients O-ADR O-ADR
had O-ADR O-ADR
aspartate B-ADR B-ADR
aminotransferase I-ADR I-ADR
greater I-ADR I-ADR
than I-ADR I-ADR
or I-ADR I-ADR
equal I-ADR I-ADR
to I-ADR I-ADR
3 I-ADR I-ADR
times I-ADR O-ADR
the I-ADR O-ADR
upper I-ADR O-ADR
limit I-ADR O-ADR
of I-ADR O-ADR
normal I-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
overall O-ADR O-ADR
treatment O-ADR O-ADR
period O-ADR O-ADR
. O-ADR O-ADR
Consider O-ADR O-ADR
these O-ADR O-ADR
factors O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
initiating O-ADR O-ADR
Qutenza O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
Acute B-ADR B-ADR
renal I-ADR I-ADR
failure I-ADR I-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
advanced O-ADR O-ADR
relapsed O-ADR O-ADR
and O-ADR O-ADR
refractory O-ADR O-ADR
multiple O-ADR O-ADR
myeloma O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
Kyprolis O-ADR O-ADR
monotherapy O-ADR O-ADR
. O-ADR O-ADR
What O-ADR O-ADR
is O-ADR O-ADR
the O-ADR O-ADR
most O-ADR O-ADR
important O-ADR O-ADR
information O-ADR O-ADR
I O-ADR O-ADR
should O-ADR O-ADR
know O-ADR O-ADR
about O-ADR O-ADR
DUAVEE O-ADR O-ADR
? O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
serious O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
described O-ADR O-ADR
in O-ADR O-ADR
greater O-ADR O-ADR
detail O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
section O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Clostridium B-ADR B-ADR
difficile I-ADR I-ADR
- I-ADR O-ADR
associated O-ADR O-ADR
diarrhea I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
either O-ADR O-ADR
indication O-ADR O-ADR
) O-ADR O-ADR
are O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
and O-ADR O-ADR
pyrexia B-ADR B-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
received O-ADR O-ADR
ERWINAZE O-ADR O-ADR
25 O-ADR O-ADR
, O-ADR O-ADR
000 O-ADR O-ADR
International O-ADR O-ADR
Unit O-ADR O-ADR
/ O-ADR O-ADR
m O-ADR O-ADR
2 O-ADR O-ADR
/ O-ADR O-ADR
dose O-ADR O-ADR
, O-ADR O-ADR
administered O-ADR O-ADR
by O-ADR O-ADR
intravenous O-ADR O-ADR
infusion O-ADR O-ADR
on O-ADR O-ADR
a O-ADR O-ADR
Monday O-ADR O-ADR
, O-ADR O-ADR
Wednesday O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
Friday O-ADR O-ADR
schedule O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
doses O-ADR O-ADR
) O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
replacement O-ADR O-ADR
for O-ADR O-ADR
doses O-ADR O-ADR
remaining O-ADR O-ADR
on O-ADR O-ADR
their O-ADR O-ADR
original O-ADR O-ADR
treatment O-ADR O-ADR
plan O-ADR O-ADR
. O-ADR O-ADR
However O-ADR O-ADR
, O-ADR O-ADR
bronchitis B-ADR B-ADR
, O-ADR O-ADR
herpes B-ADR B-ADR
zoster I-ADR I-ADR
, O-ADR O-ADR
influenza B-ADR B-ADR
, O-ADR O-ADR
sinusitis B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
pneumonia B-ADR B-ADR
were O-ADR O-ADR
more O-ADR O-ADR
common O-ADR O-ADR
in O-ADR O-ADR
GILENYA O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
They O-ADR O-ADR
are O-ADR O-ADR
not O-ADR O-ADR
interchangeable O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
other O-ADR O-ADR
preparations O-ADR O-ADR
of O-ADR O-ADR
botulinum O-ADR O-ADR
toxin O-ADR O-ADR
products O-ADR O-ADR
and O-ADR O-ADR
, O-ADR O-ADR
therefore O-ADR O-ADR
, O-ADR O-ADR
Units O-ADR O-ADR
of O-ADR O-ADR
biological O-ADR O-ADR
activity O-ADR O-ADR
of O-ADR O-ADR
XEOMIN O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
or O-ADR O-ADR
converted O-ADR O-ADR
into O-ADR O-ADR
Units O-ADR O-ADR
of O-ADR O-ADR
any O-ADR O-ADR
other O-ADR O-ADR
botulinum O-ADR O-ADR
toxin O-ADR O-ADR
products O-ADR O-ADR
assessed O-ADR O-ADR
with O-ADR O-ADR
any O-ADR O-ADR
other O-ADR O-ADR
specific O-ADR O-ADR
assay O-ADR O-ADR
method O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Description O-ADR O-ADR
( O-ADR O-ADR
11 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
When O-ADR O-ADR
switching O-ADR O-ADR
to O-ADR O-ADR
GILENYA O-ADR O-ADR
from O-ADR O-ADR
immune O-ADR O-ADR
- O-ADR O-ADR
modulating O-ADR O-ADR
or O-ADR O-ADR
immunosuppressive O-ADR O-ADR
medications O-ADR O-ADR
, O-ADR O-ADR
consider O-ADR O-ADR
the O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
their O-ADR O-ADR
effects O-ADR O-ADR
and O-ADR O-ADR
their O-ADR O-ADR
mode O-ADR O-ADR
of O-ADR O-ADR
action O-ADR O-ADR
to O-ADR O-ADR
avoid O-ADR O-ADR
unintended O-ADR O-ADR
additive O-ADR O-ADR
immunosuppressive O-ADR O-ADR
effects O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Hypothyroidism B-ADR B-ADR
requiring O-ADR O-ADR
thyroid O-ADR O-ADR
hormone O-ADR O-ADR
replacement O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
. O-ADR O-ADR
Whether O-ADR O-ADR
antipsychotic O-ADR O-ADR
drug O-ADR O-ADR
products O-ADR O-ADR
differ O-ADR O-ADR
in O-ADR O-ADR
their O-ADR O-ADR
potential O-ADR O-ADR
to O-ADR O-ADR
cause O-ADR O-ADR
tardive O-ADR B-ADR
dyskinesia O-ADR I-ADR
is O-ADR O-ADR
unknown O-ADR O-ADR
. O-ADR O-ADR
Provide O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
diarrheal O-ADR O-ADR
agent O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
loperamide O-ADR O-ADR
) O-ADR O-ADR
for O-ADR O-ADR
self O-ADR O-ADR
- O-ADR O-ADR
administration O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
onset O-ADR O-ADR
of O-ADR O-ADR
diarrhea O-ADR O-ADR
and O-ADR O-ADR
instruct O-ADR O-ADR
patients O-ADR O-ADR
to O-ADR O-ADR
continue O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
diarrheal O-ADR O-ADR
therapy O-ADR O-ADR
until O-ADR O-ADR
loose O-ADR O-ADR
bowel O-ADR O-ADR
movements O-ADR O-ADR
cease O-ADR O-ADR
for O-ADR O-ADR
12 O-ADR O-ADR
hours O-ADR O-ADR
. O-ADR O-ADR
BENLYSTA O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
administered O-ADR O-ADR
by O-ADR O-ADR
healthcare O-ADR O-ADR
providers O-ADR O-ADR
prepared O-ADR O-ADR
to O-ADR O-ADR
manage O-ADR O-ADR
anaphylaxis O-ADR O-ADR
. O-ADR O-ADR
BOXED O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
SUPINE B-ADR B-ADR
HYPERTENSION I-ADR I-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
SUPINE B-ADR B-ADR
HYPERTENSION I-ADR I-ADR
Monitor O-ADR O-ADR
supine O-ADR O-ADR
blood O-ADR O-ADR
pressure O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
and O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
and O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
when O-ADR O-ADR
increasing O-ADR O-ADR
doses O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
While O-ADR O-ADR
the O-ADR O-ADR
effect O-ADR O-ADR
of O-ADR O-ADR
weak O-ADR O-ADR
CYP3A4 O-ADR O-ADR
inhibitors O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
summarizes O-ADR O-ADR
all O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
or O-ADR O-ADR
more O-ADR O-ADR
patients O-ADR O-ADR
) O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
described O-ADR O-ADR
above O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
: O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Occurring O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
Treatment O-ADR O-ADR
- O-ADR O-ADR
Naive O-ADR O-ADR
GD1 O-ADR O-ADR
Patients O-ADR O-ADR
and O-ADR O-ADR
More O-ADR O-ADR
Frequently O-ADR O-ADR
than O-ADR O-ADR
Placebo O-ADR O-ADR
( O-ADR O-ADR
Trial O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
CERDELGA O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
20 O-ADR O-ADR
) O-ADR O-ADR
Placebo O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
20 O-ADR O-ADR
) O-ADR O-ADR
Adverse O-ADR O-ADR
Reaction O-ADR O-ADR
Patientsn O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Patientsn O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Arthralgia B-ADR B-ADR
9 O-ADR O-ADR
( O-ADR O-ADR
45 O-ADR O-ADR
) O-ADR O-ADR
2 O-ADR O-ADR
( O-ADR O-ADR
10 O-ADR O-ADR
) O-ADR O-ADR
Headache B-ADR B-ADR
8 O-ADR O-ADR
( O-ADR O-ADR
40 O-ADR O-ADR
) O-ADR O-ADR
6 O-ADR O-ADR
( O-ADR O-ADR
30 O-ADR O-ADR
) O-ADR O-ADR
Migraine B-ADR B-ADR
2 O-ADR O-ADR
( O-ADR O-ADR
10 O-ADR O-ADR
) O-ADR O-ADR
0 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
) O-ADR O-ADR
Flatulence B-ADR B-ADR
2 O-ADR O-ADR
( O-ADR O-ADR
10 O-ADR O-ADR
) O-ADR O-ADR
1 O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
Nausea B-ADR B-ADR
2 O-ADR O-ADR
( O-ADR O-ADR
10 O-ADR O-ADR
) O-ADR O-ADR
1 O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
Oropharyngeal B-ADR B-ADR
pain I-ADR I-ADR
2 O-ADR O-ADR
( O-ADR O-ADR
10 O-ADR O-ADR
) O-ADR O-ADR
1 O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
presents O-ADR O-ADR
the O-ADR O-ADR
profile O-ADR O-ADR
from O-ADR O-ADR
the O-ADR O-ADR
12 O-ADR O-ADR
- O-ADR O-ADR
month O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
, O-ADR O-ADR
randomized O-ADR O-ADR
, O-ADR O-ADR
imiglucerase O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trial O-ADR O-ADR
of O-ADR O-ADR
159 O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
switching O-ADR O-ADR
from O-ADR O-ADR
enzyme O-ADR O-ADR
replacement O-ADR O-ADR
therapy O-ADR O-ADR
( O-ADR O-ADR
ERT O-ADR O-ADR
) O-ADR O-ADR
( O-ADR O-ADR
Trial O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
laboratory O-ADR O-ADR
abnormalities O-ADR O-ADR
were O-ADR O-ADR
elevated B-ADR B-ADR
total I-ADR I-ADR
bilirubin I-ADR I-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
1 O-ADR O-ADR
subject O-ADR O-ADR
each O-ADR O-ADR
. O-ADR O-ADR
ELIQUIS2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
po O-ADR O-ADR
bid35 O-ADR O-ADR
+ O-ADR O-ADR
/ O-ADR O-ADR
- O-ADR O-ADR
3 O-ADR O-ADR
days O-ADR O-ADR
Enoxaparin O-ADR O-ADR
40 O-ADR O-ADR
mg O-ADR O-ADR
sc O-ADR O-ADR
qd O-ADR O-ADR
35 O-ADR O-ADR
+ O-ADR O-ADR
/ O-ADR O-ADR
- O-ADR O-ADR
3 O-ADR O-ADR
days O-ADR O-ADR
ELIQUIS O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
po O-ADR O-ADR
bid O-ADR O-ADR
12 O-ADR O-ADR
+ O-ADR O-ADR
/ O-ADR O-ADR
- O-ADR O-ADR
2 O-ADR O-ADR
days O-ADR O-ADR
Enoxaparin O-ADR O-ADR
40 O-ADR O-ADR
mg O-ADR O-ADR
sc O-ADR O-ADR
qd O-ADR O-ADR
12 O-ADR O-ADR
+ O-ADR O-ADR
/ O-ADR O-ADR
- O-ADR O-ADR
2 O-ADR O-ADR
days O-ADR O-ADR
ELIQUIS O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
po O-ADR O-ADR
bid O-ADR O-ADR
12 O-ADR O-ADR
+ O-ADR O-ADR
/ O-ADR O-ADR
- O-ADR O-ADR
2 O-ADR O-ADR
days O-ADR O-ADR
Enoxaparin O-ADR O-ADR
30 O-ADR O-ADR
mg O-ADR O-ADR
sc O-ADR O-ADR
q12h O-ADR O-ADR
12 O-ADR O-ADR
+ O-ADR O-ADR
/ O-ADR O-ADR
- O-ADR O-ADR
2 O-ADR O-ADR
days O-ADR O-ADR
First O-ADR O-ADR
dose O-ADR O-ADR
12 O-ADR O-ADR
to O-ADR O-ADR
24 O-ADR O-ADR
hours O-ADR O-ADR
post O-ADR O-ADR
surgery O-ADR O-ADR
First O-ADR O-ADR
dose O-ADR O-ADR
9 O-ADR O-ADR
to O-ADR O-ADR
15 O-ADR O-ADR
hours O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
surgery O-ADR O-ADR
First O-ADR O-ADR
dose O-ADR O-ADR
12 O-ADR O-ADR
to O-ADR O-ADR
24 O-ADR O-ADR
hours O-ADR O-ADR
post O-ADR O-ADR
surgery O-ADR O-ADR
First O-ADR O-ADR
dose O-ADR O-ADR
9 O-ADR O-ADR
to O-ADR O-ADR
15 O-ADR O-ADR
hours O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
surgery O-ADR O-ADR
First O-ADR O-ADR
dose O-ADR O-ADR
12 O-ADR O-ADR
to O-ADR O-ADR
24 O-ADR O-ADR
hours O-ADR O-ADR
post O-ADR O-ADR
surgery O-ADR O-ADR
First O-ADR O-ADR
dose O-ADR O-ADR
12 O-ADR O-ADR
to O-ADR O-ADR
24 O-ADR O-ADR
hours O-ADR O-ADR
post O-ADR O-ADR
surgery O-ADR O-ADR
All O-ADR O-ADR
treated O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
2673 O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
2659 O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
1501 O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
1508 O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
1596 O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
1588 O-ADR O-ADR
Major O-ADR O-ADR
( O-ADR O-ADR
including O-ADR O-ADR
surgical O-ADR B-ADR
site O-ADR O-ADR
) O-ADR O-ADR
22 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
82 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
18 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
68 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
9 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
60 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
? O-ADR O-ADR
Flush O-ADR O-ADR
immediately O-ADR O-ADR
with O-ADR O-ADR
water O-ADR O-ADR
if O-ADR O-ADR
ULESFIA O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
Lotion O-ADR O-ADR
comes O-ADR O-ADR
into O-ADR O-ADR
contact O-ADR O-ADR
with O-ADR O-ADR
eyes O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Risks O-ADR O-ADR
of O-ADR O-ADR
Treatment O-ADR O-ADR
in O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
Infectious O-ADR O-ADR
Diarrhea O-ADR O-ADR
If O-ADR O-ADR
infectious O-ADR O-ADR
etiologies O-ADR O-ADR
are O-ADR O-ADR
not O-ADR O-ADR
considered O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
FULYZAQ O-ADR O-ADR
is O-ADR O-ADR
initiated O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
a O-ADR O-ADR
presumptive O-ADR O-ADR
diagnosis O-ADR O-ADR
of O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
infectious O-ADR O-ADR
diarrhea O-ADR O-ADR
, O-ADR O-ADR
then O-ADR O-ADR
there O-ADR O-ADR
is O-ADR O-ADR
a O-ADR O-ADR
risk O-ADR O-ADR
that O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
infectious O-ADR O-ADR
etiologies O-ADR O-ADR
will O-ADR O-ADR
not O-ADR O-ADR
receive O-ADR O-ADR
the O-ADR O-ADR
appropriate O-ADR O-ADR
treatments O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
their O-ADR O-ADR
disease O-ADR O-ADR
may O-ADR O-ADR
worsen O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Pulmonary B-ADR B-ADR
Toxicity I-ADR I-ADR
: O-ADR O-ADR
Monitor O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
new O-ADR O-ADR
or O-ADR O-ADR
worsening O-ADR O-ADR
symptoms O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
10 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
13 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
TANZEUM O-ADR O-ADR
is O-ADR O-ADR
contraindicated O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
personal O-ADR O-ADR
or O-ADR O-ADR
family O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
MTC O-ADR O-ADR
or O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
Multiple O-ADR O-ADR
Endocrine O-ADR O-ADR
Neoplasia O-ADR O-ADR
syndrome O-ADR O-ADR
type O-ADR O-ADR
2 O-ADR O-ADR
( O-ADR O-ADR
MEN O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
An O-ADR O-ADR
increased O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
stroke B-ADR B-ADR
was O-ADR O-ADR
observed O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
transition O-ADR O-ADR
from O-ADR O-ADR
ELIQUIS O-ADR O-ADR
to O-ADR O-ADR
warfarin O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
in O-ADR O-ADR
atrial O-ADR O-ADR
fibrillation O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Other O-ADR O-ADR
GLP O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
receptor O-ADR O-ADR
agonists O-ADR O-ADR
have O-ADR O-ADR
caused O-ADR O-ADR
dose O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
and O-ADR O-ADR
treatment O-ADR O-ADR
- O-ADR O-ADR
duration O-ADR O-ADR
- O-ADR O-ADR
dependent O-ADR O-ADR
thyroid B-ADR B-ADR
C I-ADR I-ADR
- O-ADR O-ADR
cell O-ADR O-ADR
tumors I-ADR I-ADR
) O-ADR O-ADR
in O-ADR O-ADR
rodents O-ADR O-ADR
. O-ADR O-ADR
Activated O-ADR O-ADR
oral O-ADR O-ADR
charcoal O-ADR O-ADR
reduces O-ADR O-ADR
absorption O-ADR O-ADR
of O-ADR O-ADR
apixaban O-ADR O-ADR
, O-ADR O-ADR
thereby O-ADR O-ADR
lowering O-ADR O-ADR
apixaban O-ADR O-ADR
plasma O-ADR O-ADR
concentration O-ADR O-ADR
[ O-ADR O-ADR
seeOverdosage O-ADR O-ADR
( O-ADR O-ADR
10 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
General O-ADR O-ADR
Disorders O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
Site O-ADR O-ADR
Conditions O-ADR O-ADR
: O-ADR O-ADR
asthenia B-ADR B-ADR
, O-ADR O-ADR
chest B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
edema B-ADR B-ADR
, O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
feeling B-ADR B-ADR
abnormal I-ADR I-ADR
, O-ADR O-ADR
gait B-ADR B-ADR
disturbance I-ADR I-ADR
, O-ADR O-ADR
influenza B-ADR B-ADR
- O-ADR O-ADR
like O-ADR O-ADR
symptoms I-ADR I-ADR
, O-ADR O-ADR
mass B-ADR B-ADR
, O-ADR O-ADR
pain B-ADR B-ADR
, O-ADR O-ADR
thirst B-ADR B-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
See O-ADR O-ADR
the O-ADR O-ADR
peginterferon O-ADR O-ADR
alfa O-ADR O-ADR
and O-ADR O-ADR
ribavirin O-ADR O-ADR
prescribing O-ADR O-ADR
information O-ADR O-ADR
for O-ADR O-ADR
description O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
their O-ADR O-ADR
use O-ADR O-ADR
. O-ADR O-ADR
Discontinuations O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
led O-ADR O-ADR
to O-ADR O-ADR
treatment O-ADR O-ADR
discontinuation O-ADR O-ADR
in O-ADR O-ADR
21 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
Studies O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
Keep O-ADR O-ADR
DUAVEE O-ADR O-ADR
and O-ADR O-ADR
all O-ADR O-ADR
other O-ADR O-ADR
medicines O-ADR O-ADR
out O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
reach O-ADR O-ADR
of O-ADR O-ADR
children O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
GE O-ADR O-ADR
Healthcare O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
654 O-ADR O-ADR
- O-ADR O-ADR
0118 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
General O-ADR O-ADR
information O-ADR O-ADR
about O-ADR O-ADR
the O-ADR O-ADR
safe O-ADR O-ADR
and O-ADR O-ADR
effective O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
DUAVEE O-ADR O-ADR
Medicines O-ADR O-ADR
are O-ADR O-ADR
sometimes O-ADR O-ADR
prescribed O-ADR O-ADR
for O-ADR O-ADR
purposes O-ADR O-ADR
other O-ADR O-ADR
than O-ADR O-ADR
those O-ADR O-ADR
listed O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
Patient O-ADR O-ADR
Information O-ADR O-ADR
leaflet O-ADR O-ADR
. O-ADR O-ADR
STENDRA O-ADR O-ADR
was O-ADR O-ADR
administered O-ADR O-ADR
to O-ADR O-ADR
2215 O-ADR O-ADR
men O-ADR O-ADR
during O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
Respiratory O-ADR O-ADR
, O-ADR O-ADR
Thoracic O-ADR O-ADR
and O-ADR O-ADR
Mediastinal O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
bronchitis B-ADR B-ADR
, O-ADR O-ADR
cough B-ADR B-ADR
, O-ADR O-ADR
dyspnea B-ADR B-ADR
, O-ADR O-ADR
epistaxis B-ADR B-ADR
, O-ADR O-ADR
nasal B-ADR B-ADR
dryness I-ADR I-ADR
, O-ADR O-ADR
paranasal B-ADR B-ADR
sinus I-ADR I-ADR
hypersecretion I-ADR I-ADR
, O-ADR O-ADR
pharyngeal B-ADR B-ADR
edema I-ADR I-ADR
, O-ADR O-ADR
respiratory B-ADR B-ADR
tract I-ADR I-ADR
congestion I-ADR I-ADR
, O-ADR O-ADR
sneezing B-ADR B-ADR
, O-ADR O-ADR
throat B-ADR B-ADR
irritation I-ADR I-ADR
, O-ADR O-ADR
upper B-ADR B-ADR
respiratory I-ADR I-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
. O-ADR O-ADR
Risk O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
increased O-ADR O-ADR
with O-ADR O-ADR
neutropenia O-ADR O-ADR
, O-ADR O-ADR
age O-ADR O-ADR
, O-ADR O-ADR
steroid O-ADR O-ADR
use O-ADR O-ADR
, O-ADR O-ADR
concomitant O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
NSAIDs O-ADR O-ADR
, O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
platelet O-ADR O-ADR
therapy O-ADR O-ADR
or O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
coagulants O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
prior O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
pelvic O-ADR O-ADR
radiotherapy O-ADR O-ADR
, O-ADR O-ADR
adhesions O-ADR B-ADR
, O-ADR O-ADR
ulceration O-ADR B-ADR
and O-ADR O-ADR
GI O-ADR B-ADR
bleeding O-ADR I-ADR
. O-ADR O-ADR
The O-ADR O-ADR
treatment O-ADR O-ADR
discontinuation O-ADR O-ADR
rate O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
anemia B-ADR B-ADR
was O-ADR O-ADR
similar O-ADR O-ADR
in O-ADR O-ADR
subjects O-ADR O-ADR
randomized O-ADR O-ADR
to O-ADR O-ADR
receive O-ADR O-ADR
ribavirin O-ADR O-ADR
dose O-ADR O-ADR
reduction O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
subjects O-ADR O-ADR
randomized O-ADR O-ADR
to O-ADR O-ADR
receive O-ADR O-ADR
ESA O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
each O-ADR O-ADR
group O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
PROMACTA O-ADR O-ADR
inhibits O-ADR O-ADR
UDP O-ADR O-ADR
- O-ADR O-ADR
glucuronosyltransferase O-ADR O-ADR
( O-ADR O-ADR
UGT O-ADR O-ADR
) O-ADR O-ADR
1A1 O-ADR O-ADR
and O-ADR O-ADR
organic O-ADR O-ADR
anion O-ADR O-ADR
- O-ADR O-ADR
transporting O-ADR O-ADR
polypeptide O-ADR O-ADR
( O-ADR O-ADR
OATP O-ADR O-ADR
) O-ADR O-ADR
1B1 O-ADR O-ADR
, O-ADR O-ADR
which O-ADR O-ADR
may O-ADR O-ADR
lead O-ADR O-ADR
to O-ADR O-ADR
indirect B-ADR B-ADR
hyperbilirubinemia I-ADR I-ADR
. O-ADR O-ADR
The O-ADR O-ADR
median O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
was O-ADR O-ADR
10 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
months O-ADR O-ADR
for O-ADR O-ADR
both O-ADR O-ADR
TAFINLAR O-ADR O-ADR
and O-ADR O-ADR
trametinib O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
- O-ADR O-ADR
mg O-ADR O-ADR
orally O-ADR O-ADR
once O-ADR O-ADR
- O-ADR O-ADR
daily O-ADR O-ADR
treatment O-ADR O-ADR
group O-ADR O-ADR
) O-ADR O-ADR
when O-ADR O-ADR
used O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
, O-ADR O-ADR
10 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
months O-ADR O-ADR
for O-ADR O-ADR
both O-ADR O-ADR
TAFINLAR O-ADR O-ADR
and O-ADR O-ADR
trametinib O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
mg O-ADR O-ADR
orally O-ADR O-ADR
once O-ADR O-ADR
- O-ADR O-ADR
daily O-ADR O-ADR
treatment O-ADR O-ADR
group O-ADR O-ADR
) O-ADR O-ADR
when O-ADR O-ADR
used O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
months O-ADR O-ADR
for O-ADR O-ADR
TAFINLAR O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
single O-ADR O-ADR
agent O-ADR O-ADR
. O-ADR O-ADR
Gastrointestinal O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
abdominal B-ADR B-ADR
distention I-ADR I-ADR
, O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
constipation B-ADR B-ADR
, O-ADR O-ADR
dry B-ADR B-ADR
mouth I-ADR I-ADR
, O-ADR O-ADR
dyspepsia B-ADR B-ADR
, O-ADR O-ADR
flatulence B-ADR B-ADR
, O-ADR O-ADR
frequent B-ADR B-ADR
stools I-ADR I-ADR
, O-ADR O-ADR
gastritis B-ADR B-ADR
, O-ADR O-ADR
gastroesophageal B-ADR B-ADR
reflux I-ADR I-ADR
disease I-ADR I-ADR
, O-ADR O-ADR
gastrointestinal B-ADR B-ADR
discomfort I-ADR I-ADR
, O-ADR O-ADR
gingival B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
haematemesis B-ADR B-ADR
, O-ADR O-ADR
hyperchlorhydria B-ADR B-ADR
, O-ADR O-ADR
hematochezia B-ADR B-ADR
, O-ADR O-ADR
mouth B-ADR B-ADR
ulceration I-ADR I-ADR
, O-ADR O-ADR
pancreatitis B-ADR B-ADR
, O-ADR O-ADR
peptic B-ADR B-ADR
ulcer I-ADR I-ADR
, O-ADR O-ADR
vomiting B-ADR B-ADR
. O-ADR O-ADR
Report O-ADR O-ADR
any O-ADR O-ADR
diagnosis O-ADR O-ADR
of O-ADR O-ADR
NSF O-ADR O-ADR
following O-ADR O-ADR
Gadavist O-ADR O-ADR
administration O-ADR O-ADR
to O-ADR O-ADR
Bayer O-ADR O-ADR
Healthcare O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
888 O-ADR O-ADR
- O-ADR O-ADR
842 O-ADR O-ADR
- O-ADR O-ADR
2937 O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
Renal O-ADR O-ADR
Impairment O-ADR O-ADR
and O-ADR O-ADR
Failure O-ADR O-ADR
Marked O-ADR O-ADR
increase B-ADR B-ADR
in I-ADR I-ADR
serum I-ADR I-ADR
creatinine I-ADR I-ADR
, O-ADR O-ADR
pre B-ADR B-ADR
- O-ADR O-ADR
renal O-ADR O-ADR
azotemia I-ADR I-ADR
and O-ADR O-ADR
acute B-ADR B-ADR
renal I-ADR I-ADR
failure I-ADR I-ADR
, O-ADR O-ADR
often O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
setting O-ADR O-ADR
of O-ADR O-ADR
heart B-ADR B-ADR
failure I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
or O-ADR O-ADR
hypovolemia B-ADR B-ADR
, O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
taking O-ADR O-ADR
MULTAQ O-ADR O-ADR
. O-ADR O-ADR
Tissue O-ADR O-ADR
culture O-ADR O-ADR
experiments O-ADR O-ADR
indicate O-ADR O-ADR
that O-ADR O-ADR
approximately O-ADR O-ADR
one O-ADR O-ADR
- O-ADR O-ADR
third O-ADR O-ADR
of O-ADR O-ADR
human O-ADR O-ADR
breast O-ADR O-ADR
cancers O-ADR O-ADR
are O-ADR O-ADR
prolactin O-ADR O-ADR
- O-ADR O-ADR
dependent O-ADR O-ADR
in O-ADR O-ADR
vitro O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
factor O-ADR O-ADR
of O-ADR O-ADR
potential O-ADR O-ADR
importance O-ADR O-ADR
if O-ADR O-ADR
the O-ADR O-ADR
prescription O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
drugs O-ADR O-ADR
is O-ADR O-ADR
considered O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
patient O-ADR O-ADR
with O-ADR O-ADR
previously O-ADR O-ADR
- O-ADR O-ADR
detected O-ADR O-ADR
breast O-ADR O-ADR
cancer O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
Local B-ADR B-ADR
skin I-ADR I-ADR
reactions I-ADR I-ADR
) O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
relapsed O-ADR O-ADR
classical O-ADR O-ADR
HL O-ADR O-ADR
and O-ADR O-ADR
sALCL O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
54 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
experienced O-ADR O-ADR
any O-ADR O-ADR
grade O-ADR O-ADR
of O-ADR O-ADR
neuropathy B-ADR B-ADR
. O-ADR O-ADR
The O-ADR O-ADR
percentage O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
exceeded O-ADR O-ADR
a O-ADR O-ADR
predetermined O-ADR O-ADR
threshold O-ADR O-ADR
value O-ADR O-ADR
is O-ADR O-ADR
shown O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Salix O-ADR O-ADR
Pharmaceuticals O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
508 O-ADR O-ADR
- O-ADR O-ADR
0024 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
Salix O-ADR O-ADR
. O-ADR O-ADR
com O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Contact B-ADR B-ADR
dermatitis I-ADR I-ADR
: O-ADR O-ADR
May O-ADR O-ADR
occur O-ADR O-ADR
with O-ADR O-ADR
ULESFIA O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
Lotion O-ADR O-ADR
. O-ADR O-ADR
Cardiomyopathy B-ADR B-ADR
was O-ADR O-ADR
identified O-ADR O-ADR
within O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
month O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
TAFINLAR O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
in O-ADR O-ADR
two O-ADR O-ADR
of O-ADR O-ADR
five O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
discontinuation O-ADR O-ADR
rate O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
bleeding B-ADR B-ADR
events O-ADR O-ADR
was O-ADR O-ADR
approximately O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
ELIQUIS O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
those O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
group O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
AMPLIFY O-ADR O-ADR
- O-ADR O-ADR
EXT O-ADR O-ADR
study O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
reactions O-ADR O-ADR
occurred O-ADR O-ADR
within O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
hour O-ADR O-ADR
after O-ADR O-ADR
dosing O-ADR O-ADR
. O-ADR O-ADR
Opportunistic B-ADR B-ADR
infections I-ADR I-ADR
have O-ADR O-ADR
also O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
ILARIS O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Advise O-ADR O-ADR
patients O-ADR O-ADR
to O-ADR O-ADR
immediately O-ADR O-ADR
seek O-ADR O-ADR
medical O-ADR O-ADR
care O-ADR O-ADR
if O-ADR O-ADR
they O-ADR O-ADR
develop O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
DVT O-ADR O-ADR
or O-ADR O-ADR
PE O-ADR O-ADR
, O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
shortness O-ADR O-ADR
of O-ADR O-ADR
breath O-ADR O-ADR
, O-ADR O-ADR
chest O-ADR O-ADR
pain O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
arm O-ADR O-ADR
or O-ADR O-ADR
leg O-ADR O-ADR
swelling O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
develop O-ADR O-ADR
a O-ADR O-ADR
new O-ADR O-ADR
infection O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
, O-ADR O-ADR
perform O-ADR O-ADR
a O-ADR O-ADR
prompt O-ADR O-ADR
and O-ADR O-ADR
complete O-ADR O-ADR
diagnostic O-ADR O-ADR
workup O-ADR O-ADR
appropriate O-ADR O-ADR
for O-ADR O-ADR
an O-ADR O-ADR
immunocompromised O-ADR O-ADR
patient O-ADR O-ADR
and O-ADR O-ADR
initiate O-ADR O-ADR
appropriate O-ADR O-ADR
antimicrobial O-ADR O-ADR
therapy O-ADR O-ADR
and O-ADR O-ADR
closely O-ADR O-ADR
monitor O-ADR O-ADR
them O-ADR O-ADR
. O-ADR O-ADR
Appropriate O-ADR O-ADR
laboratory O-ADR O-ADR
testing O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
initiating O-ADR O-ADR
therapy O-ADR O-ADR
and O-ADR O-ADR
monitoring O-ADR O-ADR
for O-ADR O-ADR
hepatotoxicity O-ADR O-ADR
during O-ADR O-ADR
therapy O-ADR O-ADR
with O-ADR O-ADR
TIVICAY O-ADR O-ADR
are O-ADR O-ADR
recommended O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
underlying O-ADR O-ADR
hepatic O-ADR O-ADR
disease O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
hepatitis O-ADR O-ADR
B O-ADR O-ADR
or O-ADR O-ADR
C O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Fat O-ADR O-ADR
Redistribution O-ADR O-ADR
buffalo B-ADR B-ADR
hump I-ADR I-ADR
, O-ADR O-ADR
facial B-ADR B-ADR
wasting I-ADR I-ADR
, O-ADR O-ADR
breast B-ADR B-ADR
enlargement I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
` O-ADR O-ADR
` O-ADR O-ADR
cushingoid B-ADR B-ADR
appearance I-ADR I-ADR
' O-ADR O-ADR
' O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
antiretroviral O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
data O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
percentage O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
whose O-ADR O-ADR
test O-ADR O-ADR
results O-ADR O-ADR
were O-ADR O-ADR
positive O-ADR O-ADR
for O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
belimumab O-ADR O-ADR
in O-ADR O-ADR
specific O-ADR O-ADR
assays O-ADR O-ADR
. O-ADR O-ADR
Of O-ADR O-ADR
the O-ADR O-ADR
609 O-ADR O-ADR
subjects O-ADR O-ADR
, O-ADR O-ADR
58 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
female O-ADR O-ADR
and O-ADR O-ADR
84 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
white O-ADR O-ADR
; O-ADR O-ADR
the O-ADR O-ADR
mean O-ADR O-ADR
age O-ADR O-ADR
was O-ADR O-ADR
40 O-ADR O-ADR
years O-ADR O-ADR
. O-ADR O-ADR
This O-ADR O-ADR
may O-ADR O-ADR
result O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
critical O-ADR B-ADR
loss B-ADR I-ADR
of I-ADR I-ADR
breathing I-ADR I-ADR
capacity I-ADR I-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
respiratory O-ADR O-ADR
disorders O-ADR O-ADR
who O-ADR O-ADR
may O-ADR O-ADR
have O-ADR O-ADR
become O-ADR O-ADR
dependent O-ADR O-ADR
upon O-ADR O-ADR
these O-ADR O-ADR
accessory O-ADR O-ADR
muscles O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Bullous O-ADR O-ADR
and O-ADR O-ADR
Exfoliative O-ADR O-ADR
Skin O-ADR O-ADR
Disorders O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
cutaneous B-ADR B-ADR
reactions I-ADR I-ADR
characterized O-ADR O-ADR
by O-ADR O-ADR
exfoliating B-ADR B-ADR
lesions I-ADR I-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
6 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
15 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
3865 O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
GILOTRIF O-ADR O-ADR
across O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Carfilzomib O-ADR O-ADR
caused O-ADR O-ADR
embryo B-ADR B-ADR
- O-ADR O-ADR
fetal O-ADR O-ADR
toxicity I-ADR I-ADR
in O-ADR O-ADR
pregnant O-ADR O-ADR
rabbits O-ADR O-ADR
at O-ADR O-ADR
doses O-ADR O-ADR
that O-ADR O-ADR
were O-ADR O-ADR
lower O-ADR O-ADR
than O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
dose O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
4 O-ADR O-ADR
lists O-ADR O-ADR
treatment O-ADR O-ADR
- O-ADR O-ADR
emergent O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
that O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
RLS O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
HORIZANT O-ADR O-ADR
and O-ADR O-ADR
numerically O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
, O-ADR O-ADR
their O-ADR O-ADR
caregivers O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
families O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
advised O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
need O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
alert O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
emergence O-ADR O-ADR
or O-ADR O-ADR
worsening O-ADR O-ADR
of O-ADR O-ADR
depression O-ADR O-ADR
, O-ADR O-ADR
suicidal O-ADR O-ADR
thoughts O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
mood O-ADR O-ADR
changes O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
if O-ADR O-ADR
such O-ADR O-ADR
changes O-ADR O-ADR
occur O-ADR O-ADR
to O-ADR O-ADR
contact O-ADR O-ADR
their O-ADR O-ADR
healthcare O-ADR O-ADR
provider O-ADR O-ADR
. O-ADR O-ADR
Although O-ADR O-ADR
the O-ADR O-ADR
prevalence O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
syndrome O-ADR O-ADR
appears O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
highest O-ADR O-ADR
among O-ADR O-ADR
the O-ADR O-ADR
elderly O-ADR O-ADR
, O-ADR O-ADR
especially O-ADR O-ADR
elderly O-ADR O-ADR
women O-ADR O-ADR
, O-ADR O-ADR
it O-ADR O-ADR
is O-ADR O-ADR
impossible O-ADR O-ADR
to O-ADR O-ADR
rely O-ADR O-ADR
on O-ADR O-ADR
prevalence O-ADR O-ADR
estimates O-ADR O-ADR
to O-ADR O-ADR
predict O-ADR O-ADR
, O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
inception O-ADR O-ADR
of O-ADR O-ADR
antipsychotic O-ADR O-ADR
treatment O-ADR O-ADR
, O-ADR O-ADR
which O-ADR O-ADR
patients O-ADR O-ADR
are O-ADR O-ADR
likely O-ADR O-ADR
to O-ADR O-ADR
develop O-ADR O-ADR
the O-ADR O-ADR
syndrome O-ADR O-ADR
. O-ADR O-ADR
Prior O-ADR O-ADR
and O-ADR O-ADR
Concomitant O-ADR O-ADR
Treatment O-ADR O-ADR
with O-ADR O-ADR
Antineoplastic O-ADR O-ADR
, O-ADR O-ADR
Immunosuppressive O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
Immune O-ADR O-ADR
- O-ADR O-ADR
Modulating O-ADR O-ADR
Therapies O-ADR O-ADR
In O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
GILENYA O-ADR O-ADR
did O-ADR O-ADR
not O-ADR O-ADR
receive O-ADR O-ADR
concomitant O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
antineoplastic O-ADR O-ADR
, O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
corticosteroid O-ADR O-ADR
immunosuppressive O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
immune O-ADR O-ADR
- O-ADR O-ADR
modulating O-ADR O-ADR
therapies O-ADR O-ADR
used O-ADR O-ADR
for O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
MS O-ADR O-ADR
. O-ADR O-ADR
Concomitant O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
GILENYA O-ADR O-ADR
with O-ADR O-ADR
any O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
therapies O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
also O-ADR O-ADR
with O-ADR O-ADR
corticosteroids O-ADR O-ADR
, O-ADR O-ADR
would O-ADR O-ADR
be O-ADR O-ADR
expected O-ADR O-ADR
to O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
immunosuppression B-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Drug O-ADR O-ADR
Interactions O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
were O-ADR O-ADR
no O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
resulting O-ADR O-ADR
in O-ADR O-ADR
permanent O-ADR O-ADR
discontinuation O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
patients O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
75 O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
age O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
cardiac O-ADR B-ADR
failure O-ADR I-ADR
is O-ADR O-ADR
increased O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Use O-ADR O-ADR
with O-ADR O-ADR
Abatacept O-ADR O-ADR
In O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
concurrent O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
TNF O-ADR O-ADR
- O-ADR O-ADR
blocker O-ADR O-ADR
and O-ADR O-ADR
abatacept O-ADR O-ADR
was O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
greater O-ADR O-ADR
proportion O-ADR O-ADR
of O-ADR O-ADR
serious O-ADR O-ADR
infections O-ADR B-ADR
than O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
TNF O-ADR O-ADR
- O-ADR O-ADR
blocker O-ADR O-ADR
alone O-ADR O-ADR
; O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
combination O-ADR O-ADR
therapy O-ADR O-ADR
, O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
TNF O-ADR O-ADR
- O-ADR O-ADR
blocker O-ADR O-ADR
alone O-ADR O-ADR
, O-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
demonstrated O-ADR O-ADR
improved O-ADR O-ADR
clinical O-ADR O-ADR
benefit O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
RA O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
both O-ADR O-ADR
Studies O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
aminotransferase B-ADR B-ADR
elevations I-ADR I-ADR
of O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
3 O-ADR O-ADR
times O-ADR O-ADR
the O-ADR O-ADR
upper O-ADR O-ADR
limit O-ADR O-ADR
of O-ADR O-ADR
normal O-ADR O-ADR
developed O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
SIRTURO O-ADR O-ADR
treatment O-ADR O-ADR
group O-ADR O-ADR
( O-ADR O-ADR
11 O-ADR O-ADR
/ O-ADR O-ADR
102 O-ADR O-ADR
[ O-ADR O-ADR
10 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
] O-ADR O-ADR
vs O-ADR O-ADR
6 O-ADR O-ADR
/ O-ADR O-ADR
105 O-ADR O-ADR
[ O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
] O-ADR O-ADR
) O-ADR O-ADR
than O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
treatment O-ADR O-ADR
group O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
incidence O-ADR O-ADR
rates O-ADR O-ADR
of O-ADR O-ADR
adjudicated O-ADR O-ADR
bone B-ADR B-ADR
fractures I-ADR I-ADR
were O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
per O-ADR O-ADR
100 O-ADR O-ADR
patient O-ADR O-ADR
- O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
exposure O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
comparator O-ADR O-ADR
, O-ADR O-ADR
INVOKANA O-ADR O-ADR
100 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
INVOKANA O-ADR O-ADR
300 O-ADR O-ADR
mg O-ADR O-ADR
groups O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
frequent O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
XALKORI O-ADR O-ADR
were O-ADR O-ADR
dyspnea B-ADR B-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
pulmonary B-ADR B-ADR
embolism I-ADR I-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
No O-ADR O-ADR
study O-ADR O-ADR
adequate O-ADR O-ADR
to O-ADR O-ADR
determine O-ADR O-ADR
whether O-ADR O-ADR
the O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
asthma O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
death O-ADR B-ADR
is O-ADR O-ADR
increased O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
ARCAPTA O-ADR O-ADR
NEOHALER O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
conducted O-ADR O-ADR
. O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
including O-ADR O-ADR
anaphylaxis B-ADR B-ADR
, O-ADR O-ADR
angioedema B-ADR B-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
, O-ADR O-ADR
urticaria B-ADR B-ADR
and O-ADR O-ADR
severe O-ADR O-ADR
cutaneous B-ADR B-ADR
adverse I-ADR I-ADR
reactions I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
Stevens B-ADR B-ADR
- O-ADR O-ADR
Johnson O-ADR O-ADR
syndrome I-ADR I-ADR
, O-ADR O-ADR
hepatic B-ADR B-ADR
enzyme I-ADR I-ADR
elevations I-ADR I-ADR
, O-ADR O-ADR
fulminant B-ADR B-ADR
hepatic I-ADR I-ADR
failure I-ADR I-ADR
, O-ADR O-ADR
severe O-ADR O-ADR
and O-ADR O-ADR
disabling O-ADR O-ADR
arthralgia B-ADR B-ADR
and O-ADR O-ADR
acute B-ADR B-ADR
pancreatitis I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Cases O-ADR O-ADR
of O-ADR O-ADR
SJS B-ADR B-ADR
and O-ADR O-ADR
TEN B-ADR B-ADR
, O-ADR O-ADR
some O-ADR O-ADR
fatal B-ADR B-ADR
, O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
when O-ADR O-ADR
TREANDA O-ADR O-ADR
was O-ADR O-ADR
administered O-ADR O-ADR
concomitantly O-ADR O-ADR
with O-ADR O-ADR
allopurinol O-ADR O-ADR
and O-ADR O-ADR
other O-ADR O-ADR
medications O-ADR O-ADR
known O-ADR O-ADR
to O-ADR O-ADR
cause O-ADR O-ADR
these O-ADR O-ADR
syndromes O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
Complications O-ADR B-ADR
of O-ADR I-ADR
myelosuppression B-ADR I-ADR
may O-ADR O-ADR
lead O-ADR O-ADR
to O-ADR O-ADR
death B-ADR B-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
of O-ADR O-ADR
sinus B-ADR B-ADR
tachycardia I-ADR I-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
exposed O-ADR O-ADR
to O-ADR O-ADR
TRULICITY O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
Reaction O-ADR O-ADR
( O-ADR O-ADR
Preferred O-ADR O-ADR
Term O-ADR O-ADR
) O-ADR O-ADR
Placebo O-ADR O-ADR
+ O-ADR O-ADR
MTX O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
324 O-ADR O-ADR
CIMZIA O-ADR O-ADR
200 O-ADR O-ADR
mg O-ADR O-ADR
EOW O-ADR O-ADR
+ O-ADR O-ADR
MTX O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
640 O-ADR O-ADR
Upper B-ADR B-ADR
respiratory I-ADR I-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
2 O-ADR O-ADR
6 O-ADR O-ADR
Headache B-ADR B-ADR
4 O-ADR O-ADR
5 O-ADR O-ADR
Hypertension B-ADR B-ADR
2 O-ADR O-ADR
5 O-ADR O-ADR
Nasopharyngitis B-ADR B-ADR
1 O-ADR O-ADR
5 O-ADR O-ADR
Back B-ADR B-ADR
pain I-ADR I-ADR
1 O-ADR O-ADR
4 O-ADR O-ADR
Pyrexia B-ADR B-ADR
2 O-ADR O-ADR
3 O-ADR O-ADR
Pharyngitis B-ADR B-ADR
1 O-ADR O-ADR
3 O-ADR O-ADR
Rash B-ADR B-ADR
1 O-ADR O-ADR
3 O-ADR O-ADR
Acute B-ADR B-ADR
bronchitis I-ADR I-ADR
1 O-ADR O-ADR
3 O-ADR O-ADR
Fatigue B-ADR B-ADR
2 O-ADR O-ADR
3 O-ADR O-ADR
Hypertensive B-ADR B-ADR
adverse I-ADR I-ADR
reactions I-ADR I-ADR
were O-ADR O-ADR
observed O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
CIMZIA O-ADR O-ADR
than O-ADR O-ADR
in O-ADR O-ADR
controls O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
Topical O-ADR O-ADR
Ophthalmic O-ADR O-ADR
Use O-ADR O-ADR
Only O-ADR O-ADR
DUREZOL O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
indicated O-ADR O-ADR
for O-ADR O-ADR
intraocular O-ADR O-ADR
administration O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
Nasopharyngitis B-ADR B-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Urinary O-ADR O-ADR
tract O-ADR O-ADR
infectionsUrinary O-ADR O-ADR
tract B-ADR I-ADR
infections I-ADR I-ADR
include O-ADR O-ADR
the O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
, O-ADR O-ADR
listed O-ADR O-ADR
in O-ADR O-ADR
order O-ADR O-ADR
of O-ADR O-ADR
frequency O-ADR O-ADR
reported O-ADR O-ADR
: O-ADR O-ADR
urinary B-ADR B-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
, O-ADR O-ADR
cystitis B-ADR B-ADR
, O-ADR O-ADR
Escherichia B-ADR B-ADR
urinary I-ADR I-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
, O-ADR O-ADR
genitourinary B-ADR B-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
, O-ADR O-ADR
pyelonephritis B-ADR B-ADR
, O-ADR O-ADR
trigonitis B-ADR B-ADR
, O-ADR O-ADR
urethritis B-ADR B-ADR
, O-ADR O-ADR
kidney B-ADR B-ADR
infection I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
prostatitis B-ADR B-ADR
. O-ADR O-ADR
TANZEUM O-ADR O-ADR
was O-ADR O-ADR
used O-ADR O-ADR
as O-ADR O-ADR
monotherapy O-ADR O-ADR
in O-ADR O-ADR
1 O-ADR O-ADR
trial O-ADR O-ADR
and O-ADR O-ADR
as O-ADR O-ADR
add O-ADR O-ADR
- O-ADR O-ADR
on O-ADR O-ADR
therapy O-ADR O-ADR
in O-ADR O-ADR
3 O-ADR O-ADR
trials O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Ninety O-ADR O-ADR
- O-ADR O-ADR
two O-ADR O-ADR
percent O-ADR O-ADR
( O-ADR O-ADR
92 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
COMETRIQ O-ADR O-ADR
arm O-ADR O-ADR
had O-ADR O-ADR
a O-ADR O-ADR
prior O-ADR O-ADR
thyroidectomy O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
89 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
taking O-ADR O-ADR
thyroid O-ADR O-ADR
hormone O-ADR O-ADR
replacement O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
dose O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Fatal B-ADR B-ADR
and O-ADR O-ADR
serious O-ADR O-ADR
intestinal B-ADR B-ADR
perforation I-ADR I-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
in O-ADR O-ADR
Zydelig O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
across O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
described O-ADR O-ADR
in O-ADR O-ADR
this O-ADR O-ADR
section O-ADR O-ADR
reflect O-ADR O-ADR
EOVIST O-ADR O-ADR
exposure O-ADR O-ADR
in O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
989 O-ADR O-ADR
subjects O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
majority O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
581 O-ADR O-ADR
subjects O-ADR O-ADR
) O-ADR O-ADR
receiving O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
dose O-ADR O-ADR
. O-ADR O-ADR
Cases O-ADR O-ADR
were O-ADR O-ADR
consistent O-ADR O-ADR
with O-ADR O-ADR
hepatocellular B-ADR B-ADR
injury I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
elevations B-ADR B-ADR
of I-ADR I-ADR
transaminases I-ADR I-ADR
. O-ADR O-ADR
gfatal O-ADR O-ADR
: O-ADR O-ADR
Adjudicated O-ADR O-ADR
major O-ADR O-ADR
bleed B-ADR B-ADR
as O-ADR O-ADR
defined O-ADR O-ADR
above O-ADR O-ADR
and O-ADR O-ADR
adjudicated O-ADR O-ADR
death B-ADR B-ADR
with O-ADR O-ADR
primary O-ADR O-ADR
cause O-ADR O-ADR
from O-ADR O-ADR
bleeding B-ADR B-ADR
but O-ADR O-ADR
without O-ADR O-ADR
symptomatic B-ADR B-ADR
intracranial I-ADR I-ADR
bleed I-ADR I-ADR
based O-ADR O-ADR
on O-ADR O-ADR
investigator O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
clinical O-ADR O-ADR
assessment O-ADR O-ADR
. O-ADR O-ADR
Although O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
may O-ADR O-ADR
control O-ADR O-ADR
COPD O-ADR O-ADR
or O-ADR O-ADR
asthma O-ADR O-ADR
symptoms O-ADR O-ADR
during O-ADR O-ADR
these O-ADR O-ADR
episodes O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
recommended O-ADR O-ADR
doses O-ADR O-ADR
it O-ADR O-ADR
supplies O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
normal O-ADR O-ADR
physiological O-ADR O-ADR
amounts O-ADR O-ADR
of O-ADR O-ADR
glucocorticoid O-ADR O-ADR
systemically O-ADR O-ADR
and O-ADR O-ADR
does O-ADR O-ADR
NOT O-ADR O-ADR
provide O-ADR O-ADR
the O-ADR O-ADR
mineralocorticoid O-ADR O-ADR
activity O-ADR O-ADR
that O-ADR O-ADR
is O-ADR O-ADR
necessary O-ADR O-ADR
for O-ADR O-ADR
coping O-ADR O-ADR
with O-ADR O-ADR
these O-ADR O-ADR
emergencies O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
majority O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
white O-ADR O-ADR
( O-ADR O-ADR
87 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
10 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
Asian O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
black O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
mean O-ADR O-ADR
CrCl O-ADR O-ADR
of O-ADR O-ADR
105 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
mL O-ADR O-ADR
/ O-ADR O-ADR
min O-ADR O-ADR
. O-ADR O-ADR
Data O-ADR O-ADR
from O-ADR O-ADR
a O-ADR O-ADR
large O-ADR O-ADR
, O-ADR O-ADR
prospective O-ADR O-ADR
cohort O-ADR O-ADR
safety O-ADR O-ADR
study O-ADR O-ADR
of O-ADR O-ADR
various O-ADR O-ADR
COCs O-ADR O-ADR
suggest O-ADR O-ADR
that O-ADR O-ADR
this O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
, O-ADR O-ADR
as O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
that O-ADR O-ADR
in O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
COC O-ADR O-ADR
users O-ADR O-ADR
, O-ADR O-ADR
is O-ADR O-ADR
greatest O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
6 O-ADR O-ADR
months O-ADR O-ADR
of O-ADR O-ADR
COC O-ADR O-ADR
use O-ADR O-ADR
. O-ADR O-ADR
TRULICITY O-ADR O-ADR
is O-ADR O-ADR
contraindicated O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
personal O-ADR O-ADR
or O-ADR O-ADR
family O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
MTC O-ADR O-ADR
or O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
MEN O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
FATAL B-ADR B-ADR
AND O-ADR O-ADR
SERIOUS O-ADR O-ADR
TOXICITIES B-ADR B-ADR
, O-ADR O-ADR
SEVERE O-ADR O-ADR
DIARRHEA B-ADR B-ADR
, O-ADR O-ADR
COLITIS B-ADR B-ADR
, O-ADR O-ADR
PNEUMONITIS B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
INTESTINAL B-ADR B-ADR
PERFORATION I-ADR I-ADR
See O-ADR O-ADR
full O-ADR O-ADR
prescribing O-ADR O-ADR
information O-ADR O-ADR
for O-ADR O-ADR
complete O-ADR O-ADR
boxed O-ADR O-ADR
warning O-ADR O-ADR
. O-ADR O-ADR
Increased B-ADR B-ADR
susceptibility I-ADR I-ADR
to I-ADR I-ADR
infection I-ADR I-ADR
and O-ADR O-ADR
the O-ADR O-ADR
possible O-ADR O-ADR
development O-ADR O-ADR
of O-ADR O-ADR
malignancies B-ADR B-ADR
may O-ADR O-ADR
result O-ADR O-ADR
from O-ADR O-ADR
immunosuppression O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
profile O-ADR O-ADR
was O-ADR O-ADR
similar O-ADR O-ADR
after O-ADR O-ADR
each O-ADR O-ADR
injection O-ADR O-ADR
, O-ADR O-ADR
regardless O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
number O-ADR O-ADR
of O-ADR O-ADR
injections O-ADR O-ADR
administered O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
Hypertension O-ADR O-ADR
Assess O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
pulse O-ADR O-ADR
and O-ADR O-ADR
blood O-ADR O-ADR
pressure O-ADR O-ADR
before O-ADR O-ADR
and O-ADR O-ADR
intermittently O-ADR O-ADR
for O-ADR O-ADR
30 O-ADR O-ADR
minutes O-ADR O-ADR
after O-ADR O-ADR
AdreView O-ADR O-ADR
administration O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
item O-ADR O-ADR
{ O-ADR O-ADR
Delayed O-ADR O-ADR
healing O-ADR O-ADR
- O-ADR O-ADR
The O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
steroids O-ADR O-ADR
after O-ADR O-ADR
cataract O-ADR O-ADR
surgery O-ADR O-ADR
may O-ADR O-ADR
delay B-ADR O-ADR
healing I-ADR O-ADR
and O-ADR O-ADR
increase B-ADR O-ADR
the I-ADR O-ADR
incidence I-ADR O-ADR
of I-ADR O-ADR
bleb I-ADR B-ADR
formation I-ADR O-ADR
. O-ADR O-ADR
Anti O-ADR O-ADR
- O-ADR O-ADR
belatacept O-ADR O-ADR
antibody O-ADR O-ADR
titers O-ADR O-ADR
did O-ADR O-ADR
not O-ADR O-ADR
increase O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
in O-ADR O-ADR
these O-ADR O-ADR
29 O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Percentage O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
Patients O-ADR O-ADR
YERVOY3 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
kgn O-ADR O-ADR
= O-ADR O-ADR
131 O-ADR O-ADR
YERVOY3 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
kg O-ADR O-ADR
+ O-ADR O-ADR
gp100n O-ADR O-ADR
= O-ADR O-ADR
380 O-ADR O-ADR
Any O-ADR O-ADR
Immune O-ADR B-ADR
- O-ADR O-ADR
mediated O-ADR O-ADR
Adverse O-ADR I-ADR
Reaction O-ADR I-ADR
15 O-ADR O-ADR
12 O-ADR O-ADR
Enterocolitisa O-ADR B-ADR
, O-ADR O-ADR
b O-ADR O-ADR
7 O-ADR O-ADR
7 O-ADR O-ADR
Hepatotoxicitya O-ADR B-ADR
1 O-ADR O-ADR
2 O-ADR O-ADR
Dermatitisa O-ADR B-ADR
2 O-ADR O-ADR
3 O-ADR O-ADR
Neuropathya O-ADR B-ADR
1 O-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
Endocrinopathy B-ADR B-ADR
4 O-ADR O-ADR
1 O-ADR O-ADR
Hypopituitarism B-ADR B-ADR
4 O-ADR O-ADR
1 O-ADR O-ADR
Adrenal B-ADR B-ADR
insufficiency I-ADR I-ADR
0 O-ADR O-ADR
1 O-ADR O-ADR
Other O-ADR O-ADR
Pneumonitis B-ADR B-ADR
0 O-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
Meningitis B-ADR B-ADR
0 O-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
Nephritis B-ADR B-ADR
1 O-ADR O-ADR
0 O-ADR O-ADR
Eosinophiliac O-ADR B-ADR
1 O-ADR O-ADR
0 O-ADR O-ADR
Pericarditisa O-ADR B-ADR
, O-ADR O-ADR
c O-ADR O-ADR
0 O-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
Across O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
that O-ADR O-ADR
utilized O-ADR O-ADR
YERVOY O-ADR O-ADR
doses O-ADR O-ADR
ranging O-ADR O-ADR
from O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
to O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
kg O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
also O-ADR O-ADR
reported O-ADR O-ADR
( O-ADR O-ADR
incidence O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
unless O-ADR O-ADR
otherwise O-ADR O-ADR
noted O-ADR O-ADR
) O-ADR O-ADR
: O-ADR O-ADR
urticaria B-ADR B-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
large B-ADR B-ADR
intestinal I-ADR I-ADR
ulcer I-ADR I-ADR
, O-ADR O-ADR
esophagitis B-ADR B-ADR
, O-ADR O-ADR
acute B-ADR B-ADR
respiratory I-ADR I-ADR
distress I-ADR I-ADR
syndrome I-ADR I-ADR
, O-ADR O-ADR
renal B-ADR B-ADR
failure I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
infusion B-ADR B-ADR
reaction I-ADR I-ADR
. O-ADR O-ADR
Therefore O-ADR O-ADR
, O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
, O-ADR O-ADR
like O-ADR O-ADR
other O-ADR O-ADR
sympathomimetic O-ADR O-ADR
amines O-ADR O-ADR
, O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
with O-ADR O-ADR
caution O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
cardiovascular O-ADR O-ADR
disorders O-ADR O-ADR
, O-ADR O-ADR
especially O-ADR O-ADR
coronary O-ADR O-ADR
insufficiency O-ADR O-ADR
, O-ADR O-ADR
cardiac O-ADR O-ADR
arrhythmias O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
hypertension O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
monitored O-ADR O-ADR
for O-ADR O-ADR
these O-ADR O-ADR
symptoms O-ADR O-ADR
when O-ADR O-ADR
discontinuing O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
PRISTIQ O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
other O-ADR O-ADR
XIAFLEX O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
9 O-ADR O-ADR
of O-ADR O-ADR
1044 O-ADR O-ADR
; O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
diagnosis O-ADR O-ADR
of O-ADR O-ADR
corporal B-ADR B-ADR
rupture I-ADR I-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
excluded O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
receiving O-ADR O-ADR
CIMZIA O-ADR O-ADR
400 O-ADR O-ADR
mg O-ADR O-ADR
as O-ADR O-ADR
monotherapy O-ADR O-ADR
every O-ADR O-ADR
4 O-ADR O-ADR
weeks O-ADR O-ADR
in O-ADR O-ADR
rheumatoid O-ADR O-ADR
arthritis O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
had O-ADR O-ADR
similar O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
to O-ADR O-ADR
those O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
CIMZIA O-ADR O-ADR
200 O-ADR O-ADR
mg O-ADR O-ADR
every O-ADR O-ADR
other O-ADR O-ADR
week O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Serious O-ADR O-ADR
Dermatologic B-ADR B-ADR
Reactions I-ADR I-ADR
, O-ADR O-ADR
Drug B-ADR B-ADR
Reaction I-ADR I-ADR
with I-ADR I-ADR
Eosinophilia I-ADR I-ADR
and I-ADR I-ADR
Systemic I-ADR I-ADR
Symptoms I-ADR I-ADR
( O-ADR O-ADR
DRESS B-ADR B-ADR
) O-ADR O-ADR
, O-ADR O-ADR
Anaphylactic B-ADR B-ADR
Reactions I-ADR I-ADR
and O-ADR O-ADR
Angioedema B-ADR B-ADR
: O-ADR O-ADR
Monitor O-ADR O-ADR
and O-ADR O-ADR
discontinue O-ADR O-ADR
if O-ADR O-ADR
another O-ADR O-ADR
cause O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
established O-ADR O-ADR
. O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
ASTHMA O-ADR O-ADR
- O-ADR O-ADR
RELATED O-ADR O-ADR
DEATH B-ADR B-ADR
See O-ADR O-ADR
full O-ADR O-ADR
prescribing O-ADR O-ADR
information O-ADR O-ADR
for O-ADR O-ADR
complete O-ADR O-ADR
boxed O-ADR O-ADR
warning O-ADR O-ADR
* O-ADR O-ADR
Long O-ADR O-ADR
- O-ADR O-ADR
acting O-ADR O-ADR
beta2 O-ADR O-ADR
- O-ADR O-ADR
adrenergic O-ADR O-ADR
agonists O-ADR O-ADR
( O-ADR O-ADR
LABA O-ADR O-ADR
) O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
asthma O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
death B-ADR B-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
causal O-ADR O-ADR
relationship O-ADR O-ADR
between O-ADR O-ADR
study O-ADR O-ADR
drug O-ADR O-ADR
and O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
was O-ADR O-ADR
not O-ADR O-ADR
always O-ADR O-ADR
established O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
study O-ADR O-ADR
of O-ADR O-ADR
55 O-ADR O-ADR
subjects O-ADR O-ADR
with O-ADR O-ADR
varying O-ADR O-ADR
degrees O-ADR O-ADR
of O-ADR O-ADR
renal O-ADR O-ADR
function O-ADR O-ADR
, O-ADR O-ADR
serum O-ADR O-ADR
calcium O-ADR O-ADR
levels O-ADR O-ADR
< O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
or O-ADR O-ADR
symptomatic B-ADR B-ADR
hypocalcemia I-ADR I-ADR
were O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
5 O-ADR O-ADR
subjects O-ADR O-ADR
. O-ADR O-ADR
Seven O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
SIRTURO O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
six O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
discontinued O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
because O-ADR O-ADR
of O-ADR O-ADR
an O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
171 O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
chemotherapy O-ADR O-ADR
arm O-ADR O-ADR
received O-ADR O-ADR
pemetrexed O-ADR O-ADR
500 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
m O-ADR O-ADR
2 O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
99 O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
docetaxel O-ADR O-ADR
75 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
m O-ADR O-ADR
2 O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
72 O-ADR O-ADR
) O-ADR O-ADR
by O-ADR O-ADR
intravenous O-ADR O-ADR
infusion O-ADR O-ADR
every O-ADR O-ADR
three O-ADR O-ADR
weeks O-ADR O-ADR
until O-ADR O-ADR
documented O-ADR O-ADR
disease O-ADR O-ADR
progression O-ADR O-ADR
, O-ADR O-ADR
intolerance O-ADR O-ADR
to O-ADR O-ADR
therapy O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
the O-ADR O-ADR
investigator O-ADR O-ADR
determined O-ADR O-ADR
that O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
was O-ADR O-ADR
no O-ADR O-ADR
longer O-ADR O-ADR
experiencing O-ADR O-ADR
clinical O-ADR O-ADR
benefit O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Associated O-ADR O-ADR
with O-ADR O-ADR
Discontinuation O-ADR O-ADR
of O-ADR O-ADR
Treatment O-ADR O-ADR
: O-ADR O-ADR
Approximately O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
38 O-ADR O-ADR
/ O-ADR O-ADR
379 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
SAPHRIS O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
discontinued O-ADR O-ADR
treatment O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
an O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
, O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
about O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
/ O-ADR O-ADR
203 O-ADR O-ADR
) O-ADR O-ADR
on O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
Malignancies O-ADR O-ADR
in O-ADR O-ADR
Adult O-ADR O-ADR
Patients O-ADR O-ADR
The O-ADR O-ADR
risks O-ADR O-ADR
and O-ADR O-ADR
benefits O-ADR O-ADR
of O-ADR O-ADR
TNF O-ADR O-ADR
- O-ADR O-ADR
blocker O-ADR O-ADR
treatment O-ADR O-ADR
including O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
initiating O-ADR O-ADR
therapy O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
known O-ADR O-ADR
malignancy O-ADR O-ADR
other O-ADR O-ADR
than O-ADR O-ADR
a O-ADR O-ADR
successfully O-ADR O-ADR
treated O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
melanoma O-ADR O-ADR
skin O-ADR O-ADR
cancer O-ADR O-ADR
( O-ADR O-ADR
NMSC O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
when O-ADR O-ADR
considering O-ADR O-ADR
continuing O-ADR O-ADR
a O-ADR O-ADR
TNF O-ADR O-ADR
- O-ADR O-ADR
blocker O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
develop O-ADR O-ADR
a O-ADR O-ADR
malignancy O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
frequently O-ADR O-ADR
reported O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
was O-ADR O-ADR
headache B-ADR B-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
This O-ADR O-ADR
may O-ADR O-ADR
result O-ADR O-ADR
in O-ADR O-ADR
critical O-ADR B-ADR
loss B-ADR I-ADR
of I-ADR I-ADR
breathing I-ADR I-ADR
capacity I-ADR I-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
respiratory O-ADR O-ADR
disorders O-ADR O-ADR
who O-ADR O-ADR
may O-ADR O-ADR
have O-ADR O-ADR
become O-ADR O-ADR
dependent O-ADR O-ADR
upon O-ADR O-ADR
these O-ADR O-ADR
accessory O-ADR O-ADR
muscles O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
data O-ADR O-ADR
described O-ADR O-ADR
below O-ADR O-ADR
are O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
two O-ADR O-ADR
12 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
efficacy O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
one O-ADR O-ADR
24 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
efficacy O-ADR O-ADR
trial O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
two O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
postmarketing O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
reported O-ADR O-ADR
voluntarily O-ADR O-ADR
from O-ADR O-ADR
a O-ADR O-ADR
population O-ADR O-ADR
of O-ADR O-ADR
uncertain O-ADR O-ADR
size O-ADR O-ADR
, O-ADR O-ADR
it O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
always O-ADR O-ADR
possible O-ADR O-ADR
to O-ADR O-ADR
reliably O-ADR O-ADR
estimate O-ADR O-ADR
their O-ADR O-ADR
frequency O-ADR O-ADR
or O-ADR O-ADR
establish O-ADR O-ADR
a O-ADR O-ADR
causal O-ADR O-ADR
relationship O-ADR O-ADR
to O-ADR O-ADR
drug O-ADR O-ADR
exposure O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
macular B-ADR B-ADR
edema I-ADR I-ADR
is O-ADR O-ADR
also O-ADR O-ADR
increased O-ADR O-ADR
in O-ADR O-ADR
MS O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
uveitis O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
instructed O-ADR O-ADR
to O-ADR O-ADR
contact O-ADR O-ADR
their O-ADR O-ADR
healthcare O-ADR O-ADR
provider O-ADR O-ADR
if O-ADR O-ADR
they O-ADR O-ADR
experience O-ADR O-ADR
new O-ADR O-ADR
or O-ADR O-ADR
worsening O-ADR O-ADR
depression O-ADR O-ADR
, O-ADR O-ADR
suicidal O-ADR O-ADR
thoughts O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
mood O-ADR O-ADR
changes O-ADR O-ADR
. O-ADR O-ADR
At O-ADR O-ADR
screening O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
mean O-ADR O-ADR
postbronchodilator O-ADR O-ADR
percent O-ADR O-ADR
predicted O-ADR O-ADR
FEV1was O-ADR O-ADR
45 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
: O-ADR O-ADR
12 O-ADR O-ADR
% O-ADR O-ADR
to O-ADR O-ADR
91 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
mean O-ADR O-ADR
postbronchodilator O-ADR O-ADR
FEV1 O-ADR O-ADR
/ O-ADR O-ADR
FVC O-ADR O-ADR
ratio O-ADR O-ADR
was O-ADR O-ADR
46 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
: O-ADR O-ADR
17 O-ADR O-ADR
% O-ADR O-ADR
to O-ADR O-ADR
81 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
indicating O-ADR O-ADR
that O-ADR O-ADR
the O-ADR O-ADR
subject O-ADR O-ADR
population O-ADR O-ADR
had O-ADR O-ADR
moderate O-ADR O-ADR
to O-ADR O-ADR
very O-ADR O-ADR
severely O-ADR O-ADR
impaired O-ADR B-ADR
airflow O-ADR O-ADR
obstruction O-ADR I-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
were O-ADR O-ADR
between O-ADR O-ADR
the O-ADR O-ADR
ages O-ADR O-ADR
of O-ADR O-ADR
16 O-ADR O-ADR
and O-ADR O-ADR
63 O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
date O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
study O-ADR O-ADR
drug O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
included O-ADR O-ADR
20 O-ADR O-ADR
males O-ADR O-ADR
and O-ADR O-ADR
20 O-ADR O-ADR
females O-ADR O-ADR
. O-ADR O-ADR
Evaluate O-ADR O-ADR
for O-ADR O-ADR
tuberculosis O-ADR O-ADR
and O-ADR O-ADR
initiate O-ADR O-ADR
treatment O-ADR O-ADR
for O-ADR O-ADR
latent O-ADR O-ADR
infection O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
NULOJIX O-ADR O-ADR
use O-ADR O-ADR
. O-ADR O-ADR
Immunogenicity O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
pool O-ADR O-ADR
of O-ADR O-ADR
7 O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
and O-ADR O-ADR
active O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
116 O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
098 O-ADR O-ADR
patients O-ADR O-ADR
exposed O-ADR O-ADR
to O-ADR O-ADR
TANZEUM O-ADR O-ADR
tested O-ADR O-ADR
positive O-ADR O-ADR
for O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
albiglutide O-ADR O-ADR
antibodies O-ADR O-ADR
at O-ADR O-ADR
any O-ADR O-ADR
time O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
Psychiatric O-ADR O-ADR
disorders O-ADR O-ADR
- O-ADR O-ADR
Depersonalization B-ADR B-ADR
, O-ADR O-ADR
bruxism B-ADR B-ADR
. O-ADR O-ADR
Bleeding B-ADR B-ADR
into I-ADR O-ADR
an I-ADR I-ADR
operated I-ADR O-ADR
joint I-ADR O-ADR
requiring O-ADR O-ADR
re O-ADR O-ADR
- O-ADR O-ADR
operation O-ADR O-ADR
or O-ADR O-ADR
intervention O-ADR O-ADR
was O-ADR O-ADR
present O-ADR O-ADR
in O-ADR O-ADR
all O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
this O-ADR O-ADR
category O-ADR O-ADR
of O-ADR O-ADR
bleeding B-ADR B-ADR
. O-ADR O-ADR
Severe O-ADR O-ADR
hypersensitivity O-ADR B-ADR
: O-ADR O-ADR
Severe O-ADR O-ADR
hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
include O-ADR O-ADR
generalized B-ADR B-ADR
rash O-ADR O-ADR
/ O-ADR O-ADR
erythema O-ADR O-ADR
, O-ADR O-ADR
hypotension B-ADR B-ADR
and O-ADR O-ADR
bronchospasm B-ADR B-ADR
. O-ADR O-ADR
Among O-ADR O-ADR
these O-ADR O-ADR
were O-ADR O-ADR
vertigo B-ADR B-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
patients O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
infections B-ADR B-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
patients O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
intra B-ADR B-ADR
- O-ADR O-ADR
abdominal O-ADR O-ADR
abscess I-ADR I-ADR
following O-ADR O-ADR
appendectomy O-ADR B-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
patient O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
It O-ADR O-ADR
is O-ADR O-ADR
unknown O-ADR O-ADR
whether O-ADR O-ADR
TANZEUM O-ADR O-ADR
causes O-ADR O-ADR
thyroid B-ADR B-ADR
C I-ADR I-ADR
- O-ADR O-ADR
cell O-ADR O-ADR
tumors I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
medullary B-ADR B-ADR
thyroid I-ADR I-ADR
carcinoma I-ADR I-ADR
( O-ADR O-ADR
MTC B-ADR B-ADR
) O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
humans O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Ophthalmic O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Avoid O-ADR O-ADR
treatment O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
periocular O-ADR O-ADR
area O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
third O-ADR O-ADR
case O-ADR O-ADR
, O-ADR O-ADR
elevation B-ADR B-ADR
in I-ADR I-ADR
ALT I-ADR I-ADR
( O-ADR O-ADR
10 O-ADR O-ADR
times O-ADR O-ADR
the O-ADR O-ADR
upper O-ADR O-ADR
limit O-ADR O-ADR
of O-ADR O-ADR
normal O-ADR O-ADR
) O-ADR O-ADR
was O-ADR O-ADR
accompanied O-ADR O-ADR
by O-ADR O-ADR
an O-ADR O-ADR
increase B-ADR B-ADR
in I-ADR I-ADR
total I-ADR I-ADR
bilirubin I-ADR I-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
times O-ADR O-ADR
the O-ADR O-ADR
upper O-ADR O-ADR
limit O-ADR O-ADR
of O-ADR O-ADR
normal O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
occurred O-ADR O-ADR
8 O-ADR O-ADR
days O-ADR O-ADR
after O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
TANZEUM O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Genital O-ADR O-ADR
Mycotic O-ADR O-ADR
Infections O-ADR O-ADR
JARDIANCE O-ADR O-ADR
increases O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
genital B-ADR B-ADR
mycotic I-ADR I-ADR
infections I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Use O-ADR O-ADR
caution O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
hemoglobin O-ADR O-ADR
< O-ADR O-ADR
10 O-ADR O-ADR
g O-ADR O-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
SAPHRIS O-ADR O-ADR
adult O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
incidences O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
related O-ADR O-ADR
to O-ADR O-ADR
abnormal B-ADR B-ADR
prolactin I-ADR I-ADR
levels I-ADR I-ADR
were O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
versus O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
Concomitant O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
drugs O-ADR O-ADR
affecting O-ADR O-ADR
hemostasis O-ADR O-ADR
increases O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
bleeding B-ADR B-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Bone O-ADR O-ADR
Effects O-ADR O-ADR
of O-ADR O-ADR
Tenofovir O-ADR O-ADR
DF O-ADR O-ADR
Bone O-ADR O-ADR
Mineral O-ADR O-ADR
Density O-ADR O-ADR
: O-ADR O-ADR
In O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
in O-ADR O-ADR
HIV O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
infected O-ADR O-ADR
adults O-ADR O-ADR
, O-ADR O-ADR
tenofovir O-ADR O-ADR
DF O-ADR O-ADR
( O-ADR O-ADR
a O-ADR O-ADR
component O-ADR O-ADR
of O-ADR O-ADR
STRIBILD O-ADR O-ADR
) O-ADR O-ADR
was O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
slightly O-ADR O-ADR
greater O-ADR O-ADR
decreases B-ADR I-ADR
in I-ADR I-ADR
bone I-ADR I-ADR
mineral I-ADR I-ADR
density I-ADR I-ADR
) O-ADR O-ADR
and O-ADR O-ADR
increases B-ADR B-ADR
in I-ADR I-ADR
biochemical I-ADR I-ADR
markers I-ADR I-ADR
of I-ADR I-ADR
bone I-ADR I-ADR
metabolism I-ADR I-ADR
, O-ADR O-ADR
suggesting O-ADR O-ADR
increased B-ADR B-ADR
bone I-ADR I-ADR
turnover I-ADR I-ADR
relative O-ADR O-ADR
to O-ADR O-ADR
comparators O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Embryofetal O-ADR O-ADR
Toxicity O-ADR O-ADR
Based O-ADR O-ADR
on O-ADR O-ADR
its O-ADR O-ADR
mechanism O-ADR O-ADR
of O-ADR O-ADR
action O-ADR O-ADR
, O-ADR O-ADR
XALKORI O-ADR O-ADR
can O-ADR O-ADR
cause O-ADR O-ADR
fetal B-ADR B-ADR
harm I-ADR I-ADR
when O-ADR O-ADR
administered O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
pregnant O-ADR O-ADR
woman O-ADR O-ADR
. O-ADR O-ADR
Nervous O-ADR O-ADR
System O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
altered B-ADR B-ADR
taste I-ADR I-ADR
, O-ADR O-ADR
balance B-ADR B-ADR
disorder I-ADR I-ADR
, O-ADR O-ADR
cerebrovascular B-ADR B-ADR
accident I-ADR I-ADR
, O-ADR O-ADR
Guillain B-ADR B-ADR
- O-ADR O-ADR
Barre O-ADR O-ADR
syndrome I-ADR I-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
hemiparesis B-ADR B-ADR
, O-ADR O-ADR
hypoesthesia B-ADR B-ADR
, O-ADR O-ADR
hyposmia B-ADR B-ADR
, O-ADR O-ADR
lacunar B-ADR B-ADR
infarction I-ADR I-ADR
, O-ADR O-ADR
lethargy B-ADR B-ADR
, O-ADR O-ADR
mental B-ADR B-ADR
impairment I-ADR I-ADR
, O-ADR O-ADR
migraine B-ADR B-ADR
, O-ADR O-ADR
paresthesia B-ADR B-ADR
, O-ADR O-ADR
somnolence B-ADR B-ADR
, O-ADR O-ADR
transient B-ADR B-ADR
ischemic I-ADR I-ADR
attack I-ADR I-ADR
, O-ADR O-ADR
tremor B-ADR B-ADR
. O-ADR O-ADR
JEVTANA O-ADR O-ADR
is O-ADR O-ADR
contraindicated O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
severe O-ADR O-ADR
hypersensitivity O-ADR O-ADR
reactions O-ADR O-ADR
to O-ADR O-ADR
cabazitaxel O-ADR O-ADR
or O-ADR O-ADR
to O-ADR O-ADR
other O-ADR O-ADR
drugs O-ADR O-ADR
formulated O-ADR O-ADR
with O-ADR O-ADR
polysorbate O-ADR O-ADR
80 O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Contraindications O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Demyelinating B-ADR B-ADR
disease I-ADR I-ADR
, O-ADR O-ADR
may O-ADR O-ADR
occur O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Worsening B-ADR B-ADR
of I-ADR I-ADR
narrow I-ADR I-ADR
- O-ADR O-ADR
angle O-ADR O-ADR
glaucoma I-ADR I-ADR
may O-ADR O-ADR
occur O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
an O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
, O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
extension O-ADR O-ADR
study O-ADR O-ADR
of O-ADR O-ADR
two O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
randomized O-ADR O-ADR
, O-ADR O-ADR
double O-ADR O-ADR
- O-ADR O-ADR
blind O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
total O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
was O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
52 O-ADR O-ADR
weeks O-ADR O-ADR
. O-ADR O-ADR
Coartem O-ADR O-ADR
Tablets O-ADR O-ADR
may O-ADR O-ADR
reduce O-ADR O-ADR
the O-ADR O-ADR
effectiveness O-ADR O-ADR
of O-ADR O-ADR
hormonal O-ADR O-ADR
contraceptives O-ADR O-ADR
. O-ADR O-ADR
Treatment O-ADR O-ADR
delay O-ADR O-ADR
or O-ADR O-ADR
dosage O-ADR O-ADR
reduction O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
necessary O-ADR O-ADR
if O-ADR O-ADR
patients O-ADR O-ADR
experience O-ADR O-ADR
Grade O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
3 O-ADR O-ADR
diarrhea O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Avoid O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
GBCAs O-ADR O-ADR
among O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
unless O-ADR O-ADR
the O-ADR O-ADR
diagnostic O-ADR O-ADR
information O-ADR O-ADR
is O-ADR O-ADR
essential O-ADR O-ADR
and O-ADR O-ADR
not O-ADR O-ADR
available O-ADR O-ADR
with O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
contrast O-ADR O-ADR
enhanced O-ADR O-ADR
MRI O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
modalities O-ADR O-ADR
. O-ADR O-ADR
Vascular O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
flushing B-ADR B-ADR
, O-ADR O-ADR
hot B-ADR B-ADR
flush I-ADR I-ADR
, O-ADR O-ADR
hypertension B-ADR B-ADR
, O-ADR O-ADR
hypotension B-ADR B-ADR
. O-ADR O-ADR
In O-ADR O-ADR
Study O-ADR O-ADR
3 O-ADR O-ADR
, O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
, O-ADR O-ADR
regardless O-ADR O-ADR
of O-ADR O-ADR
causality O-ADR O-ADR
, O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
25 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
ADCETRIS O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Therefore O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
using O-ADR O-ADR
oral O-ADR O-ADR
, O-ADR O-ADR
transdermal O-ADR O-ADR
patch O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
systemic O-ADR O-ADR
hormonal O-ADR O-ADR
contraceptives O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
advised O-ADR O-ADR
to O-ADR O-ADR
use O-ADR O-ADR
an O-ADR O-ADR
additional O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
hormonal O-ADR O-ADR
method O-ADR O-ADR
of O-ADR O-ADR
birth O-ADR O-ADR
control O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Drug O-ADR O-ADR
Interactions O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Psychiatric O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
agitation B-ADR B-ADR
, O-ADR O-ADR
anxiety B-ADR B-ADR
, O-ADR O-ADR
depression B-ADR B-ADR
, O-ADR O-ADR
insomnia B-ADR B-ADR
, O-ADR O-ADR
irritability B-ADR B-ADR
, O-ADR O-ADR
libido B-ADR B-ADR
decreased I-ADR I-ADR
, O-ADR O-ADR
nervousness B-ADR B-ADR
, O-ADR O-ADR
panic B-ADR B-ADR
attack I-ADR I-ADR
, O-ADR O-ADR
personality B-ADR B-ADR
change I-ADR I-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Serious O-ADR O-ADR
infections B-ADR B-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
hospitalization O-ADR O-ADR
or O-ADR O-ADR
death B-ADR B-ADR
including O-ADR O-ADR
tuberculosis B-ADR B-ADR
( O-ADR O-ADR
TB B-ADR B-ADR
) O-ADR O-ADR
, O-ADR O-ADR
bacterial B-ADR B-ADR
sepsis I-ADR I-ADR
, O-ADR O-ADR
histoplasmosis B-ADR B-ADR
have O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
led O-ADR O-ADR
to O-ADR O-ADR
dose O-ADR O-ADR
reductions O-ADR O-ADR
in O-ADR O-ADR
49 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
dose O-ADR O-ADR
interruptions O-ADR O-ADR
in O-ADR O-ADR
67 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TAFINLAR O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
chronic O-ADR O-ADR
or O-ADR O-ADR
recurrent O-ADR O-ADR
genital O-ADR O-ADR
mycotic O-ADR O-ADR
infections O-ADR O-ADR
were O-ADR O-ADR
more O-ADR O-ADR
likely O-ADR O-ADR
to O-ADR O-ADR
develop O-ADR O-ADR
mycotic B-ADR B-ADR
genital I-ADR I-ADR
infections I-ADR I-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Negative O-ADR O-ADR
Inotropy O-ADR O-ADR
Dihydropyridine O-ADR O-ADR
calcium O-ADR O-ADR
channel O-ADR O-ADR
blockers O-ADR O-ADR
can O-ADR O-ADR
produce O-ADR O-ADR
negative B-ADR B-ADR
inotropic I-ADR I-ADR
effects I-ADR I-ADR
and O-ADR O-ADR
exacerbate B-ADR B-ADR
heart I-ADR I-ADR
failure I-ADR I-ADR
. O-ADR O-ADR
b O-ADR O-ADR
Includes O-ADR O-ADR
all O-ADR O-ADR
preferred O-ADR O-ADR
terms O-ADR O-ADR
within O-ADR O-ADR
the O-ADR O-ADR
' O-ADR O-ADR
infections O-ADR O-ADR
and O-ADR O-ADR
infestations O-ADR O-ADR
' O-ADR O-ADR
system O-ADR O-ADR
organ O-ADR O-ADR
class O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
being O-ADR O-ADR
nasopharyngitis B-ADR B-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
pneumonia B-ADR B-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
urinary B-ADR B-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
bronchitis B-ADR B-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
sinusitis B-ADR B-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
also O-ADR O-ADR
including O-ADR O-ADR
aspergillosis B-ADR B-ADR
( O-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
candidiasis B-ADR B-ADR
( O-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
sepsis B-ADR B-ADR
( O-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
are O-ADR O-ADR
no O-ADR O-ADR
adequate O-ADR O-ADR
and O-ADR O-ADR
well O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
studies O-ADR O-ADR
in O-ADR O-ADR
pregnant O-ADR O-ADR
women O-ADR O-ADR
using O-ADR O-ADR
Kyprolis O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
incidence O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
30 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
stomatitis B-ADR B-ADR
, O-ADR O-ADR
infections B-ADR B-ADR
, O-ADR O-ADR
asthenia B-ADR B-ADR
, O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
cough B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
diarrhea B-ADR B-ADR
. O-ADR O-ADR
Long O-ADR O-ADR
- O-ADR O-ADR
Term O-ADR O-ADR
, O-ADR O-ADR
Open O-ADR O-ADR
- O-ADR O-ADR
Label O-ADR O-ADR
Trials O-ADR O-ADR
with O-ADR O-ADR
NORTHERA O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
, O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
extension O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
422 O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
mean O-ADR O-ADR
age O-ADR O-ADR
65 O-ADR O-ADR
years O-ADR O-ADR
, O-ADR O-ADR
were O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
NORTHERA O-ADR O-ADR
for O-ADR O-ADR
a O-ADR O-ADR
mean O-ADR O-ADR
total O-ADR O-ADR
exposure O-ADR O-ADR
of O-ADR O-ADR
approximately O-ADR O-ADR
one O-ADR O-ADR
year O-ADR O-ADR
. O-ADR O-ADR
However O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
syndrome O-ADR O-ADR
can O-ADR O-ADR
develop O-ADR O-ADR
, O-ADR O-ADR
although O-ADR O-ADR
much O-ADR O-ADR
less O-ADR O-ADR
commonly O-ADR O-ADR
, O-ADR O-ADR
after O-ADR O-ADR
relatively O-ADR O-ADR
brief O-ADR O-ADR
treatment O-ADR O-ADR
periods O-ADR O-ADR
at O-ADR O-ADR
low O-ADR O-ADR
doses O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
assessment O-ADR O-ADR
is O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
all O-ADR O-ADR
data O-ADR O-ADR
from O-ADR O-ADR
1203 O-ADR O-ADR
subjects O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Phase O-ADR O-ADR
3 O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
TMC125 O-ADR O-ADR
- O-ADR O-ADR
C206 O-ADR O-ADR
and O-ADR O-ADR
TMC125 O-ADR O-ADR
- O-ADR O-ADR
C216 O-ADR O-ADR
, O-ADR O-ADR
conducted O-ADR O-ADR
in O-ADR O-ADR
antiretroviral O-ADR O-ADR
treatment O-ADR O-ADR
- O-ADR O-ADR
experienced O-ADR O-ADR
HIV O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
infected O-ADR O-ADR
adult O-ADR O-ADR
subjects O-ADR O-ADR
, O-ADR O-ADR
599 O-ADR O-ADR
of O-ADR O-ADR
whom O-ADR O-ADR
received O-ADR O-ADR
INTELENCE O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
( O-ADR O-ADR
200 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
What O-ADR O-ADR
is O-ADR O-ADR
DUAVEE O-ADR O-ADR
used O-ADR O-ADR
for O-ADR O-ADR
? O-ADR O-ADR
Somnolence B-ADR B-ADR
includes O-ADR O-ADR
the O-ADR O-ADR
following O-ADR O-ADR
events O-ADR O-ADR
: O-ADR O-ADR
somnolence B-ADR B-ADR
, O-ADR O-ADR
sedation B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
hypersomnia B-ADR B-ADR
. O-ADR O-ADR
A O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
651 O-ADR O-ADR
pediatric O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
SAPHRIS O-ADR O-ADR
. O-ADR O-ADR
Use O-ADR O-ADR
of O-ADR O-ADR
INVOKANA O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
increased O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
renal B-ADR B-ADR
- O-ADR O-ADR
related O-ADR O-ADR
adverse I-ADR I-ADR
reactions I-ADR I-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
increased B-ADR B-ADR
blood I-ADR I-ADR
creatinine I-ADR I-ADR
, O-ADR O-ADR
decreased B-ADR B-ADR
glomerular I-ADR I-ADR
filtration I-ADR I-ADR
rate I-ADR I-ADR
, O-ADR O-ADR
renal B-ADR B-ADR
impairment I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
acute B-ADR B-ADR
renal I-ADR I-ADR
failure I-ADR I-ADR
) O-ADR O-ADR
, O-ADR O-ADR
particularly O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
moderate O-ADR O-ADR
renal O-ADR O-ADR
impairment O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
3 O-ADR O-ADR
and O-ADR O-ADR
Table O-ADR O-ADR
4 O-ADR O-ADR
present O-ADR O-ADR
adverse O-ADR O-ADR
drug O-ADR O-ADR
reactions O-ADR O-ADR
and O-ADR O-ADR
laboratory O-ADR O-ADR
abnormalities O-ADR O-ADR
identified O-ADR O-ADR
from O-ADR O-ADR
analyses O-ADR O-ADR
of O-ADR O-ADR
Trial O-ADR O-ADR
1 O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Inform O-ADR O-ADR
patients O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
anaphylaxis O-ADR O-ADR
and O-ADR O-ADR
have O-ADR O-ADR
them O-ADR O-ADR
seek O-ADR O-ADR
immediate O-ADR O-ADR
medical O-ADR O-ADR
care O-ADR O-ADR
should O-ADR O-ADR
symptoms O-ADR O-ADR
occur O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
for O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
during O-ADR O-ADR
therapy O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Impairment B-ADR B-ADR
in I-ADR I-ADR
Renal I-ADR I-ADR
Function I-ADR I-ADR
: O-ADR O-ADR
Monitor O-ADR O-ADR
renal O-ADR O-ADR
function O-ADR O-ADR
during O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
Permanent O-ADR O-ADR
discontinuation O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
an O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
34 O-ADR O-ADR
/ O-ADR O-ADR
359 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
receiving O-ADR O-ADR
INLYTA O-ADR O-ADR
and O-ADR O-ADR
46 O-ADR O-ADR
/ O-ADR O-ADR
355 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
13 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
receiving O-ADR O-ADR
sorafenib O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
proportion O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
increase B-ADR B-ADR
in I-ADR I-ADR
body I-ADR I-ADR
weight I-ADR I-ADR
( O-ADR O-ADR
at O-ADR O-ADR
Endpoint O-ADR O-ADR
) O-ADR O-ADR
was O-ADR O-ADR
14 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
5provides O-ADR O-ADR
the O-ADR O-ADR
mean O-ADR O-ADR
weight B-ADR B-ADR
change I-ADR I-ADR
from O-ADR O-ADR
baseline O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
proportion O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
weight B-ADR B-ADR
gain I-ADR I-ADR
of O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
categorized O-ADR O-ADR
by O-ADR O-ADR
Body O-ADR O-ADR
Mass O-ADR O-ADR
Index O-ADR O-ADR
( O-ADR O-ADR
BMI O-ADR O-ADR
) O-ADR O-ADR
at O-ADR O-ADR
baseline O-ADR O-ADR
. O-ADR O-ADR
Hepatobiliary O-ADR O-ADR
disorders O-ADR O-ADR
: O-ADR O-ADR
Elevated B-ADR B-ADR
liver I-ADR I-ADR
enzymes I-ADR I-ADR
and O-ADR O-ADR
hepatitis B-ADR B-ADR
. O-ADR O-ADR
Do O-ADR O-ADR
not O-ADR O-ADR
administer O-ADR O-ADR
COMETRIQ O-ADR O-ADR
to O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
severe O-ADR O-ADR
hemorrhage O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Neurological O-ADR O-ADR
Toxicities O-ADR O-ADR
In O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
BLINCYTO O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
neurological B-ADR B-ADR
toxicities I-ADR I-ADR
have O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
approximately O-ADR O-ADR
50 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Concomitant O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
aspirin O-ADR O-ADR
, O-ADR O-ADR
nonsteroidal O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
inflammatory O-ADR O-ADR
drugs O-ADR O-ADR
, O-ADR O-ADR
warfarin O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
other O-ADR O-ADR
anticoagulants O-ADR O-ADR
may O-ADR O-ADR
add O-ADR O-ADR
to O-ADR O-ADR
this O-ADR O-ADR
risk O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Neutropenia O-ADR O-ADR
and O-ADR O-ADR
Febrile O-ADR O-ADR
Neutropenia O-ADR O-ADR
Neutropenia B-ADR B-ADR
and O-ADR O-ADR
febrile B-ADR B-ADR
neutropenia I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
cases O-ADR O-ADR
, O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
BLINCYTO O-ADR O-ADR
. O-ADR O-ADR
Based O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
experience O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
entire O-ADR O-ADR
clinical O-ADR O-ADR
program O-ADR O-ADR
for O-ADR O-ADR
melanoma O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
and O-ADR O-ADR
severity O-ADR O-ADR
of O-ADR O-ADR
enterocolitis B-ADR B-ADR
and O-ADR O-ADR
hepatitis B-ADR B-ADR
appear O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
dose O-ADR O-ADR
dependent O-ADR O-ADR
. O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
lymphopenia B-ADR B-ADR
( O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
hyperglycemia B-ADR B-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
high B-ADR B-ADR
alanine I-ADR I-ADR
aminotransferase I-ADR I-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
occurred O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
rate O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
ZYTIGA O-ADR O-ADR
arm O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
physician O-ADR O-ADR
responsible O-ADR O-ADR
for O-ADR O-ADR
maintenance O-ADR O-ADR
therapy O-ADR O-ADR
should O-ADR O-ADR
have O-ADR O-ADR
complete O-ADR O-ADR
information O-ADR O-ADR
requisite O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
follow O-ADR O-ADR
- O-ADR O-ADR
up O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Discontinue O-ADR O-ADR
Zydelig O-ADR O-ADR
for O-ADR O-ADR
intestinal O-ADR O-ADR
perforation O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
was O-ADR O-ADR
one O-ADR O-ADR
death B-ADR B-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
arrhythmia B-ADR B-ADR
and O-ADR O-ADR
one O-ADR O-ADR
patient O-ADR O-ADR
with O-ADR O-ADR
sudden B-ADR B-ADR
death I-ADR I-ADR
in O-ADR O-ADR
the O-ADR O-ADR
ZYTIGA O-ADR O-ADR
arms O-ADR O-ADR
and O-ADR O-ADR
no O-ADR O-ADR
deaths B-ADR B-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
arms O-ADR O-ADR
. O-ADR O-ADR
One O-ADR O-ADR
HALAVEN O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patient O-ADR O-ADR
without O-ADR O-ADR
documented O-ADR O-ADR
liver O-ADR O-ADR
metastases O-ADR O-ADR
had O-ADR O-ADR
concomitant O-ADR O-ADR
Grade O-ADR O-ADR
2 O-ADR O-ADR
elevations B-ADR B-ADR
in I-ADR I-ADR
bilirubin I-ADR I-ADR
; O-ADR O-ADR
these O-ADR O-ADR
abnormalities O-ADR O-ADR
resolved O-ADR O-ADR
and O-ADR O-ADR
did O-ADR O-ADR
not O-ADR O-ADR
recur O-ADR O-ADR
with O-ADR O-ADR
re O-ADR O-ADR
- O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
HALAVEN O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
addition O-ADR O-ADR
to O-ADR O-ADR
ADCETRIS O-ADR O-ADR
therapy O-ADR O-ADR
, O-ADR O-ADR
other O-ADR O-ADR
possible O-ADR O-ADR
contributory O-ADR O-ADR
factors O-ADR O-ADR
include O-ADR O-ADR
prior O-ADR O-ADR
therapies O-ADR O-ADR
and O-ADR O-ADR
underlying O-ADR O-ADR
disease O-ADR O-ADR
that O-ADR O-ADR
may O-ADR O-ADR
cause O-ADR O-ADR
immunosuppression O-ADR O-ADR
. O-ADR O-ADR
Bleeding B-ADR B-ADR
events O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
4 O-ADR O-ADR
pivotal O-ADR O-ADR
studies O-ADR O-ADR
were O-ADR O-ADR
classified O-ADR O-ADR
as O-ADR O-ADR
major O-ADR O-ADR
bleeding B-ADR B-ADR
events O-ADR O-ADR
if O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
one O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
following O-ADR O-ADR
criteria O-ADR O-ADR
applied O-ADR O-ADR
: O-ADR O-ADR
fatal B-ADR B-ADR
bleeding B-ADR B-ADR
, O-ADR O-ADR
symptomatic B-ADR B-ADR
bleeding I-ADR I-ADR
in I-ADR I-ADR
a I-ADR I-ADR
critical I-ADR I-ADR
area I-ADR I-ADR
with O-ADR O-ADR
compartment B-ADR B-ADR
syndrome I-ADR I-ADR
, O-ADR O-ADR
retroperitoneal B-ADR B-ADR
bleeding I-ADR I-ADR
, O-ADR O-ADR
intra B-ADR B-ADR
- O-ADR O-ADR
articular O-ADR O-ADR
bleeding I-ADR I-ADR
, O-ADR O-ADR
or O-ADR O-ADR
pericardial B-ADR B-ADR
bleeding I-ADR I-ADR
) O-ADR O-ADR
, O-ADR O-ADR
bleeding B-ADR B-ADR
causing O-ADR O-ADR
a O-ADR O-ADR
fall B-ADR B-ADR
in I-ADR I-ADR
hemoglobin I-ADR I-ADR
level I-ADR I-ADR
of O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
g O-ADR O-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
24 O-ADR O-ADR
mmol O-ADR O-ADR
/ O-ADR O-ADR
L O-ADR O-ADR
or O-ADR O-ADR
more O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
transfusion O-ADR O-ADR
of O-ADR O-ADR
2 O-ADR O-ADR
or O-ADR O-ADR
more O-ADR O-ADR
units O-ADR O-ADR
of O-ADR O-ADR
whole O-ADR O-ADR
blood O-ADR O-ADR
or O-ADR O-ADR
red O-ADR O-ADR
cells O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
11 O-ADR O-ADR
Serious O-ADR O-ADR
Dermatologic O-ADR O-ADR
Reactions O-ADR O-ADR
Stevens B-ADR B-ADR
- O-ADR O-ADR
Johnson O-ADR O-ADR
syndrome I-ADR I-ADR
( O-ADR O-ADR
SJS B-ADR B-ADR
) O-ADR O-ADR
and O-ADR O-ADR
toxic B-ADR B-ADR
epidermal I-ADR I-ADR
necrolysis I-ADR I-ADR
( O-ADR O-ADR
TEN B-ADR B-ADR
) O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
fatal B-ADR B-ADR
outcomes O-ADR O-ADR
, O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
ADCETRIS O-ADR O-ADR
. O-ADR O-ADR
Overall O-ADR O-ADR
, O-ADR O-ADR
59 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
subjects O-ADR O-ADR
were O-ADR O-ADR
men O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
ethnic O-ADR O-ADR
distribution O-ADR O-ADR
was O-ADR O-ADR
64 O-ADR O-ADR
% O-ADR O-ADR
Caucasian O-ADR O-ADR
, O-ADR O-ADR
22 O-ADR O-ADR
% O-ADR O-ADR
Asian O-ADR O-ADR
, O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
Hispanic O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
Black O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
consisted O-ADR O-ADR
of O-ADR O-ADR
other O-ADR O-ADR
ethnic O-ADR O-ADR
groups O-ADR O-ADR
. O-ADR O-ADR
At O-ADR O-ADR
three O-ADR O-ADR
years O-ADR O-ADR
after O-ADR O-ADR
transplantation O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
total O-ADR O-ADR
cholesterol O-ADR O-ADR
, O-ADR O-ADR
HDL O-ADR O-ADR
, O-ADR O-ADR
LDL O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
triglycerides O-ADR O-ADR
were O-ADR O-ADR
176 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
, O-ADR O-ADR
49 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
, O-ADR O-ADR
100 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
141 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
NULOJIX O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
193 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
, O-ADR O-ADR
48 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
, O-ADR O-ADR
106 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
180 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
in O-ADR O-ADR
cyclosporine O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
mean O-ADR O-ADR
age O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
population O-ADR O-ADR
was O-ADR O-ADR
55 O-ADR O-ADR
years O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
older O-ADR O-ADR
than O-ADR O-ADR
75 O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
age O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
QT B-ADR B-ADR
Interval I-ADR I-ADR
Prolongation I-ADR I-ADR
: O-ADR O-ADR
ZYKADIA O-ADR O-ADR
can O-ADR O-ADR
cause O-ADR O-ADR
QTc B-ADR B-ADR
interval I-ADR I-ADR
prolongation I-ADR I-ADR
. O-ADR O-ADR
Most O-ADR O-ADR
patients O-ADR O-ADR
received O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
CIMZIA O-ADR O-ADR
or O-ADR O-ADR
higher O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
clinical O-ADR O-ADR
significance O-ADR O-ADR
of O-ADR O-ADR
this O-ADR O-ADR
increase O-ADR O-ADR
in O-ADR O-ADR
early B-ADR O-ADR
proteinuria I-ADR B-ADR
is O-ADR O-ADR
unknown O-ADR O-ADR
. O-ADR O-ADR
Doses O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
related O-ADR O-ADR
beta2 O-ADR O-ADR
- O-ADR O-ADR
adrenoceptor O-ADR O-ADR
agonist O-ADR O-ADR
albuterol O-ADR O-ADR
, O-ADR O-ADR
when O-ADR O-ADR
administered O-ADR O-ADR
intravenously O-ADR O-ADR
, O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
to O-ADR O-ADR
aggravate B-ADR O-ADR
preexisting I-ADR O-ADR
diabetes I-ADR I-ADR
mellitus I-ADR I-ADR
. O-ADR O-ADR
Advise O-ADR O-ADR
patients O-ADR O-ADR
to O-ADR O-ADR
refrain O-ADR O-ADR
from O-ADR O-ADR
driving O-ADR O-ADR
and O-ADR O-ADR
engaging O-ADR O-ADR
in O-ADR O-ADR
hazardous O-ADR O-ADR
occupations O-ADR O-ADR
or O-ADR O-ADR
activities O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
operating O-ADR O-ADR
heavy O-ADR O-ADR
or O-ADR O-ADR
potentially O-ADR O-ADR
dangerous O-ADR O-ADR
machinery O-ADR O-ADR
while O-ADR O-ADR
BLINCYTO O-ADR O-ADR
is O-ADR O-ADR
being O-ADR O-ADR
administered O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
serious O-ADR O-ADR
GI B-ADR B-ADR
events I-ADR I-ADR
was O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TECFIDERA O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
, O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Myelosuppression O-ADR O-ADR
TREANDA O-ADR O-ADR
caused O-ADR O-ADR
severe O-ADR O-ADR
myelosuppression B-ADR B-ADR
( O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
98 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
two O-ADR O-ADR
NHL O-ADR O-ADR
studies O-ADR O-ADR
( O-ADR O-ADR
see O-ADR O-ADR
Table O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
frequent O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
that O-ADR O-ADR
led O-ADR O-ADR
to O-ADR O-ADR
dose O-ADR O-ADR
reduction O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
XALKORI O-ADR O-ADR
were O-ADR O-ADR
ALT B-ADR B-ADR
) I-ADR I-ADR
elevation I-ADR I-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
including O-ADR O-ADR
some O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
concurrent O-ADR O-ADR
AST B-ADR B-ADR
) I-ADR I-ADR
elevation I-ADR I-ADR
, O-ADR O-ADR
QTc B-ADR B-ADR
prolongation I-ADR I-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
neutropenia B-ADR B-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Additionally O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
adjusted O-ADR O-ADR
BMD B-ADR B-ADR
declines I-ADR I-ADR
were I-ADR O-ADR
0 I-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% I-ADR O-ADR
at I-ADR O-ADR
the I-ADR O-ADR
femoral I-ADR O-ADR
neck I-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
randomized O-ADR O-ADR
to O-ADR O-ADR
INVOKANA O-ADR O-ADR
300 O-ADR O-ADR
mg O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
If O-ADR O-ADR
irritation O-ADR O-ADR
of O-ADR O-ADR
eyes O-ADR O-ADR
or O-ADR O-ADR
airway O-ADR O-ADR
occurs O-ADR O-ADR
, O-ADR O-ADR
remove O-ADR O-ADR
the O-ADR O-ADR
affected O-ADR O-ADR
individual O-ADR O-ADR
from O-ADR O-ADR
the O-ADR O-ADR
vicinity O-ADR O-ADR
of O-ADR O-ADR
Qutenza O-ADR O-ADR
and O-ADR O-ADR
flush O-ADR O-ADR
the O-ADR O-ADR
mucous O-ADR O-ADR
membranes O-ADR O-ADR
or O-ADR O-ADR
eyes O-ADR O-ADR
with O-ADR O-ADR
water O-ADR O-ADR
. O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
One O-ADR O-ADR
death B-ADR B-ADR
was O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
disseminated B-ADR O-ADR
primary I-ADR B-ADR
herpes I-ADR I-ADR
zoster I-ADR I-ADR
and O-ADR O-ADR
the O-ADR O-ADR
other O-ADR O-ADR
to O-ADR O-ADR
herpes B-ADR B-ADR
simplex I-ADR I-ADR
encephalitis I-ADR I-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
: O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
in O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
Reaction O-ADR O-ADR
Rate O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
2813 O-ADR O-ADR
Nausea B-ADR B-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
Headache B-ADR B-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
Injection B-ADR B-ADR
Site I-ADR I-ADR
Pain I-ADR I-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
Injection B-ADR B-ADR
Site I-ADR I-ADR
Coldness I-ADR I-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
Burning B-ADR O-ADR
Sensation I-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
that O-ADR O-ADR
occurred O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
frequency O-ADR O-ADR
< O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
DOTAREM O-ADR O-ADR
include O-ADR O-ADR
: O-ADR O-ADR
feeling B-ADR B-ADR
cold I-ADR I-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
, O-ADR O-ADR
somnolence B-ADR B-ADR
, O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
dizziness B-ADR B-ADR
, O-ADR O-ADR
vomiting B-ADR B-ADR
, O-ADR O-ADR
pruritus B-ADR B-ADR
, O-ADR O-ADR
paresthesia B-ADR B-ADR
, O-ADR O-ADR
dysgeusia B-ADR B-ADR
, O-ADR O-ADR
pain B-ADR B-ADR
in I-ADR I-ADR
extremity I-ADR I-ADR
, O-ADR O-ADR
anxiety B-ADR B-ADR
, O-ADR O-ADR
hypertension B-ADR B-ADR
, O-ADR O-ADR
palpitations B-ADR B-ADR
, O-ADR O-ADR
oropharyngeal B-ADR B-ADR
discomfort I-ADR I-ADR
, O-ADR O-ADR
serum B-ADR B-ADR
creatinine I-ADR I-ADR
increased I-ADR I-ADR
and O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
reactions I-ADR I-ADR
. O-ADR O-ADR
Dysphagia B-ADR B-ADR
may O-ADR O-ADR
persist O-ADR O-ADR
for O-ADR O-ADR
several O-ADR O-ADR
months O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
require O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
feeding O-ADR O-ADR
tube O-ADR O-ADR
to O-ADR O-ADR
maintain O-ADR O-ADR
adequate O-ADR O-ADR
nutrition O-ADR O-ADR
and O-ADR O-ADR
hydration O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Tardive O-ADR O-ADR
Dyskinesia O-ADR O-ADR
Tardive B-ADR B-ADR
dyskinesia I-ADR I-ADR
is O-ADR O-ADR
a O-ADR O-ADR
syndrome O-ADR O-ADR
consisting O-ADR O-ADR
of O-ADR O-ADR
potentially O-ADR O-ADR
irreversible O-ADR O-ADR
, O-ADR O-ADR
involuntary B-ADR B-ADR
, I-ADR I-ADR
dyskinetic I-ADR I-ADR
movements I-ADR I-ADR
, O-ADR O-ADR
which O-ADR O-ADR
may O-ADR O-ADR
develop O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
antipsychotic O-ADR O-ADR
drugs O-ADR O-ADR
. O-ADR O-ADR
None O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
subjects O-ADR O-ADR
tested O-ADR O-ADR
positive O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Using O-ADR O-ADR
estrogens O-ADR O-ADR
may O-ADR O-ADR
increase O-ADR O-ADR
your O-ADR O-ADR
chance O-ADR O-ADR
of O-ADR O-ADR
getting O-ADR O-ADR
dementia O-ADR O-ADR
, O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
a O-ADR O-ADR
study O-ADR O-ADR
of O-ADR O-ADR
women O-ADR O-ADR
65 O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
age O-ADR O-ADR
or O-ADR O-ADR
older O-ADR O-ADR
. O-ADR O-ADR
Withhold O-ADR O-ADR
Kyprolis O-ADR O-ADR
for O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
or O-ADR O-ADR
4 O-ADR O-ADR
cardiac O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
until O-ADR O-ADR
recovery O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
consider O-ADR O-ADR
whether O-ADR O-ADR
to O-ADR O-ADR
restart O-ADR O-ADR
Kyprolis O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
dose O-ADR O-ADR
level O-ADR O-ADR
reduction O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
a O-ADR O-ADR
benefit O-ADR O-ADR
/ O-ADR O-ADR
risk O-ADR O-ADR
assessment O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Approximately O-ADR O-ADR
1000 O-ADR O-ADR
patients O-ADR O-ADR
received O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
2 O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
GILENYA O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
symptoms O-ADR O-ADR
is O-ADR O-ADR
probably O-ADR O-ADR
greatest O-ADR O-ADR
in O-ADR O-ADR
children O-ADR O-ADR
treated O-ADR O-ADR
for O-ADR O-ADR
spasticity O-ADR O-ADR
but O-ADR O-ADR
symptoms O-ADR O-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
in O-ADR O-ADR
adults O-ADR O-ADR
treated O-ADR O-ADR
for O-ADR O-ADR
spasticity O-ADR O-ADR
and O-ADR O-ADR
other O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
particularly O-ADR O-ADR
in O-ADR O-ADR
those O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
have O-ADR O-ADR
underlying O-ADR O-ADR
conditions O-ADR O-ADR
that O-ADR O-ADR
would O-ADR O-ADR
predispose O-ADR O-ADR
them O-ADR O-ADR
to O-ADR O-ADR
these O-ADR O-ADR
symptoms O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
EMTP O-ADR O-ADR
trial O-ADR O-ADR
enrolled O-ADR O-ADR
1368 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
ALL O-ADR O-ADR
or O-ADR O-ADR
lymphoblastic O-ADR O-ADR
lymphoma O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
ERWINAZE O-ADR O-ADR
after O-ADR O-ADR
developing O-ADR O-ADR
systemic O-ADR O-ADR
hypersensitivity O-ADR O-ADR
to O-ADR O-ADR
an O-ADR O-ADR
E O-ADR O-ADR
. O-ADR O-ADR
coli O-ADR O-ADR
- O-ADR O-ADR
derived O-ADR O-ADR
asparaginase O-ADR O-ADR
. O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
drug O-ADR O-ADR
reactions O-ADR O-ADR
of O-ADR O-ADR
moderate O-ADR O-ADR
to O-ADR O-ADR
severe O-ADR O-ADR
intensity O-ADR O-ADR
( O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
which O-ADR O-ADR
occurred O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
higher O-ADR O-ADR
rate O-ADR O-ADR
than O-ADR O-ADR
placebo O-ADR O-ADR
in O-ADR O-ADR
adults O-ADR O-ADR
are O-ADR O-ADR
rash B-ADR B-ADR
and O-ADR O-ADR
peripheral B-ADR B-ADR
neuropathy I-ADR I-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
with O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
100 O-ADR O-ADR
/ O-ADR O-ADR
25 O-ADR O-ADR
with O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
Incidence O-ADR O-ADR
and O-ADR O-ADR
More O-ADR O-ADR
Common O-ADR O-ADR
than O-ADR O-ADR
Placebo O-ADR O-ADR
in O-ADR O-ADR
Subjects O-ADR O-ADR
with O-ADR O-ADR
Asthma O-ADR O-ADR
( O-ADR O-ADR
Trial O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
Adverse O-ADR O-ADR
Reaction O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
100 O-ADR O-ADR
/ O-ADR O-ADR
25 O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
201 O-ADR O-ADR
) O-ADR O-ADR
% O-ADR O-ADR
Fluticasone O-ADR O-ADR
Furoate O-ADR O-ADR
100 O-ADR O-ADR
mcg O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
205 O-ADR O-ADR
) O-ADR O-ADR
% O-ADR O-ADR
Placebo O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
203 O-ADR O-ADR
) O-ADR O-ADR
% O-ADR O-ADR
Infections O-ADR O-ADR
and O-ADR O-ADR
infestations O-ADR O-ADR
Nasopharyngitis B-ADR B-ADR
10 O-ADR O-ADR
7 O-ADR O-ADR
7 O-ADR O-ADR
Oral B-ADR B-ADR
candidiasis I-ADR I-ADR
a O-ADR O-ADR
2 O-ADR O-ADR
2 O-ADR O-ADR
0 O-ADR O-ADR
Nervous O-ADR O-ADR
system O-ADR O-ADR
disorders O-ADR O-ADR
Headache B-ADR B-ADR
5 O-ADR O-ADR
4 O-ADR O-ADR
4 O-ADR O-ADR
Respiratory O-ADR O-ADR
, O-ADR O-ADR
thoracic O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
mediastinal O-ADR O-ADR
disorders O-ADR O-ADR
Oropharyngeal B-ADR B-ADR
pain I-ADR I-ADR
2 O-ADR O-ADR
2 O-ADR O-ADR
1 O-ADR O-ADR
Dysphonia B-ADR B-ADR
2 O-ADR O-ADR
1 O-ADR O-ADR
0 O-ADR O-ADR
a O-ADR O-ADR
Includes O-ADR O-ADR
oral B-ADR B-ADR
candidiasis I-ADR I-ADR
and O-ADR O-ADR
oropharyngeal B-ADR B-ADR
candidiasis I-ADR I-ADR
. O-ADR O-ADR
Renal B-ADR B-ADR
impairment I-ADR I-ADR
as O-ADR O-ADR
a O-ADR O-ADR
consequence O-ADR O-ADR
of O-ADR O-ADR
diarrhea B-ADR B-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
GILOTRIF O-ADR O-ADR
, O-ADR O-ADR
out O-ADR O-ADR
of O-ADR O-ADR
which O-ADR O-ADR
3 O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
Bleeding B-ADR B-ADR
results O-ADR O-ADR
from O-ADR O-ADR
the O-ADR O-ADR
AMPLIFY O-ADR O-ADR
study O-ADR O-ADR
are O-ADR O-ADR
summarized O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
Intracranial B-ADR B-ADR
hemorrhage I-ADR I-ADR
was O-ADR O-ADR
fatal B-ADR B-ADR
in O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
/ O-ADR O-ADR
55 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
TAFINLAR O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
. O-ADR O-ADR
Cases O-ADR O-ADR
of O-ADR O-ADR
active O-ADR B-ADR
tuberculosis O-ADR I-ADR
have O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
subcutaneous O-ADR O-ADR
formulation O-ADR O-ADR
of O-ADR O-ADR
golimumab O-ADR O-ADR
during O-ADR O-ADR
and O-ADR O-ADR
after O-ADR O-ADR
treatment O-ADR O-ADR
for O-ADR O-ADR
latent O-ADR O-ADR
tuberculosis O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
STENDRA O-ADR O-ADR
for O-ADR O-ADR
use O-ADR O-ADR
as O-ADR O-ADR
needed O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
493 O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
exposed O-ADR O-ADR
for O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
or O-ADR O-ADR
equal O-ADR O-ADR
to O-ADR O-ADR
6 O-ADR O-ADR
months O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
153 O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
treated O-ADR O-ADR
for O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
or O-ADR O-ADR
equal O-ADR O-ADR
to O-ADR O-ADR
12 O-ADR O-ADR
months O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
median O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
was O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
days O-ADR O-ADR
in O-ADR O-ADR
both O-ADR O-ADR
treatment O-ADR O-ADR
groups O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
are O-ADR O-ADR
discussed O-ADR O-ADR
in O-ADR O-ADR
more O-ADR O-ADR
detail O-ADR O-ADR
in O-ADR O-ADR
other O-ADR O-ADR
sections O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
labeling O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Hypertension B-ADR B-ADR
, O-ADR O-ADR
Hypokalemia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
Fluid B-ADR B-ADR
Retention I-ADR I-ADR
due O-ADR O-ADR
to O-ADR O-ADR
Mineralocorticoid B-ADR B-ADR
Excess I-ADR I-ADR
[ O-ADR O-ADR
seeWarnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Treatment O-ADR O-ADR
for O-ADR O-ADR
latent O-ADR O-ADR
infection O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
initiated O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
CIMZIA O-ADR O-ADR
use O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Hypersensitivity O-ADR O-ADR
Reactions O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
may O-ADR O-ADR
occur O-ADR O-ADR
within O-ADR O-ADR
a O-ADR O-ADR
few O-ADR O-ADR
minutes O-ADR O-ADR
following O-ADR O-ADR
the O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
infusion O-ADR O-ADR
of O-ADR O-ADR
JEVTANA O-ADR O-ADR
, O-ADR O-ADR
thus O-ADR O-ADR
facilities O-ADR O-ADR
and O-ADR O-ADR
equipment O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
hypotension O-ADR O-ADR
and O-ADR O-ADR
bronchospasm O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
available O-ADR O-ADR
. O-ADR O-ADR
Monitoring O-ADR O-ADR
Closely O-ADR O-ADR
monitor O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
development O-ADR O-ADR
of O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
infection O-ADR O-ADR
during O-ADR O-ADR
and O-ADR O-ADR
after O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
who O-ADR O-ADR
remain O-ADR O-ADR
averse O-ADR O-ADR
to O-ADR O-ADR
food O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
closely O-ADR O-ADR
monitored O-ADR O-ADR
as O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
recrudescence O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
greater O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
If O-ADR O-ADR
members O-ADR O-ADR
of O-ADR O-ADR
your O-ADR O-ADR
family O-ADR O-ADR
have O-ADR O-ADR
had O-ADR O-ADR
breast O-ADR O-ADR
cancer O-ADR O-ADR
or O-ADR O-ADR
if O-ADR O-ADR
you O-ADR O-ADR
have O-ADR O-ADR
ever O-ADR O-ADR
had O-ADR O-ADR
breast O-ADR O-ADR
lumps O-ADR O-ADR
or O-ADR O-ADR
an O-ADR O-ADR
abnormal O-ADR O-ADR
mammogram O-ADR O-ADR
, O-ADR O-ADR
you O-ADR O-ADR
may O-ADR O-ADR
need O-ADR O-ADR
to O-ADR O-ADR
have O-ADR O-ADR
breast O-ADR O-ADR
exams O-ADR O-ADR
more O-ADR O-ADR
often O-ADR O-ADR
. O-ADR O-ADR
Test O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
latent O-ADR O-ADR
tuberculosis O-ADR O-ADR
before O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
use O-ADR O-ADR
and O-ADR O-ADR
during O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
Post O-ADR O-ADR
- O-ADR O-ADR
baseline O-ADR O-ADR
QT B-ADR B-ADR
prolongations I-ADR I-ADR
exceeding O-ADR O-ADR
500 O-ADR O-ADR
msec O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
at O-ADR O-ADR
comparable O-ADR O-ADR
rates O-ADR O-ADR
for O-ADR O-ADR
SAPHRIS O-ADR O-ADR
and O-ADR O-ADR
placebo O-ADR O-ADR
in O-ADR O-ADR
these O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
Counsel O-ADR O-ADR
women O-ADR O-ADR
of O-ADR O-ADR
childbearing O-ADR O-ADR
potential O-ADR O-ADR
regarding O-ADR O-ADR
appropriate O-ADR O-ADR
contraceptive O-ADR O-ADR
choices O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
This O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
turn O-ADR O-ADR
, O-ADR O-ADR
may O-ADR O-ADR
inhibit B-ADR B-ADR
reproductive I-ADR I-ADR
function I-ADR I-ADR
by O-ADR O-ADR
impairing B-ADR B-ADR
gonadal I-ADR I-ADR
steroidogenesis I-ADR I-ADR
in O-ADR O-ADR
both O-ADR O-ADR
female O-ADR O-ADR
and O-ADR O-ADR
male O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Lymphoma B-ADR B-ADR
and O-ADR O-ADR
other O-ADR O-ADR
malignancies B-ADR B-ADR
, O-ADR O-ADR
some O-ADR O-ADR
fatal B-ADR B-ADR
, O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
children O-ADR O-ADR
and O-ADR O-ADR
adolescent O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TNF O-ADR O-ADR
blockers O-ADR O-ADR
, O-ADR O-ADR
of O-ADR O-ADR
which O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
is O-ADR O-ADR
a O-ADR O-ADR
member O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
evaluated O-ADR O-ADR
for O-ADR O-ADR
tuberculosis O-ADR O-ADR
risk O-ADR O-ADR
factors O-ADR O-ADR
and O-ADR O-ADR
tested O-ADR O-ADR
for O-ADR O-ADR
latent O-ADR O-ADR
infection O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
initiating O-ADR O-ADR
CIMZIA O-ADR O-ADR
and O-ADR O-ADR
periodically O-ADR O-ADR
during O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
Hyperprolactinemia B-ADR B-ADR
may O-ADR O-ADR
suppress B-ADR B-ADR
hypothalamic I-ADR I-ADR
GnRH I-ADR I-ADR
, O-ADR O-ADR
resulting O-ADR O-ADR
in O-ADR O-ADR
reduced B-ADR B-ADR
pituitary I-ADR I-ADR
gonadotropin I-ADR I-ADR
secretion I-ADR I-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Not O-ADR O-ADR
for O-ADR O-ADR
acute O-ADR O-ADR
use O-ADR O-ADR
: O-ADR O-ADR
Not O-ADR O-ADR
for O-ADR O-ADR
use O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
rescue O-ADR O-ADR
medication O-ADR O-ADR
. O-ADR O-ADR
Severe O-ADR O-ADR
hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
include O-ADR O-ADR
generalized B-ADR B-ADR
rash O-ADR O-ADR
/ O-ADR O-ADR
erythema O-ADR O-ADR
, O-ADR O-ADR
hypotension B-ADR B-ADR
and O-ADR O-ADR
bronchospasm B-ADR B-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
tested O-ADR O-ADR
for O-ADR O-ADR
latent O-ADR O-ADR
tuberculosis O-ADR O-ADR
before O-ADR O-ADR
CIMZIA O-ADR O-ADR
use O-ADR O-ADR
and O-ADR O-ADR
during O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
Infections O-ADR O-ADR
and O-ADR O-ADR
Infestations O-ADR O-ADR
: O-ADR O-ADR
herpes B-ADR B-ADR
zoster I-ADR I-ADR
. O-ADR O-ADR
Skin O-ADR O-ADR
and O-ADR O-ADR
subcutaneous O-ADR O-ADR
tissue O-ADR O-ADR
disorders O-ADR O-ADR
- O-ADR O-ADR
Rash B-ADR B-ADR
, O-ADR O-ADR
alopecia B-ADR B-ADR
, O-ADR O-ADR
photosensitivity B-ADR B-ADR
reaction O-ADR I-ADR
, O-ADR O-ADR
angioedema B-ADR B-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Laboratory O-ADR O-ADR
test O-ADR O-ADR
alterations O-ADR O-ADR
: O-ADR O-ADR
Elevations B-ADR B-ADR
of I-ADR I-ADR
serum I-ADR I-ADR
creatinine I-ADR I-ADR
may O-ADR O-ADR
occur O-ADR O-ADR
. O-ADR O-ADR
Of O-ADR O-ADR
the O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
reported O-ADR O-ADR
neuropathy B-ADR B-ADR
, O-ADR O-ADR
51 O-ADR O-ADR
% O-ADR O-ADR
had O-ADR O-ADR
residual B-ADR O-ADR
neuropathy I-ADR B-ADR
at O-ADR O-ADR
the O-ADR O-ADR
time O-ADR O-ADR
of O-ADR O-ADR
their O-ADR O-ADR
last O-ADR O-ADR
evaluation O-ADR O-ADR
. O-ADR O-ADR
One O-ADR O-ADR
patient O-ADR O-ADR
experienced O-ADR O-ADR
related O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
flushing B-ADR B-ADR
. O-ADR O-ADR
Symptomatic B-ADR B-ADR
hypotension I-ADR I-ADR
may O-ADR O-ADR
occur O-ADR O-ADR
after O-ADR O-ADR
initiating O-ADR O-ADR
JARDIANCE O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
particularly O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
renal O-ADR O-ADR
impairment O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
elderly O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
low O-ADR O-ADR
systolic O-ADR O-ADR
blood O-ADR O-ADR
pressure O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
on O-ADR O-ADR
diuretics O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Takeda O-ADR O-ADR
Pharmaceuticals O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
877 O-ADR O-ADR
- O-ADR O-ADR
TAKEDA O-ADR O-ADR
- O-ADR O-ADR
7 O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
877 O-ADR O-ADR
- O-ADR O-ADR
825 O-ADR O-ADR
- O-ADR O-ADR
3327 O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Postmarketing O-ADR O-ADR
Experience O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
identified O-ADR O-ADR
during O-ADR O-ADR
post O-ADR O-ADR
- O-ADR O-ADR
approval O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
PRISTIQ O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
with O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
100 O-ADR O-ADR
/ O-ADR O-ADR
25 O-ADR O-ADR
with O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
Incidence O-ADR O-ADR
and O-ADR O-ADR
More O-ADR O-ADR
Common O-ADR O-ADR
than O-ADR O-ADR
Placebo O-ADR O-ADR
in O-ADR O-ADR
Subjects O-ADR O-ADR
with O-ADR O-ADR
Chronic O-ADR O-ADR
Obstructive O-ADR O-ADR
Pulmonary O-ADR O-ADR
Disease O-ADR O-ADR
Adverse O-ADR O-ADR
Reaction O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
100 O-ADR O-ADR
/ O-ADR O-ADR
25 O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
410 O-ADR O-ADR
) O-ADR O-ADR
% O-ADR O-ADR
Vilanterol O-ADR O-ADR
25 O-ADR O-ADR
mcg O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
408 O-ADR O-ADR
) O-ADR O-ADR
% O-ADR O-ADR
Fluticasone O-ADR O-ADR
Furoate O-ADR O-ADR
100 O-ADR O-ADR
mcg O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
410 O-ADR O-ADR
) O-ADR O-ADR
% O-ADR O-ADR
Placebo O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
412 O-ADR O-ADR
) O-ADR O-ADR
% O-ADR O-ADR
Infections O-ADR O-ADR
and O-ADR O-ADR
infestations O-ADR O-ADR
Nasopharyngitis B-ADR B-ADR
9 O-ADR O-ADR
10 O-ADR O-ADR
8 O-ADR O-ADR
8 O-ADR O-ADR
Upper B-ADR B-ADR
respiratory I-ADR I-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
7 O-ADR O-ADR
5 O-ADR O-ADR
4 O-ADR O-ADR
3 O-ADR O-ADR
Oropharyngeal B-ADR B-ADR
candidiasis I-ADR I-ADR
a O-ADR O-ADR
5 O-ADR O-ADR
2 O-ADR O-ADR
3 O-ADR O-ADR
2 O-ADR O-ADR
Nervous O-ADR O-ADR
system O-ADR O-ADR
disorders O-ADR O-ADR
Headache B-ADR B-ADR
7 O-ADR O-ADR
9 O-ADR O-ADR
7 O-ADR O-ADR
5 O-ADR O-ADR
a O-ADR O-ADR
Includes O-ADR O-ADR
oral B-ADR B-ADR
candidiasis I-ADR I-ADR
, O-ADR O-ADR
oropharyngeal B-ADR B-ADR
candidiasis I-ADR I-ADR
, O-ADR O-ADR
candidiasis B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
fungal B-ADR B-ADR
oropharyngitis I-ADR I-ADR
. O-ADR O-ADR
Withhold O-ADR O-ADR
GILOTRIF O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
develop O-ADR O-ADR
worsening O-ADR O-ADR
of O-ADR O-ADR
liver O-ADR O-ADR
function O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Discontinue O-ADR O-ADR
TIVICAY O-ADR O-ADR
and O-ADR O-ADR
other O-ADR O-ADR
suspect O-ADR O-ADR
agents O-ADR O-ADR
immediately O-ADR O-ADR
if O-ADR O-ADR
signs O-ADR O-ADR
or O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
hypersensitivity O-ADR O-ADR
reactions O-ADR O-ADR
develop O-ADR O-ADR
( O-ADR O-ADR
including O-ADR O-ADR
, O-ADR O-ADR
but O-ADR O-ADR
not O-ADR O-ADR
limited O-ADR O-ADR
to O-ADR O-ADR
, O-ADR O-ADR
severe O-ADR O-ADR
rash O-ADR O-ADR
or O-ADR O-ADR
rash O-ADR O-ADR
accompanied O-ADR O-ADR
by O-ADR O-ADR
fever O-ADR O-ADR
, O-ADR O-ADR
general O-ADR O-ADR
malaise O-ADR O-ADR
, O-ADR O-ADR
fatigue O-ADR O-ADR
, O-ADR O-ADR
muscle O-ADR O-ADR
or O-ADR O-ADR
joint O-ADR O-ADR
aches O-ADR O-ADR
, O-ADR O-ADR
blisters O-ADR O-ADR
or O-ADR O-ADR
peeling O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
skin O-ADR O-ADR
, O-ADR O-ADR
oral O-ADR O-ADR
blisters O-ADR O-ADR
or O-ADR O-ADR
lesions O-ADR O-ADR
, O-ADR O-ADR
conjunctivitis O-ADR O-ADR
, O-ADR O-ADR
facial O-ADR O-ADR
edema O-ADR O-ADR
, O-ADR O-ADR
hepatitis O-ADR O-ADR
, O-ADR O-ADR
eosinophilia O-ADR B-ADR
, O-ADR O-ADR
angioedema O-ADR B-ADR
, O-ADR O-ADR
difficulty O-ADR B-ADR
breathing O-ADR I-ADR
) O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
QT B-ADR B-ADR
prolongation I-ADR I-ADR
: O-ADR O-ADR
Prolongs B-ADR B-ADR
QT I-ADR I-ADR
interval I-ADR I-ADR
and O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
arrhythmia B-ADR B-ADR
and O-ADR O-ADR
sudden B-ADR B-ADR
death O-ADR I-ADR
- O-ADR O-ADR
consider O-ADR O-ADR
using O-ADR O-ADR
other O-ADR O-ADR
antipsychotics O-ADR O-ADR
first O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
drug O-ADR O-ADR
reactions O-ADR O-ADR
in O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
pediatric O-ADR O-ADR
patients O-ADR O-ADR
are O-ADR O-ADR
rash B-ADR B-ADR
and O-ADR O-ADR
diarrhea B-ADR B-ADR
. O-ADR O-ADR
In O-ADR O-ADR
total O-ADR O-ADR
, O-ADR O-ADR
from O-ADR O-ADR
the O-ADR O-ADR
281 O-ADR O-ADR
subjects O-ADR O-ADR
treated O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
studies O-ADR O-ADR
and O-ADR O-ADR
tested O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
presence O-ADR O-ADR
of O-ADR O-ADR
neutralizing O-ADR O-ADR
antibodies O-ADR O-ADR
, O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
developed O-ADR O-ADR
neutralizing O-ADR O-ADR
antibodies O-ADR O-ADR
after O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Sunovion O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
877 O-ADR O-ADR
- O-ADR O-ADR
737 O-ADR O-ADR
- O-ADR O-ADR
7226 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
224 O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
DUAVEE O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
069 O-ADR O-ADR
patients O-ADR O-ADR
received O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
develop O-ADR O-ADR
HBV O-ADR O-ADR
reactivation O-ADR O-ADR
, O-ADR O-ADR
TNF O-ADR O-ADR
- O-ADR O-ADR
blockers O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
stopped O-ADR O-ADR
and O-ADR O-ADR
antiviral O-ADR O-ADR
therapy O-ADR O-ADR
with O-ADR O-ADR
appropriate O-ADR O-ADR
supportive O-ADR O-ADR
treatment O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
initiated O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Hypersensitivity O-ADR O-ADR
Reactions O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
botulinum O-ADR O-ADR
toxin O-ADR O-ADR
products O-ADR O-ADR
( O-ADR O-ADR
anaphylaxis B-ADR B-ADR
, O-ADR O-ADR
serum B-ADR B-ADR
sickness I-ADR I-ADR
, O-ADR O-ADR
urticaria B-ADR B-ADR
, O-ADR O-ADR
soft B-ADR B-ADR
tissue I-ADR I-ADR
edema I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
dyspnea B-ADR B-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
lists O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
that O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
DOTAREM O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
genital O-ADR O-ADR
mycotic O-ADR O-ADR
infections O-ADR O-ADR
were O-ADR O-ADR
more O-ADR O-ADR
likely O-ADR O-ADR
to O-ADR O-ADR
develop O-ADR O-ADR
genital B-ADR B-ADR
mycotic I-ADR I-ADR
infections I-ADR I-ADR
on O-ADR O-ADR
INVOKANA O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
ECGs O-ADR O-ADR
. O-ADR O-ADR
ARCAPTA O-ADR O-ADR
NEOHALER O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
indicated O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
asthma O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
119 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
CP O-ADR O-ADR
CML O-ADR O-ADR
previously O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
both O-ADR O-ADR
imatinib O-ADR O-ADR
and O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
1 O-ADR O-ADR
additional O-ADR O-ADR
TKI O-ADR O-ADR
who O-ADR O-ADR
had O-ADR O-ADR
a O-ADR O-ADR
median O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
BOSULIF O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
9 O-ADR O-ADR
months O-ADR O-ADR
and O-ADR O-ADR
a O-ADR O-ADR
median O-ADR O-ADR
dose O-ADR O-ADR
intensity O-ADR O-ADR
of O-ADR O-ADR
475 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
day O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
males B-ADR B-ADR
, I-ADR I-ADR
discontinuations I-ADR I-ADR
due I-ADR I-ADR
to I-ADR I-ADR
genital I-ADR I-ADR
mycotic I-ADR I-ADR
infections I-ADR I-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
and O-ADR O-ADR
INVOKANA O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
Skin B-ADR B-ADR
infections I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
erysipelas B-ADR B-ADR
and O-ADR O-ADR
cellulitis B-ADR B-ADR
, O-ADR O-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
hospitalization O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
Prolia O-ADR O-ADR
( O-ADR O-ADR
< O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
placebo O-ADR O-ADR
vs O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
Prolia O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Increased O-ADR O-ADR
Mortality O-ADR O-ADR
In O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
there O-ADR O-ADR
was O-ADR O-ADR
a O-ADR O-ADR
statistically O-ADR O-ADR
significant O-ADR O-ADR
increased B-ADR O-ADR
mortality I-ADR B-ADR
risk O-ADR O-ADR
by O-ADR O-ADR
Week O-ADR O-ADR
120 O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
SIRTURO O-ADR O-ADR
treatment O-ADR O-ADR
group O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
treatment O-ADR O-ADR
group O-ADR O-ADR
( O-ADR O-ADR
9 O-ADR O-ADR
/ O-ADR O-ADR
79 O-ADR O-ADR
( O-ADR O-ADR
11 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
versus O-ADR O-ADR
2 O-ADR O-ADR
/ O-ADR O-ADR
81 O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
p O-ADR O-ADR
- O-ADR O-ADR
value O-ADR O-ADR
= O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
03 O-ADR O-ADR
, O-ADR O-ADR
an O-ADR O-ADR
exact O-ADR O-ADR
95 O-ADR O-ADR
% O-ADR O-ADR
confidence O-ADR O-ADR
interval O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
difference O-ADR O-ADR
[ O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
18 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
] O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Withdrawal O-ADR O-ADR
of O-ADR O-ADR
APTIOM O-ADR O-ADR
: O-ADR O-ADR
Withdraw O-ADR O-ADR
APTIOM O-ADR O-ADR
gradually O-ADR O-ADR
to O-ADR O-ADR
minimize O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
increased O-ADR O-ADR
seizure O-ADR O-ADR
frequency O-ADR O-ADR
and O-ADR O-ADR
status O-ADR O-ADR
epilepticus O-ADR O-ADR
. O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Myelosuppression B-ADR B-ADR
: O-ADR O-ADR
Delay O-ADR O-ADR
or O-ADR O-ADR
reduce O-ADR O-ADR
dose O-ADR O-ADR
. O-ADR O-ADR
Overall O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
therapy O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
was O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
with O-ADR O-ADR
NESINA O-ADR O-ADR
25 O-ADR O-ADR
mg O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
or O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
with O-ADR O-ADR
active O-ADR O-ADR
comparator O-ADR O-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
all O-ADR O-ADR
patients O-ADR O-ADR
developed O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
drug O-ADR O-ADR
antibodies O-ADR O-ADR
, O-ADR O-ADR
associations O-ADR O-ADR
between O-ADR O-ADR
antibody O-ADR O-ADR
titers O-ADR O-ADR
and O-ADR O-ADR
reductions O-ADR O-ADR
in O-ADR O-ADR
treatment O-ADR O-ADR
effect O-ADR O-ADR
or O-ADR O-ADR
the O-ADR O-ADR
occurrence O-ADR O-ADR
of O-ADR O-ADR
anaphylaxis O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
hypersensitivity O-ADR O-ADR
reactions O-ADR O-ADR
could O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
determined O-ADR O-ADR
. O-ADR O-ADR
Life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
anaphylactic B-ADR B-ADR
reactions I-ADR I-ADR
have O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
some O-ADR O-ADR
patients O-ADR O-ADR
during O-ADR O-ADR
Vimizim O-ADR O-ADR
infusions O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
Elevated O-ADR O-ADR
Liver O-ADR O-ADR
Enzymes O-ADR O-ADR
Treatment O-ADR O-ADR
with O-ADR O-ADR
BLINCYTO O-ADR O-ADR
was O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
transient O-ADR O-ADR
elevations B-ADR B-ADR
in I-ADR I-ADR
liver I-ADR I-ADR
enzymes I-ADR I-ADR
. O-ADR O-ADR
During O-ADR O-ADR
marketing O-ADR O-ADR
of O-ADR O-ADR
SNRIs O-ADR O-ADR
( O-ADR O-ADR
Serotonin O-ADR O-ADR
and O-ADR O-ADR
Norepinephrine O-ADR O-ADR
Reuptake O-ADR O-ADR
Inhibitors O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
SSRIs O-ADR O-ADR
( O-ADR O-ADR
Selective O-ADR O-ADR
Serotonin O-ADR O-ADR
Reuptake O-ADR O-ADR
Inhibitors O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
there O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
spontaneous O-ADR O-ADR
reports O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
occurring O-ADR O-ADR
upon O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
drugs O-ADR O-ADR
, O-ADR O-ADR
particularly O-ADR O-ADR
when O-ADR O-ADR
abrupt O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
the O-ADR O-ADR
following O-ADR O-ADR
: O-ADR O-ADR
dysphoric O-ADR B-ADR
mood O-ADR I-ADR
, O-ADR O-ADR
irritability O-ADR B-ADR
, O-ADR O-ADR
agitation O-ADR B-ADR
, O-ADR O-ADR
dizziness O-ADR B-ADR
, O-ADR O-ADR
sensory O-ADR B-ADR
disturbances O-ADR I-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
paresthesia O-ADR B-ADR
, O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
electric O-ADR B-ADR
shock O-ADR I-ADR
sensations O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
anxiety O-ADR B-ADR
, O-ADR O-ADR
confusion O-ADR B-ADR
, O-ADR O-ADR
headache O-ADR B-ADR
, O-ADR O-ADR
lethargy O-ADR O-ADR
, O-ADR O-ADR
emotional O-ADR B-ADR
lability O-ADR O-ADR
, O-ADR O-ADR
insomnia O-ADR B-ADR
, O-ADR O-ADR
hypomania O-ADR B-ADR
, O-ADR O-ADR
tinnitus O-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
seizures O-ADR B-ADR
. O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Eli O-ADR O-ADR
Lilly O-ADR O-ADR
and O-ADR O-ADR
Company O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
LillyRx O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
545 O-ADR O-ADR
- O-ADR O-ADR
5979 O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
Experience O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
drug O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
drug O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
of O-ADR O-ADR
first B-ADR B-ADR
degree I-ADR I-ADR
AV I-ADR I-ADR
block I-ADR I-ADR
occurred O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TRULICITY O-ADR O-ADR
than O-ADR O-ADR
placebo O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
TRULICITY O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
75 O-ADR O-ADR
mg O-ADR O-ADR
and O-ADR O-ADR
TRULICITY O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Cases O-ADR O-ADR
with O-ADR O-ADR
serum B-ADR B-ADR
sodium I-ADR I-ADR
lower I-ADR I-ADR
than I-ADR I-ADR
110 I-ADR I-ADR
mmol I-ADR I-ADR
/ O-ADR O-ADR
L O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
that O-ADR O-ADR
led O-ADR O-ADR
to O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
Zydelig O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
11 O-ADR O-ADR
( O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
subjects O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Osteonecrosis B-ADR B-ADR
of I-ADR I-ADR
the I-ADR I-ADR
jaw I-ADR I-ADR
: O-ADR O-ADR
Discontinue O-ADR O-ADR
COMETRIQ O-ADR O-ADR
. O-ADR O-ADR
Skin O-ADR O-ADR
and O-ADR O-ADR
subcutaneous O-ADR O-ADR
tissue O-ADR O-ADR
disorders O-ADR O-ADR
: O-ADR O-ADR
Dermatitis B-ADR B-ADR
, O-ADR O-ADR
erythema B-ADR B-ADR
nodosum I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
urticaria B-ADR B-ADR
. O-ADR O-ADR
Dose O-ADR O-ADR
modification O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
vomiting B-ADR B-ADR
, O-ADR O-ADR
or O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
38 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
COCs O-ADR O-ADR
increases O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
venous B-ADR B-ADR
thromboembolism I-ADR I-ADR
. O-ADR O-ADR
The O-ADR O-ADR
skin B-ADR B-ADR
discoloration I-ADR I-ADR
is O-ADR O-ADR
generally O-ADR O-ADR
described O-ADR O-ADR
as O-ADR O-ADR
blue O-ADR O-ADR
, O-ADR O-ADR
but O-ADR O-ADR
has O-ADR O-ADR
also O-ADR O-ADR
been O-ADR O-ADR
described O-ADR O-ADR
as O-ADR O-ADR
grey O-ADR O-ADR
- O-ADR O-ADR
blue O-ADR O-ADR
or O-ADR O-ADR
brown O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
pancreatitis O-ADR O-ADR
is O-ADR O-ADR
confirmed O-ADR O-ADR
, O-ADR O-ADR
TRULICITY O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
restarted O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
radiation O-ADR O-ADR
dose O-ADR O-ADR
to O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
severe O-ADR O-ADR
renal O-ADR O-ADR
impairment O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
increased O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
delayed O-ADR O-ADR
elimination O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
drug O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Serious O-ADR O-ADR
Infections O-ADR O-ADR
and O-ADR O-ADR
Opportunistic O-ADR O-ADR
Infections O-ADR O-ADR
Serious O-ADR O-ADR
infections B-ADR B-ADR
and O-ADR O-ADR
opportunistic B-ADR B-ADR
infections I-ADR I-ADR
such O-ADR O-ADR
as O-ADR O-ADR
pneumonia B-ADR B-ADR
, O-ADR O-ADR
bacteremia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
sepsis B-ADR B-ADR
or O-ADR O-ADR
septic B-ADR B-ADR
shock I-ADR I-ADR
( O-ADR O-ADR
including O-ADR O-ADR
fatal B-ADR B-ADR
outcomes O-ADR O-ADR
) O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
ADCETRIS O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
Transferring O-ADR O-ADR
Patients O-ADR O-ADR
from O-ADR O-ADR
Systemic O-ADR O-ADR
Corticosteroid O-ADR O-ADR
Therapy O-ADR O-ADR
Particular O-ADR O-ADR
care O-ADR O-ADR
is O-ADR O-ADR
needed O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
transferred O-ADR O-ADR
from O-ADR O-ADR
systemically O-ADR O-ADR
active O-ADR O-ADR
corticosteroids O-ADR O-ADR
to O-ADR O-ADR
inhaled O-ADR O-ADR
corticosteroids O-ADR O-ADR
because O-ADR O-ADR
deaths O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
adrenal O-ADR O-ADR
insufficiency O-ADR O-ADR
have O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
asthma O-ADR O-ADR
during O-ADR O-ADR
and O-ADR O-ADR
after O-ADR O-ADR
transfer O-ADR O-ADR
from O-ADR O-ADR
systemic O-ADR O-ADR
corticosteroids O-ADR O-ADR
to O-ADR O-ADR
less O-ADR O-ADR
systemically O-ADR O-ADR
available O-ADR O-ADR
inhaled O-ADR O-ADR
corticosteroids O-ADR O-ADR
. O-ADR O-ADR
No O-ADR O-ADR
patients O-ADR O-ADR
developed O-ADR O-ADR
malignant B-ADR B-ADR
hypertension I-ADR I-ADR
. O-ADR O-ADR
In O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
population O-ADR O-ADR
had O-ADR O-ADR
a O-ADR O-ADR
median O-ADR O-ADR
age O-ADR O-ADR
of O-ADR O-ADR
53 O-ADR O-ADR
years O-ADR O-ADR
at O-ADR O-ADR
entry O-ADR O-ADR
; O-ADR O-ADR
approximately O-ADR O-ADR
80 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
females O-ADR O-ADR
, O-ADR O-ADR
93 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
Caucasian O-ADR O-ADR
and O-ADR O-ADR
all O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
suffering O-ADR O-ADR
from O-ADR O-ADR
active O-ADR O-ADR
rheumatoid O-ADR O-ADR
arthritis O-ADR O-ADR
, O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
median O-ADR O-ADR
disease O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
years O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
seizures O-ADR O-ADR
were O-ADR O-ADR
excluded O-ADR O-ADR
from O-ADR O-ADR
pre O-ADR O-ADR
- O-ADR O-ADR
marketing O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
. O-ADR O-ADR
Immunogenicity O-ADR O-ADR
Across O-ADR O-ADR
four O-ADR O-ADR
Phase O-ADR O-ADR
2 O-ADR O-ADR
and O-ADR O-ADR
five O-ADR O-ADR
Phase O-ADR O-ADR
3 O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
64 O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
TRULICITY O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
developed O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
drug O-ADR O-ADR
antibodies O-ADR O-ADR
( O-ADR O-ADR
ADAs O-ADR O-ADR
) O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
active O-ADR O-ADR
ingredient O-ADR O-ADR
in O-ADR O-ADR
TRULICITY O-ADR O-ADR
( O-ADR O-ADR
i O-ADR O-ADR
. O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
dulaglutide O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
population O-ADR O-ADR
with O-ADR O-ADR
RLS O-ADR O-ADR
ranged O-ADR O-ADR
from O-ADR O-ADR
18 O-ADR O-ADR
to O-ADR O-ADR
82 O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
age O-ADR O-ADR
, O-ADR O-ADR
with O-ADR O-ADR
60 O-ADR O-ADR
% O-ADR O-ADR
being O-ADR O-ADR
female O-ADR O-ADR
and O-ADR O-ADR
95 O-ADR O-ADR
% O-ADR O-ADR
being O-ADR O-ADR
Caucasian O-ADR O-ADR
. O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
Most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
incidence O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
20 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
are O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
thrombocytopenia B-ADR B-ADR
, O-ADR O-ADR
vomiting B-ADR B-ADR
, O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
, O-ADR O-ADR
anemia B-ADR B-ADR
, O-ADR O-ADR
pyrexia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
fatigue B-ADR B-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Neurological B-ADR B-ADR
Adverse I-ADR I-ADR
Reactions I-ADR I-ADR
: O-ADR O-ADR
Monitor O-ADR O-ADR
for O-ADR O-ADR
dizziness O-ADR O-ADR
, O-ADR O-ADR
disturbance O-ADR O-ADR
in O-ADR O-ADR
gait O-ADR O-ADR
and O-ADR O-ADR
coordination O-ADR O-ADR
, O-ADR O-ADR
somnolence O-ADR O-ADR
, O-ADR O-ADR
fatigue O-ADR O-ADR
, O-ADR O-ADR
cognitive O-ADR O-ADR
dysfunction O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
visual O-ADR O-ADR
changes O-ADR O-ADR
. O-ADR O-ADR
Schizophrenia O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
- O-ADR O-ADR
weeks O-ADR O-ADR
) O-ADR O-ADR
Bipolar O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
weeks O-ADR O-ADR
) O-ADR O-ADR
Placebo O-ADR O-ADR
SAPHRIS O-ADR O-ADR
Placebo O-ADR O-ADR
SAPHRIS5 O-ADR O-ADR
or O-ADR O-ADR
10 O-ADR O-ADR
mgtwice O-ADR O-ADR
daily O-ADR O-ADR
5 O-ADR O-ADR
mgtwice O-ADR O-ADR
daily O-ADR O-ADR
10 O-ADR O-ADR
mgtwice O-ADR O-ADR
daily O-ADR O-ADR
5 O-ADR O-ADR
or O-ADR O-ADR
10 O-ADR O-ADR
mgtwice O-ADR O-ADR
daily O-ADR O-ADR
S O-ADR O-ADR
Change O-ADR O-ADR
from O-ADR O-ADR
Baseline O-ADR O-ADR
( O-ADR O-ADR
kg O-ADR O-ADR
) O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
* O-ADR O-ADR
) O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
( O-ADR O-ADR
348 O-ADR O-ADR
) O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
( O-ADR O-ADR
251 O-ADR O-ADR
) O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
( O-ADR O-ADR
200 O-ADR O-ADR
) O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
( O-ADR O-ADR
532 O-ADR O-ADR
) O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
( O-ADR O-ADR
171 O-ADR O-ADR
) O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
( O-ADR O-ADR
336 O-ADR O-ADR
) O-ADR O-ADR
Proportion O-ADR O-ADR
of O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
Increase B-ADR B-ADR
in I-ADR I-ADR
Body I-ADR I-ADR
Weight I-ADR I-ADR
% O-ADR O-ADR
with O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
increase B-ADR B-ADR
in I-ADR I-ADR
body I-ADR I-ADR
weight I-ADR I-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
Adult O-ADR O-ADR
Patients O-ADR O-ADR
: O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
52 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
, O-ADR O-ADR
double O-ADR O-ADR
- O-ADR O-ADR
blind O-ADR O-ADR
, O-ADR O-ADR
comparator O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
adult O-ADR O-ADR
trial O-ADR O-ADR
that O-ADR O-ADR
included O-ADR O-ADR
primarily O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
schizophrenia O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
mean O-ADR O-ADR
weight B-ADR B-ADR
gain I-ADR I-ADR
from O-ADR O-ADR
baseline O-ADR O-ADR
was O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
kg O-ADR O-ADR
. O-ADR O-ADR
One O-ADR O-ADR
death B-ADR B-ADR
occurred O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
24 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
SIRTURO O-ADR O-ADR
treatment O-ADR O-ADR
period O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
subjects O-ADR O-ADR
did O-ADR O-ADR
not O-ADR O-ADR
receive O-ADR O-ADR
calcium O-ADR O-ADR
and O-ADR O-ADR
vitamin O-ADR O-ADR
D O-ADR O-ADR
supplementation O-ADR O-ADR
. O-ADR O-ADR
Males O-ADR O-ADR
represented O-ADR O-ADR
73 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
53 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
adult O-ADR O-ADR
and O-ADR O-ADR
pediatric O-ADR O-ADR
populations O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Asthma O-ADR O-ADR
- O-ADR O-ADR
Related O-ADR O-ADR
Death O-ADR B-ADR
[ O-ADR O-ADR
See O-ADR O-ADR
Boxed O-ADR O-ADR
Warning O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Data O-ADR O-ADR
from O-ADR O-ADR
a O-ADR O-ADR
large O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
study O-ADR O-ADR
in O-ADR O-ADR
asthma O-ADR O-ADR
patients O-ADR O-ADR
showed O-ADR O-ADR
that O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
acting O-ADR O-ADR
beta O-ADR O-ADR
2 O-ADR O-ADR
- O-ADR O-ADR
adrenergic O-ADR O-ADR
agonists O-ADR O-ADR
may O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
asthma O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
death B-ADR B-ADR
. O-ADR O-ADR
Median O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
was O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
months O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
XALKORI O-ADR O-ADR
after O-ADR O-ADR
cross O-ADR O-ADR
over O-ADR O-ADR
from O-ADR O-ADR
chemotherapy O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Occurring O-ADR O-ADR
at O-ADR O-ADR
an O-ADR O-ADR
Incidence O-ADR O-ADR
of O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
or O-ADR O-ADR
More O-ADR O-ADR
Among O-ADR O-ADR
SAPHRIS O-ADR O-ADR
- O-ADR O-ADR
Treated O-ADR O-ADR
( O-ADR O-ADR
Monotherapy O-ADR O-ADR
) O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
Bipolar O-ADR O-ADR
I O-ADR O-ADR
Disorder O-ADR O-ADR
: O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
SAPHRIS O-ADR O-ADR
( O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
or O-ADR O-ADR
greater O-ADR O-ADR
, O-ADR O-ADR
rounded O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
nearest O-ADR O-ADR
percent O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
SAPHRIS O-ADR O-ADR
incidence O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
placebo O-ADR O-ADR
) O-ADR O-ADR
that O-ADR O-ADR
occurred O-ADR O-ADR
during O-ADR O-ADR
acute O-ADR O-ADR
monotherapy O-ADR O-ADR
( O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
weeks O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
bipolar O-ADR O-ADR
mania O-ADR O-ADR
) O-ADR O-ADR
are O-ADR O-ADR
shown O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
9 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
described O-ADR O-ADR
in O-ADR O-ADR
greater O-ADR O-ADR
detail O-ADR O-ADR
in O-ADR O-ADR
other O-ADR O-ADR
sections O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Severe O-ADR O-ADR
hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Adult O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
Schizophrenia O-ADR O-ADR
: O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
findings O-ADR O-ADR
are O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
pre O-ADR O-ADR
- O-ADR O-ADR
marketing O-ADR O-ADR
trials O-ADR O-ADR
for O-ADR O-ADR
schizophrenia O-ADR O-ADR
( O-ADR O-ADR
a O-ADR O-ADR
pool O-ADR O-ADR
of O-ADR O-ADR
three O-ADR O-ADR
6 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
fixed O-ADR O-ADR
- O-ADR O-ADR
dose O-ADR O-ADR
trials O-ADR O-ADR
and O-ADR O-ADR
one O-ADR O-ADR
6 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
flexible O-ADR O-ADR
- O-ADR O-ADR
dose O-ADR O-ADR
trial O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
which O-ADR O-ADR
sublingual O-ADR O-ADR
SAPHRIS O-ADR O-ADR
was O-ADR O-ADR
administered O-ADR O-ADR
in O-ADR O-ADR
doses O-ADR O-ADR
ranging O-ADR O-ADR
from O-ADR O-ADR
5 O-ADR O-ADR
to O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Weight B-ADR B-ADR
Gain I-ADR I-ADR
: O-ADR O-ADR
Weight O-ADR B-ADR
gain O-ADR I-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
. O-ADR O-ADR
Advise O-ADR O-ADR
patients O-ADR O-ADR
to O-ADR O-ADR
contact O-ADR O-ADR
their O-ADR O-ADR
healthcare O-ADR O-ADR
provider O-ADR O-ADR
if O-ADR O-ADR
they O-ADR O-ADR
become O-ADR O-ADR
pregnant O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
if O-ADR O-ADR
pregnancy O-ADR O-ADR
is O-ADR O-ADR
suspected O-ADR O-ADR
, O-ADR O-ADR
while O-ADR O-ADR
taking O-ADR O-ADR
GILOTRIF O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
1and8 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
profile O-ADR O-ADR
of O-ADR O-ADR
CERDELGA O-ADR O-ADR
is O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
two O-ADR O-ADR
controlled O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
Trials O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Neonatal O-ADR O-ADR
Toxicity O-ADR O-ADR
Intravenous O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
products O-ADR O-ADR
containing O-ADR O-ADR
benzyl O-ADR O-ADR
alcohol O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
neonatal B-ADR B-ADR
gasping I-ADR I-ADR
syndrome I-ADR I-ADR
consisting O-ADR O-ADR
of O-ADR O-ADR
severe O-ADR O-ADR
metabolic B-ADR B-ADR
acidosis I-ADR I-ADR
, O-ADR O-ADR
gasping B-ADR B-ADR
respirations I-ADR I-ADR
, O-ADR O-ADR
progressive B-ADR B-ADR
hypotension I-ADR I-ADR
, O-ADR O-ADR
seizures B-ADR B-ADR
, O-ADR O-ADR
central B-ADR B-ADR
nervous I-ADR I-ADR
system I-ADR I-ADR
depression I-ADR I-ADR
, O-ADR O-ADR
intraventricular B-ADR B-ADR
hemorrhage I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
death B-ADR B-ADR
in O-ADR O-ADR
preterm O-ADR O-ADR
, O-ADR O-ADR
low O-ADR O-ADR
birth O-ADR O-ADR
weight O-ADR O-ADR
infants O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Serious O-ADR O-ADR
infections B-ADR B-ADR
and O-ADR O-ADR
opportunistic B-ADR B-ADR
infections I-ADR I-ADR
: O-ADR O-ADR
Closely O-ADR O-ADR
monitor O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
emergence O-ADR O-ADR
of O-ADR O-ADR
bacterial O-ADR O-ADR
, O-ADR O-ADR
fungal O-ADR O-ADR
or O-ADR O-ADR
viral O-ADR O-ADR
infections O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
More O-ADR O-ADR
patients O-ADR O-ADR
experienced O-ADR O-ADR
these O-ADR O-ADR
events O-ADR O-ADR
during O-ADR O-ADR
PRISTIQ O-ADR O-ADR
treatment O-ADR O-ADR
as O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
Concomitant O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
P O-ADR O-ADR
- O-ADR O-ADR
gp O-ADR O-ADR
inhibitors O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
renal O-ADR O-ADR
impairment O-ADR O-ADR
is O-ADR O-ADR
expected O-ADR O-ADR
to O-ADR O-ADR
produce O-ADR O-ADR
increased O-ADR O-ADR
exposure O-ADR O-ADR
of O-ADR O-ADR
dabigatran O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
that O-ADR O-ADR
seen O-ADR O-ADR
with O-ADR O-ADR
either O-ADR O-ADR
factor O-ADR O-ADR
alone O-ADR O-ADR
. O-ADR O-ADR
One O-ADR O-ADR
patient O-ADR O-ADR
discontinued O-ADR O-ADR
treatment O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
potential O-ADR O-ADR
infection B-ADR B-ADR
. O-ADR O-ADR
Common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
gingival B-ADR B-ADR
bleeding I-ADR I-ADR
, O-ADR O-ADR
epistaxis B-ADR B-ADR
, O-ADR O-ADR
contusion B-ADR B-ADR
, O-ADR O-ADR
hematuria B-ADR B-ADR
, O-ADR O-ADR
rectal B-ADR B-ADR
hemorrhage I-ADR I-ADR
, O-ADR O-ADR
hematoma B-ADR B-ADR
, O-ADR O-ADR
menorrhagia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
hemoptysis B-ADR B-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Hypersensitivity O-ADR O-ADR
Reactions O-ADR O-ADR
, O-ADR O-ADR
Including O-ADR O-ADR
Anaphylaxis O-ADR O-ADR
Potentially O-ADR O-ADR
serious O-ADR O-ADR
hypersensitivity B-ADR B-ADR
reactions O-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
anaphylaxis B-ADR B-ADR
, O-ADR O-ADR
have O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
KALBITOR O-ADR O-ADR
. O-ADR O-ADR
Assess O-ADR O-ADR
LVEF O-ADR O-ADR
by O-ADR O-ADR
echocardiogram O-ADR O-ADR
or O-ADR O-ADR
multigated O-ADR O-ADR
acquisition O-ADR O-ADR
( O-ADR O-ADR
MUGA O-ADR O-ADR
) O-ADR O-ADR
scan O-ADR O-ADR
before O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
TAFINLAR O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
, O-ADR O-ADR
one O-ADR O-ADR
month O-ADR O-ADR
after O-ADR O-ADR
initiation O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
then O-ADR O-ADR
at O-ADR O-ADR
2 O-ADR O-ADR
- O-ADR O-ADR
to O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
month O-ADR O-ADR
intervals O-ADR O-ADR
while O-ADR O-ADR
on O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
combination O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
Experience O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
VICTRELIS O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
drug O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Have O-ADR O-ADR
a O-ADR O-ADR
pelvic O-ADR O-ADR
exam O-ADR O-ADR
, O-ADR O-ADR
breast O-ADR O-ADR
exam O-ADR O-ADR
and O-ADR O-ADR
mammogram O-ADR O-ADR
( O-ADR O-ADR
breast O-ADR O-ADR
X O-ADR O-ADR
- O-ADR O-ADR
ray O-ADR O-ADR
) O-ADR O-ADR
every O-ADR O-ADR
year O-ADR O-ADR
unless O-ADR O-ADR
your O-ADR O-ADR
healthcare O-ADR O-ADR
provider O-ADR O-ADR
tells O-ADR O-ADR
you O-ADR O-ADR
something O-ADR O-ADR
else O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Invasive B-ADR B-ADR
fungal I-ADR I-ADR
infections I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
histoplasmosis B-ADR B-ADR
, O-ADR O-ADR
coccidioidomycosis B-ADR B-ADR
, O-ADR O-ADR
candidiasis B-ADR B-ADR
, O-ADR O-ADR
aspergillosis B-ADR B-ADR
, O-ADR O-ADR
blastomycosis B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
pneumocystosis B-ADR B-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
that O-ADR O-ADR
led O-ADR O-ADR
to O-ADR O-ADR
treatment O-ADR O-ADR
discontinuation O-ADR O-ADR
in O-ADR O-ADR
2 O-ADR O-ADR
or O-ADR O-ADR
more O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
peripheral B-ADR B-ADR
sensory I-ADR I-ADR
neuropathy I-ADR I-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
peripheral B-ADR B-ADR
motor I-ADR I-ADR
neuropathy I-ADR I-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
acute B-ADR B-ADR
respiratory I-ADR I-ADR
distress I-ADR I-ADR
syndrome I-ADR I-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
paraesthesia B-ADR B-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
vomiting B-ADR B-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
chronic O-ADR O-ADR
hepatitis O-ADR O-ADR
C O-ADR O-ADR
, O-ADR O-ADR
PROMACTA O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
interferon O-ADR O-ADR
and O-ADR O-ADR
ribavirin O-ADR O-ADR
may O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
hepatic B-ADR B-ADR
decompensation I-ADR I-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
wet O-ADR O-ADR
AMD O-ADR O-ADR
, O-ADR O-ADR
RVO O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
DME O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
pre O-ADR O-ADR
- O-ADR O-ADR
treatment O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
immunoreactivity O-ADR O-ADR
to O-ADR O-ADR
EYLEA O-ADR O-ADR
was O-ADR O-ADR
approximately O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
to O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
across O-ADR O-ADR
treatment O-ADR O-ADR
groups O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
causal O-ADR O-ADR
relationship O-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
established O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
There O-ADR O-ADR
is O-ADR O-ADR
a O-ADR O-ADR
potential O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
arterial B-ADR B-ADR
thromboembolic I-ADR I-ADR
events I-ADR I-ADR
following O-ADR O-ADR
intravitreal O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
VEGF O-ADR O-ADR
inhibitors O-ADR O-ADR
. O-ADR O-ADR
Long O-ADR B-ADR
- O-ADR O-ADR
standing O-ADR O-ADR
hyperprolactinemia B-ADR I-ADR
when O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
hypogonadism B-ADR B-ADR
may O-ADR O-ADR
lead O-ADR O-ADR
to O-ADR O-ADR
decreased B-ADR B-ADR
bone I-ADR I-ADR
density I-ADR I-ADR
in O-ADR O-ADR
both O-ADR O-ADR
female O-ADR O-ADR
and O-ADR O-ADR
male O-ADR O-ADR
subjects O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
include O-ADR O-ADR
aspirin O-ADR O-ADR
and O-ADR O-ADR
other O-ADR O-ADR
antiplatelet O-ADR O-ADR
agents O-ADR O-ADR
, O-ADR O-ADR
other O-ADR O-ADR
anticoagulants O-ADR O-ADR
, O-ADR O-ADR
heparin O-ADR O-ADR
, O-ADR O-ADR
thrombolytic O-ADR O-ADR
agents O-ADR O-ADR
, O-ADR O-ADR
selective O-ADR O-ADR
serotonin O-ADR O-ADR
reuptake O-ADR O-ADR
inhibitors O-ADR O-ADR
, O-ADR O-ADR
serotonin O-ADR O-ADR
norepinephrine O-ADR O-ADR
reuptake O-ADR O-ADR
inhibitors O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
nonsteroidal O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
inflammatory O-ADR O-ADR
drugs O-ADR O-ADR
( O-ADR O-ADR
NSAIDs O-ADR O-ADR
) O-ADR O-ADR
[ O-ADR O-ADR
seeDrug O-ADR O-ADR
Interactions O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Pheochromocytoma O-ADR O-ADR
and O-ADR O-ADR
Neuroblastoma O-ADR O-ADR
Serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
not O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
AdreView O-ADR O-ADR
clinical O-ADR O-ADR
study O-ADR O-ADR
. O-ADR O-ADR
Use O-ADR O-ADR
with O-ADR O-ADR
caution O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
severe O-ADR O-ADR
hypersensitivity O-ADR O-ADR
to O-ADR O-ADR
milk O-ADR O-ADR
proteins O-ADR O-ADR
. O-ADR O-ADR
After O-ADR O-ADR
dosing O-ADR O-ADR
with O-ADR O-ADR
EYLEA O-ADR O-ADR
for O-ADR O-ADR
24 O-ADR O-ADR
- O-ADR O-ADR
100 O-ADR O-ADR
weeks O-ADR O-ADR
, O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
EYLEA O-ADR O-ADR
were O-ADR O-ADR
detected O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
similar O-ADR O-ADR
percentage O-ADR O-ADR
range O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
83 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
White O-ADR O-ADR
, O-ADR O-ADR
13 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
Black O-ADR O-ADR
, O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
Asian O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
Hispanic O-ADR O-ADR
. O-ADR O-ADR
Instruct O-ADR O-ADR
patients O-ADR O-ADR
to O-ADR O-ADR
consult O-ADR O-ADR
a O-ADR O-ADR
physician O-ADR O-ADR
immediately O-ADR O-ADR
should O-ADR O-ADR
any O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
signs O-ADR O-ADR
or O-ADR O-ADR
symptoms O-ADR O-ADR
develop O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
commonly O-ADR O-ADR
reported O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
: O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
reaction I-ADR I-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
drug O-ADR O-ADR
reactions O-ADR O-ADR
listed O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
showed O-ADR O-ADR
higher O-ADR O-ADR
rates O-ADR O-ADR
than O-ADR O-ADR
placebo O-ADR O-ADR
from O-ADR O-ADR
both O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
reactions O-ADR O-ADR
either O-ADR O-ADR
resolved O-ADR O-ADR
spontaneously O-ADR O-ADR
or O-ADR O-ADR
following O-ADR O-ADR
the O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
corticosteroids O-ADR O-ADR
and O-ADR O-ADR
antihistamines O-ADR O-ADR
. O-ADR O-ADR
More O-ADR O-ADR
frequent O-ADR O-ADR
monitoring O-ADR O-ADR
is O-ADR O-ADR
recommended O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
eGFR O-ADR O-ADR
below O-ADR O-ADR
60 O-ADR O-ADR
mL O-ADR O-ADR
/ O-ADR O-ADR
min O-ADR O-ADR
/ O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
73 O-ADR O-ADR
m O-ADR O-ADR
2 O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Hypoglycemia B-ADR B-ADR
: O-ADR O-ADR
Consider O-ADR O-ADR
lowering O-ADR O-ADR
the O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
insulin O-ADR O-ADR
secretagogue O-ADR O-ADR
or O-ADR O-ADR
insulin O-ADR O-ADR
to O-ADR O-ADR
reduce O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
hypoglycemia O-ADR O-ADR
when O-ADR O-ADR
initiating O-ADR O-ADR
JARDIANCE O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Genital B-ADR B-ADR
mycotic I-ADR I-ADR
infections I-ADR I-ADR
: O-ADR O-ADR
Monitor O-ADR O-ADR
and O-ADR O-ADR
treat O-ADR O-ADR
as O-ADR O-ADR
appropriate O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Urinary B-ADR B-ADR
tract I-ADR I-ADR
infections I-ADR I-ADR
: O-ADR O-ADR
Monitor O-ADR O-ADR
and O-ADR O-ADR
treat O-ADR O-ADR
as O-ADR O-ADR
appropriate O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Increased B-ADR B-ADR
LDL I-ADR I-ADR
- O-ADR O-ADR
C O-ADR O-ADR
: O-ADR O-ADR
Monitor O-ADR O-ADR
and O-ADR O-ADR
treat O-ADR O-ADR
as O-ADR O-ADR
appropriate O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Macrovascular O-ADR O-ADR
outcomes O-ADR O-ADR
: O-ADR O-ADR
There O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
no O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
establishing O-ADR O-ADR
conclusive O-ADR O-ADR
evidence O-ADR O-ADR
of O-ADR O-ADR
macrovascular O-ADR O-ADR
risk O-ADR O-ADR
reduction O-ADR O-ADR
with O-ADR O-ADR
JARDIANCE O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Hypotension O-ADR O-ADR
JARDIANCE O-ADR O-ADR
causes O-ADR O-ADR
intravascular B-ADR B-ADR
volume I-ADR I-ADR
contraction I-ADR I-ADR
. O-ADR O-ADR
The O-ADR O-ADR
median O-ADR O-ADR
age O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
study O-ADR O-ADR
population O-ADR O-ADR
was O-ADR O-ADR
37 O-ADR O-ADR
years O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
: O-ADR O-ADR
18 O-ADR O-ADR
to O-ADR O-ADR
79 O-ADR O-ADR
years O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
63 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
male O-ADR O-ADR
, O-ADR O-ADR
79 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
White O-ADR O-ADR
, O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
Asian O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
Black O-ADR O-ADR
or O-ADR O-ADR
African O-ADR O-ADR
American O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
Renal O-ADR O-ADR
angiomyolipoma O-ADR O-ADR
with O-ADR O-ADR
TSC O-ADR O-ADR
: O-ADR O-ADR
Most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
( O-ADR O-ADR
incidence O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
30 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
is O-ADR O-ADR
stomatitis B-ADR B-ADR
. O-ADR O-ADR
Decreases B-ADR B-ADR
in I-ADR I-ADR
hemoglobin I-ADR I-ADR
may O-ADR O-ADR
also O-ADR O-ADR
occur O-ADR O-ADR
. O-ADR O-ADR
This O-ADR O-ADR
trial O-ADR O-ADR
did O-ADR O-ADR
not O-ADR O-ADR
have O-ADR O-ADR
a O-ADR O-ADR
placebo O-ADR O-ADR
arm O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
CrCl O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
daily O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
changing O-ADR O-ADR
renal O-ADR O-ADR
function O-ADR O-ADR
and O-ADR O-ADR
adjust O-ADR O-ADR
the O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
ZERBAXA O-ADR O-ADR
accordingly O-ADR O-ADR
. O-ADR O-ADR
Dysphagia B-ADR B-ADR
may O-ADR O-ADR
persist O-ADR O-ADR
for O-ADR O-ADR
several O-ADR O-ADR
weeks O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
require O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
feeding O-ADR O-ADR
tube O-ADR O-ADR
to O-ADR O-ADR
maintain O-ADR O-ADR
adequate O-ADR O-ADR
nutrition O-ADR O-ADR
and O-ADR O-ADR
hydration O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Dyslipidemia B-ADR B-ADR
: O-ADR O-ADR
Undesirable O-ADR B-ADR
alterations O-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
atypical O-ADR O-ADR
antipsychotics O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
to O-ADR O-ADR
CERDELGA O-ADR O-ADR
( O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
126 O-ADR O-ADR
GD1 O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
CERDELGA O-ADR O-ADR
across O-ADR O-ADR
Trials O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
back B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
pain B-ADR B-ADR
in I-ADR I-ADR
extremities I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
upper B-ADR B-ADR
abdominal I-ADR I-ADR
pain I-ADR I-ADR
. O-ADR O-ADR
Advise O-ADR O-ADR
females O-ADR O-ADR
of O-ADR O-ADR
reproductive O-ADR O-ADR
potential O-ADR O-ADR
to O-ADR O-ADR
use O-ADR O-ADR
highly O-ADR O-ADR
effective O-ADR O-ADR
contraception O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
for O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
2 O-ADR O-ADR
weeks O-ADR O-ADR
after O-ADR O-ADR
the O-ADR O-ADR
last O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
GILOTRIF O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Associated O-ADR O-ADR
with O-ADR O-ADR
Discontinuation O-ADR O-ADR
of O-ADR O-ADR
Treatment O-ADR O-ADR
: O-ADR O-ADR
A O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
SAPHRIS O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
discontinued O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
a O-ADR O-ADR
patient O-ADR O-ADR
requires O-ADR O-ADR
antipsychotic O-ADR O-ADR
drug O-ADR O-ADR
treatment O-ADR O-ADR
after O-ADR O-ADR
recovery O-ADR O-ADR
from O-ADR O-ADR
NMS O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
reintroduction O-ADR O-ADR
of O-ADR O-ADR
drug O-ADR O-ADR
therapy O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
carefully O-ADR O-ADR
considered O-ADR O-ADR
. O-ADR O-ADR
Herpes O-ADR O-ADR
Viral O-ADR O-ADR
Infections O-ADR O-ADR
In O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
herpetic B-ADR B-ADR
infections I-ADR I-ADR
was O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
GILENYA O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
and O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
on O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Venous B-ADR B-ADR
Thrombosis I-ADR I-ADR
: O-ADR O-ADR
Thromboprophylaxis O-ADR O-ADR
is O-ADR O-ADR
recommended O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
diagnostic O-ADR O-ADR
evaluation O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
this O-ADR O-ADR
syndrome O-ADR O-ADR
is O-ADR O-ADR
complicated O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Elderly O-ADR O-ADR
Patients O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
randomized O-ADR O-ADR
clinical O-ADR O-ADR
trial O-ADR O-ADR
, O-ADR O-ADR
3 O-ADR O-ADR
of O-ADR O-ADR
131 O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
patients O-ADR O-ADR
< O-ADR O-ADR
65 O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
age O-ADR O-ADR
and O-ADR O-ADR
15 O-ADR O-ADR
of O-ADR O-ADR
240 O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
65 O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
age O-ADR O-ADR
died B-ADR B-ADR
of O-ADR O-ADR
causes O-ADR O-ADR
other O-ADR O-ADR
than O-ADR O-ADR
disease O-ADR O-ADR
progression O-ADR O-ADR
within O-ADR O-ADR
30 O-ADR O-ADR
days O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
last O-ADR O-ADR
cabazitaxel O-ADR O-ADR
dose O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
KALBITOR O-ADR O-ADR
were O-ADR O-ADR
between O-ADR O-ADR
the O-ADR O-ADR
ages O-ADR O-ADR
of O-ADR O-ADR
10 O-ADR O-ADR
and O-ADR O-ADR
78 O-ADR O-ADR
years O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
of O-ADR O-ADR
any O-ADR O-ADR
toxicity O-ADR O-ADR
grade O-ADR O-ADR
reported O-ADR O-ADR
for O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
20 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Phase O-ADR O-ADR
1 O-ADR O-ADR
/ O-ADR O-ADR
2 O-ADR O-ADR
safety O-ADR O-ADR
population O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
546 O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
diarrhea B-ADR B-ADR
( O-ADR O-ADR
82 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
( O-ADR O-ADR
46 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
thrombocytopenia B-ADR B-ADR
( O-ADR O-ADR
41 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
vomiting B-ADR B-ADR
( O-ADR O-ADR
39 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
( O-ADR O-ADR
37 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
( O-ADR O-ADR
35 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
anemia B-ADR B-ADR
( O-ADR O-ADR
27 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
pyrexia B-ADR B-ADR
( O-ADR O-ADR
26 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
fatigue B-ADR B-ADR
( O-ADR O-ADR
24 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
wear O-ADR O-ADR
contact O-ADR O-ADR
lenses O-ADR O-ADR
if O-ADR O-ADR
they O-ADR O-ADR
have O-ADR O-ADR
signs O-ADR O-ADR
or O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
bacterial O-ADR O-ADR
conjunctivitis O-ADR O-ADR
or O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
course O-ADR O-ADR
of O-ADR O-ADR
therapy O-ADR O-ADR
with O-ADR O-ADR
Besivance O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Topical O-ADR O-ADR
Ophthalmic O-ADR O-ADR
Use O-ADR O-ADR
Only O-ADR O-ADR
NOT O-ADR O-ADR
FOR O-ADR O-ADR
INJECTION O-ADR B-ADR
INTO O-ADR O-ADR
THE O-ADR O-ADR
EYE O-ADR O-ADR
. O-ADR O-ADR
TEN O-ADR B-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
for O-ADR O-ADR
rituximab O-ADR O-ADR
( O-ADR O-ADR
see O-ADR O-ADR
rituximab O-ADR O-ADR
package O-ADR O-ADR
insert O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
included O-ADR O-ADR
no O-ADR O-ADR
subjects O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
normal O-ADR O-ADR
renal O-ADR O-ADR
function O-ADR O-ADR
group O-ADR O-ADR
, O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
creatinine O-ADR O-ADR
clearance O-ADR O-ADR
50 O-ADR O-ADR
to O-ADR O-ADR
80 O-ADR O-ADR
mL O-ADR O-ADR
/ O-ADR O-ADR
min O-ADR O-ADR
group O-ADR O-ADR
, O-ADR O-ADR
29 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
creatinine O-ADR O-ADR
clearance O-ADR O-ADR
< O-ADR O-ADR
30 O-ADR O-ADR
mL O-ADR O-ADR
/ O-ADR O-ADR
min O-ADR O-ADR
group O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
29 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
hemodialysis O-ADR O-ADR
group O-ADR O-ADR
. O-ADR O-ADR
Among O-ADR O-ADR
ENTEREG O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
undergoing O-ADR O-ADR
surgeries O-ADR O-ADR
that O-ADR O-ADR
included O-ADR O-ADR
a O-ADR O-ADR
bowel O-ADR O-ADR
resection O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
( O-ADR O-ADR
incidence O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
occurring O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
higher O-ADR O-ADR
frequency O-ADR O-ADR
than O-ADR O-ADR
placebo O-ADR O-ADR
was O-ADR O-ADR
dyspepsia B-ADR B-ADR
( O-ADR O-ADR
ENTEREG O-ADR O-ADR
, O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
; O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
median O-ADR O-ADR
time O-ADR O-ADR
to O-ADR O-ADR
death B-ADR B-ADR
for O-ADR O-ADR
the O-ADR O-ADR
remaining O-ADR O-ADR
eight O-ADR O-ADR
subjects O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
SIRTURO O-ADR O-ADR
treatment O-ADR O-ADR
group O-ADR O-ADR
was O-ADR O-ADR
329 O-ADR O-ADR
days O-ADR O-ADR
after O-ADR O-ADR
last O-ADR O-ADR
intake O-ADR O-ADR
of O-ADR O-ADR
SIRTURO O-ADR O-ADR
. O-ADR O-ADR
To O-ADR O-ADR
manage O-ADR O-ADR
gastrointestinal O-ADR O-ADR
toxicity O-ADR O-ADR
, O-ADR O-ADR
withhold O-ADR O-ADR
, O-ADR O-ADR
dose O-ADR O-ADR
reduce O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
discontinue O-ADR O-ADR
BOSULIF O-ADR O-ADR
as O-ADR O-ADR
necessary O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Postmarketing O-ADR O-ADR
Experience O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
identified O-ADR O-ADR
during O-ADR O-ADR
post O-ADR O-ADR
- O-ADR O-ADR
approval O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
TREANDA O-ADR O-ADR
. O-ADR O-ADR
Symptomatic B-ADR B-ADR
hypotension I-ADR I-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
after O-ADR O-ADR
initiating O-ADR O-ADR
INVOKANA O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
particularly O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
impaired O-ADR O-ADR
renal O-ADR O-ADR
function O-ADR O-ADR
( O-ADR O-ADR
eGFR O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
60 O-ADR O-ADR
mL O-ADR O-ADR
/ O-ADR O-ADR
min O-ADR O-ADR
/ O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
73 O-ADR O-ADR
m O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
elderly O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
on O-ADR O-ADR
either O-ADR O-ADR
diuretics O-ADR O-ADR
or O-ADR O-ADR
medications O-ADR O-ADR
that O-ADR O-ADR
interfere O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
renin O-ADR O-ADR
- O-ADR O-ADR
angiotensin O-ADR O-ADR
- O-ADR O-ADR
aldosterone O-ADR O-ADR
system O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
angiotensin O-ADR O-ADR
- O-ADR O-ADR
converting O-ADR O-ADR
- O-ADR O-ADR
enzyme O-ADR O-ADR
[ O-ADR O-ADR
ACE O-ADR O-ADR
] O-ADR O-ADR
inhibitors O-ADR O-ADR
, O-ADR O-ADR
angiotensin O-ADR O-ADR
receptor O-ADR O-ADR
blockers O-ADR O-ADR
[ O-ADR O-ADR
ARBs O-ADR O-ADR
] O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
low O-ADR O-ADR
systolic O-ADR O-ADR
blood O-ADR O-ADR
pressure O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Hypoglycemia B-ADR B-ADR
: O-ADR O-ADR
When O-ADR O-ADR
an O-ADR O-ADR
insulin O-ADR O-ADR
secretagogue O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
sulfonylurea O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
insulin O-ADR O-ADR
is O-ADR O-ADR
used O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
NESINA O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
lower O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
insulin O-ADR O-ADR
secretagogue O-ADR O-ADR
or O-ADR O-ADR
insulin O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
required O-ADR O-ADR
to O-ADR O-ADR
minimize O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
hypoglycemia O-ADR O-ADR
. O-ADR O-ADR
Hyperglycemia O-ADR O-ADR
and O-ADR O-ADR
Diabetes O-ADR O-ADR
Mellitus O-ADR O-ADR
Hyperglycemia B-ADR B-ADR
, O-ADR O-ADR
in O-ADR O-ADR
some O-ADR O-ADR
cases O-ADR O-ADR
extreme O-ADR O-ADR
and O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
ketoacidosis B-ADR B-ADR
or O-ADR O-ADR
hyperosmolar B-ADR B-ADR
coma I-ADR I-ADR
or O-ADR O-ADR
death B-ADR B-ADR
, O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
atypical O-ADR O-ADR
antipsychotics O-ADR O-ADR
including O-ADR O-ADR
FANAPT O-ADR O-ADR
. O-ADR O-ADR
Other O-ADR O-ADR
serious O-ADR O-ADR
or O-ADR O-ADR
significant O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
controlled O-ADR O-ADR
and O-ADR O-ADR
uncontrolled O-ADR O-ADR
studies O-ADR O-ADR
in O-ADR O-ADR
Crohn O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
disease O-ADR O-ADR
and O-ADR O-ADR
other O-ADR O-ADR
diseases O-ADR O-ADR
, O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
CIMZIA O-ADR O-ADR
at O-ADR O-ADR
doses O-ADR O-ADR
of O-ADR O-ADR
400 O-ADR O-ADR
mg O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
doses O-ADR O-ADR
include O-ADR O-ADR
: O-ADR O-ADR
Blood O-ADR O-ADR
and O-ADR O-ADR
lymphatic O-ADR O-ADR
system O-ADR O-ADR
disorders O-ADR O-ADR
: O-ADR O-ADR
Anemia B-ADR B-ADR
, O-ADR O-ADR
leukopenia B-ADR B-ADR
, O-ADR O-ADR
lymphadenopathy B-ADR B-ADR
, O-ADR O-ADR
pancytopenia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
thrombophilia B-ADR B-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
item O-ADR O-ADR
{ O-ADR O-ADR
Bacterial O-ADR O-ADR
infections O-ADR O-ADR
- O-ADR O-ADR
Prolonged O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
corticosteroids O-ADR O-ADR
may O-ADR O-ADR
suppress B-ADR B-ADR
the I-ADR I-ADR
host I-ADR I-ADR
response I-ADR I-ADR
and O-ADR O-ADR
thus O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
hazard O-ADR O-ADR
of O-ADR O-ADR
secondary B-ADR B-ADR
ocular I-ADR I-ADR
infections I-ADR I-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
YERVOY O-ADR O-ADR
at O-ADR O-ADR
3 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
kg O-ADR O-ADR
were O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
pruritus B-ADR B-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
colitis B-ADR B-ADR
. O-ADR O-ADR
Funduscopic B-ADR B-ADR
abnormalities I-ADR I-ADR
have O-ADR O-ADR
most O-ADR O-ADR
commonly O-ADR O-ADR
been O-ADR O-ADR
described O-ADR O-ADR
as O-ADR O-ADR
perivascular B-ADR B-ADR
pigmentation I-ADR I-ADR
( I-ADR O-ADR
bone I-ADR B-ADR
spicule I-ADR I-ADR
pattern I-ADR I-ADR
) I-ADR O-ADR
in I-ADR O-ADR
the I-ADR O-ADR
retinal I-ADR O-ADR
periphery I-ADR I-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
as O-ADR O-ADR
areas O-ADR B-ADR
of O-ADR O-ADR
focal B-ADR B-ADR
retinal I-ADR I-ADR
pigment I-ADR I-ADR
epithelium I-ADR I-ADR
clumping I-ADR I-ADR
. O-ADR O-ADR
If O-ADR O-ADR
infectious O-ADR O-ADR
etiologies O-ADR O-ADR
are O-ADR O-ADR
not O-ADR O-ADR
considered O-ADR O-ADR
, O-ADR O-ADR
there O-ADR O-ADR
is O-ADR O-ADR
a O-ADR O-ADR
risk O-ADR O-ADR
that O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
infectious O-ADR O-ADR
etiologies O-ADR O-ADR
will O-ADR O-ADR
not O-ADR O-ADR
receive O-ADR O-ADR
the O-ADR O-ADR
appropriate O-ADR O-ADR
therapy O-ADR O-ADR
and O-ADR O-ADR
their O-ADR O-ADR
disease O-ADR O-ADR
may O-ADR O-ADR
worsen O-ADR O-ADR
. O-ADR O-ADR
PRISTIQ O-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
systematically O-ADR O-ADR
evaluated O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
seizure O-ADR O-ADR
disorder O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
major O-ADR O-ADR
bleeds B-ADR B-ADR
was O-ADR O-ADR
similar O-ADR O-ADR
with O-ADR O-ADR
PRADAXA O-ADR O-ADR
150 O-ADR O-ADR
mg O-ADR O-ADR
and O-ADR O-ADR
warfarin O-ADR O-ADR
across O-ADR O-ADR
major O-ADR O-ADR
subgroups O-ADR O-ADR
defined O-ADR O-ADR
by O-ADR O-ADR
baseline O-ADR O-ADR
characteristics O-ADR O-ADR
( O-ADR O-ADR
see O-ADR O-ADR
Figure O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
exception O-ADR O-ADR
of O-ADR O-ADR
age O-ADR O-ADR
, O-ADR O-ADR
where O-ADR O-ADR
there O-ADR O-ADR
was O-ADR O-ADR
a O-ADR O-ADR
trend O-ADR O-ADR
towards O-ADR O-ADR
a O-ADR O-ADR
higher O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
major O-ADR O-ADR
bleeding B-ADR B-ADR
on O-ADR O-ADR
PRADAXA O-ADR O-ADR
( O-ADR O-ADR
hazard O-ADR O-ADR
ratio O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
95 O-ADR O-ADR
% O-ADR O-ADR
CI O-ADR O-ADR
: O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
to O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
75 O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
age O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Embryofetal B-ADR B-ADR
Toxicity I-ADR I-ADR
: O-ADR O-ADR
ZYKADIA O-ADR O-ADR
may O-ADR O-ADR
cause O-ADR O-ADR
fetal B-ADR B-ADR
harm I-ADR I-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Uterine B-ADR B-ADR
bleeding I-ADR I-ADR
: O-ADR O-ADR
Evaluate O-ADR O-ADR
irregular O-ADR O-ADR
bleeding O-ADR O-ADR
or O-ADR O-ADR
amenorrhea O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
described O-ADR O-ADR
in O-ADR O-ADR
greater O-ADR O-ADR
detail O-ADR O-ADR
in O-ADR O-ADR
other O-ADR O-ADR
sections O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Paradoxical B-ADR B-ADR
bronchospasm I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Worsening B-ADR B-ADR
of I-ADR I-ADR
narrow I-ADR I-ADR
- O-ADR O-ADR
angle O-ADR O-ADR
glaucoma I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Worsening B-ADR B-ADR
of I-ADR I-ADR
urinary I-ADR I-ADR
retention I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Immediate B-ADR O-ADR
Hypersensitivity I-ADR O-ADR
Reactions I-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
Most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
incidence O-ADR O-ADR
and O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
placebo O-ADR O-ADR
) O-ADR O-ADR
are O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
nasopharyngitis B-ADR B-ADR
and O-ADR O-ADR
cough B-ADR B-ADR
. O-ADR O-ADR
The O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
postpartum O-ADR B-ADR
thromboembolism O-ADR I-ADR
decreases O-ADR O-ADR
after O-ADR O-ADR
the O-ADR O-ADR
third O-ADR O-ADR
postpartum O-ADR O-ADR
week O-ADR O-ADR
, O-ADR O-ADR
whereas O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
ovulation O-ADR B-ADR
increases O-ADR O-ADR
after O-ADR O-ADR
the O-ADR O-ADR
third O-ADR O-ADR
postpartum O-ADR O-ADR
week O-ADR O-ADR
. O-ADR O-ADR
Interrupt O-ADR O-ADR
or O-ADR O-ADR
adjust O-ADR O-ADR
dosage O-ADR O-ADR
until O-ADR O-ADR
recovery O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
permanently O-ADR O-ADR
discontinue O-ADR O-ADR
Beleodaq O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
severity O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
hepatic O-ADR O-ADR
toxicity O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
the O-ADR O-ADR
AdreView O-ADR O-ADR
imaging O-ADR O-ADR
information O-ADR O-ADR
is O-ADR O-ADR
essential O-ADR O-ADR
for O-ADR O-ADR
clinical O-ADR O-ADR
care O-ADR O-ADR
, O-ADR O-ADR
consider O-ADR O-ADR
the O-ADR O-ADR
withdrawal O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
following O-ADR O-ADR
categories O-ADR O-ADR
of O-ADR O-ADR
medications O-ADR O-ADR
if O-ADR O-ADR
the O-ADR O-ADR
withdrawal O-ADR O-ADR
can O-ADR O-ADR
be O-ADR O-ADR
accomplished O-ADR O-ADR
safely O-ADR O-ADR
: O-ADR O-ADR
antihypertensives O-ADR O-ADR
that O-ADR O-ADR
deplete O-ADR O-ADR
norepinephrine O-ADR O-ADR
stores O-ADR O-ADR
or O-ADR O-ADR
inhibit O-ADR O-ADR
reuptake O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
reserpine O-ADR O-ADR
, O-ADR O-ADR
labetalol O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
antidepressants O-ADR O-ADR
that O-ADR O-ADR
inhibit O-ADR O-ADR
norepinephrine O-ADR O-ADR
transporter O-ADR O-ADR
function O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
amitriptyline O-ADR O-ADR
and O-ADR O-ADR
derivatives O-ADR O-ADR
, O-ADR O-ADR
imipramine O-ADR O-ADR
and O-ADR O-ADR
derivatives O-ADR O-ADR
, O-ADR O-ADR
selective O-ADR O-ADR
serotonin O-ADR O-ADR
reuptake O-ADR O-ADR
inhibitors O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
sympathomimetic O-ADR O-ADR
amines O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
phenylephrine O-ADR O-ADR
, O-ADR O-ADR
phenylpropanolamine O-ADR O-ADR
, O-ADR O-ADR
pseudoephedrine O-ADR O-ADR
and O-ADR O-ADR
ephedrine O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Out O-ADR O-ADR
of O-ADR O-ADR
715 O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
two O-ADR O-ADR
concurrent O-ADR O-ADR
injections O-ADR O-ADR
of O-ADR O-ADR
XIAFLEX O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
58 O-ADR O-ADR
mg O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
same O-ADR O-ADR
hand O-ADR O-ADR
( O-ADR O-ADR
1450 O-ADR O-ADR
XIAFLEX O-ADR O-ADR
injections O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
Study O-ADR O-ADR
3 O-ADR O-ADR
, O-ADR O-ADR
one O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
patient O-ADR O-ADR
experienced O-ADR O-ADR
a O-ADR O-ADR
tendon B-ADR B-ADR
rupture I-ADR I-ADR
of I-ADR I-ADR
the I-ADR I-ADR
treated I-ADR I-ADR
finger I-ADR I-ADR
within O-ADR O-ADR
3 O-ADR O-ADR
days O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
injection O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Hepatotoxicity B-ADR B-ADR
: O-ADR O-ADR
Increases B-ADR B-ADR
in I-ADR I-ADR
liver I-ADR I-ADR
enzymes I-ADR I-ADR
have O-ADR O-ADR
led O-ADR O-ADR
to O-ADR O-ADR
drug O-ADR O-ADR
interruption O-ADR O-ADR
, O-ADR O-ADR
dose O-ADR O-ADR
modification O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
discontinuation O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Infection B-ADR B-ADR
: O-ADR O-ADR
Serious O-ADR O-ADR
and O-ADR O-ADR
fatal B-ADR B-ADR
infections B-ADR B-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
pneumonia B-ADR B-ADR
and O-ADR O-ADR
sepsis B-ADR B-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Both O-ADR O-ADR
the O-ADR O-ADR
loading O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
400 O-ADR O-ADR
mg O-ADR O-ADR
every O-ADR O-ADR
other O-ADR O-ADR
week O-ADR O-ADR
at O-ADR O-ADR
Weeks O-ADR O-ADR
0 O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
and O-ADR O-ADR
4 O-ADR O-ADR
and O-ADR O-ADR
concomitant O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
MTX O-ADR O-ADR
were O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
reduced O-ADR O-ADR
immunogenicity O-ADR O-ADR
. O-ADR O-ADR
Use O-ADR O-ADR
ZYTIGA O-ADR O-ADR
with O-ADR O-ADR
caution O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
cardiovascular O-ADR O-ADR
disease O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
not O-ADR O-ADR
eligible O-ADR O-ADR
for O-ADR O-ADR
AdreView O-ADR O-ADR
imaging O-ADR O-ADR
if O-ADR O-ADR
they O-ADR O-ADR
were O-ADR O-ADR
receiving O-ADR O-ADR
medications O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
above O-ADR O-ADR
categories O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
risks O-ADR O-ADR
for O-ADR O-ADR
medication O-ADR O-ADR
withdrawal O-ADR O-ADR
were O-ADR O-ADR
unacceptable O-ADR O-ADR
or O-ADR O-ADR
if O-ADR O-ADR
they O-ADR O-ADR
were O-ADR O-ADR
not O-ADR O-ADR
clinically O-ADR O-ADR
stable O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
experiencing O-ADR O-ADR
continuing O-ADR O-ADR
chest O-ADR O-ADR
pain O-ADR O-ADR
, O-ADR O-ADR
hemodynamic O-ADR O-ADR
instability O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
clinically O-ADR O-ADR
significant O-ADR O-ADR
arrhythmia O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
other O-ADR O-ADR
trials O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
Permanently O-ADR O-ADR
discontinue O-ADR O-ADR
YERVOY O-ADR O-ADR
and O-ADR O-ADR
initiate O-ADR O-ADR
systemic O-ADR O-ADR
high O-ADR O-ADR
- O-ADR O-ADR
dose O-ADR O-ADR
corticosteroid O-ADR O-ADR
therapy O-ADR O-ADR
for O-ADR O-ADR
severe O-ADR O-ADR
immune O-ADR O-ADR
- O-ADR O-ADR
mediated O-ADR O-ADR
reactions O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
immune O-ADR O-ADR
- O-ADR O-ADR
mediated O-ADR O-ADR
reactions O-ADR I-ADR
may O-ADR O-ADR
involve O-ADR O-ADR
any O-ADR O-ADR
organ O-ADR O-ADR
system O-ADR O-ADR
; O-ADR O-ADR
however O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
severe O-ADR O-ADR
immune B-ADR B-ADR
- O-ADR O-ADR
mediated O-ADR O-ADR
adverse I-ADR I-ADR
reactions I-ADR I-ADR
are O-ADR O-ADR
enterocolitis B-ADR B-ADR
, O-ADR O-ADR
hepatitis B-ADR B-ADR
, O-ADR O-ADR
dermatitis B-ADR B-ADR
( O-ADR O-ADR
including O-ADR O-ADR
toxic B-ADR B-ADR
epidermal I-ADR I-ADR
necrolysis I-ADR I-ADR
) O-ADR O-ADR
, O-ADR O-ADR
neuropathy B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
endocrinopathy B-ADR B-ADR
. O-ADR O-ADR
Therefore O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
efficacy O-ADR O-ADR
and O-ADR O-ADR
safety O-ADR O-ADR
of O-ADR O-ADR
XIAFLEX O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
anticoagulant O-ADR O-ADR
medications O-ADR O-ADR
( O-ADR O-ADR
other O-ADR O-ADR
than O-ADR O-ADR
low O-ADR O-ADR
- O-ADR O-ADR
dose O-ADR O-ADR
aspirin O-ADR O-ADR
, O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
150 O-ADR O-ADR
mg O-ADR O-ADR
per O-ADR O-ADR
day O-ADR O-ADR
) O-ADR O-ADR
within O-ADR O-ADR
7 O-ADR O-ADR
days O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
XIAFLEX O-ADR O-ADR
administration O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
known O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
, O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Hepatotoxicity O-ADR O-ADR
Drug O-ADR O-ADR
- O-ADR O-ADR
induced O-ADR O-ADR
hepatotoxicity B-ADR B-ADR
with O-ADR O-ADR
fatal B-ADR B-ADR
outcome O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
2 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
1669 O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
XALKORI O-ADR O-ADR
across O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
NSCLC O-ADR O-ADR
. O-ADR O-ADR
pneumonia O-ADR O-ADR
, O-ADR O-ADR
systemic O-ADR O-ADR
infection O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
untreated O-ADR O-ADR
or O-ADR O-ADR
inadequately O-ADR O-ADR
treated O-ADR O-ADR
extrapyramidal O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
( O-ADR O-ADR
EPS O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
acute O-ADR O-ADR
reactions O-ADR O-ADR
requiring O-ADR O-ADR
intervention O-ADR O-ADR
were O-ADR O-ADR
managed O-ADR O-ADR
by O-ADR O-ADR
either O-ADR O-ADR
temporarily O-ADR O-ADR
interrupting O-ADR O-ADR
or O-ADR O-ADR
discontinuing O-ADR O-ADR
infusion O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
administering O-ADR O-ADR
additional O-ADR O-ADR
antihistamine O-ADR O-ADR
, O-ADR O-ADR
antipyretics O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
corticosteroids O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Serious O-ADR O-ADR
asthma O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
events O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
death B-ADR B-ADR
, O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
with O-ADR O-ADR
ARCAPTA O-ADR O-ADR
NEOHALER O-ADR O-ADR
. O-ADR O-ADR
Doses O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
related O-ADR O-ADR
beta2 O-ADR O-ADR
- O-ADR O-ADR
agonist O-ADR O-ADR
albuterol O-ADR O-ADR
, O-ADR O-ADR
when O-ADR O-ADR
administered O-ADR O-ADR
intravenously O-ADR O-ADR
, O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
to O-ADR O-ADR
aggravate B-ADR O-ADR
pre I-ADR O-ADR
- O-ADR O-ADR
existing O-ADR O-ADR
diabetes I-ADR I-ADR
mellitus I-ADR I-ADR
. O-ADR O-ADR
The O-ADR O-ADR
onset O-ADR O-ADR
of O-ADR O-ADR
vision B-ADR B-ADR
disorder I-ADR I-ADR
generally O-ADR O-ADR
was O-ADR O-ADR
within O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
week O-ADR O-ADR
of O-ADR O-ADR
drug O-ADR O-ADR
administration O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
CIMZIA O-ADR O-ADR
( O-ADR O-ADR
for O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
2 O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
higher O-ADR O-ADR
incidence O-ADR O-ADR
than O-ADR O-ADR
placebo O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
CIMZIA O-ADR O-ADR
, O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
placebo O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
CIMZIA O-ADR O-ADR
, O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
placebo O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
intestinal B-ADR B-ADR
obstruction I-ADR I-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
CIMZIA O-ADR O-ADR
, O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
placebo O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Gastrointestinal O-ADR O-ADR
Perforation O-ADR O-ADR
and O-ADR O-ADR
Fistula O-ADR O-ADR
Formation O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
study O-ADR O-ADR
with O-ADR O-ADR
INLYTA O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
RCC O-ADR O-ADR
, O-ADR O-ADR
gastrointestinal B-ADR B-ADR
perforation I-ADR I-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
1 O-ADR O-ADR
/ O-ADR O-ADR
359 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
receiving O-ADR O-ADR
INLYTA O-ADR O-ADR
and O-ADR O-ADR
none O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
sorafenib O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
monotherapy O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
Edarbi O-ADR O-ADR
80 O-ADR O-ADR
mg O-ADR O-ADR
daily O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
on O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
Discontinue O-ADR O-ADR
for O-ADR O-ADR
life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
cutaneous O-ADR O-ADR
reactions O-ADR O-ADR
. O-ADR O-ADR
Other O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Observed O-ADR O-ADR
During O-ADR O-ADR
the O-ADR O-ADR
Premarketing O-ADR O-ADR
Evaluation O-ADR O-ADR
of O-ADR O-ADR
SAPHRIS O-ADR O-ADR
: O-ADR O-ADR
Following O-ADR O-ADR
is O-ADR O-ADR
a O-ADR O-ADR
list O-ADR O-ADR
of O-ADR O-ADR
MedDRA O-ADR O-ADR
terms O-ADR O-ADR
that O-ADR O-ADR
reflect O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
reported O-ADR O-ADR
by O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
sublingual O-ADR O-ADR
SAPHRIS O-ADR O-ADR
at O-ADR O-ADR
multiple O-ADR O-ADR
doses O-ADR O-ADR
of O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
during O-ADR O-ADR
any O-ADR O-ADR
phase O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
trial O-ADR O-ADR
within O-ADR O-ADR
the O-ADR O-ADR
database O-ADR O-ADR
of O-ADR O-ADR
adult O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Malignancy O-ADR O-ADR
The O-ADR O-ADR
impact O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
BENLYSTA O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
development O-ADR O-ADR
of O-ADR O-ADR
malignancies B-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
known O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
involvement O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
tongue O-ADR O-ADR
, O-ADR O-ADR
hypopharynx O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
larynx O-ADR O-ADR
occurs O-ADR O-ADR
, O-ADR O-ADR
fesoterodine O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
promptly O-ADR O-ADR
discontinued O-ADR O-ADR
and O-ADR O-ADR
appropriate O-ADR O-ADR
therapy O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
measures O-ADR O-ADR
to O-ADR O-ADR
ensure O-ADR O-ADR
a O-ADR O-ADR
patent O-ADR O-ADR
airway O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
promptly O-ADR O-ADR
provided O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
suicidal B-ADR B-ADR
thoughts I-ADR I-ADR
with O-ADR O-ADR
AEDs O-ADR O-ADR
was O-ADR O-ADR
observed O-ADR O-ADR
as O-ADR O-ADR
early O-ADR O-ADR
as O-ADR O-ADR
1 O-ADR O-ADR
week O-ADR O-ADR
after O-ADR O-ADR
starting O-ADR O-ADR
drug O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
AEDs O-ADR O-ADR
and O-ADR O-ADR
persisted O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
assessed O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
DUAVEE O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
swallowed O-ADR O-ADR
whole O-ADR O-ADR
. O-ADR O-ADR
Closely O-ADR O-ADR
observe O-ADR O-ADR
patients O-ADR O-ADR
during O-ADR O-ADR
and O-ADR O-ADR
after O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
administration O-ADR O-ADR
and O-ADR O-ADR
be O-ADR O-ADR
prepared O-ADR O-ADR
to O-ADR O-ADR
manage O-ADR O-ADR
anaphylaxis O-ADR O-ADR
and O-ADR O-ADR
hypersensitivity O-ADR O-ADR
reactions O-ADR O-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
myocardial O-ADR B-ADR
infarction O-ADR I-ADR
with O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
use O-ADR O-ADR
, O-ADR O-ADR
ENTEREG O-ADR O-ADR
is O-ADR O-ADR
available O-ADR O-ADR
only O-ADR O-ADR
through O-ADR O-ADR
a O-ADR O-ADR
restricted O-ADR O-ADR
program O-ADR O-ADR
for O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
use O-ADR O-ADR
( O-ADR O-ADR
15 O-ADR O-ADR
doses O-ADR O-ADR
) O-ADR O-ADR
under O-ADR O-ADR
a O-ADR O-ADR
Risk O-ADR O-ADR
Evaluation O-ADR O-ADR
and O-ADR O-ADR
Mitigation O-ADR O-ADR
Strategy O-ADR O-ADR
( O-ADR O-ADR
REMS O-ADR O-ADR
) O-ADR O-ADR
called O-ADR O-ADR
the O-ADR O-ADR
ENTEREG O-ADR O-ADR
Access O-ADR O-ADR
Support O-ADR O-ADR
and O-ADR O-ADR
Education O-ADR O-ADR
( O-ADR O-ADR
E O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
. O-ADR O-ADR
S O-ADR O-ADR
. O-ADR O-ADR
E O-ADR O-ADR
. O-ADR O-ADR
Severe O-ADR O-ADR
acute O-ADR B-ADR
exacerbations O-ADR I-ADR
of O-ADR I-ADR
hepatitis O-ADR I-ADR
B O-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
are O-ADR O-ADR
coinfected O-ADR O-ADR
with O-ADR O-ADR
HBV O-ADR O-ADR
and O-ADR O-ADR
HIV O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
have O-ADR O-ADR
discontinued O-ADR O-ADR
emtricitabine O-ADR O-ADR
or O-ADR O-ADR
tenofovir O-ADR O-ADR
DF O-ADR O-ADR
, O-ADR O-ADR
two O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
components O-ADR O-ADR
of O-ADR O-ADR
STRIBILD O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
majority O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
cases O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
in O-ADR O-ADR
women O-ADR O-ADR
. O-ADR O-ADR
Safety O-ADR O-ADR
results O-ADR O-ADR
are O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
a O-ADR O-ADR
median O-ADR O-ADR
follow O-ADR O-ADR
- O-ADR O-ADR
up O-ADR O-ADR
of O-ADR O-ADR
approximately O-ADR O-ADR
13 O-ADR O-ADR
months O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
median O-ADR O-ADR
time O-ADR O-ADR
between O-ADR O-ADR
diagnosis O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
cuSCC B-ADR B-ADR
and O-ADR O-ADR
the O-ADR O-ADR
second O-ADR O-ADR
cuSCC B-ADR B-ADR
was O-ADR O-ADR
6 O-ADR O-ADR
weeks O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
10 O-ADR O-ADR
Glucose O-ADR O-ADR
- O-ADR O-ADR
6 O-ADR O-ADR
- O-ADR O-ADR
Phosphate O-ADR O-ADR
Dehydrogenase O-ADR O-ADR
Deficiency O-ADR O-ADR
TAFINLAR O-ADR O-ADR
, O-ADR O-ADR
which O-ADR O-ADR
contains O-ADR O-ADR
a O-ADR O-ADR
sulfonamide O-ADR O-ADR
moiety O-ADR O-ADR
, O-ADR O-ADR
confers O-ADR O-ADR
a O-ADR O-ADR
potential O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
hemolytic B-ADR B-ADR
anemia I-ADR I-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
glucose O-ADR O-ADR
- O-ADR O-ADR
6 O-ADR O-ADR
- O-ADR O-ADR
phosphate O-ADR O-ADR
dehydrogenase O-ADR O-ADR
( O-ADR O-ADR
G6PD O-ADR O-ADR
) O-ADR O-ADR
deficiency O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
test O-ADR O-ADR
results O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
ecallantide O-ADR O-ADR
program O-ADR O-ADR
were O-ADR O-ADR
determined O-ADR O-ADR
using O-ADR O-ADR
one O-ADR O-ADR
of O-ADR O-ADR
two O-ADR O-ADR
assay O-ADR O-ADR
formats O-ADR O-ADR
: O-ADR O-ADR
ELISA O-ADR O-ADR
and O-ADR O-ADR
bridging O-ADR O-ADR
electrochemiluminescence O-ADR O-ADR
( O-ADR O-ADR
ECL O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Tumor O-ADR O-ADR
Promotion O-ADR O-ADR
in O-ADR O-ADR
BRAF O-ADR O-ADR
Wild O-ADR O-ADR
- O-ADR O-ADR
Type O-ADR O-ADR
Melanoma O-ADR O-ADR
In O-ADR O-ADR
vitro O-ADR O-ADR
experiments O-ADR O-ADR
have O-ADR O-ADR
demonstrated O-ADR O-ADR
paradoxical O-ADR B-ADR
activation O-ADR I-ADR
of O-ADR I-ADR
MAP O-ADR I-ADR
- O-ADR O-ADR
kinase O-ADR O-ADR
signaling O-ADR I-ADR
and O-ADR O-ADR
increased B-ADR B-ADR
cell I-ADR I-ADR
proliferation I-ADR I-ADR
in O-ADR O-ADR
BRAF O-ADR O-ADR
wild O-ADR O-ADR
- O-ADR O-ADR
type O-ADR O-ADR
cells O-ADR O-ADR
which O-ADR O-ADR
are O-ADR O-ADR
exposed O-ADR O-ADR
to O-ADR O-ADR
BRAF O-ADR O-ADR
inhibitors O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
following O-ADR O-ADR
grade O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
higher O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
65 O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
age O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
younger O-ADR O-ADR
patients O-ADR O-ADR
; O-ADR O-ADR
neutropenia B-ADR B-ADR
( O-ADR O-ADR
87 O-ADR O-ADR
% O-ADR O-ADR
vs O-ADR O-ADR
. O-ADR O-ADR
74 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
febrile B-ADR B-ADR
neutropenia I-ADR I-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
vs O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Evaluate O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
develop O-ADR O-ADR
fever O-ADR O-ADR
and O-ADR O-ADR
lung O-ADR O-ADR
infiltrates O-ADR O-ADR
or O-ADR O-ADR
respiratory O-ADR O-ADR
distress O-ADR O-ADR
after O-ADR O-ADR
receiving O-ADR O-ADR
GRANIX O-ADR O-ADR
, O-ADR O-ADR
for O-ADR O-ADR
ARDS O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
PRISTIQ O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
approved O-ADR O-ADR
for O-ADR O-ADR
use O-ADR O-ADR
in O-ADR O-ADR
pediatric O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
possibility O-ADR O-ADR
that O-ADR O-ADR
GRANIX O-ADR O-ADR
acts O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
growth B-ADR O-ADR
factor I-ADR O-ADR
for I-ADR O-ADR
any I-ADR O-ADR
tumor I-ADR O-ADR
type O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
myeloid B-ADR O-ADR
malignancies I-ADR O-ADR
and O-ADR O-ADR
myelodysplasia B-ADR O-ADR
, O-ADR O-ADR
diseases O-ADR O-ADR
for O-ADR O-ADR
which O-ADR O-ADR
GRANIX O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
approved O-ADR O-ADR
, O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
excluded O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
blood O-ADR O-ADR
pressure O-ADR O-ADR
regularly O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
Crohn O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
disease O-ADR O-ADR
that O-ADR O-ADR
require O-ADR O-ADR
chronic O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
immunosuppressant O-ADR O-ADR
therapies O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
at O-ADR O-ADR
higher O-ADR O-ADR
risk O-ADR O-ADR
than O-ADR O-ADR
the O-ADR O-ADR
general O-ADR O-ADR
population O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
development O-ADR O-ADR
of O-ADR O-ADR
lymphoma B-ADR B-ADR
, O-ADR O-ADR
even O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
absence O-ADR O-ADR
of O-ADR O-ADR
TNF O-ADR O-ADR
blocker O-ADR O-ADR
therapy O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
were O-ADR O-ADR
no O-ADR O-ADR
reports O-ADR O-ADR
of O-ADR O-ADR
seizures B-ADR B-ADR
in O-ADR O-ADR
pediatric O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
SAPHRIS O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
, O-ADR O-ADR
bipolar O-ADR O-ADR
mania O-ADR O-ADR
trial O-ADR O-ADR
. O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
Most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
drug O-ADR O-ADR
reactions O-ADR O-ADR
to O-ADR O-ADR
STRIBILD O-ADR O-ADR
( O-ADR O-ADR
incidence O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
or O-ADR O-ADR
equal O-ADR O-ADR
to O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
all O-ADR O-ADR
grades O-ADR O-ADR
) O-ADR O-ADR
are O-ADR O-ADR
nausea B-ADR B-ADR
and O-ADR O-ADR
diarrhea B-ADR B-ADR
. O-ADR O-ADR
It O-ADR O-ADR
is O-ADR O-ADR
generally O-ADR O-ADR
believed O-ADR O-ADR
( O-ADR O-ADR
though O-ADR O-ADR
not O-ADR O-ADR
established O-ADR O-ADR
in O-ADR O-ADR
controlled O-ADR O-ADR
studies O-ADR O-ADR
) O-ADR O-ADR
that O-ADR O-ADR
treating O-ADR O-ADR
such O-ADR O-ADR
an O-ADR O-ADR
episode O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
antidepressant O-ADR O-ADR
alone O-ADR O-ADR
may O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
likelihood O-ADR O-ADR
of O-ADR O-ADR
precipitation B-ADR O-ADR
of I-ADR O-ADR
a I-ADR O-ADR
mixed I-ADR O-ADR
/ O-ADR O-ADR
manic O-ADR O-ADR
episode I-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
at O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
bipolar O-ADR O-ADR
disorder O-ADR O-ADR
. O-ADR O-ADR
Only O-ADR O-ADR
anemia B-ADR B-ADR
and O-ADR O-ADR
fatigue B-ADR B-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
as O-ADR O-ADR
events O-ADR O-ADR
that O-ADR O-ADR
led O-ADR O-ADR
to O-ADR O-ADR
discontinuation O-ADR O-ADR
in O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
in O-ADR O-ADR
any O-ADR O-ADR
arm O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
usefulness O-ADR O-ADR
of O-ADR O-ADR
hemodialysis O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
prevention O-ADR O-ADR
of O-ADR O-ADR
NSF O-ADR O-ADR
is O-ADR O-ADR
unknown O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
large O-ADR O-ADR
, O-ADR O-ADR
randomized O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
study O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
generalized O-ADR O-ADR
effect B-ADR O-ADR
of I-ADR O-ADR
estrogens I-ADR O-ADR
on I-ADR O-ADR
blood I-ADR O-ADR
pressure I-ADR O-ADR
was O-ADR O-ADR
not O-ADR O-ADR
seen O-ADR O-ADR
. O-ADR O-ADR
Of O-ADR O-ADR
the O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
reported O-ADR O-ADR
neuropathy B-ADR B-ADR
, O-ADR O-ADR
59 O-ADR O-ADR
% O-ADR O-ADR
had O-ADR O-ADR
complete O-ADR O-ADR
resolution O-ADR O-ADR
and O-ADR O-ADR
41 O-ADR O-ADR
% O-ADR O-ADR
had O-ADR O-ADR
residual B-ADR O-ADR
neuropathy I-ADR B-ADR
( O-ADR O-ADR
26 O-ADR O-ADR
% O-ADR O-ADR
partial O-ADR O-ADR
improvement O-ADR O-ADR
, O-ADR O-ADR
15 O-ADR O-ADR
% O-ADR O-ADR
no O-ADR O-ADR
improvement O-ADR O-ADR
) O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
time O-ADR O-ADR
of O-ADR O-ADR
their O-ADR O-ADR
last O-ADR O-ADR
evaluation O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Gilead O-ADR O-ADR
Sciences O-ADR O-ADR
, O-ADR O-ADR
Inc O-ADR O-ADR
. O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
GILEAD O-ADR O-ADR
- O-ADR O-ADR
5 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Hypersensitivity O-ADR O-ADR
Reactions O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
symptoms O-ADR O-ADR
that O-ADR O-ADR
could O-ADR O-ADR
be O-ADR O-ADR
compatible O-ADR O-ADR
with O-ADR O-ADR
hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
rarely O-ADR O-ADR
following O-ADR O-ADR
CIMZIA O-ADR O-ADR
administration O-ADR O-ADR
to O-ADR O-ADR
patients O-ADR O-ADR
: O-ADR O-ADR
angioedema B-ADR B-ADR
, O-ADR O-ADR
dyspnea B-ADR B-ADR
, O-ADR O-ADR
hypotension B-ADR B-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
, O-ADR O-ADR
serum B-ADR B-ADR
sickness I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
urticaria B-ADR B-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
discussed O-ADR O-ADR
in O-ADR O-ADR
greater O-ADR O-ADR
detail O-ADR O-ADR
in O-ADR O-ADR
other O-ADR O-ADR
sections O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
prescribing O-ADR O-ADR
information O-ADR O-ADR
. O-ADR O-ADR
As O-ADR O-ADR
with O-ADR O-ADR
other O-ADR O-ADR
antipsychotic O-ADR O-ADR
drugs O-ADR O-ADR
, O-ADR O-ADR
SAPHRIS O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
with O-ADR O-ADR
caution O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
seizures O-ADR O-ADR
or O-ADR O-ADR
with O-ADR O-ADR
conditions O-ADR O-ADR
that O-ADR O-ADR
potentially O-ADR O-ADR
lower O-ADR O-ADR
the O-ADR O-ADR
seizure O-ADR O-ADR
threshold O-ADR O-ADR
. O-ADR O-ADR
Appropriate O-ADR O-ADR
care O-ADR O-ADR
is O-ADR O-ADR
advised O-ADR O-ADR
when O-ADR O-ADR
prescribing O-ADR O-ADR
SAPHRIS O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
will O-ADR O-ADR
be O-ADR O-ADR
experiencing O-ADR O-ADR
conditions O-ADR O-ADR
that O-ADR O-ADR
may O-ADR O-ADR
contribute O-ADR O-ADR
to O-ADR O-ADR
an O-ADR O-ADR
elevation O-ADR O-ADR
in O-ADR O-ADR
core O-ADR O-ADR
body O-ADR O-ADR
temperature O-ADR O-ADR
, O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
exercising O-ADR O-ADR
strenuously O-ADR O-ADR
, O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
extreme O-ADR O-ADR
heat O-ADR O-ADR
, O-ADR O-ADR
receiving O-ADR O-ADR
concomitant O-ADR O-ADR
medication O-ADR O-ADR
with O-ADR O-ADR
anticholinergic O-ADR O-ADR
activity O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
being O-ADR O-ADR
subject O-ADR O-ADR
to O-ADR O-ADR
dehydration O-ADR O-ADR
. O-ADR O-ADR
DAMPA O-ADR O-ADR
interferes O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
measurement O-ADR O-ADR
of O-ADR O-ADR
methotrexate O-ADR O-ADR
concentration O-ADR O-ADR
using O-ADR O-ADR
immunoassays O-ADR O-ADR
resulting O-ADR O-ADR
in O-ADR O-ADR
an O-ADR O-ADR
erroneous O-ADR O-ADR
measurement O-ADR O-ADR
which O-ADR O-ADR
overestimates O-ADR O-ADR
the O-ADR O-ADR
methotrexate O-ADR O-ADR
concentration O-ADR O-ADR
. O-ADR O-ADR
Laboratory O-ADR O-ADR
Tests O-ADR O-ADR
Increase B-ADR O-ADR
in I-ADR O-ADR
Low I-ADR O-ADR
- O-ADR O-ADR
Density O-ADR O-ADR
Lipoprotein I-ADR O-ADR
Cholesterol I-ADR O-ADR
( O-ADR O-ADR
LDL O-ADR O-ADR
- O-ADR O-ADR
C O-ADR O-ADR
) O-ADR O-ADR
Dose O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
increases B-ADR B-ADR
in I-ADR I-ADR
low I-ADR I-ADR
- O-ADR O-ADR
density O-ADR O-ADR
lipoprotein I-ADR I-ADR
cholesterol I-ADR I-ADR
( O-ADR O-ADR
LDL O-ADR O-ADR
- O-ADR O-ADR
C O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
JARDIANCE O-ADR O-ADR
. O-ADR O-ADR
TAFINLAR O-ADR O-ADR
and O-ADR O-ADR
trametinib O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
resumed O-ADR O-ADR
at O-ADR O-ADR
lower O-ADR O-ADR
dose O-ADR O-ADR
levels O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
improvement O-ADR O-ADR
or O-ADR O-ADR
recovery O-ADR O-ADR
from O-ADR O-ADR
skin O-ADR O-ADR
toxicity O-ADR O-ADR
within O-ADR O-ADR
3 O-ADR O-ADR
weeks O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
symptoms O-ADR O-ADR
, O-ADR O-ADR
anxiety B-ADR B-ADR
, O-ADR O-ADR
agitation B-ADR B-ADR
, O-ADR O-ADR
panic B-ADR B-ADR
attacks I-ADR I-ADR
, O-ADR O-ADR
insomnia B-ADR B-ADR
, O-ADR O-ADR
irritability B-ADR B-ADR
, O-ADR O-ADR
hostility B-ADR B-ADR
, O-ADR O-ADR
aggressiveness B-ADR B-ADR
, O-ADR O-ADR
impulsivity B-ADR B-ADR
, O-ADR O-ADR
akathisia B-ADR B-ADR
( O-ADR O-ADR
psychomotor B-ADR B-ADR
restlessness I-ADR I-ADR
) O-ADR O-ADR
, O-ADR O-ADR
hypomania B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
mania B-ADR B-ADR
, O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
adult O-ADR O-ADR
and O-ADR O-ADR
pediatric O-ADR O-ADR
patients O-ADR O-ADR
being O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
antidepressants O-ADR O-ADR
for O-ADR O-ADR
major O-ADR O-ADR
depressive O-ADR O-ADR
disorder O-ADR O-ADR
as O-ADR O-ADR
well O-ADR O-ADR
as O-ADR O-ADR
for O-ADR O-ADR
other O-ADR O-ADR
indications O-ADR O-ADR
, O-ADR O-ADR
both O-ADR O-ADR
psychiatric O-ADR O-ADR
and O-ADR O-ADR
nonpsychiatric O-ADR O-ADR
. O-ADR O-ADR
GILENYA O-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
tested O-ADR O-ADR
in O-ADR O-ADR
MS O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
compromised O-ADR O-ADR
respiratory O-ADR O-ADR
function O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Postmarketing O-ADR O-ADR
Experience O-ADR O-ADR
Similar O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
postmarketing O-ADR O-ADR
as O-ADR O-ADR
described O-ADR O-ADR
for O-ADR O-ADR
clinical O-ADR O-ADR
trial O-ADR O-ADR
experience O-ADR O-ADR
. O-ADR O-ADR
Additionally O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
observed O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
antibody O-ADR O-ADR
( O-ADR O-ADR
including O-ADR O-ADR
neutralizing O-ADR O-ADR
antibody O-ADR O-ADR
) O-ADR O-ADR
positivity O-ADR O-ADR
in O-ADR O-ADR
an O-ADR O-ADR
assay O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
influenced O-ADR O-ADR
by O-ADR O-ADR
several O-ADR O-ADR
factors O-ADR O-ADR
including O-ADR O-ADR
assay O-ADR O-ADR
methodology O-ADR O-ADR
, O-ADR O-ADR
sample O-ADR O-ADR
handling O-ADR O-ADR
, O-ADR O-ADR
timing O-ADR O-ADR
of O-ADR O-ADR
sample O-ADR O-ADR
collection O-ADR O-ADR
, O-ADR O-ADR
concomitant O-ADR O-ADR
medications O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
underlying O-ADR O-ADR
disease O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
) O-ADR O-ADR
Program O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Side O-ADR O-ADR
effects O-ADR O-ADR
are O-ADR O-ADR
grouped O-ADR O-ADR
by O-ADR O-ADR
how O-ADR O-ADR
serious O-ADR O-ADR
they O-ADR O-ADR
are O-ADR O-ADR
and O-ADR O-ADR
how O-ADR O-ADR
often O-ADR O-ADR
they O-ADR O-ADR
happen O-ADR O-ADR
when O-ADR O-ADR
you O-ADR O-ADR
are O-ADR O-ADR
treated O-ADR O-ADR
. O-ADR O-ADR
Etiologies O-ADR O-ADR
included O-ADR O-ADR
infection B-ADR B-ADR
, O-ADR O-ADR
cardiovascular B-ADR B-ADR
disease I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
suicide B-ADR B-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Gastrointestinal B-ADR B-ADR
Adverse I-ADR I-ADR
Reactions I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Immune B-ADR B-ADR
- O-ADR O-ADR
mediated O-ADR O-ADR
hepatitis I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Discontinuations O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
for O-ADR O-ADR
16 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
XTANDI O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
18 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Consider O-ADR O-ADR
follow O-ADR O-ADR
- O-ADR O-ADR
up O-ADR O-ADR
renal O-ADR O-ADR
function O-ADR O-ADR
assessments O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
renal O-ADR O-ADR
dysfunction O-ADR O-ADR
. O-ADR O-ADR
4Includes O-ADR O-ADR
the O-ADR O-ADR
preferred O-ADR O-ADR
terms O-ADR O-ADR
fatigue B-ADR O-ADR
and O-ADR O-ADR
lethargy B-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
with O-ADR O-ADR
INLYTA O-ADR O-ADR
, O-ADR O-ADR
venous B-ADR B-ADR
thromboembolic I-ADR I-ADR
events I-ADR I-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
22 O-ADR O-ADR
/ O-ADR O-ADR
715 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
with O-ADR O-ADR
two O-ADR O-ADR
deaths B-ADR B-ADR
secondary O-ADR O-ADR
to O-ADR O-ADR
pulmonary B-ADR B-ADR
embolism I-ADR I-ADR
. O-ADR O-ADR
There O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
no O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
Edarbi O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
unilateral O-ADR O-ADR
or O-ADR O-ADR
bilateral O-ADR O-ADR
renal O-ADR O-ADR
artery O-ADR O-ADR
stenosis O-ADR O-ADR
, O-ADR O-ADR
but O-ADR O-ADR
similar O-ADR O-ADR
results O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
expected O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
( O-ADR O-ADR
per O-ADR O-ADR
patient O-ADR O-ADR
incidence O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
Prolia O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
bone O-ADR O-ADR
loss O-ADR O-ADR
receiving O-ADR O-ADR
androgen O-ADR O-ADR
deprivation O-ADR O-ADR
therapy O-ADR O-ADR
for O-ADR O-ADR
prostate O-ADR O-ADR
cancer O-ADR O-ADR
or O-ADR O-ADR
adjuvant O-ADR O-ADR
aromatase O-ADR O-ADR
inhibitor O-ADR O-ADR
therapy O-ADR O-ADR
for O-ADR O-ADR
breast O-ADR O-ADR
cancer O-ADR O-ADR
are O-ADR O-ADR
arthralgia B-ADR B-ADR
and O-ADR O-ADR
back B-ADR B-ADR
pain I-ADR I-ADR
. O-ADR O-ADR
This O-ADR O-ADR
was O-ADR O-ADR
not O-ADR O-ADR
clinically O-ADR O-ADR
significant O-ADR O-ADR
among O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
development O-ADR O-ADR
program O-ADR O-ADR
but O-ADR O-ADR
could O-ADR O-ADR
be O-ADR O-ADR
a O-ADR O-ADR
factor O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
whose O-ADR O-ADR
diabetes O-ADR O-ADR
is O-ADR O-ADR
difficult O-ADR O-ADR
to O-ADR O-ADR
control O-ADR O-ADR
. O-ADR O-ADR
Free O-ADR O-ADR
T4 O-ADR O-ADR
and O-ADR O-ADR
free O-ADR O-ADR
T3 O-ADR O-ADR
concentrations O-ADR O-ADR
are O-ADR O-ADR
unaltered O-ADR O-ADR
. O-ADR O-ADR
Based O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
Visual O-ADR O-ADR
Symptom O-ADR O-ADR
Assessment O-ADR O-ADR
Questionnaire O-ADR O-ADR
( O-ADR O-ADR
VSAQ O-ADR O-ADR
- O-ADR O-ADR
ALK O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
XALKORI O-ADR O-ADR
in O-ADR O-ADR
Studies O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
reported O-ADR O-ADR
a O-ADR O-ADR
higher O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
visual B-ADR B-ADR
disturbances I-ADR I-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
chemotherapy O-ADR O-ADR
. O-ADR O-ADR
Other O-ADR O-ADR
important O-ADR O-ADR
considerations O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
differential O-ADR O-ADR
diagnosis O-ADR O-ADR
include O-ADR O-ADR
central O-ADR O-ADR
anticholinergic O-ADR O-ADR
toxicity O-ADR O-ADR
, O-ADR O-ADR
heat O-ADR O-ADR
stroke O-ADR O-ADR
, O-ADR O-ADR
drug O-ADR O-ADR
fever O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
primary O-ADR O-ADR
central O-ADR O-ADR
nervous O-ADR O-ADR
system O-ADR O-ADR
pathology O-ADR O-ADR
. O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Contraindications O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
Abnormal O-ADR O-ADR
Thyroid O-ADR O-ADR
Function O-ADR O-ADR
Tests O-ADR O-ADR
Dose O-ADR O-ADR
- O-ADR O-ADR
dependent O-ADR O-ADR
decreases B-ADR B-ADR
in I-ADR I-ADR
serum I-ADR I-ADR
T3 I-ADR I-ADR
and I-ADR I-ADR
T4 I-ADR I-ADR
( I-ADR O-ADR
free I-ADR O-ADR
) O-ADR O-ADR
values O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
taking O-ADR O-ADR
APTIOM O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
included O-ADR O-ADR
febrile B-ADR B-ADR
neutropenia I-ADR I-ADR
, O-ADR O-ADR
pyrexia B-ADR B-ADR
, O-ADR O-ADR
pneumonia B-ADR B-ADR
, O-ADR O-ADR
sepsis B-ADR B-ADR
, O-ADR O-ADR
neutropenia B-ADR B-ADR
, O-ADR O-ADR
device B-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
infection I-ADR I-ADR
, O-ADR O-ADR
tremor B-ADR B-ADR
, O-ADR O-ADR
encephalopathy B-ADR B-ADR
, O-ADR O-ADR
infection B-ADR B-ADR
, O-ADR O-ADR
overdose B-ADR B-ADR
, O-ADR O-ADR
confusion B-ADR B-ADR
, O-ADR O-ADR
Staphylococcal B-ADR B-ADR
bacteremia I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
headache B-ADR B-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
for O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
during O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
Among O-ADR O-ADR
those O-ADR O-ADR
, O-ADR O-ADR
2110 O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
2 O-ADR O-ADR
mg O-ADR O-ADR
. O-ADR O-ADR
Serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
related O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
injection O-ADR O-ADR
procedure O-ADR O-ADR
have O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
< O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
intravitreal O-ADR O-ADR
injections O-ADR O-ADR
with O-ADR O-ADR
EYLEA O-ADR O-ADR
including O-ADR O-ADR
endophthalmitis B-ADR B-ADR
and O-ADR O-ADR
retinal B-ADR B-ADR
detachment I-ADR I-ADR
. O-ADR O-ADR
Immune O-ADR O-ADR
System O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
sarcoidosis B-ADR B-ADR
BOXED O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
SERIOUS O-ADR O-ADR
INFECTIONS B-ADR B-ADR
AND O-ADR O-ADR
MALIGNANCY B-ADR B-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
SERIOUS O-ADR O-ADR
INFECTIONS B-ADR B-ADR
AND O-ADR O-ADR
MALIGNANCY B-ADR B-ADR
SERIOUS O-ADR O-ADR
INFECTIONS O-ADR B-ADR
Patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
CIMZIA O-ADR O-ADR
are O-ADR O-ADR
at O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
developing O-ADR O-ADR
serious O-ADR O-ADR
infections B-ADR B-ADR
that O-ADR O-ADR
may O-ADR O-ADR
lead O-ADR O-ADR
to O-ADR O-ADR
hospitalization O-ADR O-ADR
or O-ADR O-ADR
death B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
NNRTI O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
rash B-ADR O-ADR
did O-ADR O-ADR
not O-ADR O-ADR
appear O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
at O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
development O-ADR O-ADR
of O-ADR O-ADR
INTELENCE O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
rash B-ADR B-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
patients O-ADR O-ADR
without O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
NNRTI O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
rash B-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Interstitial O-ADR O-ADR
Lung O-ADR O-ADR
Disease O-ADR O-ADR
( O-ADR O-ADR
ILD O-ADR O-ADR
) O-ADR O-ADR
/ O-ADR O-ADR
Pneumonitis O-ADR O-ADR
Severe O-ADR O-ADR
, O-ADR O-ADR
life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
fatal B-ADR B-ADR
ILD O-ADR O-ADR
/ O-ADR O-ADR
pneumonitis O-ADR O-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
ZYKADIA O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
5 O-ADR O-ADR
shows O-ADR O-ADR
the O-ADR O-ADR
number O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
experiencing O-ADR O-ADR
bleeding B-ADR B-ADR
events O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
study O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
mechanism O-ADR O-ADR
of O-ADR O-ADR
Ferriprox O-ADR O-ADR
- O-ADR O-ADR
associated O-ADR O-ADR
agranulocytosis B-ADR B-ADR
is O-ADR O-ADR
unknown O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
with O-ADR O-ADR
liver O-ADR O-ADR
laboratory O-ADR O-ADR
tests O-ADR O-ADR
including O-ADR O-ADR
ALT O-ADR O-ADR
, O-ADR O-ADR
aspartate O-ADR O-ADR
aminotransferase O-ADR O-ADR
( O-ADR O-ADR
AST O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
total O-ADR O-ADR
bilirubin O-ADR O-ADR
once O-ADR O-ADR
a O-ADR O-ADR
month O-ADR O-ADR
and O-ADR O-ADR
as O-ADR O-ADR
clinically O-ADR O-ADR
indicated O-ADR O-ADR
, O-ADR O-ADR
with O-ADR O-ADR
more O-ADR O-ADR
frequent O-ADR O-ADR
testing O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
develop O-ADR O-ADR
transaminase O-ADR O-ADR
elevations O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
Embryofetal O-ADR O-ADR
Toxicity O-ADR O-ADR
Based O-ADR O-ADR
on O-ADR O-ADR
its O-ADR O-ADR
mechanism O-ADR O-ADR
of O-ADR O-ADR
action O-ADR O-ADR
, O-ADR O-ADR
ZYKADIA O-ADR O-ADR
may O-ADR O-ADR
cause O-ADR O-ADR
fetal B-ADR B-ADR
harm I-ADR I-ADR
when O-ADR O-ADR
administered O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
pregnant O-ADR O-ADR
woman O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
Assess O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
enterocolitis O-ADR O-ADR
, O-ADR O-ADR
dermatitis O-ADR O-ADR
, O-ADR O-ADR
neuropathy O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
endocrinopathy O-ADR O-ADR
and O-ADR O-ADR
evaluate O-ADR O-ADR
clinical O-ADR O-ADR
chemistries O-ADR O-ADR
including O-ADR O-ADR
liver O-ADR O-ADR
function O-ADR O-ADR
tests O-ADR O-ADR
and O-ADR O-ADR
thyroid O-ADR O-ADR
function O-ADR O-ADR
tests O-ADR O-ADR
at O-ADR O-ADR
baseline O-ADR O-ADR
and O-ADR O-ADR
before O-ADR O-ADR
each O-ADR O-ADR
dose O-ADR O-ADR
. O-ADR O-ADR
Mean O-ADR O-ADR
percent O-ADR B-ADR
changes B-ADR I-ADR
from I-ADR I-ADR
baseline I-ADR I-ADR
at I-ADR I-ADR
Week I-ADR I-ADR
24 I-ADR I-ADR
, I-ADR O-ADR
were I-ADR O-ADR
0 I-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% I-ADR O-ADR
versus I-ADR O-ADR
2 I-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% I-ADR O-ADR
for I-ADR O-ADR
total I-ADR O-ADR
cholesterol I-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
and O-ADR O-ADR
FARXIGA O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
groups O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
11 O-ADR O-ADR
Hepatic O-ADR O-ADR
Impairment O-ADR O-ADR
COMETRIQ O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
recommended O-ADR O-ADR
for O-ADR O-ADR
use O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
moderate O-ADR O-ADR
or O-ADR O-ADR
severe O-ADR O-ADR
hepatic O-ADR O-ADR
impairment O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Based O-ADR O-ADR
on O-ADR O-ADR
patient O-ADR O-ADR
diaries O-ADR O-ADR
, O-ADR O-ADR
amenorrhea O-ADR B-ADR
occurs O-ADR O-ADR
in O-ADR O-ADR
approximately O-ADR O-ADR
16 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
cycles O-ADR O-ADR
in O-ADR O-ADR
women O-ADR O-ADR
using O-ADR O-ADR
Natazia O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
addition O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
reactions O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
in O-ADR O-ADR
TRULICITY O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
than O-ADR O-ADR
placebo O-ADR O-ADR
( O-ADR O-ADR
frequencies O-ADR O-ADR
listed O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
, O-ADR O-ADR
as O-ADR O-ADR
: O-ADR O-ADR
placebo O-ADR O-ADR
; O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
75 O-ADR O-ADR
mg O-ADR O-ADR
; O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
) O-ADR O-ADR
: O-ADR O-ADR
constipation B-ADR B-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
flatulence B-ADR B-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
abdominal B-ADR B-ADR
distension I-ADR I-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
gastroesophageal B-ADR B-ADR
reflux I-ADR I-ADR
disease I-ADR I-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
eructation B-ADR B-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
liver O-ADR O-ADR
transplant O-ADR O-ADR
recipient O-ADR O-ADR
was O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
6 O-ADR O-ADR
months O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
NULOJIX O-ADR O-ADR
dosage O-ADR O-ADR
regimen O-ADR O-ADR
that O-ADR O-ADR
was O-ADR O-ADR
more O-ADR O-ADR
intensive O-ADR O-ADR
than O-ADR O-ADR
that O-ADR O-ADR
studied O-ADR O-ADR
in O-ADR O-ADR
kidney O-ADR O-ADR
transplant O-ADR O-ADR
recipients O-ADR O-ADR
, O-ADR O-ADR
MMF O-ADR O-ADR
at O-ADR O-ADR
doses O-ADR O-ADR
higher O-ADR O-ADR
than O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
dose O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
corticosteroids O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
profile O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
PsA O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
CIMZIA O-ADR O-ADR
was O-ADR O-ADR
similar O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
safety O-ADR O-ADR
profile O-ADR O-ADR
seen O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
RA O-ADR O-ADR
and O-ADR O-ADR
previous O-ADR O-ADR
experience O-ADR O-ADR
with O-ADR O-ADR
CIMZIA O-ADR O-ADR
. O-ADR O-ADR
Galactorrhea B-ADR B-ADR
, O-ADR O-ADR
amenorrhea B-ADR B-ADR
, O-ADR O-ADR
gynecomastia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
impotence B-ADR B-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
prolactin O-ADR O-ADR
- O-ADR O-ADR
elevating O-ADR O-ADR
compounds O-ADR O-ADR
. O-ADR O-ADR
high O-ADR O-ADR
tumor O-ADR O-ADR
burden O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
sizes O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
studies O-ADR O-ADR
were O-ADR O-ADR
not O-ADR O-ADR
adequate O-ADR O-ADR
to O-ADR O-ADR
precisely O-ADR O-ADR
quantify O-ADR O-ADR
the O-ADR O-ADR
differences O-ADR O-ADR
in O-ADR O-ADR
serious O-ADR O-ADR
asthma O-ADR O-ADR
exacerbation O-ADR O-ADR
rates O-ADR O-ADR
between O-ADR O-ADR
treatment O-ADR O-ADR
groups O-ADR O-ADR
. O-ADR O-ADR
Hazardous O-ADR O-ADR
Activities O-ADR O-ADR
Prescribers O-ADR O-ADR
should O-ADR O-ADR
advise O-ADR O-ADR
patients O-ADR O-ADR
against O-ADR O-ADR
engaging O-ADR O-ADR
in O-ADR O-ADR
hazardous O-ADR O-ADR
activities O-ADR O-ADR
requiring O-ADR O-ADR
mental O-ADR O-ADR
alertness O-ADR O-ADR
, O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
operating O-ADR O-ADR
motor O-ADR O-ADR
vehicles O-ADR O-ADR
or O-ADR O-ADR
dangerous O-ADR O-ADR
machinery O-ADR O-ADR
, O-ADR O-ADR
until O-ADR O-ADR
the O-ADR O-ADR
effect O-ADR O-ADR
of O-ADR O-ADR
APTIOM O-ADR O-ADR
is O-ADR O-ADR
known O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
moderate O-ADR O-ADR
renal O-ADR O-ADR
impairment O-ADR O-ADR
at O-ADR O-ADR
baseline O-ADR O-ADR
had O-ADR O-ADR
larger O-ADR O-ADR
mean O-ADR O-ADR
changes O-ADR O-ADR
. O-ADR O-ADR
Closely O-ADR O-ADR
supervise O-ADR O-ADR
high O-ADR O-ADR
- O-ADR O-ADR
risk O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Concurrent O-ADR O-ADR
elevations B-ADR B-ADR
in I-ADR I-ADR
alanine I-ADR I-ADR
aminotransferase I-ADR I-ADR
) O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
or O-ADR O-ADR
equal O-ADR O-ADR
to O-ADR O-ADR
three O-ADR O-ADR
times O-ADR O-ADR
the O-ADR O-ADR
upper O-ADR O-ADR
limit O-ADR O-ADR
of O-ADR O-ADR
normal O-ADR O-ADR
( O-ADR O-ADR
ULN O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
total B-ADR B-ADR
bilirubin I-ADR I-ADR
greater I-ADR I-ADR
than I-ADR I-ADR
or I-ADR I-ADR
equal I-ADR I-ADR
to I-ADR I-ADR
two I-ADR I-ADR
times I-ADR I-ADR
the I-ADR I-ADR
ULN I-ADR I-ADR
, O-ADR O-ADR
with O-ADR O-ADR
normal O-ADR O-ADR
alkaline O-ADR O-ADR
phosphatase O-ADR O-ADR
, O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
10 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
XALKORI O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
: O-ADR O-ADR
Shift O-ADR O-ADR
from O-ADR O-ADR
Baseline O-ADR O-ADR
to O-ADR O-ADR
Lowest O-ADR O-ADR
Observed O-ADR O-ADR
eGFR O-ADR O-ADR
Group O-ADR O-ADR
During O-ADR O-ADR
Treatment O-ADR O-ADR
Safety O-ADR O-ADR
Population O-ADR O-ADR
in O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
818 O-ADR O-ADR
) O-ADR O-ADR
Among O-ADR O-ADR
the O-ADR O-ADR
818 O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
eGFR O-ADR O-ADR
was O-ADR O-ADR
missing O-ADR O-ADR
in O-ADR O-ADR
5 O-ADR O-ADR
patients O-ADR O-ADR
at O-ADR O-ADR
baseline O-ADR O-ADR
or O-ADR O-ADR
on O-ADR O-ADR
- O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
Serious O-ADR O-ADR
Infections O-ADR O-ADR
S O-ADR O-ADR
erious O-ADR O-ADR
infection B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
1 O-ADR O-ADR
patient O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
group O-ADR O-ADR
and O-ADR O-ADR
no O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Prolia O-ADR O-ADR
group O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
currently O-ADR O-ADR
have O-ADR O-ADR
or O-ADR O-ADR
have O-ADR O-ADR
had O-ADR O-ADR
liver O-ADR O-ADR
problems O-ADR O-ADR
* O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
diagnosed O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
bleeding O-ADR O-ADR
disorder O-ADR O-ADR
* O-ADR O-ADR
think O-ADR O-ADR
you O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
pregnant O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Possible O-ADR O-ADR
clinically O-ADR O-ADR
significant O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
from O-ADR O-ADR
greater O-ADR O-ADR
exposures O-ADR O-ADR
of O-ADR O-ADR
concomitant O-ADR O-ADR
drugs O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
discussed O-ADR O-ADR
below O-ADR O-ADR
and O-ADR O-ADR
also O-ADR O-ADR
elsewhere O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
labeling O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Hypocalcemia B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Serious O-ADR O-ADR
Infections B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Dermatologic B-ADR B-ADR
Adverse I-ADR I-ADR
Reactions I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Osteonecrosis B-ADR B-ADR
of I-ADR I-ADR
the I-ADR I-ADR
Jaw I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Atypical B-ADR B-ADR
Subtrochanteric I-ADR I-ADR
and I-ADR I-ADR
Diaphyseal I-ADR I-ADR
Femoral I-ADR I-ADR
Fractures I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
Prolia O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
postmenopausal O-ADR O-ADR
osteoporosis O-ADR O-ADR
are O-ADR O-ADR
back B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
pain B-ADR B-ADR
in I-ADR I-ADR
extremity I-ADR I-ADR
, O-ADR O-ADR
musculoskeletal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
hypercholesterolemia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
cystitis B-ADR B-ADR
. O-ADR O-ADR
Do O-ADR O-ADR
not O-ADR O-ADR
use O-ADR O-ADR
to O-ADR O-ADR
treat O-ADR O-ADR
acute O-ADR O-ADR
symptoms O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
monitored O-ADR O-ADR
for O-ADR O-ADR
hypertension O-ADR O-ADR
and O-ADR O-ADR
treated O-ADR O-ADR
as O-ADR O-ADR
needed O-ADR O-ADR
with O-ADR O-ADR
standard O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
hypertensive O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Seattle O-ADR O-ADR
Genetics O-ADR O-ADR
, O-ADR O-ADR
Inc O-ADR O-ADR
. O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
855 O-ADR O-ADR
- O-ADR O-ADR
473 O-ADR O-ADR
- O-ADR O-ADR
2436 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
Galactorrhea B-ADR B-ADR
or O-ADR O-ADR
dysmenorrhea B-ADR B-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
SAPHRIS O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
SAPHRIS O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
SAPHRIS O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
mean O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
NESINA O-ADR O-ADR
was O-ADR O-ADR
40 O-ADR O-ADR
weeks O-ADR O-ADR
with O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
2400 O-ADR O-ADR
subjects O-ADR O-ADR
treated O-ADR O-ADR
for O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
one O-ADR O-ADR
year O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Pancreatitis B-ADR B-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Diarrhea O-ADR B-ADR
: O-ADR O-ADR
Diarrhea B-ADR B-ADR
may O-ADR O-ADR
result O-ADR O-ADR
in O-ADR O-ADR
dehydration B-ADR B-ADR
and O-ADR O-ADR
renal B-ADR B-ADR
failure I-ADR I-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
discussed O-ADR O-ADR
in O-ADR O-ADR
greater O-ADR O-ADR
detail O-ADR O-ADR
in O-ADR O-ADR
another O-ADR O-ADR
section O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
label O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Bone B-ADR B-ADR
Marrow I-ADR I-ADR
Suppression I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
laboratory O-ADR O-ADR
abnormalities O-ADR O-ADR
( O-ADR O-ADR
incidence O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
50 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
hypercholesterolemia B-ADR B-ADR
, O-ADR O-ADR
hyperglycemia B-ADR B-ADR
, O-ADR O-ADR
increased B-ADR B-ADR
aspartate I-ADR I-ADR
transaminase I-ADR I-ADR
) O-ADR O-ADR
, O-ADR O-ADR
anemia B-ADR B-ADR
, O-ADR O-ADR
leukopenia B-ADR B-ADR
, O-ADR O-ADR
thrombocytopenia B-ADR B-ADR
, O-ADR O-ADR
lymphopenia B-ADR B-ADR
, O-ADR O-ADR
increased B-ADR B-ADR
alanine I-ADR I-ADR
transaminase I-ADR I-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
hypertriglyceridemia B-ADR B-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
221 O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
KALYDECO O-ADR O-ADR
were O-ADR O-ADR
headache B-ADR B-ADR
( O-ADR O-ADR
17 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
upper B-ADR B-ADR
respiratory I-ADR I-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
( O-ADR O-ADR
16 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
nasal B-ADR B-ADR
congestion I-ADR I-ADR
( O-ADR O-ADR
16 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
( O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
( O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
rhinitis B-ADR B-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
dizziness B-ADR B-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
arthralgia B-ADR B-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
bacteria B-ADR B-ADR
in I-ADR I-ADR
sputum I-ADR I-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Confirm O-ADR O-ADR
evidence O-ADR O-ADR
of O-ADR O-ADR
BRAF O-ADR O-ADR
V600E O-ADR O-ADR
or O-ADR O-ADR
V600K O-ADR O-ADR
mutation O-ADR O-ADR
status O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
TAFINLAR O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
single O-ADR O-ADR
agent O-ADR O-ADR
or O-ADR O-ADR
combination O-ADR O-ADR
therapy O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Indications O-ADR O-ADR
and O-ADR O-ADR
Usage O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
As O-ADR O-ADR
with O-ADR O-ADR
all O-ADR O-ADR
therapeutic O-ADR O-ADR
proteins O-ADR O-ADR
, O-ADR O-ADR
there O-ADR O-ADR
is O-ADR O-ADR
a O-ADR O-ADR
potential O-ADR O-ADR
for O-ADR O-ADR
immunogenicity O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
KALBITOR O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
Trial O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
new O-ADR B-ADR
primary B-ADR I-ADR
malignant I-ADR I-ADR
melanomas I-ADR I-ADR
was O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
/ O-ADR O-ADR
187 O-ADR O-ADR
) O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
TAFINLAR O-ADR O-ADR
while O-ADR O-ADR
no O-ADR O-ADR
dacarbazine O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patient O-ADR O-ADR
was O-ADR O-ADR
diagnosed O-ADR O-ADR
with O-ADR O-ADR
new O-ADR O-ADR
primary O-ADR O-ADR
malignant O-ADR B-ADR
melanoma O-ADR I-ADR
. O-ADR O-ADR
Tuberculosis O-ADR O-ADR
Tuberculosis B-ADR B-ADR
was O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
NULOJIX O-ADR O-ADR
than O-ADR O-ADR
cyclosporine O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Abnormal B-ADR B-ADR
Bleeding I-ADR I-ADR
: O-ADR O-ADR
PRISTIQ O-ADR O-ADR
may O-ADR O-ADR
increase O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
bleeding B-ADR B-ADR
events O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
11 O-ADR O-ADR
Vaccinations O-ADR O-ADR
During O-ADR O-ADR
AFINITOR O-ADR O-ADR
treatment O-ADR O-ADR
, O-ADR O-ADR
avoid O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
live O-ADR O-ADR
vaccines O-ADR O-ADR
and O-ADR O-ADR
avoid O-ADR O-ADR
close O-ADR O-ADR
contact O-ADR O-ADR
with O-ADR O-ADR
individuals O-ADR O-ADR
who O-ADR O-ADR
have O-ADR O-ADR
received O-ADR O-ADR
live O-ADR O-ADR
vaccines O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
intranasal O-ADR O-ADR
influenza O-ADR O-ADR
, O-ADR O-ADR
measles O-ADR O-ADR
, O-ADR O-ADR
mumps O-ADR O-ADR
, O-ADR O-ADR
rubella O-ADR O-ADR
, O-ADR O-ADR
oral O-ADR O-ADR
polio O-ADR O-ADR
, O-ADR O-ADR
BCG O-ADR O-ADR
, O-ADR O-ADR
yellow O-ADR O-ADR
fever O-ADR O-ADR
, O-ADR O-ADR
varicella O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
TY21a O-ADR O-ADR
typhoid O-ADR O-ADR
vaccines O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Overestimation O-ADR O-ADR
of O-ADR O-ADR
Extent O-ADR O-ADR
of O-ADR O-ADR
Malignant O-ADR O-ADR
Disease O-ADR O-ADR
in O-ADR O-ADR
MRI O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
Breast O-ADR O-ADR
Gadavist O-ADR O-ADR
MRI O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
breast O-ADR O-ADR
overestimated O-ADR O-ADR
the O-ADR O-ADR
histologically O-ADR O-ADR
confirmed O-ADR O-ADR
extent O-ADR O-ADR
of O-ADR O-ADR
malignancy O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
diseased O-ADR O-ADR
breast O-ADR O-ADR
in O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
50 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
patients O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
14 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Determine O-ADR O-ADR
cardiac O-ADR O-ADR
rhythm O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
once O-ADR O-ADR
every O-ADR O-ADR
3 O-ADR O-ADR
months O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Clostridium O-ADR O-ADR
difficile O-ADR O-ADR
- O-ADR O-ADR
Associated O-ADR O-ADR
Diarrhea O-ADR O-ADR
Clostridium B-ADR B-ADR
difficile I-ADR I-ADR
- I-ADR I-ADR
associated O-ADR O-ADR
diarrhea I-ADR I-ADR
( O-ADR O-ADR
CDAD B-ADR B-ADR
) O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
for O-ADR O-ADR
nearly O-ADR O-ADR
all O-ADR O-ADR
systemic O-ADR O-ADR
antibacterial O-ADR O-ADR
agents O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
Teflaro O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
range O-ADR O-ADR
in O-ADR O-ADR
severity O-ADR O-ADR
from O-ADR O-ADR
mild O-ADR O-ADR
diarrhea B-ADR B-ADR
to O-ADR O-ADR
fatal B-ADR B-ADR
colitis B-ADR B-ADR
. O-ADR O-ADR
Median O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
was O-ADR O-ADR
7 O-ADR O-ADR
cycles O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
, O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
16 O-ADR O-ADR
) O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Have O-ADR O-ADR
resuscitation O-ADR O-ADR
equipment O-ADR O-ADR
and O-ADR O-ADR
trained O-ADR O-ADR
personnel O-ADR O-ADR
available O-ADR O-ADR
at O-ADR O-ADR
time O-ADR O-ADR
of O-ADR O-ADR
Vizamyl O-ADR O-ADR
administration O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Image O-ADR O-ADR
interpretation O-ADR O-ADR
errors O-ADR O-ADR
( O-ADR O-ADR
especially O-ADR O-ADR
false O-ADR O-ADR
positives O-ADR O-ADR
) O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Radiation B-ADR B-ADR
risk I-ADR I-ADR
: O-ADR O-ADR
Vizamyl O-ADR O-ADR
, O-ADR O-ADR
similar O-ADR O-ADR
to O-ADR O-ADR
all O-ADR O-ADR
radiopharmaceuticals O-ADR O-ADR
, O-ADR O-ADR
contributes O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
patient O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
long B-ADR B-ADR
- O-ADR O-ADR
term O-ADR O-ADR
cumulative I-ADR I-ADR
radiation I-ADR I-ADR
exposure I-ADR I-ADR
. O-ADR O-ADR
When O-ADR O-ADR
Coartem O-ADR O-ADR
Tablets O-ADR O-ADR
are O-ADR O-ADR
coadministered O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
inhibitor O-ADR O-ADR
of O-ADR O-ADR
CYP3A4 O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
grapefruit O-ADR O-ADR
juice O-ADR O-ADR
it O-ADR O-ADR
may O-ADR O-ADR
result O-ADR O-ADR
in O-ADR O-ADR
increased O-ADR O-ADR
concentrations O-ADR O-ADR
of O-ADR O-ADR
artemether O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
lumefantrine O-ADR O-ADR
and O-ADR O-ADR
potentiate O-ADR O-ADR
QT B-ADR O-ADR
prolongation I-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
reactions O-ADR O-ADR
occurred O-ADR O-ADR
several O-ADR O-ADR
weeks O-ADR O-ADR
to O-ADR O-ADR
3 O-ADR O-ADR
years O-ADR O-ADR
after O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
infusions O-ADR O-ADR
. O-ADR O-ADR
Serotonin B-ADR B-ADR
syndrome I-ADR I-ADR
symptoms O-ADR I-ADR
may O-ADR O-ADR
include O-ADR O-ADR
mental B-ADR B-ADR
status I-ADR I-ADR
changes I-ADR I-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
agitation B-ADR B-ADR
, O-ADR O-ADR
hallucinations B-ADR B-ADR
, O-ADR O-ADR
delirium B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
coma B-ADR B-ADR
) O-ADR O-ADR
, O-ADR O-ADR
autonomic B-ADR B-ADR
instability I-ADR I-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
tachycardia B-ADR B-ADR
, O-ADR O-ADR
labile B-ADR B-ADR
blood I-ADR I-ADR
pressure I-ADR I-ADR
, O-ADR O-ADR
dizziness B-ADR B-ADR
, O-ADR O-ADR
diaphoresis B-ADR B-ADR
, O-ADR O-ADR
flushing B-ADR B-ADR
, O-ADR O-ADR
hyperthermia B-ADR B-ADR
) O-ADR O-ADR
, O-ADR O-ADR
neuromuscular B-ADR B-ADR
symptoms I-ADR I-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
tremor B-ADR B-ADR
, O-ADR O-ADR
rigidity B-ADR B-ADR
, O-ADR O-ADR
myoclonus B-ADR B-ADR
, O-ADR O-ADR
hyperreflexia B-ADR B-ADR
, O-ADR O-ADR
incoordination B-ADR B-ADR
) O-ADR O-ADR
, O-ADR O-ADR
seizures B-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
gastrointestinal B-ADR O-ADR
symptoms I-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
nausea B-ADR O-ADR
, O-ADR O-ADR
vomiting B-ADR O-ADR
, O-ADR O-ADR
diarrhea B-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Before O-ADR O-ADR
EOVIST O-ADR O-ADR
administration O-ADR O-ADR
, O-ADR O-ADR
assess O-ADR O-ADR
all O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
any O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
reaction O-ADR O-ADR
to O-ADR O-ADR
contrast O-ADR O-ADR
media O-ADR O-ADR
, O-ADR O-ADR
bronchial O-ADR O-ADR
asthma O-ADR O-ADR
and O-ADR O-ADR
allergic O-ADR O-ADR
disorders O-ADR O-ADR
. O-ADR O-ADR
Severe O-ADR O-ADR
Aplastic O-ADR O-ADR
Anemia O-ADR O-ADR
: O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
single O-ADR O-ADR
- O-ADR O-ADR
arm O-ADR O-ADR
, O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
trial O-ADR O-ADR
, O-ADR O-ADR
43 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
severe O-ADR O-ADR
aplastic O-ADR O-ADR
anemia O-ADR O-ADR
received O-ADR O-ADR
PROMACTA O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
estrogen O-ADR O-ADR
- O-ADR O-ADR
alone O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
to O-ADR O-ADR
result O-ADR O-ADR
in O-ADR O-ADR
an O-ADR O-ADR
increase O-ADR B-ADR
in O-ADR I-ADR
abnormal O-ADR I-ADR
mammograms O-ADR I-ADR
requiring O-ADR O-ADR
further O-ADR O-ADR
evaluation O-ADR O-ADR
. O-ADR O-ADR
Prescriptions O-ADR O-ADR
for O-ADR O-ADR
PRISTIQ O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
written O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
smallest O-ADR O-ADR
quantity O-ADR O-ADR
of O-ADR O-ADR
tablets O-ADR O-ADR
consistent O-ADR O-ADR
with O-ADR O-ADR
good O-ADR O-ADR
patient O-ADR O-ADR
management O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
order O-ADR O-ADR
to O-ADR O-ADR
reduce O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
overdose O-ADR O-ADR
. O-ADR O-ADR
Safety O-ADR O-ADR
of O-ADR O-ADR
combined O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
PDE5 O-ADR O-ADR
inhibitors O-ADR O-ADR
and O-ADR O-ADR
alpha O-ADR O-ADR
- O-ADR O-ADR
blockers O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
affected O-ADR O-ADR
by O-ADR O-ADR
other O-ADR O-ADR
variables O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
intravascular O-ADR O-ADR
volume O-ADR O-ADR
depletion O-ADR O-ADR
and O-ADR O-ADR
other O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
hypertensive O-ADR O-ADR
drugs O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Drug O-ADR O-ADR
Interactions O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Six O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
again O-ADR O-ADR
experienced O-ADR O-ADR
liver B-ADR B-ADR
test I-ADR I-ADR
abnormalities I-ADR I-ADR
( O-ADR O-ADR
predominantly O-ADR O-ADR
Grade O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
resulting O-ADR O-ADR
in O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
PROMACTA O-ADR O-ADR
in O-ADR O-ADR
one O-ADR O-ADR
patient O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Drug O-ADR O-ADR
Interactions O-ADR O-ADR
with O-ADR O-ADR
CYP3A4 O-ADR O-ADR
When O-ADR O-ADR
Coartem O-ADR O-ADR
Tablets O-ADR O-ADR
are O-ADR O-ADR
coadministered O-ADR O-ADR
with O-ADR O-ADR
substrates O-ADR O-ADR
of O-ADR O-ADR
CYP3A4 O-ADR O-ADR
it O-ADR O-ADR
may O-ADR O-ADR
result O-ADR O-ADR
in O-ADR O-ADR
decreased O-ADR O-ADR
concentrations O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
substrate O-ADR O-ADR
and O-ADR O-ADR
potential O-ADR O-ADR
loss O-ADR O-ADR
of O-ADR O-ADR
substrate O-ADR O-ADR
efficacy O-ADR O-ADR
. O-ADR O-ADR
Refer O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
prescribing O-ADR O-ADR
information O-ADR O-ADR
for O-ADR O-ADR
ribavirin O-ADR O-ADR
for O-ADR O-ADR
additional O-ADR O-ADR
information O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
14 O-ADR O-ADR
Suicide O-ADR O-ADR
The O-ADR O-ADR
possibility O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
suicide O-ADR O-ADR
attempt O-ADR O-ADR
is O-ADR O-ADR
inherent O-ADR O-ADR
in O-ADR O-ADR
psychotic O-ADR O-ADR
illnesses O-ADR O-ADR
and O-ADR O-ADR
bipolar O-ADR O-ADR
disorder O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
close O-ADR O-ADR
supervision O-ADR O-ADR
of O-ADR O-ADR
high O-ADR O-ADR
- O-ADR O-ADR
risk O-ADR O-ADR
patients O-ADR O-ADR
should O-ADR O-ADR
accompany O-ADR O-ADR
drug O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
an O-ADR O-ADR
allergic O-ADR O-ADR
reaction O-ADR O-ADR
to O-ADR O-ADR
Teflaro O-ADR O-ADR
occurs O-ADR O-ADR
, O-ADR O-ADR
discontinue O-ADR O-ADR
Teflaro O-ADR O-ADR
and O-ADR O-ADR
institute O-ADR O-ADR
appropriate O-ADR O-ADR
treatment O-ADR O-ADR
and O-ADR O-ADR
supportive O-ADR O-ADR
measures O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
identified O-ADR O-ADR
during O-ADR O-ADR
post O-ADR O-ADR
- O-ADR O-ADR
approval O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
subcutaneous O-ADR O-ADR
formulation O-ADR O-ADR
of O-ADR O-ADR
golimumab O-ADR O-ADR
. O-ADR O-ADR
Conditions O-ADR O-ADR
that O-ADR O-ADR
lower O-ADR O-ADR
the O-ADR O-ADR
seizure O-ADR O-ADR
threshold O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
more O-ADR O-ADR
prevalent O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
65 O-ADR O-ADR
years O-ADR O-ADR
or O-ADR O-ADR
older O-ADR O-ADR
. O-ADR O-ADR
ALT O-ADR O-ADR
= O-ADR O-ADR
Alanine O-ADR O-ADR
aminotransferase O-ADR O-ADR
; O-ADR O-ADR
AST O-ADR O-ADR
= O-ADR O-ADR
Aspartate O-ADR O-ADR
aminotransferase O-ADR O-ADR
; O-ADR O-ADR
GGT O-ADR O-ADR
= O-ADR O-ADR
Gamma O-ADR O-ADR
glutamyltransferase O-ADR O-ADR
. O-ADR O-ADR
Other O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
which O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
2 O-ADR O-ADR
- O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
were O-ADR O-ADR
eye B-ADR B-ADR
irritation I-ADR I-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
nasopharyngitis B-ADR B-ADR
. O-ADR O-ADR
One O-ADR O-ADR
additional O-ADR O-ADR
patient O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
death B-ADR B-ADR
was O-ADR O-ADR
attributed O-ADR O-ADR
to O-ADR O-ADR
neutropenia B-ADR B-ADR
without O-ADR O-ADR
a O-ADR O-ADR
documented O-ADR O-ADR
infection B-ADR B-ADR
. O-ADR O-ADR
Spirometric O-ADR O-ADR
evaluation O-ADR O-ADR
of O-ADR O-ADR
respiratory O-ADR O-ADR
function O-ADR O-ADR
and O-ADR O-ADR
evaluation O-ADR O-ADR
of O-ADR O-ADR
DLCO O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
performed O-ADR O-ADR
during O-ADR O-ADR
therapy O-ADR O-ADR
with O-ADR O-ADR
GILENYA O-ADR O-ADR
if O-ADR O-ADR
clinically O-ADR O-ADR
indicated O-ADR O-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
anaphylaxis O-ADR O-ADR
, O-ADR O-ADR
KALBITOR O-ADR O-ADR
should O-ADR O-ADR
only O-ADR O-ADR
be O-ADR O-ADR
administered O-ADR O-ADR
by O-ADR O-ADR
a O-ADR O-ADR
healthcare O-ADR O-ADR
professional O-ADR O-ADR
with O-ADR O-ADR
appropriate O-ADR O-ADR
medical O-ADR O-ADR
support O-ADR O-ADR
to O-ADR O-ADR
manage O-ADR O-ADR
anaphylaxis O-ADR O-ADR
and O-ADR O-ADR
hereditary O-ADR O-ADR
angioedema O-ADR O-ADR
. O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
Exclusive O-ADR O-ADR
of O-ADR O-ADR
an O-ADR O-ADR
uncommon O-ADR O-ADR
, O-ADR O-ADR
mild O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
reaction I-ADR I-ADR
, O-ADR O-ADR
no O-ADR O-ADR
other O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
Serious O-ADR O-ADR
allergic B-ADR B-ADR
reactions I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
anaphylactic B-ADR B-ADR
reactions I-ADR I-ADR
, O-ADR O-ADR
may O-ADR O-ADR
occur O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
who O-ADR O-ADR
are O-ADR O-ADR
coinfected O-ADR O-ADR
with O-ADR O-ADR
HIV O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
HBV O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
closely O-ADR O-ADR
monitored O-ADR O-ADR
with O-ADR O-ADR
both O-ADR O-ADR
clinical O-ADR O-ADR
and O-ADR O-ADR
laboratory O-ADR O-ADR
follow O-ADR O-ADR
- O-ADR O-ADR
up O-ADR O-ADR
for O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
several O-ADR O-ADR
months O-ADR O-ADR
after O-ADR O-ADR
stopping O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
STRIBILD O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
all O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
trials O-ADR O-ADR
combined O-ADR O-ADR
, O-ADR O-ADR
857 O-ADR O-ADR
, O-ADR O-ADR
701 O-ADR O-ADR
, O-ADR O-ADR
529 O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
105 O-ADR O-ADR
patients O-ADR O-ADR
received O-ADR O-ADR
Toviaz O-ADR O-ADR
for O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
6 O-ADR O-ADR
months O-ADR O-ADR
, O-ADR O-ADR
1 O-ADR O-ADR
year O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
years O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
3 O-ADR O-ADR
years O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
Although O-ADR O-ADR
the O-ADR O-ADR
causes O-ADR O-ADR
of O-ADR O-ADR
death B-ADR B-ADR
were O-ADR O-ADR
varied O-ADR O-ADR
, O-ADR O-ADR
most O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
deaths B-ADR B-ADR
appeared O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
either O-ADR O-ADR
cardiovascular O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
heart B-ADR O-ADR
failure I-ADR I-ADR
, O-ADR O-ADR
sudden B-ADR B-ADR
death I-ADR I-ADR
) O-ADR O-ADR
or O-ADR O-ADR
infectious O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
pneumonia B-ADR B-ADR
) O-ADR O-ADR
in O-ADR O-ADR
nature O-ADR O-ADR
. O-ADR O-ADR
Serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
, O-ADR O-ADR
whether O-ADR O-ADR
considered O-ADR O-ADR
drug O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
or O-ADR O-ADR
not O-ADR O-ADR
by O-ADR O-ADR
the O-ADR O-ADR
investigators O-ADR O-ADR
, O-ADR O-ADR
that O-ADR O-ADR
occurred O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
in O-ADR O-ADR
KALYDECO O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
included O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
increased B-ADR B-ADR
hepatic I-ADR I-ADR
enzymes I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
hypoglycemia B-ADR B-ADR
. O-ADR O-ADR
There O-ADR O-ADR
were O-ADR O-ADR
no O-ADR O-ADR
reports O-ADR O-ADR
of O-ADR O-ADR
gynecomastia B-ADR B-ADR
in O-ADR O-ADR
this O-ADR O-ADR
trial O-ADR O-ADR
. O-ADR O-ADR
Symptoms O-ADR O-ADR
of O-ADR O-ADR
taking O-ADR O-ADR
too O-ADR O-ADR
much O-ADR O-ADR
DUAVEE O-ADR O-ADR
include O-ADR O-ADR
: O-ADR O-ADR
nauseavomitingbreast O-ADR B-ADR
tendernessdizzinessabdominal O-ADR I-ADR
painfeeling O-ADR I-ADR
tiredvaginal O-ADR B-ADR
bleeding O-ADR I-ADR
What O-ADR O-ADR
are O-ADR O-ADR
the O-ADR O-ADR
possible O-ADR O-ADR
side O-ADR O-ADR
effects O-ADR O-ADR
of O-ADR O-ADR
DUAVEE O-ADR O-ADR
? O-ADR O-ADR
Approximately O-ADR O-ADR
8500 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
type O-ADR O-ADR
2 O-ADR O-ADR
diabetes O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
NESINA O-ADR O-ADR
in O-ADR O-ADR
14 O-ADR O-ADR
randomized O-ADR O-ADR
, O-ADR O-ADR
double O-ADR O-ADR
- O-ADR O-ADR
blind O-ADR O-ADR
, O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
with O-ADR O-ADR
approximately O-ADR O-ADR
2900 O-ADR O-ADR
subjects O-ADR O-ADR
randomized O-ADR O-ADR
to O-ADR O-ADR
placebo O-ADR O-ADR
and O-ADR O-ADR
approximately O-ADR O-ADR
2200 O-ADR O-ADR
to O-ADR O-ADR
an O-ADR O-ADR
active O-ADR O-ADR
comparator O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
median O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
was O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
months O-ADR O-ADR
with O-ADR O-ADR
XTANDI O-ADR O-ADR
and O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
months O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
of O-ADR O-ADR
gabapentin O-ADR O-ADR
as O-ADR O-ADR
adjunctive O-ADR O-ADR
therapy O-ADR O-ADR
in O-ADR O-ADR
epilepsy O-ADR O-ADR
comprising O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
085 O-ADR O-ADR
patient O-ADR O-ADR
- O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
exposure O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
> O-ADR O-ADR
12 O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
age O-ADR O-ADR
, O-ADR O-ADR
new O-ADR O-ADR
tumors B-ADR O-ADR
, O-ADR O-ADR
1 O-ADR O-ADR
non B-ADR B-ADR
- O-ADR O-ADR
Hodgkin O-ADR O-ADR
' I-ADR I-ADR
s O-ADR O-ADR
lymphoma I-ADR I-ADR
, O-ADR O-ADR
1 O-ADR O-ADR
endometrial B-ADR B-ADR
carcinoma I-ADR I-ADR
in I-ADR I-ADR
situ I-ADR I-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
preexisting O-ADR O-ADR
tumors B-ADR B-ADR
worsened I-ADR O-ADR
in I-ADR O-ADR
11 I-ADR O-ADR
patients I-ADR O-ADR
( I-ADR O-ADR
9 I-ADR O-ADR
brain I-ADR O-ADR
) O-ADR O-ADR
during O-ADR O-ADR
or O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
2 O-ADR O-ADR
years O-ADR O-ADR
following O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
gabapentin O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
drug O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
assessed O-ADR O-ADR
as O-ADR O-ADR
causally O-ADR O-ADR
related O-ADR O-ADR
by O-ADR O-ADR
the O-ADR O-ADR
investigator O-ADR O-ADR
or O-ADR O-ADR
ADRs O-ADR O-ADR
) O-ADR O-ADR
are O-ADR O-ADR
discussed O-ADR O-ADR
in O-ADR O-ADR
other O-ADR O-ADR
sections O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
labeling O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
reactions O-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
who O-ADR O-ADR
experienced O-ADR O-ADR
bradycardia B-ADR B-ADR
were O-ADR O-ADR
generally O-ADR O-ADR
asymptomatic O-ADR O-ADR
, O-ADR O-ADR
but O-ADR O-ADR
some O-ADR O-ADR
patients O-ADR O-ADR
experienced O-ADR O-ADR
hypotension B-ADR B-ADR
, O-ADR O-ADR
dizziness B-ADR B-ADR
, O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
palpitations B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
chest B-ADR B-ADR
pain I-ADR I-ADR
that O-ADR O-ADR
usually O-ADR O-ADR
resolved O-ADR O-ADR
within O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
24 O-ADR O-ADR
hours O-ADR O-ADR
on O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
Healthcare O-ADR O-ADR
providers O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
aware O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
hypersensitivity O-ADR O-ADR
reactions O-ADR O-ADR
, O-ADR O-ADR
which O-ADR O-ADR
may O-ADR O-ADR
present O-ADR O-ADR
as O-ADR O-ADR
infusion O-ADR O-ADR
reactions O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
monitor O-ADR O-ADR
patients O-ADR O-ADR
closely O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
eyelid B-ADR B-ADR
ptosis I-ADR I-ADR
did O-ADR O-ADR
not O-ADR O-ADR
increase O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
safety O-ADR O-ADR
studies O-ADR O-ADR
with O-ADR O-ADR
multiple O-ADR O-ADR
re O-ADR O-ADR
- O-ADR O-ADR
treatments O-ADR O-ADR
at O-ADR O-ADR
intervals O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
three O-ADR O-ADR
months O-ADR O-ADR
. O-ADR O-ADR
Perform O-ADR O-ADR
hepatic O-ADR O-ADR
enzyme O-ADR O-ADR
tests O-ADR O-ADR
monthly O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
three O-ADR O-ADR
months O-ADR O-ADR
of O-ADR O-ADR
BOSULIF O-ADR O-ADR
treatment O-ADR O-ADR
and O-ADR O-ADR
as O-ADR O-ADR
clinically O-ADR O-ADR
indicated O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
were O-ADR O-ADR
no O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
kidney O-ADR B-ADR
failure O-ADR I-ADR
at O-ADR O-ADR
baseline O-ADR O-ADR
. O-ADR O-ADR
Use O-ADR O-ADR
caution O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
patient O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
angioedema O-ADR O-ADR
with O-ADR O-ADR
another O-ADR O-ADR
DPP O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
inhibitor O-ADR O-ADR
because O-ADR O-ADR
it O-ADR O-ADR
is O-ADR O-ADR
unknown O-ADR O-ADR
whether O-ADR O-ADR
such O-ADR O-ADR
patients O-ADR O-ADR
will O-ADR O-ADR
be O-ADR O-ADR
predisposed O-ADR O-ADR
to O-ADR O-ADR
angioedema O-ADR O-ADR
with O-ADR O-ADR
NESINA O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Anaphylaxis O-ADR O-ADR
and O-ADR O-ADR
Hypersensitivity O-ADR O-ADR
Reactions O-ADR O-ADR
Anaphylaxis B-ADR B-ADR
and O-ADR O-ADR
hypersensitivity B-ADR B-ADR
reactions O-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
Vimizim O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
this O-ADR O-ADR
drug O-ADR O-ADR
is O-ADR O-ADR
used O-ADR O-ADR
during O-ADR O-ADR
pregnancy O-ADR O-ADR
or O-ADR O-ADR
if O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
becomes O-ADR O-ADR
pregnant O-ADR O-ADR
while O-ADR O-ADR
taking O-ADR O-ADR
this O-ADR O-ADR
drug O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
apprised O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
hazard O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
fetus O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Anyone O-ADR O-ADR
considering O-ADR O-ADR
prescribing O-ADR O-ADR
APTIOM O-ADR O-ADR
or O-ADR O-ADR
any O-ADR O-ADR
other O-ADR O-ADR
AED O-ADR O-ADR
must O-ADR O-ADR
balance O-ADR O-ADR
this O-ADR O-ADR
risk O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
untreated O-ADR O-ADR
illness O-ADR O-ADR
. O-ADR O-ADR
Eosinophilia B-ADR B-ADR
is O-ADR O-ADR
often O-ADR O-ADR
present O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
11 O-ADR O-ADR
, O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Perforations O-ADR O-ADR
and O-ADR O-ADR
Fistulas O-ADR O-ADR
GI B-ADR B-ADR
) I-ADR I-ADR
perforations I-ADR I-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
COMETRIQ O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
RETINAL B-ADR B-ADR
ABNORMALITIES I-ADR I-ADR
AND O-ADR O-ADR
POTENTIAL O-ADR O-ADR
VISION B-ADR B-ADR
LOSS I-ADR I-ADR
See O-ADR O-ADR
full O-ADR O-ADR
prescribing O-ADR O-ADR
information O-ADR O-ADR
for O-ADR O-ADR
complete O-ADR O-ADR
boxed O-ADR O-ADR
warning O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Spinal O-ADR O-ADR
/ O-ADR O-ADR
Epidural O-ADR O-ADR
Anesthesia O-ADR O-ADR
or O-ADR O-ADR
Puncture O-ADR O-ADR
When O-ADR O-ADR
neuraxial O-ADR O-ADR
anesthesia O-ADR O-ADR
( O-ADR O-ADR
spinal O-ADR O-ADR
/ O-ADR O-ADR
epidural O-ADR O-ADR
anesthesia O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
spinal O-ADR O-ADR
puncture O-ADR O-ADR
is O-ADR O-ADR
employed O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
anticoagulant O-ADR O-ADR
agents O-ADR O-ADR
are O-ADR O-ADR
at O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
developing O-ADR O-ADR
an O-ADR O-ADR
spinal B-ADR B-ADR
hematoma I-ADR I-ADR
which O-ADR O-ADR
can O-ADR O-ADR
result O-ADR O-ADR
in O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
or O-ADR O-ADR
paralysis B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Boxed O-ADR O-ADR
Warning O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Assess O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
enterocolitis O-ADR O-ADR
, O-ADR O-ADR
dermatitis O-ADR O-ADR
, O-ADR O-ADR
neuropathy O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
endocrinopathy O-ADR O-ADR
and O-ADR O-ADR
evaluate O-ADR O-ADR
clinical O-ADR O-ADR
chemistries O-ADR O-ADR
including O-ADR O-ADR
liver O-ADR O-ADR
function O-ADR O-ADR
tests O-ADR O-ADR
and O-ADR O-ADR
thyroid O-ADR O-ADR
function O-ADR O-ADR
tests O-ADR O-ADR
at O-ADR O-ADR
baseline O-ADR O-ADR
and O-ADR O-ADR
before O-ADR O-ADR
each O-ADR O-ADR
dose O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
hypertension O-ADR O-ADR
, O-ADR O-ADR
hypokalemia O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
fluid O-ADR O-ADR
retention O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
once O-ADR O-ADR
a O-ADR O-ADR
month O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
this O-ADR O-ADR
situation O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
requires O-ADR O-ADR
immediate O-ADR O-ADR
reevaluation O-ADR O-ADR
with O-ADR O-ADR
reassessment O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
regimen O-ADR O-ADR
, O-ADR O-ADR
giving O-ADR O-ADR
special O-ADR O-ADR
consideration O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
possible O-ADR O-ADR
need O-ADR O-ADR
for O-ADR O-ADR
replacing O-ADR O-ADR
the O-ADR O-ADR
current O-ADR O-ADR
strength O-ADR O-ADR
of O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
higher O-ADR O-ADR
strength O-ADR O-ADR
, O-ADR O-ADR
adding O-ADR O-ADR
additional O-ADR O-ADR
inhaled O-ADR O-ADR
corticosteroid O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
initiating O-ADR O-ADR
systemic O-ADR O-ADR
corticosteroids O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
hepatotoxicity O-ADR O-ADR
, O-ADR O-ADR
rule O-ADR O-ADR
out O-ADR O-ADR
infectious O-ADR O-ADR
or O-ADR O-ADR
malignant O-ADR O-ADR
causes O-ADR O-ADR
and O-ADR O-ADR
increase O-ADR O-ADR
frequency O-ADR O-ADR
of O-ADR O-ADR
liver O-ADR O-ADR
function O-ADR O-ADR
test O-ADR O-ADR
monitoring O-ADR O-ADR
until O-ADR O-ADR
resolution O-ADR O-ADR
. O-ADR O-ADR
Bradycardia B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
as O-ADR O-ADR
an O-ADR O-ADR
adverse O-ADR O-ADR
drug O-ADR O-ADR
reaction O-ADR O-ADR
in O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Failure O-ADR O-ADR
to O-ADR O-ADR
block O-ADR O-ADR
thyroid O-ADR O-ADR
iodine O-ADR O-ADR
uptake O-ADR O-ADR
may O-ADR O-ADR
result O-ADR O-ADR
in O-ADR O-ADR
iodine O-ADR O-ADR
123 O-ADR O-ADR
accumulation O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
thyroid O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Embryo B-ADR B-ADR
- O-ADR O-ADR
fetal O-ADR O-ADR
toxicity I-ADR I-ADR
: O-ADR O-ADR
Beleodaq O-ADR O-ADR
may O-ADR O-ADR
cause O-ADR O-ADR
fetal B-ADR B-ADR
harm I-ADR I-ADR
when O-ADR O-ADR
administered O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
pregnant O-ADR O-ADR
woman O-ADR O-ADR
. O-ADR O-ADR
At O-ADR O-ADR
the O-ADR O-ADR
time O-ADR O-ADR
of O-ADR O-ADR
perforation O-ADR B-ADR
, O-ADR O-ADR
some O-ADR O-ADR
patients O-ADR O-ADR
had O-ADR O-ADR
moderate O-ADR O-ADR
to O-ADR O-ADR
severe O-ADR O-ADR
diarrhea B-ADR B-ADR
. O-ADR O-ADR
Advise O-ADR O-ADR
females O-ADR O-ADR
of O-ADR O-ADR
reproductive O-ADR O-ADR
potential O-ADR O-ADR
to O-ADR O-ADR
avoid O-ADR O-ADR
becoming O-ADR O-ADR
pregnant O-ADR O-ADR
while O-ADR O-ADR
taking O-ADR O-ADR
Zydelig O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
concomitant O-ADR O-ADR
immunosuppressant O-ADR O-ADR
therapy O-ADR O-ADR
( O-ADR O-ADR
MTX O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
RA O-ADR O-ADR
- O-ADR O-ADR
I O-ADR O-ADR
, O-ADR O-ADR
RA O-ADR O-ADR
- O-ADR O-ADR
II O-ADR O-ADR
, O-ADR O-ADR
RA O-ADR O-ADR
- O-ADR O-ADR
III O-ADR O-ADR
had O-ADR O-ADR
a O-ADR O-ADR
lower O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
neutralizing O-ADR O-ADR
antibody O-ADR O-ADR
formation O-ADR O-ADR
overall O-ADR O-ADR
than O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
CIMZIA O-ADR O-ADR
monotherapy O-ADR O-ADR
in O-ADR O-ADR
RA O-ADR O-ADR
- O-ADR O-ADR
IV O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
vs O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
Reaction O-ADR O-ADR
Placebo O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
568 O-ADR O-ADR
) O-ADR O-ADR
% O-ADR O-ADR
Trulicity O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
75 O-ADR O-ADR
mg O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
836 O-ADR O-ADR
) O-ADR O-ADR
% O-ADR O-ADR
Trulicity O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
834 O-ADR O-ADR
) O-ADR O-ADR
% O-ADR O-ADR
Nausea B-ADR B-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
21 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Diarrhea B-ADR B-ADR
a O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Vomiting B-ADR B-ADR
b O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
Abdominal B-ADR B-ADR
Pain I-ADR I-ADR
c O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
9 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Decreased B-ADR B-ADR
Appetite I-ADR I-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Dyspepsia B-ADR B-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
Fatigue B-ADR B-ADR
d O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Gastrointestinal O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
pool O-ADR O-ADR
of O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
gastrointestinal B-ADR B-ADR
adverse I-ADR I-ADR
reactions I-ADR I-ADR
occurred O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
among O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
TRULICITY O-ADR O-ADR
than O-ADR O-ADR
placebo O-ADR O-ADR
( O-ADR O-ADR
placebo O-ADR O-ADR
21 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
75 O-ADR O-ADR
mg O-ADR O-ADR
31 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
41 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
with O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
incidence O-ADR O-ADR
for O-ADR O-ADR
any O-ADR O-ADR
grade O-ADR O-ADR
or O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
incidence O-ADR O-ADR
for O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
or O-ADR O-ADR
higher O-ADR O-ADR
are O-ADR O-ADR
summarized O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
immune B-ADR O-ADR
- O-ADR O-ADR
mediated O-ADR O-ADR
reactions I-ADR I-ADR
may O-ADR O-ADR
involve O-ADR O-ADR
any O-ADR O-ADR
organ O-ADR O-ADR
system O-ADR O-ADR
; O-ADR O-ADR
however O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
severe O-ADR O-ADR
immune B-ADR B-ADR
- O-ADR O-ADR
mediated O-ADR O-ADR
adverse I-ADR I-ADR
reactions I-ADR I-ADR
are O-ADR O-ADR
enterocolitis B-ADR B-ADR
, O-ADR O-ADR
hepatitis B-ADR B-ADR
, O-ADR O-ADR
dermatitis B-ADR B-ADR
( O-ADR O-ADR
including O-ADR O-ADR
toxic B-ADR B-ADR
epidermal I-ADR I-ADR
necrolysis I-ADR I-ADR
) O-ADR O-ADR
, O-ADR O-ADR
neuropathy B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
endocrinopathy B-ADR B-ADR
. O-ADR O-ADR
Adequately O-ADR O-ADR
supplement O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
calcium O-ADR O-ADR
and O-ADR O-ADR
vitamin O-ADR O-ADR
D O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Osteonecrosis B-ADR B-ADR
of I-ADR I-ADR
the I-ADR I-ADR
jaw I-ADR I-ADR
: O-ADR O-ADR
Has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
Prolia O-ADR O-ADR
. O-ADR O-ADR
Therefore O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
lower O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
insulin O-ADR O-ADR
or O-ADR O-ADR
insulin O-ADR O-ADR
secretagogue O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
required O-ADR O-ADR
to O-ADR O-ADR
minimize O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
hypoglycemia O-ADR O-ADR
when O-ADR O-ADR
used O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
NESINA O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
4 O-ADR O-ADR
: O-ADR O-ADR
Incidence O-ADR O-ADR
of O-ADR O-ADR
Hematology O-ADR O-ADR
Laboratory O-ADR O-ADR
Abnormalities O-ADR O-ADR
in O-ADR O-ADR
Patients O-ADR O-ADR
Who O-ADR O-ADR
Received O-ADR O-ADR
TREANDA O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
NHL O-ADR O-ADR
Studies O-ADR O-ADR
Percent O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
Hematology O-ADR O-ADR
variable O-ADR O-ADR
All O-ADR O-ADR
Grades O-ADR O-ADR
Grades O-ADR O-ADR
3 O-ADR O-ADR
/ O-ADR O-ADR
4 O-ADR O-ADR
Lymphocytes B-ADR B-ADR
Decreased I-ADR I-ADR
99 O-ADR O-ADR
94 O-ADR O-ADR
Leukocytes B-ADR B-ADR
Decreased I-ADR I-ADR
94 O-ADR O-ADR
56 O-ADR O-ADR
Hemoglobin B-ADR B-ADR
Decreased I-ADR I-ADR
88 O-ADR O-ADR
11 O-ADR O-ADR
Neutrophils B-ADR B-ADR
Decreased I-ADR I-ADR
86 O-ADR O-ADR
60 O-ADR O-ADR
Platelets B-ADR B-ADR
Decreased I-ADR I-ADR
86 O-ADR O-ADR
25 O-ADR O-ADR
In O-ADR O-ADR
both O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
, O-ADR O-ADR
regardless O-ADR O-ADR
of O-ADR O-ADR
causality O-ADR O-ADR
, O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
37 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
TREANDA O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Macrovascular O-ADR O-ADR
Outcomes O-ADR O-ADR
There O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
no O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
establishing O-ADR O-ADR
conclusive O-ADR O-ADR
evidence O-ADR O-ADR
of O-ADR O-ADR
macrovascular O-ADR O-ADR
risk O-ADR O-ADR
reduction O-ADR O-ADR
with O-ADR O-ADR
NESINA O-ADR O-ADR
or O-ADR O-ADR
any O-ADR O-ADR
other O-ADR O-ADR
antidiabetic O-ADR O-ADR
drug O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
frequent O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
PRADAXA O-ADR O-ADR
were O-ADR O-ADR
bleeding B-ADR B-ADR
and O-ADR O-ADR
gastrointestinal B-ADR B-ADR
events I-ADR I-ADR
( O-ADR O-ADR
i O-ADR O-ADR
. O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
dyspepsia B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
upper B-ADR B-ADR
abdominal I-ADR I-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
gastrointestinal B-ADR B-ADR
hemorrhage I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
diarrhea B-ADR B-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
nonfatal O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
was O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
group O-ADR O-ADR
and O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Prolia O-ADR O-ADR
group O-ADR O-ADR
. O-ADR O-ADR
An O-ADR O-ADR
increased O-ADR O-ADR
incidence O-ADR O-ADR
was O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
300 O-ADR O-ADR
mg O-ADR O-ADR
dose O-ADR O-ADR
. O-ADR O-ADR
Increasing O-ADR O-ADR
inhaled O-ADR O-ADR
beta2 O-ADR O-ADR
- O-ADR O-ADR
agonist O-ADR O-ADR
use O-ADR O-ADR
is O-ADR O-ADR
a O-ADR O-ADR
signal O-ADR O-ADR
of O-ADR O-ADR
deteriorating O-ADR O-ADR
disease O-ADR O-ADR
for O-ADR O-ADR
which O-ADR O-ADR
prompt O-ADR O-ADR
medical O-ADR O-ADR
attention O-ADR O-ADR
is O-ADR O-ADR
indicated O-ADR O-ADR
. O-ADR O-ADR
Five O-ADR O-ADR
patients O-ADR O-ADR
experienced O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
of O-ADR O-ADR
hypersensitivity B-ADR B-ADR
with O-ADR O-ADR
INVOKANA O-ADR O-ADR
, O-ADR O-ADR
which O-ADR O-ADR
included O-ADR O-ADR
4 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
urticaria B-ADR B-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
patient O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
diffuse B-ADR B-ADR
rash I-ADR I-ADR
and O-ADR O-ADR
urticaria B-ADR B-ADR
occurring O-ADR O-ADR
within O-ADR O-ADR
hours O-ADR O-ADR
of O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
INVOKANA O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Radiation B-ADR B-ADR
risk I-ADR I-ADR
: O-ADR O-ADR
Amyvid O-ADR O-ADR
, O-ADR O-ADR
similar O-ADR O-ADR
to O-ADR O-ADR
all O-ADR O-ADR
radiopharmaceuticals O-ADR O-ADR
, O-ADR O-ADR
contributes O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
patient O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
long B-ADR B-ADR
- O-ADR O-ADR
term O-ADR O-ADR
cumulative I-ADR I-ADR
radiation I-ADR I-ADR
exposure I-ADR I-ADR
. O-ADR O-ADR
None O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
abnormalities O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
group O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Extravasation O-ADR O-ADR
and O-ADR O-ADR
Injection O-ADR O-ADR
Site O-ADR O-ADR
Reactions O-ADR O-ADR
Ensure O-ADR O-ADR
catheter O-ADR O-ADR
and O-ADR O-ADR
venous O-ADR O-ADR
patency O-ADR O-ADR
before O-ADR O-ADR
the O-ADR O-ADR
injection O-ADR O-ADR
of O-ADR O-ADR
DOTAREM O-ADR O-ADR
. O-ADR O-ADR
INLYTA O-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
studied O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
had O-ADR O-ADR
an O-ADR O-ADR
arterial O-ADR O-ADR
thromboembolic O-ADR O-ADR
event O-ADR O-ADR
within O-ADR O-ADR
the O-ADR O-ADR
previous O-ADR O-ADR
12 O-ADR O-ADR
months O-ADR O-ADR
. O-ADR O-ADR
Use O-ADR O-ADR
of O-ADR O-ADR
live O-ADR O-ADR
vaccines O-ADR O-ADR
could O-ADR O-ADR
result O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
infections O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
disseminated O-ADR O-ADR
infections O-ADR O-ADR
. O-ADR O-ADR
Two O-ADR O-ADR
suicides B-ADR B-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
BENLYSTA O-ADR O-ADR
. O-ADR O-ADR
Discontinue O-ADR O-ADR
if O-ADR O-ADR
significant O-ADR O-ADR
liver O-ADR O-ADR
injury O-ADR O-ADR
occurs O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
premarketing O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
all O-ADR O-ADR
patient O-ADR O-ADR
populations O-ADR O-ADR
combined O-ADR O-ADR
the O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
upper B-ADR B-ADR
respiratory I-ADR I-ADR
infections I-ADR I-ADR
( O-ADR O-ADR
18 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
( O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
urinary B-ADR B-ADR
tract I-ADR I-ADR
infections I-ADR I-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Other O-ADR O-ADR
Reactions O-ADR O-ADR
During O-ADR O-ADR
the O-ADR O-ADR
Premarketing O-ADR O-ADR
Evaluation O-ADR O-ADR
of O-ADR O-ADR
FANAPT O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
is O-ADR O-ADR
a O-ADR O-ADR
list O-ADR O-ADR
of O-ADR O-ADR
MedDRA O-ADR O-ADR
terms O-ADR O-ADR
that O-ADR O-ADR
reflect O-ADR O-ADR
treatment O-ADR O-ADR
- O-ADR O-ADR
emergent O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
FANAPT O-ADR O-ADR
at O-ADR O-ADR
multiple O-ADR O-ADR
doses O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
4 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
day O-ADR O-ADR
during O-ADR O-ADR
any O-ADR O-ADR
phase O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
trial O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
database O-ADR O-ADR
of O-ADR O-ADR
3210 O-ADR O-ADR
FANAPT O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Do O-ADR O-ADR
not O-ADR O-ADR
take O-ADR O-ADR
2 O-ADR O-ADR
doses O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
same O-ADR O-ADR
time O-ADR O-ADR
unless O-ADR O-ADR
your O-ADR O-ADR
healthcare O-ADR O-ADR
provider O-ADR O-ADR
tells O-ADR O-ADR
you O-ADR O-ADR
to O-ADR O-ADR
. O-ADR O-ADR
More O-ADR O-ADR
GILOTRIF O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
; O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
experienced O-ADR O-ADR
ventricular B-ADR B-ADR
dysfunction I-ADR I-ADR
( O-ADR O-ADR
defined O-ADR O-ADR
as O-ADR O-ADR
diastolic B-ADR B-ADR
dysfunction I-ADR I-ADR
, O-ADR O-ADR
left B-ADR B-ADR
ventricular I-ADR I-ADR
dysfunction I-ADR I-ADR
, O-ADR O-ADR
or O-ADR O-ADR
ventricular B-ADR B-ADR
dilation I-ADR I-ADR
; O-ADR O-ADR
all O-ADR O-ADR
< O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
chemotherapy O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
; O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Dose O-ADR O-ADR
reductions O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
12 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
JEVTANA O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
mitoxantrone O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Appropriate O-ADR O-ADR
screening O-ADR O-ADR
tests O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
performed O-ADR O-ADR
in O-ADR O-ADR
all O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Allergic O-ADR O-ADR
Reactions O-ADR O-ADR
Serious O-ADR O-ADR
allergic B-ADR B-ADR
reactions I-ADR I-ADR
including O-ADR O-ADR
anaphylaxis B-ADR B-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
human O-ADR O-ADR
granulocyte O-ADR O-ADR
colony O-ADR O-ADR
- O-ADR O-ADR
stimulating O-ADR O-ADR
factors O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
ECG B-ADR B-ADR
Changes I-ADR O-ADR
and O-ADR O-ADR
Potential O-ADR O-ADR
for O-ADR O-ADR
Cardiac B-ADR O-ADR
Arrhythmias I-ADR O-ADR
: O-ADR O-ADR
Not O-ADR O-ADR
recommended O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
pre O-ADR O-ADR
- O-ADR O-ADR
existing O-ADR O-ADR
cardiac O-ADR O-ADR
disease O-ADR O-ADR
, O-ADR O-ADR
long O-ADR O-ADR
QT O-ADR O-ADR
syndrome O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
concomitant O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
Class O-ADR O-ADR
IA O-ADR O-ADR
and O-ADR O-ADR
Class O-ADR O-ADR
III O-ADR O-ADR
antiarrhythmics O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Drug O-ADR O-ADR
- O-ADR O-ADR
Drug O-ADR O-ADR
Interactions O-ADR O-ADR
Eliglustat O-ADR O-ADR
is O-ADR O-ADR
a O-ADR O-ADR
CYP2D6 O-ADR O-ADR
and O-ADR O-ADR
CYP3A O-ADR O-ADR
substrate O-ADR O-ADR
. O-ADR O-ADR
Data O-ADR O-ADR
from O-ADR O-ADR
a O-ADR O-ADR
large O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
US O-ADR O-ADR
trial O-ADR O-ADR
that O-ADR O-ADR
compared O-ADR O-ADR
the O-ADR O-ADR
safety O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
LABA O-ADR O-ADR
( O-ADR O-ADR
salmeterol O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
placebo O-ADR O-ADR
added O-ADR O-ADR
to O-ADR O-ADR
usual O-ADR O-ADR
asthma O-ADR O-ADR
therapy O-ADR O-ADR
showed O-ADR O-ADR
an O-ADR O-ADR
increase O-ADR O-ADR
in O-ADR O-ADR
asthma O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
deaths B-ADR B-ADR
in O-ADR O-ADR
subjects O-ADR O-ADR
receiving O-ADR O-ADR
salmeterol O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Maintain O-ADR O-ADR
aseptic O-ADR O-ADR
technique O-ADR O-ADR
. O-ADR O-ADR
Volume O-ADR O-ADR
Depletion O-ADR O-ADR
JARDIANCE O-ADR O-ADR
causes O-ADR O-ADR
an O-ADR O-ADR
osmotic B-ADR B-ADR
diuresis I-ADR I-ADR
, O-ADR O-ADR
which O-ADR O-ADR
may O-ADR O-ADR
lead O-ADR O-ADR
to O-ADR O-ADR
intravascular B-ADR B-ADR
volume I-ADR I-ADR
contraction I-ADR I-ADR
and O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
related O-ADR O-ADR
to O-ADR O-ADR
volume B-ADR B-ADR
depletion I-ADR I-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Patients O-ADR O-ADR
who O-ADR O-ADR
receive O-ADR O-ADR
prolonged O-ADR O-ADR
Cleviprex O-ADR O-ADR
infusions O-ADR O-ADR
and O-ADR O-ADR
are O-ADR O-ADR
not O-ADR O-ADR
transitioned O-ADR O-ADR
to O-ADR O-ADR
other O-ADR O-ADR
antihypertensive O-ADR O-ADR
therapies O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
monitored O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
possibility O-ADR O-ADR
of O-ADR O-ADR
rebound O-ADR O-ADR
hypertension O-ADR O-ADR
for O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
8 O-ADR O-ADR
hours O-ADR O-ADR
after O-ADR O-ADR
the O-ADR O-ADR
infusion O-ADR O-ADR
is O-ADR O-ADR
stopped O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
is O-ADR O-ADR
insufficient O-ADR O-ADR
information O-ADR O-ADR
to O-ADR O-ADR
determine O-ADR O-ADR
the O-ADR O-ADR
reversibility O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
decrease B-ADR B-ADR
of I-ADR I-ADR
DLCO I-ADR I-ADR
after O-ADR O-ADR
drug O-ADR O-ADR
discontinuation O-ADR O-ADR
. O-ADR O-ADR
PRISTIQ O-ADR O-ADR
should O-ADR O-ADR
also O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
started O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
patient O-ADR O-ADR
who O-ADR O-ADR
is O-ADR O-ADR
being O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
MAOIs O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
linezolid O-ADR O-ADR
or O-ADR O-ADR
intravenous O-ADR O-ADR
methylene O-ADR O-ADR
blue O-ADR O-ADR
. O-ADR O-ADR
Antimalarials O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
given O-ADR O-ADR
concomitantly O-ADR O-ADR
with O-ADR O-ADR
Coartem O-ADR O-ADR
Tablets O-ADR O-ADR
, O-ADR O-ADR
unless O-ADR O-ADR
there O-ADR O-ADR
is O-ADR O-ADR
no O-ADR O-ADR
other O-ADR O-ADR
treatment O-ADR O-ADR
option O-ADR O-ADR
, O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
limited O-ADR O-ADR
safety O-ADR O-ADR
data O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
Greater O-ADR O-ADR
than O-ADR O-ADR
Placebo O-ADR O-ADR
) O-ADR O-ADR
from O-ADR O-ADR
Two O-ADR O-ADR
Placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
Trials O-ADR O-ADR
in O-ADR O-ADR
Adults O-ADR O-ADR
with O-ADR O-ADR
Chronic O-ADR O-ADR
Hepatitis O-ADR O-ADR
C O-ADR O-ADR
Adverse O-ADR O-ADR
Reaction O-ADR O-ADR
PROMACTA O-ADR O-ADR
+ O-ADR O-ADR
Peginterferon O-ADR O-ADR
/ O-ADR O-ADR
Ribavirin O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
955 O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Placebo O-ADR O-ADR
+ O-ADR O-ADR
Peginterferon O-ADR O-ADR
/ O-ADR O-ADR
Ribavirin O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
484 O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Anemia B-ADR B-ADR
40 O-ADR O-ADR
35 O-ADR O-ADR
Pyrexia B-ADR B-ADR
30 O-ADR O-ADR
24 O-ADR O-ADR
Fatigue B-ADR B-ADR
28 O-ADR O-ADR
23 O-ADR O-ADR
Headache B-ADR B-ADR
21 O-ADR O-ADR
20 O-ADR O-ADR
Nausea B-ADR B-ADR
19 O-ADR O-ADR
14 O-ADR O-ADR
Diarrhea B-ADR B-ADR
19 O-ADR O-ADR
11 O-ADR O-ADR
Decreased B-ADR B-ADR
appetite I-ADR I-ADR
18 O-ADR O-ADR
14 O-ADR O-ADR
Influenza B-ADR B-ADR
- O-ADR O-ADR
like O-ADR O-ADR
illness I-ADR I-ADR
18 O-ADR O-ADR
16 O-ADR O-ADR
Asthenia B-ADR B-ADR
16 O-ADR O-ADR
13 O-ADR O-ADR
Insomnia B-ADR B-ADR
16 O-ADR O-ADR
15 O-ADR O-ADR
Cough B-ADR B-ADR
15 O-ADR O-ADR
12 O-ADR O-ADR
Pruritus B-ADR B-ADR
15 O-ADR O-ADR
13 O-ADR O-ADR
Chills B-ADR B-ADR
14 O-ADR O-ADR
9 O-ADR O-ADR
Myalgia B-ADR B-ADR
12 O-ADR O-ADR
10 O-ADR O-ADR
Alopecia B-ADR B-ADR
10 O-ADR O-ADR
6 O-ADR O-ADR
Peripheral B-ADR B-ADR
edema I-ADR I-ADR
10 O-ADR O-ADR
5 O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
two O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
chronic O-ADR O-ADR
hepatitis O-ADR O-ADR
C O-ADR O-ADR
, O-ADR O-ADR
hyperbilirubinemia B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
PROMACTA O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
risks O-ADR O-ADR
and O-ADR O-ADR
benefits O-ADR O-ADR
of O-ADR O-ADR
re O-ADR O-ADR
- O-ADR O-ADR
administering O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
following O-ADR O-ADR
an O-ADR O-ADR
immune O-ADR O-ADR
- O-ADR O-ADR
mediated O-ADR O-ADR
reaction O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
placebo O-ADR O-ADR
controlled O-ADR O-ADR
study O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
permanent O-ADR O-ADR
AF O-ADR O-ADR
increased O-ADR B-ADR
rates O-ADR I-ADR
of O-ADR I-ADR
heart B-ADR I-ADR
failure I-ADR I-ADR
were O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
normal O-ADR O-ADR
left O-ADR O-ADR
ventricular O-ADR O-ADR
function O-ADR O-ADR
and O-ADR O-ADR
no O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
symptomatic O-ADR O-ADR
heart O-ADR O-ADR
failure O-ADR O-ADR
, O-ADR O-ADR
as O-ADR O-ADR
well O-ADR O-ADR
as O-ADR O-ADR
those O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
heart O-ADR O-ADR
failure O-ADR O-ADR
or O-ADR O-ADR
left O-ADR O-ADR
ventricular O-ADR O-ADR
dysfunction O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Hypersensitivity O-ADR O-ADR
Reactions O-ADR O-ADR
hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
with O-ADR O-ADR
cardiovascular O-ADR O-ADR
, O-ADR O-ADR
respiratory O-ADR O-ADR
or O-ADR O-ADR
cutaneous O-ADR O-ADR
manifestations O-ADR O-ADR
, O-ADR O-ADR
ranging O-ADR O-ADR
from O-ADR O-ADR
mild O-ADR O-ADR
to O-ADR O-ADR
severe O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
death B-ADR B-ADR
, O-ADR O-ADR
have O-ADR O-ADR
uncommonly O-ADR O-ADR
occurred O-ADR O-ADR
following O-ADR O-ADR
Gadavist O-ADR O-ADR
administration O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Based O-ADR O-ADR
on O-ADR O-ADR
published O-ADR O-ADR
literature O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
annual O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
NAION O-ADR B-ADR
is O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
- O-ADR O-ADR
11 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
cases O-ADR O-ADR
per O-ADR O-ADR
100 O-ADR O-ADR
, O-ADR O-ADR
000 O-ADR O-ADR
in O-ADR O-ADR
males O-ADR O-ADR
aged O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
50 O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
infusion O-ADR B-ADR
reaction O-ADR I-ADR
in O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
was O-ADR O-ADR
rash B-ADR B-ADR
. O-ADR O-ADR
Advise O-ADR O-ADR
patients O-ADR O-ADR
to O-ADR O-ADR
consult O-ADR O-ADR
a O-ADR O-ADR
physician O-ADR O-ADR
if O-ADR O-ADR
they O-ADR O-ADR
develop O-ADR O-ADR
signs O-ADR O-ADR
or O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
heart O-ADR O-ADR
failure O-ADR O-ADR
, O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
weight O-ADR O-ADR
gain O-ADR O-ADR
, O-ADR O-ADR
dependent O-ADR O-ADR
edema O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
increasing O-ADR O-ADR
shortness O-ADR O-ADR
of O-ADR O-ADR
breath O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
ELISA O-ADR O-ADR
assay O-ADR O-ADR
is O-ADR O-ADR
subject O-ADR O-ADR
to O-ADR O-ADR
interference O-ADR O-ADR
by O-ADR O-ADR
co O-ADR O-ADR
- O-ADR O-ADR
present O-ADR O-ADR
golimumab O-ADR O-ADR
and O-ADR O-ADR
thus O-ADR O-ADR
the O-ADR O-ADR
results O-ADR O-ADR
are O-ADR O-ADR
an O-ADR O-ADR
underestimate O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
product O-ADR O-ADR
immunogenicity O-ADR O-ADR
and O-ADR O-ADR
are O-ADR O-ADR
in O-ADR O-ADR
addition O-ADR O-ADR
highly O-ADR O-ADR
dependent O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
sensitivity O-ADR O-ADR
and O-ADR O-ADR
specificity O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
assay O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
drug O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
discussed O-ADR O-ADR
in O-ADR O-ADR
other O-ADR O-ADR
sections O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
labeling O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Lactic B-ADR O-ADR
Acidosis O-ADR O-ADR
/ O-ADR O-ADR
Severe O-ADR O-ADR
Hepatomegaly B-ADR B-ADR
with O-ADR O-ADR
Steatosis B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Boxed O-ADR O-ADR
Warning O-ADR O-ADR
, O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Strictly O-ADR O-ADR
avoid O-ADR O-ADR
intramuscular O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
EOVIST O-ADR O-ADR
because O-ADR O-ADR
it O-ADR O-ADR
may O-ADR O-ADR
cause O-ADR O-ADR
myocyte O-ADR O-ADR
necrosis O-ADR O-ADR
and O-ADR O-ADR
inflammation O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Nonclinical O-ADR O-ADR
Toxicology O-ADR O-ADR
( O-ADR O-ADR
13 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
these O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
reported O-ADR O-ADR
voluntarily O-ADR O-ADR
from O-ADR O-ADR
a O-ADR O-ADR
population O-ADR O-ADR
of O-ADR O-ADR
uncertain O-ADR O-ADR
size O-ADR O-ADR
, O-ADR O-ADR
it O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
always O-ADR O-ADR
possible O-ADR O-ADR
to O-ADR O-ADR
reliably O-ADR O-ADR
estimate O-ADR O-ADR
their O-ADR O-ADR
frequency O-ADR O-ADR
or O-ADR O-ADR
establish O-ADR O-ADR
a O-ADR O-ADR
causal O-ADR O-ADR
relationship O-ADR O-ADR
. O-ADR O-ADR
All O-ADR O-ADR
reports O-ADR O-ADR
with O-ADR O-ADR
methylene O-ADR O-ADR
blue O-ADR O-ADR
that O-ADR O-ADR
provided O-ADR O-ADR
information O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
route O-ADR O-ADR
of O-ADR O-ADR
administration O-ADR O-ADR
involved O-ADR O-ADR
intravenous O-ADR O-ADR
administration O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
dose O-ADR O-ADR
range O-ADR O-ADR
of O-ADR O-ADR
1 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
kg O-ADR O-ADR
to O-ADR O-ADR
8 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
kg O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
absolute O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
probable O-ADR O-ADR
dementia B-ADR B-ADR
for O-ADR O-ADR
CE O-ADR O-ADR
- O-ADR O-ADR
alone O-ADR O-ADR
versus O-ADR O-ADR
placebo O-ADR O-ADR
was O-ADR O-ADR
37 O-ADR O-ADR
versus O-ADR O-ADR
25 O-ADR O-ADR
cases O-ADR O-ADR
per O-ADR O-ADR
10 O-ADR O-ADR
, O-ADR O-ADR
000 O-ADR O-ADR
women O-ADR O-ADR
- O-ADR O-ADR
years O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Pulmonary O-ADR O-ADR
Toxicity O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
trial O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
classical O-ADR O-ADR
HL O-ADR O-ADR
that O-ADR O-ADR
studied O-ADR O-ADR
ADCETRIS O-ADR O-ADR
with O-ADR O-ADR
bleomycin O-ADR O-ADR
as O-ADR O-ADR
part O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
combination O-ADR O-ADR
regimen O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
non B-ADR B-ADR
- O-ADR O-ADR
infectious O-ADR O-ADR
pulmonary I-ADR I-ADR
toxicity I-ADR I-ADR
was O-ADR O-ADR
higher O-ADR O-ADR
than O-ADR O-ADR
the O-ADR O-ADR
historical O-ADR O-ADR
incidence O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
ABVD O-ADR O-ADR
( O-ADR O-ADR
adriamycin O-ADR O-ADR
, O-ADR O-ADR
bleomycin O-ADR O-ADR
, O-ADR O-ADR
vinblastine O-ADR O-ADR
, O-ADR O-ADR
dacarbazine O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
MS O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
dyspnea B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
GILENYA O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
and O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
95 O-ADR O-ADR
% O-ADR O-ADR
confidence O-ADR O-ADR
limits O-ADR O-ADR
that O-ADR O-ADR
are O-ADR O-ADR
shown O-ADR O-ADR
do O-ADR O-ADR
not O-ADR O-ADR
take O-ADR O-ADR
into O-ADR O-ADR
account O-ADR O-ADR
how O-ADR O-ADR
many O-ADR O-ADR
comparisons O-ADR O-ADR
were O-ADR O-ADR
made O-ADR O-ADR
, O-ADR O-ADR
nor O-ADR O-ADR
do O-ADR O-ADR
they O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
effect O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
particular O-ADR O-ADR
factor O-ADR O-ADR
after O-ADR O-ADR
adjustment O-ADR O-ADR
for O-ADR O-ADR
all O-ADR O-ADR
other O-ADR O-ADR
factors O-ADR O-ADR
. O-ADR O-ADR
As O-ADR O-ADR
in O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
dose O-ADR O-ADR
- O-ADR O-ADR
dependent O-ADR O-ADR
increase O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
seizures B-ADR B-ADR
has O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
with O-ADR O-ADR
AMPYRA O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
MS O-ADR O-ADR
as O-ADR O-ADR
follows O-ADR O-ADR
: O-ADR O-ADR
AMPYRA O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
41 O-ADR O-ADR
per O-ADR O-ADR
100 O-ADR O-ADR
person O-ADR O-ADR
- O-ADR O-ADR
years O-ADR O-ADR
( O-ADR O-ADR
95 O-ADR O-ADR
% O-ADR O-ADR
confidence O-ADR O-ADR
interval O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
13 O-ADR O-ADR
- O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
96 O-ADR O-ADR
) O-ADR O-ADR
; O-ADR O-ADR
dalfampridine O-ADR O-ADR
15 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
per O-ADR O-ADR
100 O-ADR O-ADR
person O-ADR O-ADR
- O-ADR O-ADR
years O-ADR O-ADR
( O-ADR O-ADR
95 O-ADR O-ADR
% O-ADR O-ADR
confidence O-ADR O-ADR
interval O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
21 O-ADR O-ADR
- O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
28 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
some O-ADR O-ADR
postmarketing O-ADR O-ADR
cases O-ADR O-ADR
, O-ADR O-ADR
hypocalcemia B-ADR B-ADR
persisted O-ADR O-ADR
for O-ADR O-ADR
weeks O-ADR O-ADR
or O-ADR O-ADR
months O-ADR O-ADR
and O-ADR O-ADR
required O-ADR O-ADR
frequent O-ADR O-ADR
monitoring O-ADR O-ADR
and O-ADR O-ADR
intravenous O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
oral O-ADR O-ADR
calcium O-ADR O-ADR
replacement O-ADR O-ADR
, O-ADR O-ADR
with O-ADR O-ADR
or O-ADR O-ADR
without O-ADR O-ADR
vitamin O-ADR O-ADR
D O-ADR O-ADR
. O-ADR O-ADR
Hypocalcemia B-ADR O-ADR
following O-ADR O-ADR
Prolia O-ADR O-ADR
administration O-ADR O-ADR
is O-ADR O-ADR
a O-ADR O-ADR
significant O-ADR O-ADR
risk O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
severe O-ADR O-ADR
renal O-ADR O-ADR
impairment O-ADR O-ADR
[ O-ADR O-ADR
creatinine O-ADR O-ADR
clearance O-ADR O-ADR
< O-ADR O-ADR
30 O-ADR O-ADR
mL O-ADR O-ADR
/ O-ADR O-ADR
min O-ADR O-ADR
] O-ADR O-ADR
or O-ADR O-ADR
receiving O-ADR O-ADR
dialysis O-ADR O-ADR
. O-ADR O-ADR
Urinary B-ADR O-ADR
Tract I-ADR O-ADR
Infections I-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
pool O-ADR O-ADR
of O-ADR O-ADR
five O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
urinary B-ADR B-ADR
tract I-ADR I-ADR
infections I-ADR I-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
urinary B-ADR B-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
, O-ADR O-ADR
asymptomatic B-ADR B-ADR
bacteriuria I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
cystitis B-ADR B-ADR
) O-ADR O-ADR
was O-ADR O-ADR
increased O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
JARDIANCE O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
placebo O-ADR O-ADR
( O-ADR O-ADR
see O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Caution O-ADR O-ADR
patients O-ADR O-ADR
about O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
activation O-ADR O-ADR
of O-ADR O-ADR
mania O-ADR O-ADR
/ O-ADR O-ADR
hypomania O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Elderly O-ADR O-ADR
Patients O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Controlled O-ADR O-ADR
Narrow O-ADR O-ADR
- O-ADR O-ADR
Angle O-ADR O-ADR
Glaucoma O-ADR O-ADR
Toviaz O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
with O-ADR O-ADR
caution O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
being O-ADR O-ADR
treated O-ADR O-ADR
for O-ADR O-ADR
narrow O-ADR O-ADR
- O-ADR O-ADR
angle O-ADR O-ADR
glaucoma O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
only O-ADR O-ADR
where O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
benefits O-ADR O-ADR
outweigh O-ADR O-ADR
the O-ADR O-ADR
risks O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Contraindications O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
frequent O-ADR O-ADR
serious O-ADR O-ADR
infections B-ADR B-ADR
included O-ADR O-ADR
pneumonia B-ADR B-ADR
, O-ADR O-ADR
urinary B-ADR B-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
, O-ADR O-ADR
cellulitis B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
bronchitis B-ADR B-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Take O-ADR O-ADR
DUAVEE O-ADR O-ADR
with O-ADR O-ADR
or O-ADR O-ADR
without O-ADR O-ADR
food O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
proportion O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
prolactin B-ADR B-ADR
elevations I-ADR I-ADR
> O-ADR O-ADR
= O-ADR O-ADR
4 O-ADR O-ADR
times O-ADR O-ADR
ULN O-ADR O-ADR
( O-ADR O-ADR
at O-ADR O-ADR
Endpoint O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
SAPHRIS O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
versus O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
extended O-ADR O-ADR
normal O-ADR O-ADR
range O-ADR O-ADR
for O-ADR O-ADR
lowered O-ADR B-ADR
hematocrit O-ADR I-ADR
was O-ADR O-ADR
defined O-ADR O-ADR
in O-ADR O-ADR
each O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
trials O-ADR O-ADR
as O-ADR O-ADR
the O-ADR O-ADR
value O-ADR O-ADR
15 O-ADR O-ADR
% O-ADR O-ADR
below O-ADR O-ADR
the O-ADR O-ADR
normal O-ADR O-ADR
range O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
centralized O-ADR O-ADR
laboratory O-ADR O-ADR
that O-ADR O-ADR
was O-ADR O-ADR
used O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
trial O-ADR O-ADR
. O-ADR O-ADR
Respiratory O-ADR O-ADR
, O-ADR O-ADR
Thoracic O-ADR O-ADR
and O-ADR O-ADR
Mediastinal O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
Infrequent O-ADR O-ADR
- O-ADR O-ADR
epistaxis B-ADR O-ADR
, O-ADR O-ADR
asthma B-ADR B-ADR
, O-ADR O-ADR
rhinorrhea B-ADR B-ADR
, O-ADR O-ADR
sinus B-ADR B-ADR
congestion I-ADR I-ADR
, O-ADR O-ADR
nasal B-ADR B-ADR
dryness I-ADR I-ADR
; O-ADR O-ADR
Rare O-ADR O-ADR
- O-ADR O-ADR
dry B-ADR O-ADR
throat I-ADR I-ADR
, O-ADR O-ADR
sleep B-ADR B-ADR
apnea I-ADR I-ADR
syndrome I-ADR I-ADR
, O-ADR O-ADR
dyspnea B-ADR B-ADR
exertional I-ADR I-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Postmarketing O-ADR O-ADR
Experience O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
identified O-ADR O-ADR
during O-ADR O-ADR
post O-ADR O-ADR
- O-ADR O-ADR
approval O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
FANAPT O-ADR O-ADR
: O-ADR O-ADR
retrograde B-ADR B-ADR
ejaculation I-ADR I-ADR
. O-ADR O-ADR
Permanently O-ADR O-ADR
discontinue O-ADR O-ADR
YERVOY O-ADR O-ADR
for O-ADR O-ADR
immune O-ADR O-ADR
- O-ADR O-ADR
mediated O-ADR O-ADR
ocular O-ADR O-ADR
disease O-ADR O-ADR
that O-ADR O-ADR
is O-ADR O-ADR
unresponsive O-ADR O-ADR
to O-ADR O-ADR
local O-ADR O-ADR
immunosuppressive O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
premature O-ADR O-ADR
discontinuation O-ADR O-ADR
because O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
11 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
dronedarone O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
group O-ADR O-ADR
. O-ADR O-ADR
Extrapyramidal B-ADR B-ADR
symptoms I-ADR I-ADR
included O-ADR O-ADR
: O-ADR O-ADR
dystonia B-ADR B-ADR
, O-ADR O-ADR
parkinsonism B-ADR B-ADR
, O-ADR O-ADR
oculogyration B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
tremor B-ADR B-ADR
( O-ADR O-ADR
excluding O-ADR O-ADR
akathisia B-ADR B-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Do O-ADR O-ADR
not O-ADR O-ADR
use O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
whose O-ADR O-ADR
asthma O-ADR O-ADR
is O-ADR O-ADR
adequately O-ADR O-ADR
controlled O-ADR O-ADR
on O-ADR O-ADR
low O-ADR O-ADR
- O-ADR O-ADR
or O-ADR O-ADR
medium O-ADR O-ADR
- O-ADR O-ADR
dose O-ADR O-ADR
ICS O-ADR O-ADR
. O-ADR O-ADR
Common O-ADR O-ADR
Adverse O-ADR O-ADR
Events O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
The O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
12 O-ADR O-ADR
cycles O-ADR O-ADR
of O-ADR O-ADR
therapy O-ADR O-ADR
that O-ADR O-ADR
occurred O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
or O-ADR O-ADR
greater O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
KRd O-ADR O-ADR
arm O-ADR O-ADR
are O-ADR O-ADR
presented O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
Persistent O-ADR O-ADR
or O-ADR O-ADR
worsening O-ADR O-ADR
bone O-ADR O-ADR
pain O-ADR O-ADR
, O-ADR O-ADR
pain O-ADR O-ADR
in O-ADR O-ADR
extremities O-ADR O-ADR
, O-ADR O-ADR
fractures O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
muscular O-ADR O-ADR
pain O-ADR O-ADR
or O-ADR O-ADR
weakness O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
manifestations O-ADR O-ADR
of O-ADR O-ADR
proximal O-ADR O-ADR
renal O-ADR O-ADR
tubulopathy O-ADR O-ADR
and O-ADR O-ADR
should O-ADR O-ADR
prompt O-ADR O-ADR
an O-ADR O-ADR
evaluation O-ADR O-ADR
of O-ADR O-ADR
renal O-ADR O-ADR
function O-ADR O-ADR
in O-ADR O-ADR
at O-ADR O-ADR
- O-ADR O-ADR
risk O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Cardiac O-ADR O-ADR
Failure O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
study O-ADR O-ADR
with O-ADR O-ADR
INLYTA O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
RCC O-ADR O-ADR
, O-ADR O-ADR
cardiac B-ADR B-ADR
failure I-ADR I-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
6 O-ADR O-ADR
/ O-ADR O-ADR
359 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
receiving O-ADR O-ADR
INLYTA O-ADR O-ADR
and O-ADR O-ADR
3 O-ADR O-ADR
/ O-ADR O-ADR
355 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
receiving O-ADR O-ADR
sorafenib O-ADR O-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
this O-ADR O-ADR
disorder O-ADR O-ADR
is O-ADR O-ADR
variable O-ADR O-ADR
in O-ADR O-ADR
its O-ADR O-ADR
expression O-ADR O-ADR
, O-ADR O-ADR
other O-ADR O-ADR
organ O-ADR O-ADR
systems O-ADR O-ADR
not O-ADR O-ADR
noted O-ADR O-ADR
here O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
involved O-ADR O-ADR
. O-ADR O-ADR
abnormal B-ADR B-ADR
platelet I-ADR I-ADR
and I-ADR I-ADR
WBC I-ADR I-ADR
counts I-ADR I-ADR
were O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
< O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
. O-ADR O-ADR
Consider O-ADR O-ADR
dose O-ADR O-ADR
adjustment O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
baseline O-ADR O-ADR
and O-ADR O-ADR
treatment O-ADR O-ADR
emergent O-ADR O-ADR
renal O-ADR O-ADR
impairment O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Perform O-ADR O-ADR
an O-ADR O-ADR
ophthalmological O-ADR O-ADR
evaluation O-ADR O-ADR
. O-ADR O-ADR
Although O-ADR O-ADR
the O-ADR O-ADR
causes O-ADR O-ADR
of O-ADR O-ADR
death B-ADR B-ADR
were O-ADR O-ADR
varied O-ADR O-ADR
, O-ADR O-ADR
most O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
deaths B-ADR B-ADR
appeared O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
either O-ADR O-ADR
cardiovascular O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
heart B-ADR O-ADR
failure I-ADR I-ADR
, O-ADR O-ADR
sudden B-ADR B-ADR
death I-ADR I-ADR
) O-ADR O-ADR
or O-ADR O-ADR
infectious O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
pneumonia B-ADR B-ADR
) O-ADR O-ADR
in O-ADR O-ADR
nature O-ADR O-ADR
. O-ADR O-ADR
Behaviors O-ADR O-ADR
of O-ADR O-ADR
concern O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
reported O-ADR O-ADR
immediately O-ADR O-ADR
to O-ADR O-ADR
healthcare O-ADR O-ADR
providers O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Hypoglycemia B-ADR B-ADR
: O-ADR O-ADR
In O-ADR O-ADR
patients O-ADR O-ADR
taking O-ADR O-ADR
insulin O-ADR O-ADR
or O-ADR O-ADR
an O-ADR O-ADR
insulin O-ADR O-ADR
secretagogue O-ADR O-ADR
with O-ADR O-ADR
FARXIGA O-ADR O-ADR
, O-ADR O-ADR
consider O-ADR O-ADR
a O-ADR O-ADR
lower O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
insulin O-ADR O-ADR
or O-ADR O-ADR
the O-ADR O-ADR
insulin O-ADR O-ADR
secretagogue O-ADR O-ADR
to O-ADR O-ADR
reduce O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
hypoglycemia O-ADR B-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
13 O-ADR O-ADR
Priapism O-ADR O-ADR
Three O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
priapism B-ADR B-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
premarketing O-ADR O-ADR
FANAPT O-ADR O-ADR
program O-ADR O-ADR
. O-ADR O-ADR
Other O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Hypoglycemia O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
summarizes O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
documented O-ADR O-ADR
hypoglycemia B-ADR B-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
. O-ADR O-ADR
Rates O-ADR O-ADR
of O-ADR O-ADR
serious O-ADR O-ADR
infections B-ADR B-ADR
in O-ADR O-ADR
the O-ADR O-ADR
200 O-ADR O-ADR
mg O-ADR O-ADR
every O-ADR O-ADR
other O-ADR O-ADR
week O-ADR O-ADR
dose O-ADR O-ADR
group O-ADR O-ADR
were O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
06 O-ADR O-ADR
per O-ADR O-ADR
patient O-ADR O-ADR
- O-ADR O-ADR
year O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
400 O-ADR O-ADR
mg O-ADR O-ADR
every O-ADR O-ADR
4 O-ADR O-ADR
weeks O-ADR O-ADR
dose O-ADR O-ADR
group O-ADR O-ADR
were O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
04 O-ADR O-ADR
per O-ADR O-ADR
patient O-ADR O-ADR
- O-ADR O-ADR
year O-ADR O-ADR
. O-ADR O-ADR
Appropriate O-ADR O-ADR
care O-ADR O-ADR
is O-ADR O-ADR
advised O-ADR O-ADR
when O-ADR O-ADR
prescribing O-ADR O-ADR
FANAPT O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
will O-ADR O-ADR
be O-ADR O-ADR
experiencing O-ADR O-ADR
conditions O-ADR O-ADR
which O-ADR O-ADR
may O-ADR O-ADR
contribute O-ADR O-ADR
to O-ADR O-ADR
an O-ADR O-ADR
elevation O-ADR O-ADR
in O-ADR O-ADR
core O-ADR O-ADR
body O-ADR O-ADR
temperature O-ADR O-ADR
, O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
exercising O-ADR O-ADR
strenuously O-ADR O-ADR
, O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
extreme O-ADR O-ADR
heat O-ADR O-ADR
, O-ADR O-ADR
receiving O-ADR O-ADR
concomitant O-ADR O-ADR
medication O-ADR O-ADR
with O-ADR O-ADR
anticholinergic O-ADR O-ADR
activity O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
being O-ADR O-ADR
subject O-ADR O-ADR
to O-ADR O-ADR
dehydration O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Psychological B-ADR B-ADR
Dependence I-ADR I-ADR
: O-ADR O-ADR
Monitor O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
substance O-ADR O-ADR
abuse O-ADR O-ADR
for O-ADR O-ADR
signs O-ADR O-ADR
of O-ADR O-ADR
habituation O-ADR O-ADR
and O-ADR O-ADR
dependence O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
, O-ADR O-ADR
9 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Suicidal B-ADR B-ADR
Behavior I-ADR I-ADR
: O-ADR O-ADR
Monitor O-ADR O-ADR
for O-ADR O-ADR
suicidal O-ADR O-ADR
thoughts O-ADR O-ADR
or O-ADR O-ADR
behaviors O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Somnolence O-ADR O-ADR
or O-ADR O-ADR
Sedation O-ADR O-ADR
ONFI O-ADR O-ADR
causes O-ADR O-ADR
somnolence B-ADR B-ADR
and O-ADR O-ADR
sedation B-ADR B-ADR
. O-ADR O-ADR
c O-ADR O-ADR
Confidence O-ADR O-ADR
interval O-ADR O-ADR
Patients O-ADR O-ADR
Major O-ADR O-ADR
bleeding B-ADR B-ADR
event O-ADR O-ADR
a O-ADR O-ADR
Bleeding B-ADR B-ADR
sites O-ADR O-ADR
for O-ADR O-ADR
MBE B-ADR B-ADR
b O-ADR O-ADR
Clinically O-ADR O-ADR
relevant O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
major O-ADR O-ADR
bleeding B-ADR B-ADR
Any O-ADR O-ADR
bleeding B-ADR B-ADR
The O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
any O-ADR O-ADR
gastrointestinal B-ADR B-ADR
bleeds I-ADR I-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
PRADAXA O-ADR O-ADR
150 O-ADR O-ADR
mg O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
full O-ADR O-ADR
treatment O-ADR O-ADR
period O-ADR O-ADR
was O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
on O-ADR O-ADR
warfarin O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
When O-ADR O-ADR
such O-ADR O-ADR
an O-ADR O-ADR
infection O-ADR O-ADR
develops O-ADR O-ADR
, O-ADR O-ADR
it O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
appropriate O-ADR O-ADR
local O-ADR O-ADR
or O-ADR O-ADR
systemic O-ADR O-ADR
( O-ADR O-ADR
i O-ADR O-ADR
. O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
oral O-ADR O-ADR
) O-ADR O-ADR
antifungal O-ADR O-ADR
therapy O-ADR O-ADR
while O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
continues O-ADR O-ADR
, O-ADR O-ADR
but O-ADR O-ADR
at O-ADR O-ADR
times O-ADR O-ADR
therapy O-ADR O-ADR
with O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
may O-ADR O-ADR
need O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
interrupted O-ADR O-ADR
. O-ADR O-ADR
Rash B-ADR B-ADR
generally O-ADR O-ADR
resolved O-ADR O-ADR
within O-ADR O-ADR
1 O-ADR O-ADR
to O-ADR O-ADR
2 O-ADR O-ADR
weeks O-ADR O-ADR
on O-ADR O-ADR
continued O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
If O-ADR O-ADR
infection O-ADR O-ADR
occurs O-ADR O-ADR
while O-ADR O-ADR
on O-ADR O-ADR
Ferriprox O-ADR O-ADR
, O-ADR O-ADR
interrupt O-ADR O-ADR
therapy O-ADR O-ADR
and O-ADR O-ADR
monitor O-ADR O-ADR
the O-ADR O-ADR
ANC O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
were O-ADR O-ADR
63 O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
moderate O-ADR O-ADR
( O-ADR O-ADR
Grade O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
dermatitis B-ADR B-ADR
. O-ADR O-ADR
Across O-ADR O-ADR
the O-ADR O-ADR
development O-ADR O-ADR
program O-ADR O-ADR
of O-ADR O-ADR
ZYKADIA O-ADR O-ADR
, O-ADR O-ADR
one O-ADR O-ADR
of O-ADR O-ADR
304 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
ZYKADIA O-ADR O-ADR
doses O-ADR O-ADR
ranging O-ADR O-ADR
from O-ADR O-ADR
50 O-ADR O-ADR
to O-ADR O-ADR
750 O-ADR O-ADR
mg O-ADR O-ADR
was O-ADR O-ADR
found O-ADR O-ADR
to O-ADR O-ADR
have O-ADR O-ADR
a O-ADR O-ADR
QTc B-ADR O-ADR
greater I-ADR O-ADR
than I-ADR O-ADR
500 I-ADR O-ADR
msec I-ADR O-ADR
and O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
had O-ADR O-ADR
an O-ADR O-ADR
increase B-ADR B-ADR
from I-ADR I-ADR
baseline I-ADR I-ADR
QTc I-ADR I-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
60 O-ADR O-ADR
msec O-ADR O-ADR
. O-ADR O-ADR
[ O-ADR O-ADR
See O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
] O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
severe O-ADR O-ADR
renal O-ADR O-ADR
impairment O-ADR O-ADR
may O-ADR O-ADR
have O-ADR O-ADR
increased O-ADR O-ADR
radiation O-ADR O-ADR
exposure O-ADR O-ADR
and O-ADR O-ADR
decreased O-ADR O-ADR
quality O-ADR O-ADR
of O-ADR O-ADR
AdreView O-ADR O-ADR
images O-ADR O-ADR
. O-ADR O-ADR
Vascular O-ADR O-ADR
disorder O-ADR O-ADR
: O-ADR O-ADR
systemic B-ADR B-ADR
vasculitis I-ADR I-ADR
has O-ADR O-ADR
been O-ADR O-ADR
identified O-ADR O-ADR
during O-ADR O-ADR
post O-ADR O-ADR
- O-ADR O-ADR
approval O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
TNF O-ADR O-ADR
blockers O-ADR O-ADR
. O-ADR O-ADR
Symptoms O-ADR O-ADR
and O-ADR O-ADR
signs O-ADR O-ADR
of O-ADR O-ADR
adrenocortical B-ADR B-ADR
insufficiency I-ADR I-ADR
may O-ADR O-ADR
be O-ADR O-ADR
masked O-ADR O-ADR
by O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
mineralocorticoid B-ADR B-ADR
excess I-ADR I-ADR
seen O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
ZYTIGA O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
this O-ADR O-ADR
setting O-ADR O-ADR
a O-ADR O-ADR
reevaluation O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
COPD O-ADR O-ADR
treatment O-ADR O-ADR
regimen O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
undertaken O-ADR O-ADR
at O-ADR O-ADR
once O-ADR O-ADR
. O-ADR O-ADR
Exposure O-ADR O-ADR
to O-ADR O-ADR
excessive O-ADR O-ADR
amounts O-ADR O-ADR
of O-ADR O-ADR
benzyl O-ADR O-ADR
alcohol O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
toxicity O-ADR O-ADR
( O-ADR O-ADR
hypotension O-ADR B-ADR
, O-ADR O-ADR
metabolic O-ADR B-ADR
acidosis O-ADR I-ADR
) O-ADR O-ADR
, O-ADR O-ADR
particularly O-ADR O-ADR
in O-ADR O-ADR
neonates O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
an O-ADR O-ADR
increased O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
kernicterus O-ADR O-ADR
, O-ADR O-ADR
particularly O-ADR O-ADR
in O-ADR O-ADR
small O-ADR O-ADR
preterm O-ADR O-ADR
infants O-ADR O-ADR
. O-ADR O-ADR
Discontinue O-ADR O-ADR
ONFI O-ADR O-ADR
gradually O-ADR O-ADR
. O-ADR O-ADR
Beleodaq O-ADR O-ADR
may O-ADR O-ADR
cause O-ADR O-ADR
teratogenicity B-ADR B-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
embryo B-ADR B-ADR
- O-ADR O-ADR
fetal O-ADR O-ADR
lethality I-ADR I-ADR
because O-ADR O-ADR
it O-ADR O-ADR
is O-ADR O-ADR
genotoxic B-ADR O-ADR
and O-ADR O-ADR
targets O-ADR O-ADR
actively O-ADR O-ADR
dividing O-ADR O-ADR
cells O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Nonclinical O-ADR O-ADR
Toxicology O-ADR O-ADR
( O-ADR O-ADR
13 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
studied O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
relief O-ADR O-ADR
of O-ADR O-ADR
acute O-ADR O-ADR
symptoms O-ADR O-ADR
and O-ADR O-ADR
extra O-ADR O-ADR
doses O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
for O-ADR O-ADR
that O-ADR O-ADR
purpose O-ADR O-ADR
. O-ADR O-ADR
However O-ADR O-ADR
, O-ADR O-ADR
there O-ADR O-ADR
is O-ADR O-ADR
controversy O-ADR O-ADR
about O-ADR O-ADR
the O-ADR O-ADR
extent O-ADR O-ADR
to O-ADR O-ADR
which O-ADR O-ADR
these O-ADR O-ADR
findings O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
differences O-ADR O-ADR
in O-ADR O-ADR
sexual O-ADR O-ADR
behavior O-ADR O-ADR
and O-ADR O-ADR
other O-ADR O-ADR
factors O-ADR O-ADR
. O-ADR O-ADR
Seven O-ADR O-ADR
( O-ADR O-ADR
54 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
YERVOY O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
severe O-ADR O-ADR
dermatitis B-ADR B-ADR
received O-ADR O-ADR
high O-ADR O-ADR
- O-ADR O-ADR
dose O-ADR O-ADR
corticosteroids O-ADR O-ADR
( O-ADR O-ADR
median O-ADR O-ADR
dose O-ADR O-ADR
60 O-ADR O-ADR
mg O-ADR O-ADR
prednisone O-ADR O-ADR
/ O-ADR O-ADR
day O-ADR O-ADR
or O-ADR O-ADR
equivalent O-ADR O-ADR
) O-ADR O-ADR
for O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
14 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
weeks O-ADR O-ADR
followed O-ADR O-ADR
by O-ADR O-ADR
corticosteroid O-ADR O-ADR
taper O-ADR O-ADR
. O-ADR O-ADR
Re O-ADR O-ADR
- O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
ZYTIGA O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
reduced O-ADR O-ADR
dose O-ADR O-ADR
level O-ADR O-ADR
may O-ADR O-ADR
take O-ADR O-ADR
place O-ADR O-ADR
only O-ADR O-ADR
after O-ADR O-ADR
return O-ADR O-ADR
of O-ADR O-ADR
liver O-ADR O-ADR
function O-ADR O-ADR
tests O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
baseline O-ADR O-ADR
or O-ADR O-ADR
to O-ADR O-ADR
AST O-ADR O-ADR
and O-ADR O-ADR
ALT O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
or O-ADR O-ADR
equal O-ADR O-ADR
to O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
* O-ADR O-ADR
ULN O-ADR O-ADR
and O-ADR O-ADR
total O-ADR O-ADR
bilirubin O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
or O-ADR O-ADR
equal O-ADR O-ADR
to O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
* O-ADR O-ADR
ULN O-ADR O-ADR
[ O-ADR O-ADR
seeDosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
HIV O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
infected O-ADR O-ADR
subjects O-ADR O-ADR
in O-ADR O-ADR
Phase O-ADR O-ADR
3 O-ADR O-ADR
trials O-ADR O-ADR
receiving O-ADR O-ADR
INTELENCE O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
discontinued O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
rash B-ADR B-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
group O-ADR O-ADR
, O-ADR O-ADR
no O-ADR O-ADR
serious O-ADR O-ADR
infection B-ADR B-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
one O-ADR O-ADR
subject O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
BLINCYTO O-ADR O-ADR
tested O-ADR O-ADR
positive O-ADR O-ADR
for O-ADR O-ADR
binding O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
blinatumomab O-ADR O-ADR
antibodies O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
35 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
Black O-ADR O-ADR
, O-ADR O-ADR
17 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
Hispanic O-ADR O-ADR
, O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
White O-ADR O-ADR
, O-ADR O-ADR
9 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
Asian O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
25 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
race O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Wound O-ADR O-ADR
Complications O-ADR O-ADR
Wound B-ADR B-ADR
complications I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
COMETRIQ O-ADR O-ADR
. O-ADR O-ADR
Of O-ADR O-ADR
the O-ADR O-ADR
28 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
moderate O-ADR O-ADR
enterocolitis B-ADR B-ADR
, O-ADR O-ADR
46 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
not O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
systemic O-ADR O-ADR
corticosteroids O-ADR O-ADR
, O-ADR O-ADR
29 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
< O-ADR O-ADR
40 O-ADR O-ADR
mg O-ADR O-ADR
prednisone O-ADR O-ADR
or O-ADR O-ADR
equivalent O-ADR O-ADR
per O-ADR O-ADR
day O-ADR O-ADR
for O-ADR O-ADR
a O-ADR O-ADR
median O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
weeks O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
25 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
high O-ADR O-ADR
- O-ADR O-ADR
dose O-ADR O-ADR
corticosteroids O-ADR O-ADR
for O-ADR O-ADR
a O-ADR O-ADR
median O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
10 O-ADR O-ADR
days O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
corticosteroid O-ADR O-ADR
taper O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
to O-ADR O-ADR
XEOMIN O-ADR O-ADR
are O-ADR O-ADR
discussed O-ADR O-ADR
in O-ADR O-ADR
greater O-ADR O-ADR
detail O-ADR O-ADR
in O-ADR O-ADR
other O-ADR O-ADR
sections O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
labeling O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Contraindications O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Dysphagia B-ADR B-ADR
and O-ADR O-ADR
Breathing B-ADR B-ADR
Difficulties I-ADR I-ADR
in O-ADR O-ADR
Treatment O-ADR O-ADR
of O-ADR O-ADR
cervical O-ADR O-ADR
dystonia O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Spread B-ADR B-ADR
of I-ADR I-ADR
Effects I-ADR I-ADR
from I-ADR I-ADR
Toxin I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
Cervical O-ADR O-ADR
Dystonia O-ADR O-ADR
: O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
commonly O-ADR O-ADR
observed O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
> O-ADR O-ADR
placebo O-ADR O-ADR
) O-ADR O-ADR
are O-ADR O-ADR
dysphagia B-ADR B-ADR
, O-ADR O-ADR
neck B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
muscle B-ADR B-ADR
weakness I-ADR I-ADR
, O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
musculoskeletal B-ADR B-ADR
pain I-ADR I-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Fatal B-ADR B-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
15 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
[ O-ADR O-ADR
See O-ADR O-ADR
Boxed O-ADR O-ADR
Warning O-ADR O-ADR
. O-ADR O-ADR
] O-ADR O-ADR
Discontinue O-ADR O-ADR
use O-ADR O-ADR
if O-ADR O-ADR
severe O-ADR O-ADR
symptoms O-ADR O-ADR
develop O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Suppression B-ADR B-ADR
of I-ADR I-ADR
bone I-ADR I-ADR
turnover I-ADR I-ADR
: O-ADR O-ADR
Significant O-ADR O-ADR
suppression O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
demonstrated O-ADR O-ADR
. O-ADR O-ADR
Observe O-ADR O-ADR
patients O-ADR O-ADR
closely O-ADR O-ADR
for O-ADR O-ADR
an O-ADR O-ADR
appropriate O-ADR O-ADR
period O-ADR O-ADR
of O-ADR O-ADR
time O-ADR O-ADR
after O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
Vimizim O-ADR O-ADR
, O-ADR O-ADR
taking O-ADR O-ADR
into O-ADR O-ADR
account O-ADR O-ADR
the O-ADR O-ADR
time O-ADR O-ADR
to O-ADR O-ADR
onset O-ADR O-ADR
of O-ADR O-ADR
anaphylaxis O-ADR O-ADR
seen O-ADR O-ADR
in O-ADR O-ADR
premarketing O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
mechanism O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
bleeding O-ADR B-ADR
events O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
well O-ADR O-ADR
understood O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
febrile B-ADR B-ADR
neutropenia I-ADR I-ADR
and O-ADR O-ADR
pneumonia B-ADR B-ADR
. O-ADR O-ADR
Should O-ADR O-ADR
suicidal O-ADR O-ADR
thoughts O-ADR O-ADR
and O-ADR O-ADR
behavior O-ADR O-ADR
emerge O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
prescriber O-ADR O-ADR
needs O-ADR O-ADR
to O-ADR O-ADR
consider O-ADR O-ADR
whether O-ADR O-ADR
the O-ADR O-ADR
emergence O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
symptoms O-ADR O-ADR
in O-ADR O-ADR
any O-ADR O-ADR
given O-ADR O-ADR
patient O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
related O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
illness O-ADR O-ADR
being O-ADR O-ADR
treated O-ADR O-ADR
. O-ADR O-ADR
Other O-ADR O-ADR
increased B-ADR O-ADR
( I-ADR O-ADR
angiotensinogen I-ADR B-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
extent O-ADR O-ADR
to O-ADR O-ADR
which O-ADR O-ADR
the O-ADR O-ADR
findings O-ADR O-ADR
of O-ADR O-ADR
increased B-ADR O-ADR
mortality I-ADR O-ADR
in O-ADR O-ADR
observational O-ADR O-ADR
studies O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
attributed O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
antipsychotic O-ADR O-ADR
drug O-ADR O-ADR
as O-ADR O-ADR
opposed O-ADR O-ADR
to O-ADR O-ADR
some O-ADR O-ADR
characteristic O-ADR O-ADR
( O-ADR O-ADR
s O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
patients O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
clear O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
QT B-ADR B-ADR
Interval I-ADR I-ADR
Prolongation I-ADR I-ADR
: O-ADR O-ADR
Occurred O-ADR O-ADR
in O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Bradycardia B-ADR B-ADR
and O-ADR I-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
atrioventricular B-ADR I-ADR
conduction I-ADR I-ADR
after O-ADR O-ADR
first O-ADR O-ADR
dose O-ADR O-ADR
: O-ADR O-ADR
Monitor O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
coagulation B-ADR B-ADR
proteins I-ADR I-ADR
were I-ADR I-ADR
decreased I-ADR I-ADR
. O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
of O-ADR O-ADR
moderate O-ADR O-ADR
to O-ADR O-ADR
severe O-ADR O-ADR
intensity O-ADR O-ADR
and O-ADR O-ADR
incidence O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
in O-ADR O-ADR
those O-ADR O-ADR
receiving O-ADR O-ADR
TIVICAY O-ADR O-ADR
in O-ADR O-ADR
any O-ADR O-ADR
one O-ADR O-ADR
adult O-ADR O-ADR
trial O-ADR O-ADR
) O-ADR O-ADR
are O-ADR O-ADR
insomnia B-ADR B-ADR
, O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
headache B-ADR B-ADR
. O-ADR O-ADR
In O-ADR O-ADR
unapproved O-ADR O-ADR
uses O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
spasticity O-ADR O-ADR
in O-ADR O-ADR
children O-ADR O-ADR
and O-ADR O-ADR
adults O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
approved O-ADR O-ADR
indications O-ADR O-ADR
, O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
spread B-ADR O-ADR
of I-ADR O-ADR
effect I-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
at O-ADR O-ADR
doses O-ADR O-ADR
comparable O-ADR O-ADR
to O-ADR O-ADR
those O-ADR O-ADR
used O-ADR O-ADR
to O-ADR O-ADR
treat O-ADR O-ADR
cervical O-ADR O-ADR
dystonia O-ADR O-ADR
and O-ADR O-ADR
at O-ADR O-ADR
lower O-ADR O-ADR
doses O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Potential O-ADR O-ADR
neonatal B-ADR B-ADR
adverse I-ADR O-ADR
effects I-ADR O-ADR
. O-ADR O-ADR
Laboratory O-ADR O-ADR
Test O-ADR O-ADR
Abnormalities O-ADR O-ADR
in O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
There O-ADR O-ADR
were O-ADR O-ADR
no O-ADR O-ADR
differences O-ADR O-ADR
between O-ADR O-ADR
FANAPT O-ADR O-ADR
and O-ADR O-ADR
placebo O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
discontinuation O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
changes O-ADR O-ADR
in O-ADR O-ADR
hematology O-ADR O-ADR
, O-ADR O-ADR
urinalysis O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
serum O-ADR O-ADR
chemistry O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
develop O-ADR O-ADR
moderate O-ADR O-ADR
to O-ADR O-ADR
severe O-ADR O-ADR
proteinuria O-ADR O-ADR
, O-ADR O-ADR
reduce O-ADR O-ADR
the O-ADR O-ADR
dose O-ADR O-ADR
or O-ADR O-ADR
temporarily O-ADR O-ADR
interrupt O-ADR O-ADR
INLYTA O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
Psoriatic O-ADR O-ADR
Arthritis O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
OTEZLA O-ADR O-ADR
was O-ADR O-ADR
evaluated O-ADR O-ADR
in O-ADR O-ADR
3 O-ADR O-ADR
multicenter O-ADR O-ADR
, O-ADR O-ADR
randomized O-ADR O-ADR
, O-ADR O-ADR
double O-ADR O-ADR
- O-ADR O-ADR
blind O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
[ O-ADR O-ADR
Studies O-ADR O-ADR
PsA O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
PsA O-ADR O-ADR
- O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
PsA O-ADR O-ADR
- O-ADR O-ADR
3 O-ADR O-ADR
] O-ADR O-ADR
of O-ADR O-ADR
similar O-ADR O-ADR
design O-ADR O-ADR
in O-ADR O-ADR
adult O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
active O-ADR O-ADR
psoriatic O-ADR O-ADR
arthritis O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Reactions O-ADR O-ADR
are O-ADR O-ADR
further O-ADR O-ADR
categorized O-ADR O-ADR
by O-ADR O-ADR
MedDRA O-ADR O-ADR
system O-ADR O-ADR
organ O-ADR O-ADR
class O-ADR O-ADR
and O-ADR O-ADR
listed O-ADR O-ADR
in O-ADR O-ADR
order O-ADR O-ADR
of O-ADR O-ADR
decreasing O-ADR O-ADR
frequency O-ADR O-ADR
according O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
following O-ADR O-ADR
definitions O-ADR O-ADR
: O-ADR O-ADR
frequent O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
are O-ADR O-ADR
those O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
1 O-ADR O-ADR
/ O-ADR O-ADR
100 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
only O-ADR O-ADR
those O-ADR O-ADR
not O-ADR O-ADR
listed O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
7 O-ADR O-ADR
appear O-ADR O-ADR
in O-ADR O-ADR
this O-ADR O-ADR
listing O-ADR O-ADR
) O-ADR O-ADR
; O-ADR O-ADR
infrequent O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
those O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
1 O-ADR O-ADR
/ O-ADR O-ADR
100 O-ADR O-ADR
to O-ADR O-ADR
1 O-ADR O-ADR
/ O-ADR O-ADR
1000 O-ADR O-ADR
patients O-ADR O-ADR
; O-ADR O-ADR
rare O-ADR O-ADR
events O-ADR O-ADR
are O-ADR O-ADR
those O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
fewer O-ADR O-ADR
than O-ADR O-ADR
1 O-ADR O-ADR
/ O-ADR O-ADR
1000 O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
who O-ADR O-ADR
tested O-ADR O-ADR
positive O-ADR O-ADR
for O-ADR O-ADR
uptake O-ADR O-ADR
inhibition O-ADR O-ADR
tended O-ADR O-ADR
to O-ADR O-ADR
have O-ADR O-ADR
higher O-ADR O-ADR
IgG O-ADR O-ADR
titers O-ADR O-ADR
than O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
tested O-ADR O-ADR
negative O-ADR O-ADR
for O-ADR O-ADR
uptake O-ADR O-ADR
inhibition O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
shows O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
KALYDECO O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
CF O-ADR O-ADR
who O-ADR O-ADR
have O-ADR O-ADR
a O-ADR O-ADR
G551D O-ADR O-ADR
mutation O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
CFTR O-ADR O-ADR
gene O-ADR O-ADR
that O-ADR O-ADR
also O-ADR O-ADR
occurred O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
higher O-ADR O-ADR
rate O-ADR O-ADR
than O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
two O-ADR O-ADR
double O-ADR O-ADR
- O-ADR O-ADR
blind O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
were O-ADR O-ADR
no O-ADR O-ADR
asthma O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
deaths B-ADR B-ADR
or O-ADR O-ADR
asthma O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
intubations O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
this O-ADR O-ADR
trial O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
you O-ADR O-ADR
are O-ADR O-ADR
not O-ADR O-ADR
sure O-ADR O-ADR
about O-ADR O-ADR
your O-ADR O-ADR
dosing O-ADR O-ADR
, O-ADR O-ADR
call O-ADR O-ADR
your O-ADR O-ADR
healthcare O-ADR O-ADR
provider O-ADR O-ADR
. O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
COPD O-ADR O-ADR
: O-ADR O-ADR
Most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
incidence O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
or O-ADR O-ADR
equal O-ADR O-ADR
to O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
are O-ADR O-ADR
nasopharyngitis B-ADR B-ADR
, O-ADR O-ADR
upper B-ADR B-ADR
respiratory I-ADR I-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
oral B-ADR B-ADR
candidiasis I-ADR I-ADR
. O-ADR O-ADR
Any O-ADR O-ADR
type O-ADR O-ADR
of O-ADR O-ADR
hemorrhagic B-ADR B-ADR
stroke I-ADR I-ADR
was O-ADR O-ADR
adjudicated O-ADR O-ADR
and O-ADR O-ADR
counted O-ADR O-ADR
as O-ADR O-ADR
an O-ADR O-ADR
intracranial B-ADR O-ADR
major I-ADR O-ADR
bleed I-ADR O-ADR
. O-ADR O-ADR
More O-ADR O-ADR
frequent O-ADR O-ADR
monitoring O-ADR O-ADR
is O-ADR O-ADR
recommended O-ADR O-ADR
when O-ADR O-ADR
AFINITOR O-ADR O-ADR
is O-ADR O-ADR
co O-ADR O-ADR
- O-ADR O-ADR
administered O-ADR O-ADR
with O-ADR O-ADR
other O-ADR O-ADR
drugs O-ADR O-ADR
that O-ADR O-ADR
may O-ADR O-ADR
induce O-ADR O-ADR
hyperglycemia O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Radiation B-ADR O-ADR
risk I-ADR O-ADR
: O-ADR O-ADR
Choline O-ADR O-ADR
C O-ADR O-ADR
11 O-ADR O-ADR
Injection O-ADR O-ADR
contributes O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
patient O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
cumulative O-ADR O-ADR
radiation O-ADR O-ADR
exposure O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
identified O-ADR O-ADR
during O-ADR O-ADR
post O-ADR O-ADR
- O-ADR O-ADR
approval O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
Cleviprex O-ADR O-ADR
: O-ADR O-ADR
increased B-ADR B-ADR
blood I-ADR I-ADR
triglycerides I-ADR I-ADR
, O-ADR O-ADR
ileus B-ADR B-ADR
, O-ADR O-ADR
hypersensitivity B-ADR B-ADR
, O-ADR O-ADR
hypotension B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
decreased B-ADR B-ADR
oxygen I-ADR I-ADR
saturation I-ADR I-ADR
( O-ADR O-ADR
possible O-ADR O-ADR
pulmonary B-ADR B-ADR
shunting I-ADR I-ADR
) O-ADR O-ADR
and O-ADR O-ADR
reflex B-ADR B-ADR
tachycardia I-ADR I-ADR
. O-ADR O-ADR
Non O-ADR O-ADR
- O-ADR O-ADR
cutaneous O-ADR O-ADR
Malignancies O-ADR O-ADR
: O-ADR O-ADR
Based O-ADR O-ADR
on O-ADR O-ADR
its O-ADR O-ADR
mechanism O-ADR O-ADR
of O-ADR O-ADR
action O-ADR O-ADR
, O-ADR O-ADR
TAFINLAR O-ADR O-ADR
may O-ADR O-ADR
promote O-ADR O-ADR
the O-ADR O-ADR
growth O-ADR O-ADR
and O-ADR O-ADR
development O-ADR O-ADR
of O-ADR O-ADR
malignancies B-ADR B-ADR
with O-ADR O-ADR
activation O-ADR O-ADR
of O-ADR O-ADR
RAS O-ADR O-ADR
through O-ADR O-ADR
mutation O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
mechanisms O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Instruct O-ADR O-ADR
all O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
severe O-ADR O-ADR
renal O-ADR O-ADR
impairment O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
those O-ADR O-ADR
receiving O-ADR O-ADR
dialysis O-ADR O-ADR
, O-ADR O-ADR
about O-ADR O-ADR
the O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
hypocalcemia O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
importance O-ADR O-ADR
of O-ADR O-ADR
maintaining O-ADR O-ADR
calcium O-ADR O-ADR
levels O-ADR O-ADR
with O-ADR O-ADR
adequate O-ADR O-ADR
calcium O-ADR O-ADR
and O-ADR O-ADR
vitamin O-ADR O-ADR
D O-ADR O-ADR
supplementation O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Gout O-ADR O-ADR
Flare O-ADR O-ADR
After O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
ULORIC O-ADR O-ADR
, O-ADR O-ADR
an O-ADR O-ADR
increase O-ADR O-ADR
in O-ADR O-ADR
gout B-ADR B-ADR
flares I-ADR I-ADR
is O-ADR O-ADR
frequently O-ADR O-ADR
observed O-ADR O-ADR
. O-ADR O-ADR
Such O-ADR O-ADR
monitoring O-ADR O-ADR
should O-ADR O-ADR
include O-ADR O-ADR
daily O-ADR O-ADR
observation O-ADR O-ADR
by O-ADR O-ADR
families O-ADR O-ADR
and O-ADR O-ADR
caregivers O-ADR O-ADR
. O-ADR O-ADR
Of O-ADR O-ADR
the O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
reported O-ADR O-ADR
neuropathy B-ADR B-ADR
, O-ADR O-ADR
51 O-ADR O-ADR
% O-ADR O-ADR
had O-ADR O-ADR
residual B-ADR O-ADR
neuropathy I-ADR B-ADR
at O-ADR O-ADR
the O-ADR O-ADR
time O-ADR O-ADR
of O-ADR O-ADR
their O-ADR O-ADR
last O-ADR O-ADR
evaluation O-ADR O-ADR
. O-ADR O-ADR
Among O-ADR O-ADR
the O-ADR O-ADR
factors O-ADR O-ADR
that O-ADR O-ADR
may O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
NSF B-ADR O-ADR
are O-ADR O-ADR
repeated O-ADR O-ADR
or O-ADR O-ADR
higher O-ADR O-ADR
than O-ADR O-ADR
recommended O-ADR O-ADR
doses O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
GBCA O-ADR O-ADR
and O-ADR O-ADR
degree O-ADR O-ADR
of O-ADR O-ADR
renal O-ADR O-ADR
impairment O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
time O-ADR O-ADR
of O-ADR O-ADR
exposure O-ADR O-ADR
. O-ADR O-ADR
Most O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
receiving O-ADR O-ADR
concomitant O-ADR O-ADR
immunosuppressants O-ADR O-ADR
. O-ADR O-ADR
Of O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
one O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patient O-ADR O-ADR
and O-ADR O-ADR
no O-ADR O-ADR
control O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
had O-ADR O-ADR
newly B-ADR O-ADR
positive I-ADR O-ADR
anti I-ADR I-ADR
- O-ADR O-ADR
dsDNA O-ADR O-ADR
antibodies I-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
cautioned O-ADR O-ADR
about O-ADR O-ADR
performing O-ADR O-ADR
activities O-ADR O-ADR
requiring O-ADR O-ADR
mental O-ADR O-ADR
alertness O-ADR O-ADR
, O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
operating O-ADR O-ADR
hazardous O-ADR O-ADR
machinery O-ADR O-ADR
or O-ADR O-ADR
operating O-ADR O-ADR
a O-ADR O-ADR
motor O-ADR O-ADR
vehicle O-ADR O-ADR
, O-ADR O-ADR
until O-ADR O-ADR
they O-ADR O-ADR
are O-ADR O-ADR
reasonably O-ADR O-ADR
certain O-ADR O-ADR
that O-ADR O-ADR
SAPHRIS O-ADR O-ADR
therapy O-ADR O-ADR
does O-ADR O-ADR
not O-ADR O-ADR
affect O-ADR O-ADR
them O-ADR O-ADR
adversely O-ADR O-ADR
. O-ADR O-ADR
Image O-ADR O-ADR
interpretation O-ADR O-ADR
is O-ADR O-ADR
performed O-ADR O-ADR
independently O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
clinical O-ADR O-ADR
information O-ADR O-ADR
. O-ADR O-ADR
No O-ADR O-ADR
data O-ADR O-ADR
are O-ADR O-ADR
available O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
effectiveness O-ADR O-ADR
of O-ADR O-ADR
vaccinations O-ADR O-ADR
with O-ADR O-ADR
inactivated O-ADR O-ADR
( O-ADR O-ADR
killed O-ADR O-ADR
) O-ADR O-ADR
antigens O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
ILARIS O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Drug O-ADR O-ADR
Interactions O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
It O-ADR O-ADR
was O-ADR O-ADR
usually O-ADR O-ADR
transient O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
highest O-ADR O-ADR
incidence O-ADR O-ADR
reported O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
week O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
heart O-ADR O-ADR
failure O-ADR O-ADR
develops O-ADR O-ADR
or O-ADR O-ADR
worsens O-ADR O-ADR
and O-ADR O-ADR
requires O-ADR O-ADR
hospitalization O-ADR O-ADR
, O-ADR O-ADR
discontinue O-ADR O-ADR
MULTAQ O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
hemodialysis O-ADR O-ADR
, O-ADR O-ADR
consider O-ADR O-ADR
the O-ADR O-ADR
prompt O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
hemodialysis O-ADR O-ADR
following O-ADR O-ADR
the O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
GBCA O-ADR O-ADR
in O-ADR O-ADR
order O-ADR O-ADR
to O-ADR O-ADR
enhance O-ADR O-ADR
the O-ADR O-ADR
contrast O-ADR O-ADR
agent O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
elimination O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Clinical O-ADR O-ADR
Pharmacology O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
events O-ADR O-ADR
( O-ADR O-ADR
regardless O-ADR O-ADR
of O-ADR O-ADR
investigator O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
causality O-ADR O-ADR
assessment O-ADR O-ADR
) O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
or O-ADR O-ADR
equal O-ADR O-ADR
to O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
receiving O-ADR O-ADR
the O-ADR O-ADR
combination O-ADR O-ADR
of O-ADR O-ADR
VICTRELIS O-ADR O-ADR
with O-ADR O-ADR
PegIntron O-ADR O-ADR
/ O-ADR O-ADR
REBETOL O-ADR O-ADR
and O-ADR O-ADR
reported O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
or O-ADR O-ADR
equal O-ADR O-ADR
to O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
than O-ADR O-ADR
PegIntron O-ADR O-ADR
/ O-ADR O-ADR
REBETOL O-ADR O-ADR
alone O-ADR O-ADR
in O-ADR O-ADR
SPRINT O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
SPRINT O-ADR O-ADR
- O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
RESPOND O-ADR O-ADR
- O-ADR O-ADR
2 O-ADR O-ADR
are O-ADR O-ADR
presented O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Severe O-ADR O-ADR
Acute B-ADR B-ADR
Exacerbations I-ADR I-ADR
of I-ADR I-ADR
Hepatitis I-ADR I-ADR
B I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Boxed O-ADR O-ADR
Warning O-ADR O-ADR
, O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Liver O-ADR O-ADR
Enzyme O-ADR O-ADR
Elevations O-ADR O-ADR
There O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reports O-ADR O-ADR
of O-ADR O-ADR
severe O-ADR O-ADR
hepatic B-ADR B-ADR
reactions I-ADR I-ADR
including O-ADR O-ADR
acute B-ADR B-ADR
liver I-ADR I-ADR
failure I-ADR I-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
TNF O-ADR O-ADR
- O-ADR O-ADR
blockers O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Probable O-ADR O-ADR
Dementia O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
WHIMS O-ADR O-ADR
estrogen O-ADR O-ADR
- O-ADR O-ADR
alone O-ADR O-ADR
ancillary O-ADR O-ADR
study O-ADR O-ADR
of O-ADR O-ADR
WHI O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
population O-ADR O-ADR
of O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
947 O-ADR O-ADR
hysterectomized O-ADR O-ADR
women O-ADR O-ADR
65 O-ADR O-ADR
to O-ADR O-ADR
79 O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
age O-ADR O-ADR
was O-ADR O-ADR
randomized O-ADR O-ADR
to O-ADR O-ADR
daily O-ADR O-ADR
CE O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
625 O-ADR O-ADR
mg O-ADR O-ADR
) O-ADR O-ADR
- O-ADR O-ADR
alone O-ADR O-ADR
or O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
Of O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
49 O-ADR O-ADR
% O-ADR O-ADR
had O-ADR O-ADR
complete O-ADR O-ADR
resolution O-ADR O-ADR
, O-ADR O-ADR
31 O-ADR O-ADR
% O-ADR O-ADR
had O-ADR O-ADR
partial O-ADR O-ADR
improvement O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
20 O-ADR O-ADR
% O-ADR O-ADR
had O-ADR O-ADR
no O-ADR O-ADR
improvement O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
Laboratory O-ADR O-ADR
Tests O-ADR O-ADR
and O-ADR O-ADR
Monitoring O-ADR O-ADR
Renal O-ADR O-ADR
Function O-ADR O-ADR
Elevations B-ADR B-ADR
of I-ADR I-ADR
serum I-ADR I-ADR
creatinine I-ADR I-ADR
and O-ADR O-ADR
proteinuria B-ADR B-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
taking O-ADR O-ADR
AFINITOR O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
, O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
, O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
DLCO B-ADR O-ADR
, I-ADR O-ADR
the I-ADR O-ADR
reduction I-ADR O-ADR
from O-ADR O-ADR
baseline O-ADR O-ADR
in O-ADR O-ADR
percent O-ADR O-ADR
of O-ADR O-ADR
predicted O-ADR O-ADR
values O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
time O-ADR O-ADR
of O-ADR O-ADR
last O-ADR O-ADR
assessment O-ADR O-ADR
on O-ADR O-ADR
drug O-ADR O-ADR
was O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
GILENYA O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
and O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
Do O-ADR O-ADR
not O-ADR O-ADR
administer O-ADR O-ADR
KALBITOR O-ADR O-ADR
to O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
known O-ADR O-ADR
clinical O-ADR O-ADR
hypersensitivity O-ADR O-ADR
to O-ADR O-ADR
KALBITOR O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
a O-ADR O-ADR
Data O-ADR O-ADR
presented O-ADR O-ADR
are O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
primary O-ADR O-ADR
endpoint O-ADR O-ADR
and O-ADR O-ADR
include O-ADR O-ADR
only O-ADR O-ADR
events O-ADR O-ADR
occurring O-ADR O-ADR
on O-ADR O-ADR
- O-ADR O-ADR
therapy O-ADR O-ADR
with O-ADR O-ADR
randomized O-ADR O-ADR
medications O-ADR O-ADR
and O-ADR O-ADR
excludes O-ADR O-ADR
events O-ADR O-ADR
occurring O-ADR O-ADR
after O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
glycemic O-ADR O-ADR
rescue O-ADR O-ADR
medications O-ADR O-ADR
( O-ADR O-ADR
i O-ADR O-ADR
. O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
primarily O-ADR O-ADR
metformin O-ADR O-ADR
or O-ADR O-ADR
insulin O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Cutaneous B-ADR B-ADR
squamous I-ADR I-ADR
cell I-ADR I-ADR
carcinoma I-ADR I-ADR
( O-ADR O-ADR
SCC B-ADR B-ADR
) O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
keratoacanthoma B-ADR B-ADR
, O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
TAFINLAR O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
and O-ADR O-ADR
19 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
TAFINLAR O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
single O-ADR O-ADR
agent O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Allergic B-ADR B-ADR
reactions I-ADR I-ADR
: O-ADR O-ADR
have O-ADR O-ADR
emergency O-ADR O-ADR
resuscitation O-ADR O-ADR
equipment O-ADR O-ADR
and O-ADR O-ADR
personnel O-ADR O-ADR
readily O-ADR O-ADR
available O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
testing O-ADR O-ADR
positive O-ADR O-ADR
in O-ADR O-ADR
tuberculosis O-ADR O-ADR
screening O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
treated O-ADR O-ADR
according O-ADR O-ADR
to O-ADR O-ADR
standard O-ADR O-ADR
medical O-ADR O-ADR
practice O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
therapy O-ADR O-ADR
with O-ADR O-ADR
ILARIS O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
10 O-ADR O-ADR
Hepatic O-ADR O-ADR
Impairment O-ADR O-ADR
Exposure O-ADR O-ADR
to O-ADR O-ADR
everolimus O-ADR O-ADR
was O-ADR O-ADR
increased O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
hepatic B-ADR O-ADR
impairment I-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Pharmacology O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Serious O-ADR O-ADR
allergic B-ADR B-ADR
reactions I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
anaphylactic B-ADR B-ADR
reactions I-ADR I-ADR
, O-ADR O-ADR
may O-ADR O-ADR
occur O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
overall O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
infections B-ADR B-ADR
was O-ADR O-ADR
71 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
BENLYSTA O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
67 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
If O-ADR O-ADR
you O-ADR O-ADR
take O-ADR O-ADR
a O-ADR O-ADR
calcium O-ADR O-ADR
or O-ADR O-ADR
vitamin O-ADR O-ADR
D O-ADR O-ADR
supplement O-ADR O-ADR
, O-ADR O-ADR
you O-ADR O-ADR
may O-ADR O-ADR
take O-ADR O-ADR
it O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
same O-ADR O-ADR
time O-ADR O-ADR
you O-ADR O-ADR
take O-ADR O-ADR
DUAVEE O-ADR O-ADR
. O-ADR O-ADR
See O-ADR O-ADR
the O-ADR O-ADR
list O-ADR O-ADR
of O-ADR O-ADR
ingredients O-ADR O-ADR
in O-ADR O-ADR
DUAVEE O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
end O-ADR O-ADR
of O-ADR O-ADR
this O-ADR O-ADR
leaflet O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Hemorrhage O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
study O-ADR O-ADR
with O-ADR O-ADR
INLYTA O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
RCC O-ADR O-ADR
, O-ADR O-ADR
hemorrhagic B-ADR B-ADR
events I-ADR I-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
58 O-ADR O-ADR
/ O-ADR O-ADR
359 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
16 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
receiving O-ADR O-ADR
INLYTA O-ADR O-ADR
and O-ADR O-ADR
64 O-ADR O-ADR
/ O-ADR O-ADR
355 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
18 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
receiving O-ADR O-ADR
sorafenib O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
ViiV O-ADR O-ADR
Healthcare O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
877 O-ADR O-ADR
- O-ADR O-ADR
844 O-ADR O-ADR
- O-ADR O-ADR
8872 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
Experience O-ADR O-ADR
in O-ADR O-ADR
Adult O-ADR O-ADR
Subjects O-ADR O-ADR
Treatment O-ADR O-ADR
- O-ADR O-ADR
emergent O-ADR O-ADR
Adverse O-ADR O-ADR
Drug O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
ADRs O-ADR O-ADR
) O-ADR O-ADR
Treatment O-ADR O-ADR
- O-ADR O-ADR
naive O-ADR O-ADR
Subjects O-ADR O-ADR
: O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
assessment O-ADR O-ADR
of O-ADR O-ADR
TIVICAY O-ADR O-ADR
in O-ADR O-ADR
HIV O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
infected O-ADR O-ADR
treatment O-ADR O-ADR
- O-ADR O-ADR
naive O-ADR O-ADR
subjects O-ADR O-ADR
is O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
analyses O-ADR O-ADR
of O-ADR O-ADR
96 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
data O-ADR O-ADR
from O-ADR O-ADR
2 O-ADR O-ADR
international O-ADR O-ADR
, O-ADR O-ADR
multicenter O-ADR O-ADR
, O-ADR O-ADR
double O-ADR O-ADR
- O-ADR O-ADR
blind O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
SPRING O-ADR O-ADR
- O-ADR O-ADR
2 O-ADR O-ADR
( O-ADR O-ADR
ING113086 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
SINGLE O-ADR O-ADR
( O-ADR O-ADR
ING114467 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
48 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
data O-ADR O-ADR
from O-ADR O-ADR
the O-ADR O-ADR
international O-ADR O-ADR
, O-ADR O-ADR
multicenter O-ADR O-ADR
, O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
FLAMINGO O-ADR O-ADR
( O-ADR O-ADR
ING114915 O-ADR O-ADR
) O-ADR O-ADR
trial O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Risk O-ADR O-ADR
for O-ADR O-ADR
Image O-ADR O-ADR
Misinterpretation O-ADR O-ADR
and O-ADR O-ADR
other O-ADR O-ADR
Errors O-ADR O-ADR
Errors O-ADR O-ADR
may O-ADR O-ADR
occur O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Amyvid O-ADR O-ADR
estimation O-ADR O-ADR
of O-ADR O-ADR
brain O-ADR O-ADR
neuritic O-ADR O-ADR
plaque O-ADR O-ADR
density O-ADR O-ADR
during O-ADR O-ADR
image O-ADR O-ADR
interpretation O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Clinical O-ADR O-ADR
manifestations O-ADR O-ADR
of O-ADR O-ADR
NMS B-ADR B-ADR
are O-ADR O-ADR
hyperpyrexia B-ADR B-ADR
, O-ADR O-ADR
muscle B-ADR B-ADR
rigidity I-ADR I-ADR
, O-ADR O-ADR
altered B-ADR B-ADR
mental I-ADR I-ADR
status I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
evidence O-ADR O-ADR
of O-ADR O-ADR
autonomic B-ADR B-ADR
instability I-ADR I-ADR
( O-ADR O-ADR
irregular B-ADR B-ADR
pulse I-ADR I-ADR
, O-ADR O-ADR
tachycardia B-ADR B-ADR
, O-ADR O-ADR
diaphoresis B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
cardiac B-ADR B-ADR
dysrhythmia I-ADR I-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Prolonged O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
elevated O-ADR O-ADR
plasma O-ADR O-ADR
ammonia O-ADR I-ADR
levels O-ADR O-ADR
can O-ADR O-ADR
rapidly O-ADR O-ADR
result O-ADR O-ADR
in O-ADR O-ADR
injury O-ADR B-ADR
to O-ADR I-ADR
the O-ADR I-ADR
brain O-ADR I-ADR
or O-ADR O-ADR
death O-ADR B-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
men O-ADR O-ADR
with O-ADR O-ADR
osteoporosis O-ADR O-ADR
and O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
with O-ADR O-ADR
Prolia O-ADR O-ADR
than O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
: O-ADR O-ADR
back B-ADR B-ADR
pain I-ADR I-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
placebo O-ADR O-ADR
vs O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
Prolia O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
arthralgia B-ADR B-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
placebo O-ADR O-ADR
vs O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
Prolia O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
nasopharyngitis B-ADR B-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
placebo O-ADR O-ADR
vs O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
Prolia O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
13 O-ADR O-ADR
Pregnancy O-ADR O-ADR
INLYTA O-ADR O-ADR
can O-ADR O-ADR
cause O-ADR O-ADR
fetal B-ADR B-ADR
harm I-ADR I-ADR
when O-ADR O-ADR
administered O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
pregnant O-ADR O-ADR
woman O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
its O-ADR O-ADR
mechanism O-ADR O-ADR
of O-ADR O-ADR
action O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Topical O-ADR O-ADR
Ophthalmic O-ADR O-ADR
Use O-ADR O-ADR
Only O-ADR O-ADR
BEPREVE O-ADR O-ADR
is O-ADR O-ADR
for O-ADR O-ADR
topical O-ADR O-ADR
ophthalmic O-ADR O-ADR
use O-ADR O-ADR
only O-ADR O-ADR
. O-ADR O-ADR
Discontinue O-ADR O-ADR
permanently O-ADR O-ADR
if O-ADR O-ADR
a O-ADR O-ADR
clinically O-ADR O-ADR
significant O-ADR O-ADR
reaction O-ADR O-ADR
occurs O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Hypocalcemia B-ADR B-ADR
: O-ADR O-ADR
Must O-ADR O-ADR
be O-ADR O-ADR
corrected O-ADR O-ADR
before O-ADR O-ADR
initiating O-ADR O-ADR
Prolia O-ADR O-ADR
. O-ADR O-ADR
Periodically O-ADR O-ADR
monitor O-ADR O-ADR
patients O-ADR O-ADR
clinically O-ADR O-ADR
for O-ADR O-ADR
atrial O-ADR O-ADR
fibrillation O-ADR O-ADR
. O-ADR O-ADR
An O-ADR O-ADR
earlier O-ADR O-ADR
onset O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
ruled O-ADR O-ADR
out O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
it O-ADR O-ADR
is O-ADR O-ADR
possible O-ADR O-ADR
that O-ADR O-ADR
retinal B-ADR B-ADR
abnormalities I-ADR I-ADR
were O-ADR O-ADR
present O-ADR O-ADR
earlier O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
course O-ADR O-ADR
of O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
POTIGA O-ADR O-ADR
. O-ADR O-ADR
Stop O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
COMETRIQ O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
28 O-ADR O-ADR
days O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
scheduled O-ADR O-ADR
surgery O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
: O-ADR O-ADR
Incidence O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
Documented O-ADR O-ADR
Hypoglycemia B-ADR B-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
in O-ADR O-ADR
Placebo O-ADR O-ADR
- O-ADR O-ADR
Controlled O-ADR O-ADR
Trials O-ADR O-ADR
Placebo O-ADR O-ADR
TRULICITY O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
75 O-ADR O-ADR
mg O-ADR O-ADR
TRULICITY O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
Add O-ADR O-ADR
- O-ADR O-ADR
on O-ADR O-ADR
to O-ADR O-ADR
Metformin O-ADR O-ADR
( O-ADR O-ADR
26 O-ADR O-ADR
weeks O-ADR O-ADR
) O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
177 O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
302 O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
304 O-ADR O-ADR
Documented O-ADR O-ADR
symptomatic O-ADR B-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
Severe O-ADR O-ADR
0 O-ADR O-ADR
0 O-ADR O-ADR
0 O-ADR O-ADR
Add O-ADR O-ADR
- O-ADR O-ADR
on O-ADR O-ADR
to O-ADR O-ADR
Metformin O-ADR O-ADR
+ O-ADR O-ADR
Pioglitazone O-ADR O-ADR
( O-ADR O-ADR
26 O-ADR O-ADR
weeks O-ADR O-ADR
) O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
141 O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
280 O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
279 O-ADR O-ADR
Documented O-ADR O-ADR
symptomatic O-ADR B-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
Severe O-ADR O-ADR
0 O-ADR O-ADR
0 O-ADR O-ADR
0 O-ADR O-ADR
Hypoglycemia B-ADR B-ADR
was O-ADR O-ADR
more O-ADR O-ADR
frequent O-ADR O-ADR
when O-ADR O-ADR
TRULICITY O-ADR O-ADR
was O-ADR O-ADR
used O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
sulfonylurea O-ADR O-ADR
or O-ADR O-ADR
insulin O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
studies O-ADR O-ADR
who O-ADR O-ADR
rolled O-ADR O-ADR
over O-ADR O-ADR
into O-ADR O-ADR
the O-ADR O-ADR
RE O-ADR O-ADR
- O-ADR O-ADR
MEDY O-ADR O-ADR
study O-ADR O-ADR
had O-ADR O-ADR
a O-ADR O-ADR
combined O-ADR O-ADR
treatment O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
3 O-ADR O-ADR
years O-ADR O-ADR
, O-ADR O-ADR
with O-ADR O-ADR
mean O-ADR O-ADR
exposure O-ADR O-ADR
of O-ADR O-ADR
473 O-ADR O-ADR
days O-ADR O-ADR
. O-ADR O-ADR
Stevens B-ADR B-ADR
- O-ADR O-ADR
Johnson O-ADR O-ADR
syndrome I-ADR I-ADR
, O-ADR O-ADR
drug O-ADR B-ADR
hypersensitivity B-ADR I-ADR
reaction O-ADR I-ADR
and O-ADR O-ADR
erythema B-ADR B-ADR
multiforme I-ADR I-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
during O-ADR O-ADR
clinical O-ADR O-ADR
development O-ADR O-ADR
with O-ADR O-ADR
INTELENCE O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Embryo O-ADR O-ADR
- O-ADR O-ADR
fetal O-ADR O-ADR
Toxicity O-ADR O-ADR
Beleodaq O-ADR O-ADR
can O-ADR O-ADR
cause O-ADR O-ADR
fetal B-ADR B-ADR
harm I-ADR I-ADR
when O-ADR O-ADR
administered O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
pregnant O-ADR O-ADR
woman O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Adrenocortical O-ADR O-ADR
Insufficiency O-ADR O-ADR
Adrenal B-ADR B-ADR
insufficiency I-ADR I-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
two O-ADR O-ADR
randomized O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
taking O-ADR O-ADR
ZYTIGA O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
taking O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
Study O-ADR O-ADR
RA O-ADR O-ADR
- O-ADR O-ADR
IV O-ADR O-ADR
( O-ADR O-ADR
monotherapy O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
ACR20 O-ADR O-ADR
response O-ADR O-ADR
was O-ADR O-ADR
33 O-ADR O-ADR
% O-ADR O-ADR
versus O-ADR O-ADR
56 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
antibody O-ADR O-ADR
- O-ADR O-ADR
positive O-ADR O-ADR
versus O-ADR O-ADR
antibody O-ADR O-ADR
- O-ADR O-ADR
negative O-ADR O-ADR
status O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Serious O-ADR O-ADR
Dermatological O-ADR O-ADR
Reactions O-ADR O-ADR
Serious O-ADR O-ADR
skin B-ADR B-ADR
reactions I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
Stevens B-ADR B-ADR
- O-ADR O-ADR
Johnson O-ADR O-ADR
syndrome I-ADR I-ADR
( O-ADR O-ADR
SJS B-ADR B-ADR
) O-ADR O-ADR
and O-ADR O-ADR
toxic B-ADR B-ADR
epidermal I-ADR I-ADR
necrolysis I-ADR I-ADR
( O-ADR O-ADR
TEN B-ADR B-ADR
) O-ADR O-ADR
, O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
ONFI O-ADR O-ADR
in O-ADR O-ADR
both O-ADR O-ADR
children O-ADR O-ADR
and O-ADR O-ADR
adults O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
post O-ADR O-ADR
- O-ADR O-ADR
marketing O-ADR O-ADR
period O-ADR O-ADR
. O-ADR O-ADR
Hypersensitivity O-ADR O-ADR
Reactions O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
symptoms O-ADR O-ADR
that O-ADR O-ADR
could O-ADR O-ADR
be O-ADR O-ADR
compatible O-ADR O-ADR
with O-ADR O-ADR
hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
rarely O-ADR O-ADR
following O-ADR O-ADR
CIMZIA O-ADR O-ADR
administration O-ADR O-ADR
to O-ADR O-ADR
patients O-ADR O-ADR
: O-ADR O-ADR
angioedema B-ADR B-ADR
, O-ADR O-ADR
dermatitis B-ADR B-ADR
allergic I-ADR I-ADR
, O-ADR O-ADR
dizziness B-ADR B-ADR
( I-ADR I-ADR
postural I-ADR I-ADR
) O-ADR O-ADR
, O-ADR O-ADR
dyspnea B-ADR B-ADR
, O-ADR O-ADR
hot B-ADR B-ADR
flush I-ADR I-ADR
, O-ADR O-ADR
hypotension B-ADR B-ADR
, O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
reactions I-ADR I-ADR
, O-ADR O-ADR
malaise B-ADR B-ADR
, O-ADR O-ADR
pyrexia B-ADR B-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
, O-ADR O-ADR
serum B-ADR B-ADR
sickness I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
( O-ADR O-ADR
vasovagal B-ADR B-ADR
) I-ADR I-ADR
syncope I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
100 O-ADR O-ADR
/ O-ADR O-ADR
25 O-ADR O-ADR
no O-ADR O-ADR
longer O-ADR O-ADR
controls O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
bronchoconstriction O-ADR O-ADR
; O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
inhaled O-ADR O-ADR
, O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
acting O-ADR O-ADR
, O-ADR O-ADR
beta2 O-ADR O-ADR
- O-ADR O-ADR
agonist O-ADR O-ADR
becomes O-ADR O-ADR
less O-ADR O-ADR
effective O-ADR O-ADR
; O-ADR O-ADR
or O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
needs O-ADR O-ADR
more O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
acting O-ADR O-ADR
beta2 O-ADR O-ADR
- O-ADR O-ADR
agonist O-ADR O-ADR
than O-ADR O-ADR
usual O-ADR O-ADR
, O-ADR O-ADR
these O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
markers O-ADR O-ADR
of O-ADR O-ADR
deterioration O-ADR O-ADR
of O-ADR O-ADR
disease O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
subset O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
had O-ADR O-ADR
recurrence O-ADR B-ADR
of O-ADR I-ADR
contracture O-ADR I-ADR
in O-ADR O-ADR
a O-ADR O-ADR
joint O-ADR O-ADR
that O-ADR O-ADR
was O-ADR O-ADR
previously O-ADR O-ADR
successfully O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
XIAFLEX O-ADR O-ADR
in O-ADR O-ADR
Study O-ADR O-ADR
4 O-ADR O-ADR
were O-ADR O-ADR
retreated O-ADR O-ADR
( O-ADR O-ADR
Study O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
However O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
attributable O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
liver B-ADR B-ADR
cancers I-ADR I-ADR
in O-ADR O-ADR
COC O-ADR O-ADR
users O-ADR O-ADR
is O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
one O-ADR O-ADR
case O-ADR O-ADR
per O-ADR O-ADR
million O-ADR O-ADR
users O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
these O-ADR O-ADR
reasons O-ADR O-ADR
, O-ADR O-ADR
comparison O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
certolizumab O-ADR O-ADR
pegol O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
other O-ADR O-ADR
products O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
misleading O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Peripheral O-ADR O-ADR
Neuropathy O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
peripheral B-ADR B-ADR
neuropathy I-ADR I-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
40 O-ADR O-ADR
/ O-ADR O-ADR
503 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
Grade O-ADR O-ADR
4 O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
/ O-ADR O-ADR
503 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
clinical O-ADR O-ADR
significance O-ADR O-ADR
of O-ADR O-ADR
CMV O-ADR O-ADR
serology O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
risk O-ADR O-ADR
factor O-ADR O-ADR
for O-ADR O-ADR
PTLD B-ADR O-ADR
remains O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
determined O-ADR O-ADR
; O-ADR O-ADR
however O-ADR O-ADR
, O-ADR O-ADR
these O-ADR O-ADR
findings O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
when O-ADR O-ADR
prescribing O-ADR O-ADR
NULOJIX O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Immune O-ADR O-ADR
- O-ADR O-ADR
mediated O-ADR O-ADR
Enterocolitis O-ADR O-ADR
In O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
severe O-ADR O-ADR
, O-ADR O-ADR
life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
fatal B-ADR B-ADR
( O-ADR O-ADR
diarrhea B-ADR B-ADR
of O-ADR O-ADR
7 O-ADR O-ADR
or O-ADR O-ADR
more O-ADR O-ADR
stools O-ADR O-ADR
above O-ADR O-ADR
baseline O-ADR O-ADR
, O-ADR O-ADR
fever B-ADR B-ADR
, O-ADR O-ADR
ileus B-ADR B-ADR
, O-ADR O-ADR
peritoneal B-ADR B-ADR
signs I-ADR I-ADR
; O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
immune B-ADR B-ADR
- O-ADR O-ADR
mediated O-ADR O-ADR
enterocolitis I-ADR I-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
34 O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
YERVOY O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
moderate O-ADR O-ADR
( O-ADR O-ADR
diarrhea B-ADR B-ADR
with O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
6 O-ADR O-ADR
stools O-ADR O-ADR
above O-ADR O-ADR
baseline O-ADR O-ADR
, O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
blood B-ADR B-ADR
in I-ADR I-ADR
stool I-ADR I-ADR
; O-ADR O-ADR
Grade O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
enterocolitis B-ADR B-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
28 O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
YERVOY O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
By O-ADR O-ADR
Week O-ADR O-ADR
24 O-ADR O-ADR
, O-ADR O-ADR
hematocrit B-ADR B-ADR
values I-ADR I-ADR
> I-ADR I-ADR
55 I-ADR I-ADR
% I-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
FARXIGA O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Note O-ADR O-ADR
: O-ADR O-ADR
Percentages O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
number O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
that O-ADR O-ADR
reported O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
1 O-ADR O-ADR
treatment O-ADR O-ADR
- O-ADR O-ADR
emergent O-ADR O-ADR
occurrence O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
? O-ADR O-ADR
Monitor O-ADR O-ADR
urine O-ADR O-ADR
protein O-ADR O-ADR
regularly O-ADR O-ADR
during O-ADR O-ADR
COMETRIQ O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
Advise O-ADR O-ADR
patients O-ADR O-ADR
to O-ADR O-ADR
seek O-ADR O-ADR
prompt O-ADR O-ADR
medical O-ADR O-ADR
attention O-ADR O-ADR
if O-ADR O-ADR
they O-ADR O-ADR
develop O-ADR O-ADR
signs O-ADR O-ADR
or O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
infection O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
cellulitis O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Dermatologic B-ADR B-ADR
reactions I-ADR I-ADR
: O-ADR O-ADR
Dermatitis B-ADR B-ADR
, O-ADR O-ADR
rashes B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
eczema B-ADR B-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
neurological O-ADR O-ADR
compromise O-ADR O-ADR
is O-ADR O-ADR
noted O-ADR O-ADR
, O-ADR O-ADR
urgent O-ADR O-ADR
diagnosis O-ADR O-ADR
and O-ADR O-ADR
treatment O-ADR O-ADR
is O-ADR O-ADR
necessary O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
median O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
was O-ADR O-ADR
2 O-ADR O-ADR
cycles O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
33 O-ADR O-ADR
cycles O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
heart O-ADR O-ADR
rate O-ADR O-ADR
and O-ADR O-ADR
blood O-ADR O-ADR
pressure O-ADR O-ADR
regularly O-ADR O-ADR
. O-ADR O-ADR
Photosensitivity B-ADR B-ADR
- O-ADR O-ADR
related O-ADR O-ADR
adverse I-ADR I-ADR
reactions I-ADR I-ADR
( O-ADR O-ADR
including O-ADR O-ADR
photosensitivity B-ADR B-ADR
reaction I-ADR I-ADR
, O-ADR O-ADR
polymorphic B-ADR B-ADR
light I-ADR I-ADR
eruption I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
sunburn B-ADR B-ADR
) O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
comparator O-ADR O-ADR
, O-ADR O-ADR
INVOKANA O-ADR O-ADR
100 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
INVOKANA O-ADR O-ADR
300 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
are O-ADR O-ADR
breastfeeding O-ADR O-ADR
or O-ADR O-ADR
plan O-ADR O-ADR
to O-ADR O-ADR
breastfeed O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
were O-ADR O-ADR
: O-ADR O-ADR
pneumonia B-ADR B-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
acute B-ADR B-ADR
renal I-ADR I-ADR
failure I-ADR I-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
disease B-ADR O-ADR
progression I-ADR I-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
pyrexia B-ADR B-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
hypercalcemia B-ADR B-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
congestive B-ADR B-ADR
heart I-ADR I-ADR
failure I-ADR I-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
multiple B-ADR B-ADR
myeloma I-ADR I-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
anemia B-ADR B-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
dyspnea B-ADR B-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
some O-ADR O-ADR
cases O-ADR O-ADR
glucose B-ADR O-ADR
intolerance I-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
irreversible O-ADR O-ADR
. O-ADR O-ADR
estimated O-ADR O-ADR
creatinine O-ADR O-ADR
clearance O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
70 O-ADR O-ADR
mL O-ADR O-ADR
per O-ADR O-ADR
minute O-ADR O-ADR
) O-ADR O-ADR
at O-ADR O-ADR
baseline O-ADR O-ADR
. O-ADR O-ADR
Serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
29 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
GILOTRIF O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
events O-ADR O-ADR
generally O-ADR O-ADR
occurred O-ADR O-ADR
within O-ADR O-ADR
hours O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
infusion O-ADR O-ADR
; O-ADR O-ADR
however O-ADR O-ADR
, O-ADR O-ADR
they O-ADR O-ADR
may O-ADR O-ADR
occur O-ADR O-ADR
later O-ADR O-ADR
. O-ADR O-ADR
Inform O-ADR O-ADR
patients O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
anaphylaxis O-ADR O-ADR
, O-ADR O-ADR
hypersensitivity O-ADR O-ADR
reactions O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
immune O-ADR O-ADR
- O-ADR O-ADR
mediated O-ADR O-ADR
reactions O-ADR O-ADR
and O-ADR O-ADR
have O-ADR O-ADR
them O-ADR O-ADR
seek O-ADR O-ADR
immediate O-ADR O-ADR
medical O-ADR O-ADR
care O-ADR O-ADR
should O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
occur O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
After O-ADR O-ADR
cross O-ADR O-ADR
- O-ADR O-ADR
over O-ADR O-ADR
to O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
AFINITOR O-ADR O-ADR
, O-ADR O-ADR
there O-ADR O-ADR
were O-ADR O-ADR
three O-ADR O-ADR
additional O-ADR O-ADR
deaths B-ADR B-ADR
, O-ADR O-ADR
one O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
hypoglycemia B-ADR B-ADR
and O-ADR O-ADR
cardiac B-ADR B-ADR
arrest I-ADR I-ADR
in O-ADR O-ADR
a O-ADR O-ADR
patient O-ADR O-ADR
with O-ADR O-ADR
insulinoma O-ADR O-ADR
, O-ADR O-ADR
one O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
myocardial B-ADR B-ADR
infarction I-ADR I-ADR
with O-ADR O-ADR
congestive B-ADR B-ADR
heart I-ADR I-ADR
failure I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
other O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
sudden B-ADR B-ADR
death I-ADR I-ADR
. O-ADR O-ADR
Fever B-ADR B-ADR
was O-ADR O-ADR
complicated O-ADR O-ADR
with O-ADR O-ADR
chills O-ADR O-ADR
/ O-ADR O-ADR
rigors O-ADR O-ADR
in O-ADR O-ADR
51 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
28 O-ADR O-ADR
/ O-ADR O-ADR
55 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
dehydration B-ADR B-ADR
in O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
/ O-ADR O-ADR
55 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
renal B-ADR B-ADR
failure I-ADR I-ADR
in O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
/ O-ADR O-ADR
55 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
syncope B-ADR B-ADR
in O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
/ O-ADR O-ADR
55 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
Trial O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
Out O-ADR O-ADR
of O-ADR O-ADR
1082 O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
58 O-ADR O-ADR
mg O-ADR O-ADR
of O-ADR O-ADR
XIAFLEX O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
controlled O-ADR O-ADR
and O-ADR O-ADR
uncontrolled O-ADR O-ADR
portions O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
XIAFLEX O-ADR O-ADR
studies O-ADR O-ADR
( O-ADR O-ADR
2630 O-ADR O-ADR
XIAFLEX O-ADR O-ADR
injections O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
3 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
patients O-ADR O-ADR
had O-ADR O-ADR
a O-ADR O-ADR
flexor B-ADR B-ADR
tendon I-ADR I-ADR
rupture I-ADR I-ADR
of I-ADR I-ADR
the I-ADR I-ADR
treated I-ADR I-ADR
finger I-ADR I-ADR
within O-ADR O-ADR
7 O-ADR O-ADR
days O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
injection O-ADR O-ADR
. O-ADR O-ADR
Patient O-ADR O-ADR
presenting O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
atypical O-ADR O-ADR
femur O-ADR O-ADR
fracture O-ADR O-ADR
should O-ADR O-ADR
also O-ADR O-ADR
be O-ADR O-ADR
assessed O-ADR O-ADR
for O-ADR O-ADR
symptoms O-ADR O-ADR
and O-ADR O-ADR
signs O-ADR O-ADR
of O-ADR O-ADR
fracture O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
contralateral O-ADR O-ADR
limb O-ADR O-ADR
. O-ADR O-ADR
On O-ADR O-ADR
average O-ADR O-ADR
, O-ADR O-ADR
women O-ADR O-ADR
with O-ADR O-ADR
hepatic O-ADR O-ADR
impairment O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
bazedoxifene O-ADR O-ADR
alone O-ADR O-ADR
showed O-ADR O-ADR
a O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
fold O-ADR O-ADR
increase O-ADR O-ADR
in O-ADR O-ADR
overall O-ADR O-ADR
exposures O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
controls O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Clinical O-ADR O-ADR
Pharmacology O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Mild O-ADR O-ADR
( O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
LLN O-ADR O-ADR
and O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
75x10 O-ADR O-ADR
9 O-ADR O-ADR
/ O-ADR O-ADR
L O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
transient O-ADR O-ADR
decreases B-ADR B-ADR
in I-ADR I-ADR
platelet I-ADR I-ADR
counts I-ADR I-ADR
were O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
3 O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
ILARIS O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
versus O-ADR O-ADR
1 O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patient O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
2 O-ADR O-ADR
- O-ADR O-ADR
year O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
reduction B-ADR B-ADR
from I-ADR I-ADR
baseline I-ADR I-ADR
in I-ADR I-ADR
the I-ADR I-ADR
percent I-ADR I-ADR
of I-ADR I-ADR
predicted I-ADR I-ADR
values I-ADR I-ADR
for I-ADR I-ADR
FEV1 I-ADR I-ADR
at O-ADR O-ADR
the O-ADR O-ADR
time O-ADR O-ADR
of O-ADR O-ADR
last O-ADR O-ADR
assessment O-ADR O-ADR
on O-ADR O-ADR
drug O-ADR O-ADR
was O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
GILENYA O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Splenic B-ADR B-ADR
Rupture I-ADR I-ADR
: O-ADR O-ADR
Discontinue O-ADR O-ADR
GRANIX O-ADR O-ADR
if O-ADR O-ADR
suspected O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Acute B-ADR B-ADR
Respiratory I-ADR I-ADR
Distress I-ADR I-ADR
Syndrome I-ADR I-ADR
( O-ADR O-ADR
ARDS B-ADR B-ADR
) O-ADR O-ADR
: O-ADR O-ADR
Monitor O-ADR O-ADR
for O-ADR O-ADR
and O-ADR O-ADR
manage O-ADR O-ADR
immediately O-ADR O-ADR
. O-ADR O-ADR
Exercise O-ADR O-ADR
caution O-ADR O-ADR
in O-ADR O-ADR
considering O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
CIMZIA O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
pre O-ADR O-ADR
- O-ADR O-ADR
existing O-ADR O-ADR
or O-ADR O-ADR
recent O-ADR O-ADR
- O-ADR O-ADR
onset O-ADR O-ADR
central O-ADR O-ADR
or O-ADR O-ADR
peripheral O-ADR O-ADR
nervous O-ADR O-ADR
system O-ADR O-ADR
demyelinating O-ADR O-ADR
disorders O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
: O-ADR O-ADR
Bleeding B-ADR B-ADR
Events O-ADR O-ADR
in O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
Nonvalvular O-ADR O-ADR
Atrial O-ADR O-ADR
Fibrillation O-ADR O-ADR
in O-ADR O-ADR
AVERROES O-ADR O-ADR
ELIQUISN O-ADR O-ADR
= O-ADR O-ADR
2798n O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
/ O-ADR O-ADR
year O-ADR O-ADR
) O-ADR O-ADR
AspirinN O-ADR O-ADR
= O-ADR O-ADR
2780n O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
/ O-ADR O-ADR
year O-ADR O-ADR
) O-ADR O-ADR
Hazard O-ADR O-ADR
Ratio O-ADR O-ADR
( O-ADR O-ADR
95 O-ADR O-ADR
% O-ADR O-ADR
CI O-ADR O-ADR
) O-ADR O-ADR
P O-ADR O-ADR
- O-ADR O-ADR
value O-ADR O-ADR
Events O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
each O-ADR O-ADR
endpoint O-ADR O-ADR
were O-ADR O-ADR
counted O-ADR O-ADR
once O-ADR O-ADR
per O-ADR O-ADR
subject O-ADR O-ADR
, O-ADR O-ADR
but O-ADR O-ADR
subjects O-ADR O-ADR
may O-ADR O-ADR
have O-ADR O-ADR
contributed O-ADR O-ADR
events O-ADR O-ADR
to O-ADR O-ADR
multiple O-ADR O-ADR
endpoints O-ADR O-ADR
. O-ADR O-ADR
11 O-ADR O-ADR
C O-ADR O-ADR
- O-ADR O-ADR
choline O-ADR O-ADR
uptake O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
specific O-ADR O-ADR
for O-ADR O-ADR
prostate O-ADR O-ADR
cancer O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
occur O-ADR O-ADR
with O-ADR O-ADR
other O-ADR O-ADR
types O-ADR O-ADR
of O-ADR O-ADR
cancer O-ADR O-ADR
( O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
lung O-ADR O-ADR
carcinoma O-ADR O-ADR
and O-ADR O-ADR
brain O-ADR O-ADR
tumors O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
efficacy O-ADR O-ADR
and O-ADR O-ADR
safety O-ADR O-ADR
of O-ADR O-ADR
DUAVEE O-ADR O-ADR
in O-ADR O-ADR
premenopausal O-ADR O-ADR
women O-ADR O-ADR
have O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
established O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
its O-ADR O-ADR
use O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
recommended O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Postmarketing O-ADR O-ADR
Experience O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
identified O-ADR O-ADR
during O-ADR O-ADR
post O-ADR O-ADR
- O-ADR O-ADR
approval O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
MULTAQ O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
receiving O-ADR O-ADR
other O-ADR O-ADR
medications O-ADR O-ADR
that O-ADR O-ADR
prolong O-ADR O-ADR
the O-ADR O-ADR
QT O-ADR O-ADR
interval O-ADR O-ADR
, O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
class O-ADR O-ADR
IA O-ADR O-ADR
( O-ADR O-ADR
quinidine O-ADR O-ADR
, O-ADR O-ADR
procainamide O-ADR O-ADR
, O-ADR O-ADR
disopyramide O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
class O-ADR O-ADR
III O-ADR O-ADR
( O-ADR O-ADR
amiodarone O-ADR O-ADR
, O-ADR O-ADR
sotalol O-ADR O-ADR
) O-ADR O-ADR
antiarrhythmic O-ADR O-ADR
agents O-ADR O-ADR
; O-ADR O-ADR
antipsychotics O-ADR O-ADR
( O-ADR O-ADR
pimozide O-ADR O-ADR
, O-ADR O-ADR
ziprasidone O-ADR O-ADR
) O-ADR O-ADR
; O-ADR O-ADR
antidepressants O-ADR O-ADR
; O-ADR O-ADR
certain O-ADR O-ADR
antibiotics O-ADR O-ADR
( O-ADR O-ADR
macrolide O-ADR O-ADR
antibiotics O-ADR O-ADR
, O-ADR O-ADR
fluoroquinolone O-ADR O-ADR
antibiotics O-ADR O-ADR
, O-ADR O-ADR
imidazole O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
triazole O-ADR O-ADR
antifungal O-ADR O-ADR
agents O-ADR O-ADR
) O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Pharmacology O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Direct O-ADR O-ADR
Coombs O-ADR O-ADR
' O-ADR O-ADR
Test O-ADR O-ADR
Seroconversion O-ADR O-ADR
Seroconversion B-ADR B-ADR
from I-ADR I-ADR
a I-ADR I-ADR
negative I-ADR I-ADR
to I-ADR I-ADR
a I-ADR I-ADR
positive I-ADR I-ADR
direct I-ADR I-ADR
Coombs I-ADR I-ADR
' I-ADR I-ADR
test I-ADR I-ADR
result I-ADR I-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
120 O-ADR O-ADR
/ O-ADR O-ADR
1114 O-ADR O-ADR
( O-ADR O-ADR
10 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
Teflaro O-ADR O-ADR
and O-ADR O-ADR
49 O-ADR O-ADR
/ O-ADR O-ADR
1116 O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
comparator O-ADR O-ADR
drugs O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
four O-ADR O-ADR
pooled O-ADR O-ADR
Phase O-ADR O-ADR
3 O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
ILARIS O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
administered O-ADR O-ADR
to O-ADR O-ADR
any O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
known O-ADR O-ADR
clinical O-ADR O-ADR
hypersensitivity O-ADR O-ADR
to O-ADR O-ADR
ILARIS O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Contraindications O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
See O-ADR O-ADR
current O-ADR O-ADR
recommended O-ADR O-ADR
immunization O-ADR O-ADR
schedules O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
website O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
Centers O-ADR O-ADR
for O-ADR O-ADR
Disease O-ADR O-ADR
Control O-ADR O-ADR
, O-ADR O-ADR
http O-ADR O-ADR
: O-ADR O-ADR
/ O-ADR O-ADR
/ O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
cdc O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
vaccines O-ADR O-ADR
/ O-ADR O-ADR
schedules O-ADR O-ADR
/ O-ADR O-ADR
index O-ADR O-ADR
. O-ADR O-ADR
html O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
All O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
were O-ADR O-ADR
positive O-ADR O-ADR
for O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
golimumab O-ADR O-ADR
had O-ADR O-ADR
neutralizing O-ADR O-ADR
antibodies O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
an O-ADR O-ADR
in O-ADR O-ADR
vitro O-ADR O-ADR
cell O-ADR O-ADR
- O-ADR O-ADR
based O-ADR O-ADR
assay O-ADR O-ADR
. O-ADR O-ADR
Decreases O-ADR O-ADR
in O-ADR O-ADR
neutrophils O-ADR O-ADR
or O-ADR O-ADR
platelets O-ADR O-ADR
may O-ADR O-ADR
require O-ADR O-ADR
a O-ADR O-ADR
decrease O-ADR O-ADR
in O-ADR O-ADR
dosage O-ADR O-ADR
or O-ADR O-ADR
interruption O-ADR O-ADR
of O-ADR O-ADR
peginterferon O-ADR O-ADR
alfa O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
therapy O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
prescribing O-ADR O-ADR
information O-ADR O-ADR
for O-ADR O-ADR
peginterferon O-ADR O-ADR
alfa O-ADR O-ADR
and O-ADR O-ADR
ribavirin O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
: O-ADR O-ADR
Laboratory O-ADR O-ADR
data O-ADR O-ADR
/ O-ADR O-ADR
ECG O-ADR O-ADR
parameters O-ADR O-ADR
not O-ADR O-ADR
necessarily O-ADR O-ADR
reported O-ADR O-ADR
as O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
Placebo O-ADR O-ADR
MULTAQ O-ADR O-ADR
400 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
2875 O-ADR O-ADR
) O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
3282 O-ADR O-ADR
) O-ADR O-ADR
Early O-ADR B-ADR
increases B-ADR I-ADR
in I-ADR I-ADR
creatinine I-ADR I-ADR
> O-ADR O-ADR
= O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
21 O-ADR O-ADR
% O-ADR O-ADR
51 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
2237 O-ADR O-ADR
) O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
2701 O-ADR O-ADR
) O-ADR O-ADR
QTc B-ADR B-ADR
prolonged I-ADR I-ADR
19 O-ADR O-ADR
% O-ADR O-ADR
28 O-ADR O-ADR
% O-ADR O-ADR
Assessment O-ADR O-ADR
of O-ADR O-ADR
demographic O-ADR O-ADR
factors O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
gender O-ADR O-ADR
or O-ADR O-ADR
age O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
- O-ADR O-ADR
emergent O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
did O-ADR O-ADR
not O-ADR O-ADR
suggest O-ADR O-ADR
an O-ADR O-ADR
excess O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
in O-ADR O-ADR
any O-ADR O-ADR
particular O-ADR O-ADR
sub O-ADR O-ADR
- O-ADR O-ADR
group O-ADR O-ADR
. O-ADR O-ADR
During O-ADR O-ADR
adult O-ADR O-ADR
pre O-ADR O-ADR
- O-ADR O-ADR
marketing O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
with O-ADR O-ADR
SAPHRIS O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
trials O-ADR O-ADR
without O-ADR O-ADR
comparison O-ADR O-ADR
to O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
dysphagia B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
/ O-ADR O-ADR
1953 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
SAPHRIS O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
controlled O-ADR O-ADR
and O-ADR O-ADR
uncontrolled O-ADR O-ADR
portions O-ADR O-ADR
of O-ADR O-ADR
Trial O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
958 O-ADR O-ADR
total O-ADR O-ADR
patient O-ADR O-ADR
- O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
follow O-ADR O-ADR
- O-ADR O-ADR
up O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
median O-ADR O-ADR
follow O-ADR O-ADR
- O-ADR O-ADR
up O-ADR O-ADR
of O-ADR O-ADR
approximately O-ADR O-ADR
92 O-ADR O-ADR
weeks O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
per O-ADR O-ADR
100 O-ADR O-ADR
patient O-ADR O-ADR
- O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
all O-ADR O-ADR
serious O-ADR O-ADR
infections B-ADR B-ADR
was O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
07 O-ADR O-ADR
( O-ADR O-ADR
CI O-ADR O-ADR
: O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
90 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
57 O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Apparent O-ADR O-ADR
homogeneity O-ADR O-ADR
or O-ADR O-ADR
heterogeneity O-ADR O-ADR
among O-ADR O-ADR
groups O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
over O-ADR O-ADR
- O-ADR O-ADR
interpreted O-ADR O-ADR
. O-ADR O-ADR
Do O-ADR O-ADR
not O-ADR O-ADR
administer O-ADR O-ADR
KALBITOR O-ADR O-ADR
to O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
known O-ADR O-ADR
clinical O-ADR O-ADR
hypersensitivity O-ADR O-ADR
to O-ADR O-ADR
KALBITOR O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Contraindications O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
No O-ADR O-ADR
dose O-ADR O-ADR
modifications O-ADR O-ADR
of O-ADR O-ADR
TAFINLAR O-ADR O-ADR
or O-ADR O-ADR
trametinib O-ADR O-ADR
are O-ADR O-ADR
required O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
develop O-ADR O-ADR
new O-ADR O-ADR
primary O-ADR O-ADR
cutaneous O-ADR O-ADR
malignancies O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
15 O-ADR O-ADR
Premenopausal O-ADR O-ADR
Women O-ADR O-ADR
There O-ADR O-ADR
is O-ADR O-ADR
no O-ADR O-ADR
indication O-ADR O-ADR
for O-ADR O-ADR
premenopausal O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
DUAVEE O-ADR O-ADR
. O-ADR O-ADR
Injection O-ADR O-ADR
Site O-ADR O-ADR
Reactions O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
pool O-ADR O-ADR
of O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
reactions I-ADR I-ADR
occurred O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
on O-ADR O-ADR
TANZEUM O-ADR O-ADR
( O-ADR O-ADR
18 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
than O-ADR O-ADR
on O-ADR O-ADR
placebo O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Therapy O-ADR O-ADR
with O-ADR O-ADR
leucovorin O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
continued O-ADR O-ADR
until O-ADR O-ADR
the O-ADR O-ADR
methotrexate O-ADR O-ADR
concentration O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
maintained O-ADR O-ADR
below O-ADR O-ADR
the O-ADR O-ADR
leucovorin O-ADR O-ADR
treatment O-ADR O-ADR
threshold O-ADR O-ADR
for O-ADR O-ADR
a O-ADR O-ADR
minimum O-ADR O-ADR
of O-ADR O-ADR
3 O-ADR O-ADR
days O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Hypotension B-ADR B-ADR
and O-ADR O-ADR
reflex B-ADR B-ADR
tachycardia I-ADR I-ADR
are O-ADR O-ADR
potential O-ADR O-ADR
consequences O-ADR O-ADR
of O-ADR O-ADR
rapid O-ADR O-ADR
upward O-ADR O-ADR
titration O-ADR O-ADR
of O-ADR O-ADR
Cleviprex O-ADR O-ADR
. O-ADR O-ADR
Deaths B-ADR B-ADR
due O-ADR O-ADR
to O-ADR O-ADR
causes O-ADR O-ADR
other O-ADR O-ADR
than O-ADR O-ADR
disease O-ADR O-ADR
progression O-ADR O-ADR
within O-ADR O-ADR
30 O-ADR O-ADR
days O-ADR O-ADR
of O-ADR O-ADR
last O-ADR O-ADR
study O-ADR O-ADR
drug O-ADR O-ADR
dose O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
18 O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
JEVTANA O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
3 O-ADR O-ADR
( O-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
mitoxantrone O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Exercise O-ADR O-ADR
caution O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
AFINITOR O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
peri O-ADR O-ADR
- O-ADR O-ADR
surgical O-ADR O-ADR
period O-ADR O-ADR
. O-ADR O-ADR
Any O-ADR O-ADR
patient O-ADR O-ADR
who O-ADR O-ADR
presents O-ADR O-ADR
with O-ADR O-ADR
thigh O-ADR O-ADR
or O-ADR O-ADR
groin O-ADR O-ADR
pain O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
suspected O-ADR O-ADR
of O-ADR O-ADR
having O-ADR O-ADR
an O-ADR O-ADR
atypical O-ADR O-ADR
fracture O-ADR O-ADR
and O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
evaluated O-ADR O-ADR
to O-ADR O-ADR
rule O-ADR O-ADR
out O-ADR O-ADR
an O-ADR O-ADR
incomplete O-ADR O-ADR
femur O-ADR O-ADR
fracture O-ADR O-ADR
. O-ADR O-ADR
All O-ADR O-ADR
patients O-ADR O-ADR
continued O-ADR O-ADR
androgen O-ADR O-ADR
deprivation O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
Figures O-ADR O-ADR
rounded O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
nearest O-ADR O-ADR
integer O-ADR O-ADR
. O-ADR O-ADR
This O-ADR O-ADR
imbalance O-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
other O-ADR O-ADR
studies O-ADR O-ADR
of O-ADR O-ADR
ENTEREG O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
opioids O-ADR O-ADR
for O-ADR O-ADR
chronic O-ADR O-ADR
pain O-ADR O-ADR
, O-ADR O-ADR
nor O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
within O-ADR O-ADR
the O-ADR O-ADR
surgical O-ADR O-ADR
setting O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
patients O-ADR O-ADR
undergoing O-ADR O-ADR
surgeries O-ADR O-ADR
that O-ADR O-ADR
included O-ADR O-ADR
bowel O-ADR O-ADR
resection O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
ENTEREG O-ADR O-ADR
12 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
for O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
7 O-ADR O-ADR
days O-ADR O-ADR
( O-ADR O-ADR
the O-ADR O-ADR
indicated O-ADR O-ADR
dose O-ADR O-ADR
and O-ADR O-ADR
patient O-ADR O-ADR
population O-ADR O-ADR
; O-ADR O-ADR
ENTEREG O-ADR O-ADR
12 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
142 O-ADR O-ADR
; O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
120 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Notable O-ADR O-ADR
requirements O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
E O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
. O-ADR O-ADR
S O-ADR O-ADR
. O-ADR O-ADR
E O-ADR O-ADR
. O-ADR O-ADR
None O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
59 O-ADR O-ADR
evaluable O-ADR O-ADR
patients O-ADR O-ADR
tested O-ADR O-ADR
positive O-ADR O-ADR
for O-ADR O-ADR
inhibition O-ADR O-ADR
of O-ADR O-ADR
enzyme O-ADR O-ADR
activity O-ADR O-ADR
. O-ADR O-ADR
BOXED O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
ASTHMA O-ADR O-ADR
- O-ADR O-ADR
RELATED O-ADR O-ADR
DEATH B-ADR B-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
ASTHMA O-ADR O-ADR
- O-ADR O-ADR
RELATED O-ADR O-ADR
DEATH B-ADR B-ADR
Long O-ADR O-ADR
- O-ADR O-ADR
acting O-ADR O-ADR
beta2 O-ADR O-ADR
- O-ADR O-ADR
adrenergic O-ADR O-ADR
agonists O-ADR O-ADR
( O-ADR O-ADR
LABA O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
vilanterol O-ADR O-ADR
, O-ADR O-ADR
one O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
active O-ADR O-ADR
ingredients O-ADR O-ADR
in O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
, O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
asthma O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
death B-ADR B-ADR
. O-ADR O-ADR
Laboratory O-ADR O-ADR
Abnormalities O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
two O-ADR O-ADR
randomized O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
Grade O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
neutropenia B-ADR B-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
15 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
XTANDI O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Before O-ADR O-ADR
DOTAREM O-ADR O-ADR
administration O-ADR O-ADR
, O-ADR O-ADR
assess O-ADR O-ADR
all O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
any O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
reaction O-ADR O-ADR
to O-ADR O-ADR
contrast O-ADR O-ADR
media O-ADR O-ADR
, O-ADR O-ADR
bronchial O-ADR O-ADR
asthma O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
allergic O-ADR O-ADR
disorders O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
Vaccinations O-ADR O-ADR
/ O-ADR O-ADR
Therapeutic O-ADR O-ADR
Infectious O-ADR O-ADR
Agents O-ADR O-ADR
Live O-ADR O-ADR
Vaccines O-ADR O-ADR
Patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
may O-ADR O-ADR
receive O-ADR O-ADR
vaccinations O-ADR O-ADR
, O-ADR O-ADR
except O-ADR O-ADR
for O-ADR O-ADR
live O-ADR O-ADR
vaccines O-ADR O-ADR
. O-ADR O-ADR
HORIZANT O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
discontinued O-ADR O-ADR
if O-ADR O-ADR
an O-ADR O-ADR
alternative O-ADR O-ADR
etiology O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
signs O-ADR O-ADR
or O-ADR O-ADR
symptoms O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
established O-ADR O-ADR
. O-ADR O-ADR
Among O-ADR O-ADR
these O-ADR O-ADR
subjects O-ADR O-ADR
, O-ADR O-ADR
42 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
women O-ADR O-ADR
and O-ADR O-ADR
99 O-ADR O-ADR
% O-ADR O-ADR
Caucasian O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
Study O-ADR O-ADR
3 O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
20 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
ADCETRIS O-ADR O-ADR
- O-ADR O-ADR
treatment O-ADR O-ADR
arm O-ADR O-ADR
, O-ADR O-ADR
regardless O-ADR O-ADR
of O-ADR O-ADR
causality O-ADR O-ADR
, O-ADR O-ADR
were O-ADR O-ADR
neutropenia B-ADR B-ADR
, O-ADR O-ADR
peripheral B-ADR B-ADR
sensory I-ADR I-ADR
neuropathy I-ADR I-ADR
, O-ADR O-ADR
thrombocytopenia B-ADR B-ADR
, O-ADR O-ADR
anemia B-ADR B-ADR
, O-ADR O-ADR
upper B-ADR B-ADR
respiratory I-ADR I-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
, O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
peripheral B-ADR B-ADR
motor I-ADR I-ADR
neuropathy I-ADR I-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
cough B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
diarrhea B-ADR B-ADR
. O-ADR O-ADR
ARCAPTA O-ADR O-ADR
NEOHALER O-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
studied O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
relief O-ADR O-ADR
of O-ADR O-ADR
acute O-ADR O-ADR
symptoms O-ADR O-ADR
and O-ADR O-ADR
extra O-ADR O-ADR
doses O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
for O-ADR O-ADR
that O-ADR O-ADR
purpose O-ADR O-ADR
. O-ADR O-ADR
Pool O-ADR O-ADR
of O-ADR O-ADR
Placebo O-ADR O-ADR
- O-ADR O-ADR
and O-ADR O-ADR
Active O-ADR O-ADR
- O-ADR O-ADR
Controlled O-ADR O-ADR
Trials O-ADR O-ADR
The O-ADR O-ADR
occurrence O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
for O-ADR O-ADR
canagliflozin O-ADR O-ADR
was O-ADR O-ADR
evaluated O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
larger O-ADR O-ADR
pool O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
participating O-ADR O-ADR
in O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
and O-ADR O-ADR
active O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
majority O-ADR O-ADR
of O-ADR O-ADR
lymphocyte B-ADR O-ADR
counts I-ADR O-ADR
remained I-ADR O-ADR
< I-ADR O-ADR
0 I-ADR O-ADR
. O-ADR O-ADR
5x10 O-ADR O-ADR
9 I-ADR O-ADR
/ I-ADR O-ADR
L O-ADR O-ADR
with O-ADR O-ADR
continued O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Interstitial O-ADR O-ADR
Lung O-ADR O-ADR
Disease O-ADR O-ADR
( O-ADR O-ADR
Pneumonitis O-ADR O-ADR
) O-ADR O-ADR
Severe O-ADR O-ADR
, O-ADR O-ADR
life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
fatal B-ADR B-ADR
interstitial B-ADR B-ADR
lung I-ADR I-ADR
disease I-ADR I-ADR
( O-ADR O-ADR
ILD B-ADR B-ADR
) O-ADR O-ADR
/ O-ADR O-ADR
pneumonitis O-ADR O-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
XALKORI O-ADR O-ADR
. O-ADR O-ADR
Worsening B-ADR B-ADR
hypertension I-ADR I-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
4 O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TREANDA O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
CLL O-ADR O-ADR
trial O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
none O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
chlorambucil O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
10 O-ADR O-ADR
Body O-ADR O-ADR
Temperature O-ADR O-ADR
Regulation O-ADR O-ADR
Disruption B-ADR B-ADR
of I-ADR I-ADR
the I-ADR I-ADR
body I-ADR I-ADR
' I-ADR I-ADR
s O-ADR O-ADR
ability I-ADR I-ADR
to I-ADR I-ADR
reduce I-ADR I-ADR
core I-ADR I-ADR
body I-ADR I-ADR
temperature I-ADR I-ADR
has O-ADR O-ADR
been O-ADR O-ADR
attributed O-ADR O-ADR
to O-ADR O-ADR
antipsychotic O-ADR O-ADR
agents O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
frequently O-ADR O-ADR
reported O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
higher O-ADR O-ADR
rate O-ADR O-ADR
with O-ADR O-ADR
FIRAZYR O-ADR O-ADR
versus O-ADR O-ADR
placebo O-ADR O-ADR
) O-ADR O-ADR
are O-ADR O-ADR
shown O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
All O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
PTLD B-ADR B-ADR
reported O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
36 O-ADR O-ADR
months O-ADR O-ADR
post O-ADR O-ADR
transplant O-ADR O-ADR
in O-ADR O-ADR
NULOJIX O-ADR O-ADR
- O-ADR O-ADR
or O-ADR O-ADR
cyclosporine O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
presented O-ADR O-ADR
within O-ADR O-ADR
18 O-ADR O-ADR
months O-ADR O-ADR
of O-ADR O-ADR
transplantation O-ADR O-ADR
. O-ADR O-ADR
Among O-ADR O-ADR
the O-ADR O-ADR
404 O-ADR O-ADR
EBV O-ADR O-ADR
seropositive O-ADR O-ADR
recipients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
dosage O-ADR O-ADR
regimen O-ADR O-ADR
of O-ADR O-ADR
NULOJIX O-ADR O-ADR
, O-ADR O-ADR
three O-ADR O-ADR
PTLD B-ADR B-ADR
cases O-ADR O-ADR
were O-ADR O-ADR
detected O-ADR O-ADR
among O-ADR O-ADR
99 O-ADR O-ADR
CMV O-ADR O-ADR
seronegative O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
there O-ADR O-ADR
was O-ADR O-ADR
no O-ADR O-ADR
case O-ADR O-ADR
detected O-ADR O-ADR
among O-ADR O-ADR
303 O-ADR O-ADR
CMV O-ADR O-ADR
seropositive O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
neutropenia O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
carefully O-ADR O-ADR
monitored O-ADR O-ADR
for O-ADR O-ADR
fever O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
symptoms O-ADR O-ADR
or O-ADR O-ADR
signs O-ADR O-ADR
of O-ADR O-ADR
infection O-ADR O-ADR
and O-ADR O-ADR
treated O-ADR O-ADR
promptly O-ADR O-ADR
if O-ADR O-ADR
such O-ADR O-ADR
symptoms O-ADR O-ADR
or O-ADR O-ADR
signs O-ADR O-ADR
occur O-ADR O-ADR
. O-ADR O-ADR
and O-ADR O-ADR
MinorMinor O-ADR O-ADR
episodes O-ADR O-ADR
of O-ADR O-ADR
hypoglycemia B-ADR O-ADR
were O-ADR O-ADR
defined O-ADR O-ADR
as O-ADR O-ADR
either O-ADR O-ADR
a O-ADR O-ADR
symptomatic O-ADR O-ADR
episode O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
plasma B-ADR O-ADR
glucose I-ADR O-ADR
measurement I-ADR O-ADR
< I-ADR O-ADR
63 I-ADR O-ADR
mg I-ADR O-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
regardless O-ADR O-ADR
of O-ADR O-ADR
need O-ADR O-ADR
for O-ADR O-ADR
external O-ADR O-ADR
assistance O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
an O-ADR O-ADR
asymptomatic O-ADR O-ADR
plasma B-ADR B-ADR
glucose I-ADR I-ADR
measurement I-ADR O-ADR
< I-ADR O-ADR
63 I-ADR O-ADR
mg I-ADR O-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
that O-ADR O-ADR
does O-ADR O-ADR
not O-ADR O-ADR
qualify O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
major O-ADR O-ADR
episode O-ADR O-ADR
. O-ADR O-ADR
Clinical O-ADR O-ADR
studies O-ADR O-ADR
of O-ADR O-ADR
HALAVEN O-ADR O-ADR
did O-ADR O-ADR
not O-ADR O-ADR
include O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
baseline O-ADR O-ADR
neutrophil O-ADR O-ADR
counts O-ADR O-ADR
below O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
500 O-ADR O-ADR
/ O-ADR O-ADR
mm O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
Avoid O-ADR O-ADR
HALAVEN O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
congenital O-ADR O-ADR
long O-ADR O-ADR
QT O-ADR O-ADR
syndrome O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
clinically O-ADR O-ADR
indicated O-ADR O-ADR
, O-ADR O-ADR
perform O-ADR O-ADR
appropriate O-ADR O-ADR
tests O-ADR O-ADR
to O-ADR O-ADR
confirm O-ADR O-ADR
the O-ADR O-ADR
diagnosis O-ADR O-ADR
of O-ADR O-ADR
adrenocortical O-ADR O-ADR
insufficiency O-ADR O-ADR
. O-ADR O-ADR
Therefore O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
lower O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
insulin O-ADR O-ADR
or O-ADR O-ADR
insulin O-ADR O-ADR
secretagogue O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
required O-ADR O-ADR
to O-ADR O-ADR
minimize O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
hypoglycemia O-ADR O-ADR
when O-ADR O-ADR
these O-ADR O-ADR
agents O-ADR O-ADR
are O-ADR O-ADR
used O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
FARXIGA O-ADR O-ADR
. O-ADR O-ADR
ONFI O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
discontinued O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
sign O-ADR O-ADR
of O-ADR O-ADR
rash O-ADR O-ADR
, O-ADR O-ADR
unless O-ADR O-ADR
the O-ADR O-ADR
rash O-ADR O-ADR
is O-ADR O-ADR
clearly O-ADR O-ADR
not O-ADR O-ADR
drug O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Severe O-ADR O-ADR
Diarrhea O-ADR O-ADR
or O-ADR O-ADR
Colitis O-ADR O-ADR
Severe O-ADR O-ADR
diarrhea B-ADR B-ADR
or O-ADR O-ADR
colitis B-ADR B-ADR
( O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
or O-ADR O-ADR
higher O-ADR O-ADR
) O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
14 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
Zydelig O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
across O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Jazz O-ADR O-ADR
Pharmaceuticals O-ADR O-ADR
, O-ADR O-ADR
Inc O-ADR O-ADR
. O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
520 O-ADR O-ADR
- O-ADR O-ADR
5568 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
controlled O-ADR O-ADR
, O-ADR O-ADR
but O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
ERWINAZE O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
other O-ADR O-ADR
drugs O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
Pool O-ADR O-ADR
of O-ADR O-ADR
Placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
Trials O-ADR O-ADR
The O-ADR O-ADR
data O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
are O-ADR O-ADR
derived O-ADR O-ADR
from O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
At O-ADR O-ADR
Week O-ADR O-ADR
24 O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
mean O-ADR O-ADR
changes B-ADR B-ADR
from I-ADR I-ADR
baseline I-ADR I-ADR
in I-ADR I-ADR
hematocrit I-ADR I-ADR
were O-ADR O-ADR
- O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
33 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
group O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
30 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
FARXIGA O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
group O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
Proteinuria O-ADR O-ADR
Proteinuria B-ADR B-ADR
was O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
4 O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
COMETRIQ O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
one O-ADR O-ADR
with O-ADR O-ADR
nephrotic B-ADR B-ADR
syndrome I-ADR I-ADR
, O-ADR O-ADR
as O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
none O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
If O-ADR O-ADR
retinal O-ADR O-ADR
pigmentary O-ADR O-ADR
abnormalities O-ADR O-ADR
or O-ADR O-ADR
vision O-ADR O-ADR
changes O-ADR O-ADR
are O-ADR O-ADR
detected O-ADR O-ADR
, O-ADR O-ADR
POTIGA O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
discontinued O-ADR O-ADR
unless O-ADR O-ADR
no O-ADR O-ADR
other O-ADR O-ADR
suitable O-ADR O-ADR
treatment O-ADR O-ADR
options O-ADR O-ADR
are O-ADR O-ADR
available O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
benefits O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
outweigh O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
vision O-ADR O-ADR
loss O-ADR O-ADR
. O-ADR O-ADR
b O-ADR O-ADR
Includes O-ADR O-ADR
retching B-ADR B-ADR
, O-ADR O-ADR
vomiting B-ADR B-ADR
, O-ADR O-ADR
vomiting B-ADR B-ADR
projectile I-ADR I-ADR
. O-ADR O-ADR
Contraception O-ADR O-ADR
and O-ADR O-ADR
Heavy O-ADR O-ADR
Menstrual O-ADR O-ADR
Bleeding O-ADR O-ADR
Studies O-ADR O-ADR
A O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
131 O-ADR O-ADR
women O-ADR O-ADR
, O-ADR O-ADR
18 O-ADR O-ADR
to O-ADR O-ADR
54 O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
age O-ADR O-ADR
, O-ADR O-ADR
who O-ADR O-ADR
took O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
one O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
Natazia O-ADR O-ADR
were O-ADR O-ADR
enrolled O-ADR O-ADR
in O-ADR O-ADR
four O-ADR O-ADR
clinical O-ADR O-ADR
phase O-ADR O-ADR
3 O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Infections O-ADR O-ADR
Fatal B-ADR B-ADR
and O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
fatal O-ADR O-ADR
infections B-ADR B-ADR
have O-ADR O-ADR
occurred O-ADR O-ADR
with O-ADR O-ADR
IMBRUVICA O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
occurring O-ADR O-ADR
less O-ADR O-ADR
frequently O-ADR O-ADR
but O-ADR O-ADR
possibly O-ADR O-ADR
related O-ADR O-ADR
to O-ADR O-ADR
TREANDA O-ADR O-ADR
treatment O-ADR O-ADR
were O-ADR O-ADR
hemolysis B-ADR B-ADR
, O-ADR O-ADR
dysgeusia O-ADR O-ADR
/ O-ADR O-ADR
taste O-ADR O-ADR
disorder B-ADR B-ADR
, O-ADR O-ADR
atypical B-ADR B-ADR
pneumonia I-ADR I-ADR
, O-ADR O-ADR
sepsis B-ADR B-ADR
, O-ADR O-ADR
herpes B-ADR B-ADR
zoster I-ADR I-ADR
, O-ADR O-ADR
erythema B-ADR B-ADR
, O-ADR O-ADR
dermatitis B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
skin B-ADR B-ADR
necrosis I-ADR I-ADR
. O-ADR O-ADR
To O-ADR O-ADR
manage O-ADR O-ADR
myelosuppression O-ADR O-ADR
, O-ADR O-ADR
withhold O-ADR O-ADR
, O-ADR O-ADR
dose O-ADR O-ADR
reduce O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
discontinue O-ADR O-ADR
BOSULIF O-ADR O-ADR
as O-ADR O-ADR
necessary O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
QT O-ADR O-ADR
Prolongation O-ADR O-ADR
SIRTURO O-ADR O-ADR
prolongs B-ADR B-ADR
the I-ADR I-ADR
QT I-ADR I-ADR
interval I-ADR I-ADR
. O-ADR O-ADR
Ocular O-ADR B-ADR
adverse O-ADR I-ADR
reactions O-ADR I-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
included O-ADR O-ADR
application B-ADR B-ADR
site I-ADR I-ADR
discomfort I-ADR I-ADR
, O-ADR O-ADR
corneal B-ADR B-ADR
pigmentation I-ADR I-ADR
, O-ADR O-ADR
episcleritis B-ADR B-ADR
, O-ADR O-ADR
eye B-ADR B-ADR
pruritis I-ADR I-ADR
, O-ADR O-ADR
eyelid B-ADR B-ADR
irritation I-ADR I-ADR
, O-ADR O-ADR
foreign B-ADR B-ADR
body I-ADR I-ADR
sensation I-ADR I-ADR
, O-ADR O-ADR
increased B-ADR B-ADR
lacrimation I-ADR I-ADR
, O-ADR O-ADR
macular B-ADR B-ADR
edema I-ADR I-ADR
, O-ADR O-ADR
sclera B-ADR B-ADR
hyperemia I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
uveitis B-ADR B-ADR
. O-ADR O-ADR
All O-ADR O-ADR
men O-ADR O-ADR
were O-ADR O-ADR
instructed O-ADR O-ADR
to O-ADR O-ADR
take O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
1000 O-ADR O-ADR
mg O-ADR O-ADR
of O-ADR O-ADR
calcium O-ADR O-ADR
and O-ADR O-ADR
400 O-ADR O-ADR
IU O-ADR O-ADR
of O-ADR O-ADR
vitamin O-ADR O-ADR
D O-ADR O-ADR
supplementation O-ADR O-ADR
per O-ADR O-ADR
day O-ADR O-ADR
. O-ADR O-ADR
Serious O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
, O-ADR O-ADR
regardless O-ADR O-ADR
of O-ADR O-ADR
causality O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
50 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
pooled O-ADR O-ADR
Kyprolis O-ADR O-ADR
monotherapy O-ADR O-ADR
studies O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
598 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
12 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
INLYTA O-ADR O-ADR
can O-ADR O-ADR
cause O-ADR O-ADR
fetal B-ADR B-ADR
harm I-ADR I-ADR
when O-ADR O-ADR
administered O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
pregnant O-ADR O-ADR
woman O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
its O-ADR O-ADR
mechanism O-ADR O-ADR
of O-ADR O-ADR
action O-ADR O-ADR
. O-ADR O-ADR
Some O-ADR O-ADR
patients O-ADR O-ADR
experienced O-ADR O-ADR
circulatory B-ADR B-ADR
collapse I-ADR I-ADR
and O-ADR O-ADR
died B-ADR B-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
diabetes O-ADR O-ADR
mellitus O-ADR O-ADR
or O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
uveitis O-ADR O-ADR
are O-ADR O-ADR
at O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
symptoms O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
hours O-ADR O-ADR
to O-ADR O-ADR
weeks O-ADR O-ADR
after O-ADR O-ADR
injection O-ADR O-ADR
. O-ADR O-ADR
Cases O-ADR O-ADR
of O-ADR O-ADR
acute O-ADR B-ADR
renal O-ADR I-ADR
failure O-ADR I-ADR
after O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
high O-ADR O-ADR
dose O-ADR O-ADR
or O-ADR O-ADR
multiple O-ADR O-ADR
NSAIDs O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
HIV O-ADR O-ADR
- O-ADR O-ADR
infected O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
risk O-ADR O-ADR
factors O-ADR O-ADR
for O-ADR O-ADR
renal O-ADR O-ADR
dysfunction O-ADR O-ADR
who O-ADR O-ADR
appeared O-ADR O-ADR
stable O-ADR O-ADR
on O-ADR O-ADR
tenofovir O-ADR O-ADR
DF O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
pancytopenia B-ADR B-ADR
, O-ADR O-ADR
leukopenia B-ADR B-ADR
, O-ADR O-ADR
neutropenia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
thrombocytopenia B-ADR B-ADR
have O-ADR O-ADR
also O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
A O-ADR O-ADR
higher O-ADR O-ADR
number O-ADR O-ADR
of O-ADR O-ADR
myocardial B-ADR B-ADR
infarctions I-ADR I-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
alvimopan O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
12 O-ADR O-ADR
- O-ADR O-ADR
month O-ADR O-ADR
study O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
opioids O-ADR O-ADR
for O-ADR O-ADR
chronic O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
cancer O-ADR O-ADR
pain O-ADR O-ADR
, O-ADR O-ADR
although O-ADR O-ADR
a O-ADR O-ADR
causal O-ADR O-ADR
relationship O-ADR O-ADR
with O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
use O-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
established O-ADR O-ADR
. O-ADR O-ADR
All O-ADR O-ADR
other O-ADR O-ADR
patients O-ADR O-ADR
tested O-ADR O-ADR
negative O-ADR O-ADR
for O-ADR O-ADR
inhibition O-ADR O-ADR
of O-ADR O-ADR
cellular O-ADR O-ADR
uptake O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
displays O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
more O-ADR O-ADR
common O-ADR O-ADR
with O-ADR O-ADR
dronedarone O-ADR O-ADR
400 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
than O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
in O-ADR O-ADR
AF O-ADR O-ADR
or O-ADR O-ADR
AFL O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
presented O-ADR O-ADR
by O-ADR O-ADR
system O-ADR O-ADR
organ O-ADR O-ADR
class O-ADR O-ADR
and O-ADR O-ADR
by O-ADR O-ADR
decreasing O-ADR O-ADR
order O-ADR O-ADR
of O-ADR O-ADR
frequency O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Potential O-ADR O-ADR
Risk O-ADR O-ADR
of O-ADR O-ADR
Myocardial O-ADR O-ADR
Infarction O-ADR O-ADR
with O-ADR O-ADR
Long O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
Use O-ADR O-ADR
There O-ADR O-ADR
were O-ADR O-ADR
more O-ADR O-ADR
reports O-ADR O-ADR
of O-ADR O-ADR
myocardial B-ADR B-ADR
infarctions I-ADR I-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
alvimopan O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
12 O-ADR O-ADR
- O-ADR O-ADR
month O-ADR O-ADR
study O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
opioids O-ADR O-ADR
for O-ADR O-ADR
chronic O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
cancer O-ADR O-ADR
pain O-ADR O-ADR
( O-ADR O-ADR
alvimopan O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
538 O-ADR O-ADR
; O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
267 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
it O-ADR O-ADR
is O-ADR O-ADR
almost O-ADR O-ADR
time O-ADR O-ADR
for O-ADR O-ADR
your O-ADR O-ADR
next O-ADR O-ADR
dose O-ADR O-ADR
, O-ADR O-ADR
skip O-ADR O-ADR
the O-ADR O-ADR
missed O-ADR O-ADR
dose O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Leading O-ADR O-ADR
to O-ADR O-ADR
Discontinuation O-ADR O-ADR
in O-ADR O-ADR
an O-ADR O-ADR
LGS O-ADR O-ADR
Placebo O-ADR O-ADR
Controlled O-ADR O-ADR
Clinical O-ADR O-ADR
Trial O-ADR O-ADR
( O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
The O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
ONFI O-ADR O-ADR
treatment O-ADR O-ADR
discontinuation O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
decreasing O-ADR O-ADR
order O-ADR O-ADR
of O-ADR O-ADR
frequency O-ADR O-ADR
included O-ADR O-ADR
lethargy B-ADR B-ADR
, O-ADR O-ADR
somnolence B-ADR B-ADR
, O-ADR O-ADR
ataxia B-ADR B-ADR
, O-ADR O-ADR
aggression B-ADR B-ADR
, O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
insomnia B-ADR B-ADR
. O-ADR O-ADR
In O-ADR O-ADR
Trial O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
any O-ADR O-ADR
skin B-ADR B-ADR
toxicity I-ADR I-ADR
was O-ADR O-ADR
similar O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
TAFINLAR O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
( O-ADR O-ADR
65 O-ADR O-ADR
% O-ADR O-ADR
[ O-ADR O-ADR
36 O-ADR O-ADR
/ O-ADR O-ADR
55 O-ADR O-ADR
] O-ADR O-ADR
) O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
TAFINLAR O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
single O-ADR O-ADR
agent O-ADR O-ADR
( O-ADR O-ADR
68 O-ADR O-ADR
% O-ADR O-ADR
[ O-ADR O-ADR
36 O-ADR O-ADR
/ O-ADR O-ADR
53 O-ADR O-ADR
] O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
continuing O-ADR O-ADR
pharmacodynamic O-ADR O-ADR
effects O-ADR O-ADR
of O-ADR O-ADR
fingolimod O-ADR O-ADR
, O-ADR O-ADR
initiating O-ADR O-ADR
other O-ADR O-ADR
drugs O-ADR O-ADR
during O-ADR O-ADR
this O-ADR O-ADR
period O-ADR O-ADR
warrants O-ADR O-ADR
the O-ADR O-ADR
same O-ADR O-ADR
considerations O-ADR O-ADR
needed O-ADR O-ADR
for O-ADR O-ADR
concomitant O-ADR O-ADR
administration O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
additive O-ADR O-ADR
immunosuppressant B-ADR O-ADR
effects I-ADR O-ADR
) O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Drug O-ADR O-ADR
Interactions O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
AMPYRA O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
discontinued O-ADR O-ADR
and O-ADR O-ADR
not O-ADR O-ADR
restarted O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
experience O-ADR O-ADR
a O-ADR O-ADR
seizure O-ADR O-ADR
while O-ADR O-ADR
on O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
All O-ADR O-ADR
patients O-ADR O-ADR
had O-ADR O-ADR
normal O-ADR O-ADR
values O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
next O-ADR O-ADR
visit O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
pooled O-ADR O-ADR
analyses O-ADR O-ADR
of O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
studies O-ADR O-ADR
in O-ADR O-ADR
children O-ADR O-ADR
and O-ADR O-ADR
adolescents O-ADR O-ADR
with O-ADR O-ADR
MDD O-ADR O-ADR
, O-ADR O-ADR
obsessive O-ADR O-ADR
compulsive O-ADR O-ADR
disorder O-ADR O-ADR
( O-ADR O-ADR
OCD O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
psychiatric O-ADR O-ADR
disorders O-ADR O-ADR
included O-ADR O-ADR
a O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
24 O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
studies O-ADR O-ADR
of O-ADR O-ADR
9 O-ADR O-ADR
antidepressant O-ADR O-ADR
drugs O-ADR O-ADR
in O-ADR O-ADR
over O-ADR O-ADR
4 O-ADR O-ADR
, O-ADR O-ADR
400 O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Beyond O-ADR O-ADR
48 O-ADR O-ADR
hours O-ADR O-ADR
after O-ADR O-ADR
VORAXAZE O-ADR O-ADR
, O-ADR O-ADR
administer O-ADR O-ADR
leucovorin O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
measured O-ADR O-ADR
methotrexate O-ADR O-ADR
concentration O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
10 O-ADR O-ADR
Counseling O-ADR O-ADR
Patients O-ADR O-ADR
about O-ADR O-ADR
Sexually O-ADR O-ADR
Transmitted O-ADR O-ADR
Diseases O-ADR O-ADR
The O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
STENDRA O-ADR O-ADR
offers O-ADR O-ADR
no O-ADR O-ADR
protection O-ADR O-ADR
against O-ADR O-ADR
sexually O-ADR O-ADR
transmitted O-ADR O-ADR
diseases O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
relative O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
probable O-ADR O-ADR
dementia B-ADR B-ADR
for O-ADR O-ADR
CE O-ADR O-ADR
- O-ADR O-ADR
alone O-ADR O-ADR
versus O-ADR O-ADR
placebo O-ADR O-ADR
was O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
49 O-ADR O-ADR
( O-ADR O-ADR
95 O-ADR O-ADR
percent O-ADR O-ADR
CI O-ADR O-ADR
, O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
83 O-ADR O-ADR
- O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
66 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
: O-ADR O-ADR
Adverse O-ADR O-ADR
Drug O-ADR O-ADR
Reactions O-ADR O-ADR
that O-ADR O-ADR
Occurred O-ADR O-ADR
in O-ADR O-ADR
at O-ADR O-ADR
Least O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
Patients O-ADR O-ADR
and O-ADR O-ADR
Were O-ADR O-ADR
More O-ADR O-ADR
Frequent O-ADR O-ADR
than O-ADR O-ADR
Placebo O-ADR O-ADR
Placebo O-ADR O-ADR
Dronedarone O-ADR O-ADR
400 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
2875 O-ADR O-ADR
) O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
3282 O-ADR O-ADR
) O-ADR O-ADR
Gastrointestinal O-ADR O-ADR
Diarrhea B-ADR B-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
Nausea B-ADR B-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
Abdominal B-ADR B-ADR
pain I-ADR I-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
Vomiting B-ADR B-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
Dyspeptic B-ADR B-ADR
signs I-ADR O-ADR
and I-ADR O-ADR
symptoms I-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
General O-ADR B-ADR
Asthenic B-ADR I-ADR
conditions I-ADR I-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
Cardiac O-ADR B-ADR
Bradycardia B-ADR I-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
Skin O-ADR B-ADR
and O-ADR O-ADR
subcutaneous O-ADR O-ADR
tissue O-ADR O-ADR
Including O-ADR O-ADR
rashes B-ADR B-ADR
) O-ADR O-ADR
, O-ADR O-ADR
pruritus B-ADR B-ADR
, O-ADR O-ADR
eczema B-ADR B-ADR
, O-ADR O-ADR
dermatitis B-ADR B-ADR
, O-ADR O-ADR
dermatitis B-ADR B-ADR
allergic I-ADR I-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
Photosensitivity B-ADR B-ADR
reaction I-ADR I-ADR
and O-ADR O-ADR
dysgeusia B-ADR B-ADR
have O-ADR O-ADR
also O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
at O-ADR O-ADR
an O-ADR O-ADR
incidence O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
MULTAQ O-ADR O-ADR
. O-ADR O-ADR
This O-ADR O-ADR
increase O-ADR O-ADR
is O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
reduction O-ADR B-ADR
in O-ADR I-ADR
serum O-ADR I-ADR
uric O-ADR I-ADR
acid O-ADR I-ADR
levels O-ADR I-ADR
, O-ADR O-ADR
resulting O-ADR O-ADR
in O-ADR O-ADR
mobilization O-ADR B-ADR
of O-ADR I-ADR
urate O-ADR I-ADR
from O-ADR O-ADR
tissue O-ADR O-ADR
deposits O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
7 O-ADR O-ADR
presents O-ADR O-ADR
the O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
drug O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
experienced O-ADR O-ADR
by O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
or O-ADR O-ADR
equal O-ADR O-ADR
to O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
PROMACTA O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
monitored O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
development O-ADR O-ADR
of O-ADR O-ADR
systemic O-ADR O-ADR
immune O-ADR O-ADR
- O-ADR O-ADR
mediated O-ADR O-ADR
reactions O-ADR O-ADR
involving O-ADR O-ADR
skin O-ADR O-ADR
and O-ADR O-ADR
other O-ADR O-ADR
organs O-ADR O-ADR
while O-ADR O-ADR
receiving O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
clinical O-ADR O-ADR
information O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
interpretation O-ADR O-ADR
of O-ADR O-ADR
Vizamyl O-ADR O-ADR
images O-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
evaluated O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
lead O-ADR O-ADR
to O-ADR O-ADR
errors O-ADR O-ADR
. O-ADR O-ADR
Eleven O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
MAS B-ADR B-ADR
were O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
201 O-ADR O-ADR
SJIA O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
canakinumab O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
Everolimus O-ADR O-ADR
caused O-ADR O-ADR
embryo B-ADR B-ADR
- O-ADR O-ADR
fetal O-ADR O-ADR
toxicities I-ADR I-ADR
in O-ADR O-ADR
animals O-ADR O-ADR
at O-ADR O-ADR
maternal O-ADR O-ADR
exposures O-ADR O-ADR
that O-ADR O-ADR
were O-ADR O-ADR
lower O-ADR O-ADR
than O-ADR O-ADR
human O-ADR O-ADR
exposures O-ADR O-ADR
. O-ADR O-ADR
Blood O-ADR O-ADR
and O-ADR O-ADR
Lymphatic O-ADR O-ADR
System O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
agranulocytosis B-ADR B-ADR
, O-ADR O-ADR
pancytopenia B-ADR B-ADR
, O-ADR O-ADR
thrombocytopenia B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
Gastrointestinal O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
mouth B-ADR B-ADR
ulceration I-ADR I-ADR
, O-ADR O-ADR
stomatitis B-ADR B-ADR
Infections O-ADR O-ADR
and O-ADR O-ADR
Infestations O-ADR O-ADR
: O-ADR O-ADR
pneumonia B-ADR B-ADR
, O-ADR O-ADR
sepsis B-ADR B-ADR
Skin O-ADR O-ADR
and O-ADR O-ADR
Subcutaneous O-ADR O-ADR
Tissue O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
angioedema B-ADR B-ADR
, O-ADR O-ADR
urticaria B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
; O-ADR O-ADR
DRESS B-ADR B-ADR
) I-ADR O-ADR
syndrome I-ADR B-ADR
, O-ADR O-ADR
exfoliative B-ADR B-ADR
rash I-ADR I-ADR
, O-ADR O-ADR
exfoliative B-ADR B-ADR
dermatitis I-ADR I-ADR
, O-ADR O-ADR
Stevens B-ADR B-ADR
- O-ADR O-ADR
Johnson O-ADR O-ADR
syndrome I-ADR I-ADR
, O-ADR O-ADR
toxic B-ADR B-ADR
skin I-ADR I-ADR
eruption I-ADR I-ADR
, O-ADR O-ADR
toxicoderma B-ADR B-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
Use O-ADR O-ADR
of O-ADR O-ADR
VICTRELIS O-ADR O-ADR
with O-ADR O-ADR
Ribavirin O-ADR O-ADR
and O-ADR O-ADR
Peginterferon O-ADR O-ADR
alfa O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Embryofetal B-ADR B-ADR
Toxicity I-ADR I-ADR
( O-ADR O-ADR
Use O-ADR O-ADR
with O-ADR O-ADR
Ribavirin O-ADR O-ADR
and O-ADR O-ADR
Peginterferon O-ADR O-ADR
Alfa O-ADR O-ADR
) O-ADR O-ADR
: O-ADR O-ADR
Ribavirin O-ADR O-ADR
may O-ADR O-ADR
cause O-ADR O-ADR
birth B-ADR B-ADR
defects I-ADR I-ADR
and O-ADR O-ADR
fetal B-ADR B-ADR
death I-ADR I-ADR
; O-ADR O-ADR
avoid O-ADR O-ADR
pregnancy O-ADR O-ADR
in O-ADR O-ADR
female O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
female O-ADR O-ADR
partners O-ADR O-ADR
of O-ADR O-ADR
male O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Consider O-ADR O-ADR
obtaining O-ADR O-ADR
periodic O-ADR O-ADR
hepatic O-ADR O-ADR
serum O-ADR O-ADR
enzymes O-ADR O-ADR
, O-ADR O-ADR
especially O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
6 O-ADR O-ADR
months O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
, O-ADR O-ADR
but O-ADR O-ADR
it O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
known O-ADR O-ADR
whether O-ADR O-ADR
routine O-ADR O-ADR
periodic O-ADR O-ADR
monitoring O-ADR O-ADR
of O-ADR O-ADR
serum O-ADR O-ADR
enzymes O-ADR O-ADR
will O-ADR O-ADR
prevent O-ADR O-ADR
the O-ADR O-ADR
development O-ADR O-ADR
of O-ADR O-ADR
severe O-ADR O-ADR
liver O-ADR B-ADR
injury O-ADR I-ADR
. O-ADR O-ADR
If O-ADR O-ADR
ribavirin O-ADR O-ADR
is O-ADR O-ADR
permanently O-ADR O-ADR
discontinued O-ADR O-ADR
, O-ADR O-ADR
then O-ADR O-ADR
peginterferon O-ADR O-ADR
alfa O-ADR O-ADR
and O-ADR O-ADR
VICTRELIS O-ADR O-ADR
must O-ADR O-ADR
also O-ADR O-ADR
be O-ADR O-ADR
discontinued O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Endometrial O-ADR O-ADR
hyperplasia O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
a O-ADR O-ADR
precursor O-ADR O-ADR
to O-ADR O-ADR
endometrial O-ADR O-ADR
cancer O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
other O-ADR O-ADR
cases O-ADR O-ADR
represented O-ADR O-ADR
a O-ADR O-ADR
variety O-ADR O-ADR
of O-ADR O-ADR
different O-ADR O-ADR
malignancies B-ADR B-ADR
and O-ADR O-ADR
included O-ADR O-ADR
rare B-ADR B-ADR
malignancies I-ADR I-ADR
usually O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
immunosuppression O-ADR B-ADR
and O-ADR O-ADR
malignancies B-ADR O-ADR
that O-ADR O-ADR
are O-ADR O-ADR
not O-ADR O-ADR
usually O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
children O-ADR O-ADR
and O-ADR O-ADR
adolescents O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
immune O-ADR O-ADR
- O-ADR O-ADR
mediated O-ADR O-ADR
reactions O-ADR O-ADR
occur O-ADR O-ADR
, O-ADR O-ADR
consider O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
initiate O-ADR O-ADR
appropriate O-ADR O-ADR
medical O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
16 O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
Concomitant O-ADR O-ADR
Illness O-ADR O-ADR
Clinical O-ADR O-ADR
experience O-ADR O-ADR
with O-ADR O-ADR
SAPHRIS O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
certain O-ADR O-ADR
concomitant O-ADR O-ADR
systemic O-ADR O-ADR
illnesses O-ADR O-ADR
is O-ADR O-ADR
limited O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Pharmacology O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Cutaneous O-ADR O-ADR
Malignancies O-ADR O-ADR
: O-ADR O-ADR
TAFINLAR O-ADR O-ADR
results O-ADR O-ADR
in O-ADR O-ADR
an O-ADR O-ADR
increased O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
cutaneous B-ADR B-ADR
squamous I-ADR I-ADR
cell I-ADR I-ADR
carcinoma I-ADR I-ADR
, O-ADR O-ADR
keratoacanthoma B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
melanoma B-ADR B-ADR
. O-ADR O-ADR
In O-ADR O-ADR
order O-ADR O-ADR
to O-ADR O-ADR
prevent O-ADR O-ADR
gout O-ADR O-ADR
flares O-ADR O-ADR
when O-ADR O-ADR
ULORIC O-ADR O-ADR
is O-ADR O-ADR
initiated O-ADR O-ADR
, O-ADR O-ADR
concurrent O-ADR O-ADR
prophylactic O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
NSAID O-ADR O-ADR
or O-ADR O-ADR
colchicine O-ADR O-ADR
is O-ADR O-ADR
recommended O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
laboratory O-ADR O-ADR
data O-ADR O-ADR
/ O-ADR O-ADR
ECG O-ADR O-ADR
parameters O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
MULTAQ O-ADR O-ADR
400 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
48 O-ADR O-ADR
hours O-ADR O-ADR
after O-ADR O-ADR
VORAXAZE O-ADR O-ADR
, O-ADR O-ADR
administer O-ADR O-ADR
the O-ADR O-ADR
same O-ADR O-ADR
leucovorin O-ADR O-ADR
dose O-ADR O-ADR
as O-ADR O-ADR
given O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
VORAXAZE O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
fractures B-ADR O-ADR
can I-ADR O-ADR
occur I-ADR O-ADR
anywhere I-ADR O-ADR
in I-ADR O-ADR
the I-ADR O-ADR
femoral I-ADR O-ADR
shaft I-ADR O-ADR
from O-ADR O-ADR
just O-ADR O-ADR
below O-ADR O-ADR
the O-ADR O-ADR
lesser O-ADR O-ADR
trochanter O-ADR O-ADR
to O-ADR O-ADR
above O-ADR O-ADR
the O-ADR O-ADR
supracondylar O-ADR O-ADR
flare O-ADR O-ADR
and O-ADR O-ADR
are O-ADR O-ADR
transverse O-ADR O-ADR
or O-ADR O-ADR
short O-ADR O-ADR
oblique O-ADR O-ADR
in O-ADR O-ADR
orientation O-ADR O-ADR
without O-ADR O-ADR
evidence O-ADR O-ADR
of O-ADR O-ADR
comminution O-ADR O-ADR
. O-ADR O-ADR
Endocarditis B-ADR B-ADR
was O-ADR O-ADR
also O-ADR O-ADR
reported O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
in O-ADR O-ADR
Prolia O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Reductions O-ADR O-ADR
in O-ADR O-ADR
immunosuppression O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
develop O-ADR O-ADR
evidence O-ADR O-ADR
of O-ADR O-ADR
PVAN O-ADR O-ADR
. O-ADR O-ADR
Assess O-ADR O-ADR
creatinine O-ADR O-ADR
clearance O-ADR O-ADR
( O-ADR O-ADR
CLcr O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
urine O-ADR O-ADR
glucose O-ADR O-ADR
and O-ADR O-ADR
urine O-ADR O-ADR
protein O-ADR O-ADR
before O-ADR O-ADR
initiating O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
STRIBILD O-ADR O-ADR
. O-ADR O-ADR
Renal O-ADR O-ADR
and O-ADR O-ADR
Urinary O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
Renal B-ADR B-ADR
impairment I-ADR I-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
frequent O-ADR O-ADR
infections B-ADR B-ADR
( O-ADR O-ADR
> O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
BENLYSTA O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
upper B-ADR B-ADR
respiratory I-ADR I-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
, O-ADR O-ADR
urinary B-ADR B-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
, O-ADR O-ADR
nasopharyngitis B-ADR B-ADR
, O-ADR O-ADR
sinusitis B-ADR B-ADR
, O-ADR O-ADR
bronchitis B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
influenza B-ADR O-ADR
. O-ADR O-ADR
Advise O-ADR O-ADR
patients O-ADR O-ADR
not O-ADR O-ADR
to O-ADR O-ADR
drive O-ADR O-ADR
or O-ADR O-ADR
operate O-ADR O-ADR
heavy O-ADR O-ADR
machinery O-ADR O-ADR
until O-ADR O-ADR
they O-ADR O-ADR
know O-ADR O-ADR
how O-ADR O-ADR
Toviaz O-ADR O-ADR
affects O-ADR O-ADR
them O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
sanofi O-ADR O-ADR
- O-ADR O-ADR
aventis O-ADR O-ADR
U O-ADR O-ADR
. O-ADR O-ADR
S O-ADR O-ADR
. O-ADR O-ADR
LLC O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
633 O-ADR O-ADR
- O-ADR O-ADR
1610 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
During O-ADR O-ADR
the O-ADR O-ADR
12 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
, O-ADR O-ADR
controlled O-ADR O-ADR
study O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
PHN O-ADR O-ADR
, O-ADR O-ADR
somnolence B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
200 O-ADR O-ADR
mg O-ADR O-ADR
of O-ADR O-ADR
HORIZANT O-ADR O-ADR
per O-ADR O-ADR
day O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
dry B-ADR B-ADR
mouth I-ADR I-ADR
was O-ADR O-ADR
higher O-ADR O-ADR
in O-ADR O-ADR
those O-ADR O-ADR
taking O-ADR O-ADR
8 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
day O-ADR O-ADR
( O-ADR O-ADR
35 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
those O-ADR O-ADR
taking O-ADR O-ADR
4 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
day O-ADR O-ADR
( O-ADR O-ADR
19 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
as O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
placebo O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Patients O-ADR O-ADR
recently O-ADR O-ADR
exposed O-ADR O-ADR
to O-ADR O-ADR
opioids O-ADR O-ADR
are O-ADR O-ADR
expected O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
more O-ADR O-ADR
sensitive O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
effects O-ADR O-ADR
of O-ADR O-ADR
ENTEREG O-ADR O-ADR
and O-ADR O-ADR
therefore O-ADR O-ADR
may O-ADR O-ADR
experience O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
and O-ADR O-ADR
vomiting B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
diarrhea B-ADR B-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Long O-ADR O-ADR
- O-ADR O-ADR
acting O-ADR O-ADR
beta2 O-ADR O-ADR
- O-ADR O-ADR
adrenergic O-ADR O-ADR
agonists O-ADR O-ADR
( O-ADR O-ADR
LABA O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
vilanterol O-ADR O-ADR
, O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
asthma O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
death B-ADR B-ADR
. O-ADR O-ADR
Initiation O-ADR O-ADR
of O-ADR O-ADR
STRIBILD O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
estimated O-ADR O-ADR
creatinine O-ADR O-ADR
clearance O-ADR O-ADR
below O-ADR O-ADR
70 O-ADR O-ADR
mL O-ADR O-ADR
per O-ADR O-ADR
minute O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
recommended O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Bradyarrhythmia O-ADR O-ADR
and O-ADR O-ADR
Atrioventricular O-ADR O-ADR
Blocks O-ADR O-ADR
Because O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
bradyarrhythmia O-ADR O-ADR
and O-ADR O-ADR
atrioventricular O-ADR O-ADR
( O-ADR O-ADR
AV O-ADR O-ADR
) O-ADR O-ADR
blocks O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
monitored O-ADR O-ADR
during O-ADR O-ADR
GILENYA O-ADR O-ADR
treatment O-ADR O-ADR
initiation O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
risk O-ADR O-ADR
appears O-ADR O-ADR
lower O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
chronic O-ADR O-ADR
, O-ADR O-ADR
moderate O-ADR O-ADR
kidney O-ADR O-ADR
disease O-ADR O-ADR
( O-ADR O-ADR
GFR O-ADR O-ADR
30 O-ADR O-ADR
- O-ADR O-ADR
59 O-ADR O-ADR
mL O-ADR O-ADR
/ O-ADR O-ADR
min O-ADR O-ADR
/ O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
73 O-ADR O-ADR
m O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
little O-ADR O-ADR
, O-ADR O-ADR
if O-ADR O-ADR
any O-ADR O-ADR
, O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
chronic O-ADR O-ADR
, O-ADR O-ADR
mild O-ADR O-ADR
kidney O-ADR O-ADR
disease O-ADR O-ADR
( O-ADR O-ADR
GFR O-ADR O-ADR
60 O-ADR O-ADR
- O-ADR O-ADR
89 O-ADR O-ADR
mL O-ADR O-ADR
/ O-ADR O-ADR
min O-ADR O-ADR
/ O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
73 O-ADR O-ADR
m O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
breathing B-ADR B-ADR
difficulties I-ADR I-ADR
can O-ADR O-ADR
be O-ADR O-ADR
life O-ADR O-ADR
threatening O-ADR O-ADR
and O-ADR O-ADR
there O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reports O-ADR O-ADR
of O-ADR O-ADR
death B-ADR B-ADR
. O-ADR O-ADR
You O-ADR O-ADR
and O-ADR O-ADR
your O-ADR O-ADR
healthcare O-ADR O-ADR
provider O-ADR O-ADR
should O-ADR O-ADR
decide O-ADR O-ADR
if O-ADR O-ADR
you O-ADR O-ADR
will O-ADR O-ADR
take O-ADR O-ADR
DUAVEE O-ADR O-ADR
or O-ADR O-ADR
breastfeed O-ADR O-ADR
. O-ADR O-ADR
Women O-ADR O-ADR
of O-ADR O-ADR
childbearing O-ADR O-ADR
potential O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
advised O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
hazard O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
fetus O-ADR O-ADR
and O-ADR O-ADR
to O-ADR O-ADR
avoid O-ADR O-ADR
becoming O-ADR O-ADR
pregnant O-ADR O-ADR
while O-ADR O-ADR
receiving O-ADR O-ADR
INLYTA O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
such O-ADR O-ADR
signs O-ADR O-ADR
or O-ADR O-ADR
symptoms O-ADR O-ADR
are O-ADR O-ADR
present O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
evaluated O-ADR O-ADR
immediately O-ADR O-ADR
. O-ADR O-ADR
Laboratory O-ADR O-ADR
Test O-ADR O-ADR
Abnormalities O-ADR O-ADR
: O-ADR O-ADR
Transaminases O-ADR O-ADR
: O-ADR O-ADR
Transient O-ADR O-ADR
elevations B-ADR B-ADR
in I-ADR I-ADR
serum I-ADR I-ADR
transaminases I-ADR I-ADR
) O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
schizophrenia O-ADR O-ADR
and O-ADR O-ADR
bipolar O-ADR O-ADR
mania O-ADR O-ADR
adult O-ADR O-ADR
trials O-ADR O-ADR
were O-ADR O-ADR
more O-ADR O-ADR
common O-ADR O-ADR
in O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Fatal B-ADR B-ADR
cerebrovascular B-ADR B-ADR
accident I-ADR I-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
1 O-ADR O-ADR
/ O-ADR O-ADR
359 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
receiving O-ADR O-ADR
INLYTA O-ADR O-ADR
and O-ADR O-ADR
none O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
sorafenib O-ADR O-ADR
[ O-ADR O-ADR
seeAdverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Cerebrovascular O-ADR O-ADR
Adverse O-ADR O-ADR
Events O-ADR O-ADR
, O-ADR O-ADR
Including O-ADR O-ADR
Stroke O-ADR O-ADR
, O-ADR O-ADR
In O-ADR O-ADR
Elderly O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
Dementia O-ADR O-ADR
- O-ADR O-ADR
Related O-ADR O-ADR
Psychosis O-ADR O-ADR
In O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
with O-ADR O-ADR
risperidone O-ADR O-ADR
, O-ADR O-ADR
aripiprazole O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
olanzapine O-ADR O-ADR
in O-ADR O-ADR
elderly O-ADR O-ADR
subjects O-ADR O-ADR
with O-ADR O-ADR
dementia O-ADR O-ADR
, O-ADR O-ADR
there O-ADR O-ADR
was O-ADR O-ADR
a O-ADR O-ADR
higher O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
cerebrovascular B-ADR B-ADR
adverse I-ADR I-ADR
reactions I-ADR I-ADR
( O-ADR O-ADR
cerebrovascular B-ADR B-ADR
accidents I-ADR I-ADR
and O-ADR O-ADR
transient B-ADR B-ADR
ischemic I-ADR I-ADR
attacks I-ADR I-ADR
) O-ADR O-ADR
including O-ADR O-ADR
fatalities B-ADR B-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
subjects O-ADR O-ADR
. O-ADR O-ADR
Specifically O-ADR O-ADR
, O-ADR O-ADR
9 O-ADR O-ADR
patients O-ADR O-ADR
had O-ADR O-ADR
a O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
or O-ADR O-ADR
4 O-ADR O-ADR
pleural B-ADR B-ADR
effusion I-ADR I-ADR
, O-ADR O-ADR
3 O-ADR O-ADR
patients O-ADR O-ADR
experienced O-ADR O-ADR
both O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
or O-ADR O-ADR
Grade O-ADR O-ADR
4 O-ADR O-ADR
pericardial B-ADR B-ADR
effusions I-ADR I-ADR
, O-ADR O-ADR
1 O-ADR O-ADR
patient O-ADR O-ADR
experienced O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
pulmonary B-ADR B-ADR
edema I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
patient O-ADR O-ADR
had O-ADR O-ADR
a O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
edema B-ADR B-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Leukopenia B-ADR B-ADR
, O-ADR O-ADR
Neutropenia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
Agranulocytosis B-ADR B-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
antipsychotics O-ADR O-ADR
. O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
or O-ADR O-ADR
higher O-ADR O-ADR
bleeding B-ADR B-ADR
events I-ADR O-ADR
( O-ADR O-ADR
subdural B-ADR B-ADR
hematoma I-ADR I-ADR
, O-ADR O-ADR
gastrointestinal B-ADR B-ADR
bleeding I-ADR I-ADR
, O-ADR O-ADR
hematuria B-ADR B-ADR
and O-ADR O-ADR
post B-ADR B-ADR
procedural I-ADR I-ADR
hemorrhage I-ADR I-ADR
) O-ADR O-ADR
have O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Serious O-ADR O-ADR
drug O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
included O-ADR O-ADR
myelosuppression B-ADR B-ADR
, O-ADR O-ADR
infection B-ADR B-ADR
, O-ADR O-ADR
pneumonia B-ADR B-ADR
, O-ADR O-ADR
tumor B-ADR B-ADR
lysis I-ADR I-ADR
syndrome I-ADR I-ADR
and O-ADR O-ADR
infusion B-ADR B-ADR
reactions I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Decisions O-ADR O-ADR
about O-ADR O-ADR
whether O-ADR O-ADR
or O-ADR O-ADR
not O-ADR O-ADR
to O-ADR O-ADR
restart O-ADR O-ADR
TECFIDERA O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
individualized O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
clinical O-ADR O-ADR
circumstances O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
242 O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
patients O-ADR O-ADR
had O-ADR O-ADR
a O-ADR O-ADR
heart B-ADR B-ADR
rate I-ADR I-ADR
less I-ADR I-ADR
than I-ADR I-ADR
50 I-ADR I-ADR
beats I-ADR I-ADR
per I-ADR I-ADR
minute I-ADR I-ADR
. O-ADR O-ADR
In O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
abnormal O-ADR O-ADR
liver O-ADR O-ADR
tests O-ADR O-ADR
, O-ADR O-ADR
NESINA O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
initiated O-ADR O-ADR
with O-ADR O-ADR
caution O-ADR O-ADR
. O-ADR O-ADR
Of O-ADR O-ADR
the O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
834 O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
12 O-ADR O-ADR
% O-ADR O-ADR
discontinued O-ADR O-ADR
treatment O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
an O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
, O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
116 O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Agranulocytosis B-ADR B-ADR
( O-ADR O-ADR
including O-ADR O-ADR
fatal B-ADR B-ADR
cases O-ADR O-ADR
) O-ADR O-ADR
has O-ADR O-ADR
also O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
. O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
CNS B-ADR B-ADR
PTLD I-ADR I-ADR
1 O-ADR O-ADR
1 O-ADR O-ADR
Non B-ADR O-ADR
- O-ADR O-ADR
CNSPTLD O-ADR O-ADR
1 O-ADR O-ADR
2 O-ADR O-ADR
1 O-ADR O-ADR
Study O-ADR O-ADR
2 O-ADR O-ADR
CNS B-ADR B-ADR
PTLD I-ADR I-ADR
1 O-ADR O-ADR
1 O-ADR O-ADR
1 O-ADR O-ADR
1 O-ADR O-ADR
Non B-ADR O-ADR
- O-ADR O-ADR
CNSPTLD O-ADR O-ADR
1 O-ADR O-ADR
Study O-ADR O-ADR
3 O-ADR O-ADR
CNS B-ADR B-ADR
PTLD I-ADR I-ADR
2 O-ADR O-ADR
Non B-ADR O-ADR
- O-ADR O-ADR
CNSPTLD O-ADR O-ADR
1 O-ADR O-ADR
Total O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
2 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
( O-ADR O-ADR
11 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
1 O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
3 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
2 O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
0 O-ADR O-ADR
0 O-ADR O-ADR
1 O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
) O-ADR O-ADR
0 O-ADR O-ADR
EBV O-ADR O-ADR
Seropositive O-ADR O-ADR
Subpopulation O-ADR O-ADR
Among O-ADR O-ADR
the O-ADR O-ADR
806 O-ADR O-ADR
EBV O-ADR O-ADR
seropositive O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
known O-ADR O-ADR
CMV O-ADR O-ADR
serostatus O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
either O-ADR O-ADR
NULOJIX O-ADR O-ADR
regimen O-ADR O-ADR
in O-ADR O-ADR
Studies O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
3 O-ADR O-ADR
, O-ADR O-ADR
two O-ADR O-ADR
percent O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
; O-ADR O-ADR
4 O-ADR O-ADR
/ O-ADR O-ADR
210 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
CMV O-ADR O-ADR
seronegative O-ADR O-ADR
patients O-ADR O-ADR
developed O-ADR O-ADR
PTLD B-ADR B-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
/ O-ADR O-ADR
596 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
CMV O-ADR O-ADR
seropositive O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
enterocolitis O-ADR O-ADR
( O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
diarrhea O-ADR O-ADR
, O-ADR O-ADR
abdominal O-ADR O-ADR
pain O-ADR O-ADR
, O-ADR O-ADR
mucus O-ADR O-ADR
or O-ADR O-ADR
blood O-ADR O-ADR
in O-ADR O-ADR
stool O-ADR O-ADR
, O-ADR O-ADR
with O-ADR O-ADR
or O-ADR O-ADR
without O-ADR O-ADR
fever O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
of O-ADR O-ADR
bowel O-ADR O-ADR
perforation O-ADR B-ADR
( O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
peritoneal O-ADR B-ADR
signs O-ADR I-ADR
and O-ADR O-ADR
ileus O-ADR B-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Pneumonitis O-ADR O-ADR
Fatal B-ADR B-ADR
and O-ADR O-ADR
serious O-ADR O-ADR
pneumonitis B-ADR B-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
Zydelig O-ADR O-ADR
. O-ADR O-ADR
Of O-ADR O-ADR
the O-ADR O-ADR
63 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
moderate O-ADR O-ADR
dermatitis B-ADR B-ADR
, O-ADR O-ADR
25 O-ADR O-ADR
( O-ADR O-ADR
40 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
systemic O-ADR O-ADR
corticosteroids O-ADR O-ADR
( O-ADR O-ADR
median O-ADR O-ADR
of O-ADR O-ADR
60 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
day O-ADR O-ADR
of O-ADR O-ADR
prednisone O-ADR O-ADR
or O-ADR O-ADR
equivalent O-ADR O-ADR
) O-ADR O-ADR
for O-ADR O-ADR
a O-ADR O-ADR
median O-ADR O-ADR
of O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
weeks O-ADR O-ADR
, O-ADR O-ADR
7 O-ADR O-ADR
( O-ADR O-ADR
11 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
only O-ADR O-ADR
topical O-ADR O-ADR
corticosteroids O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
31 O-ADR O-ADR
( O-ADR O-ADR
49 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
did O-ADR O-ADR
not O-ADR O-ADR
receive O-ADR O-ADR
systemic O-ADR O-ADR
or O-ADR O-ADR
topical O-ADR O-ADR
corticosteroids O-ADR O-ADR
. O-ADR O-ADR
Advise O-ADR O-ADR
patients O-ADR O-ADR
to O-ADR O-ADR
promptly O-ADR O-ADR
report O-ADR O-ADR
any O-ADR O-ADR
new O-ADR O-ADR
or O-ADR O-ADR
worsening O-ADR O-ADR
abdominal O-ADR O-ADR
pain O-ADR O-ADR
, O-ADR O-ADR
chills O-ADR O-ADR
, O-ADR O-ADR
fever O-ADR O-ADR
, O-ADR O-ADR
nausea O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
vomiting O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
QT B-ADR B-ADR
interval I-ADR I-ADR
prolongation I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
and O-ADR O-ADR
treat O-ADR O-ADR
appropriately O-ADR O-ADR
. O-ADR O-ADR
ALT B-ADR B-ADR
abnormalities I-ADR I-ADR
occurred O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
in O-ADR O-ADR
hepatitis O-ADR O-ADR
B O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
hepatitis O-ADR O-ADR
C O-ADR O-ADR
virus O-ADR O-ADR
co O-ADR O-ADR
- O-ADR O-ADR
infected O-ADR O-ADR
subjects O-ADR O-ADR
for O-ADR O-ADR
both O-ADR O-ADR
treatment O-ADR O-ADR
groups O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
bleeding O-ADR O-ADR
persists O-ADR O-ADR
or O-ADR O-ADR
occurs O-ADR O-ADR
after O-ADR O-ADR
previously O-ADR O-ADR
regular O-ADR O-ADR
cycles O-ADR O-ADR
, O-ADR O-ADR
check O-ADR O-ADR
for O-ADR O-ADR
causes O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
pregnancy O-ADR O-ADR
or O-ADR O-ADR
malignancy O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Embryo O-ADR O-ADR
- O-ADR O-ADR
Fetal O-ADR O-ADR
Toxicity O-ADR O-ADR
There O-ADR O-ADR
are O-ADR O-ADR
no O-ADR O-ADR
adequate O-ADR O-ADR
and O-ADR O-ADR
well O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
studies O-ADR O-ADR
of O-ADR O-ADR
HALAVEN O-ADR O-ADR
in O-ADR O-ADR
pregnant O-ADR O-ADR
women O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
portions O-ADR O-ADR
of O-ADR O-ADR
Studies O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
through O-ADR O-ADR
Day O-ADR O-ADR
90 O-ADR O-ADR
, O-ADR O-ADR
98 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
51 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
XIAFLEX O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
and O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
had O-ADR O-ADR
an O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
after O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
3 O-ADR O-ADR
injections O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
Ferriprox O-ADR O-ADR
is O-ADR O-ADR
used O-ADR O-ADR
during O-ADR O-ADR
pregnancy O-ADR O-ADR
or O-ADR O-ADR
if O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
becomes O-ADR O-ADR
pregnant O-ADR O-ADR
while O-ADR O-ADR
taking O-ADR O-ADR
Ferriprox O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
apprised O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
hazard O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
fetus O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
Pancreatitis O-ADR O-ADR
Pancreatitis B-ADR B-ADR
, O-ADR O-ADR
including O-ADR O-ADR
one O-ADR O-ADR
fatality B-ADR B-ADR
, O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
ZYKADIA O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
After O-ADR O-ADR
excluding O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
whom O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
study O-ADR O-ADR
drug O-ADR O-ADR
was O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
one O-ADR O-ADR
year O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
time O-ADR O-ADR
of O-ADR O-ADR
diagnosis O-ADR O-ADR
of O-ADR O-ADR
bladder B-ADR O-ADR
cancer I-ADR O-ADR
, O-ADR O-ADR
there O-ADR O-ADR
were O-ADR O-ADR
4 O-ADR O-ADR
cases O-ADR O-ADR
with O-ADR O-ADR
FARXIGA O-ADR O-ADR
and O-ADR O-ADR
no O-ADR O-ADR
cases O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
/ O-ADR O-ADR
comparator O-ADR O-ADR
. O-ADR O-ADR
Pooled O-ADR O-ADR
analyses O-ADR O-ADR
of O-ADR O-ADR
199 O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
( O-ADR O-ADR
mono O-ADR O-ADR
- O-ADR O-ADR
and O-ADR O-ADR
adjunctive O-ADR O-ADR
therapy O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
11 O-ADR O-ADR
different O-ADR O-ADR
AEDs O-ADR O-ADR
showed O-ADR O-ADR
that O-ADR O-ADR
patients O-ADR O-ADR
randomized O-ADR O-ADR
to O-ADR O-ADR
one O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
AEDs O-ADR O-ADR
had O-ADR O-ADR
approximately O-ADR O-ADR
twice O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
( O-ADR O-ADR
adjusted O-ADR O-ADR
relative O-ADR O-ADR
risk O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
, O-ADR O-ADR
95 O-ADR O-ADR
% O-ADR O-ADR
confidence O-ADR O-ADR
interval O-ADR O-ADR
[ O-ADR O-ADR
CI O-ADR O-ADR
] O-ADR O-ADR
: O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
suicidal B-ADR B-ADR
thinking I-ADR I-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
patients O-ADR O-ADR
randomized O-ADR O-ADR
to O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
shows O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
, O-ADR O-ADR
excluding O-ADR O-ADR
hypoglycemia B-ADR B-ADR
, O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
TRULICITY O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
pool O-ADR O-ADR
of O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Hypertension O-ADR O-ADR
COMETRIQ O-ADR O-ADR
treatment O-ADR O-ADR
results O-ADR O-ADR
in O-ADR O-ADR
an O-ADR O-ADR
increased O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
- O-ADR O-ADR
emergent O-ADR O-ADR
hypertension B-ADR B-ADR
with O-ADR O-ADR
Joint O-ADR O-ADR
National O-ADR O-ADR
Committee O-ADR O-ADR
on O-ADR O-ADR
Prevention O-ADR O-ADR
, O-ADR O-ADR
Detection O-ADR O-ADR
, O-ADR O-ADR
Evaluation O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
Treatment O-ADR O-ADR
of O-ADR O-ADR
High O-ADR O-ADR
Blood O-ADR O-ADR
Pressure O-ADR O-ADR
( O-ADR O-ADR
modified O-ADR O-ADR
JNC O-ADR O-ADR
criteria O-ADR O-ADR
) O-ADR O-ADR
stage O-ADR O-ADR
1 O-ADR O-ADR
or O-ADR O-ADR
2 O-ADR O-ADR
hypertension B-ADR B-ADR
identified O-ADR O-ADR
in O-ADR O-ADR
61 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
COMETRIQ O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
30 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
randomized O-ADR O-ADR
trial O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
impact O-ADR O-ADR
of O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
CIMZIA O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
development O-ADR O-ADR
of O-ADR O-ADR
autoimmune O-ADR O-ADR
diseases O-ADR O-ADR
is O-ADR O-ADR
unknown O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
1915 O-ADR O-ADR
05 O-ADR O-ADR
Skin O-ADR O-ADR
and O-ADR O-ADR
subcutaneous O-ADR O-ADR
tissue O-ADR O-ADR
disorders O-ADR O-ADR
RashRash O-ADR O-ADR
includes O-ADR O-ADR
the O-ADR O-ADR
following O-ADR O-ADR
terms O-ADR O-ADR
: O-ADR O-ADR
erythema B-ADR B-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
, O-ADR O-ADR
erythematous B-ADR B-ADR
rash I-ADR I-ADR
, O-ADR O-ADR
generalized B-ADR B-ADR
rash I-ADR I-ADR
, O-ADR O-ADR
macular B-ADR B-ADR
rash I-ADR I-ADR
, O-ADR O-ADR
maculo B-ADR B-ADR
- O-ADR O-ADR
papular O-ADR O-ADR
rash I-ADR I-ADR
, O-ADR O-ADR
papular B-ADR B-ADR
rash I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
vesicular B-ADR B-ADR
rash I-ADR I-ADR
. O-ADR O-ADR
Whenever O-ADR O-ADR
clinical O-ADR O-ADR
judgment O-ADR O-ADR
dictates O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
examined O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
aid O-ADR O-ADR
of O-ADR O-ADR
magnification O-ADR O-ADR
, O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
slit O-ADR O-ADR
- O-ADR O-ADR
lamp O-ADR O-ADR
biomicroscopy O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
, O-ADR O-ADR
where O-ADR O-ADR
appropriate O-ADR O-ADR
, O-ADR O-ADR
fluorescein O-ADR O-ADR
staining O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
infections B-ADR B-ADR
( O-ADR O-ADR
60 O-ADR O-ADR
% O-ADR O-ADR
vs O-ADR O-ADR
58 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
serious O-ADR O-ADR
infections B-ADR B-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
vs O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
was O-ADR O-ADR
similar O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TECFIDERA O-ADR O-ADR
or O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
Three O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
4 O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
described O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
hypertensive B-ADR B-ADR
crisis I-ADR I-ADR
and O-ADR O-ADR
were O-ADR O-ADR
managed O-ADR O-ADR
with O-ADR O-ADR
oral O-ADR O-ADR
medications O-ADR O-ADR
and O-ADR O-ADR
resolved O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
QT O-ADR O-ADR
Interval O-ADR O-ADR
Effect O-ADR O-ADR
A O-ADR O-ADR
study O-ADR O-ADR
of O-ADR O-ADR
cardiac O-ADR O-ADR
conduction O-ADR O-ADR
showed O-ADR O-ADR
that O-ADR O-ADR
POTIGA O-ADR O-ADR
produced O-ADR O-ADR
a O-ADR O-ADR
mean O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
- O-ADR O-ADR
msec O-ADR O-ADR
QT B-ADR B-ADR
prolongation I-ADR I-ADR
in O-ADR O-ADR
healthy O-ADR O-ADR
volunteers O-ADR O-ADR
titrated O-ADR O-ADR
to O-ADR O-ADR
400 O-ADR O-ADR
mg O-ADR O-ADR
3 O-ADR O-ADR
times O-ADR O-ADR
daily O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
imbalance O-ADR O-ADR
in O-ADR O-ADR
deaths B-ADR B-ADR
is O-ADR O-ADR
unexplained O-ADR O-ADR
. O-ADR O-ADR
Discontinue O-ADR O-ADR
SIRTURO O-ADR O-ADR
if O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
aminotransferase O-ADR O-ADR
elevations O-ADR O-ADR
are O-ADR O-ADR
accompanied O-ADR O-ADR
by O-ADR O-ADR
total O-ADR O-ADR
bilirubin O-ADR O-ADR
elevation O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
two O-ADR O-ADR
times O-ADR O-ADR
the O-ADR O-ADR
upper O-ADR O-ADR
limit O-ADR O-ADR
of O-ADR O-ADR
normal O-ADR O-ADR
* O-ADR O-ADR
aminotransferase O-ADR O-ADR
elevations O-ADR O-ADR
are O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
eight O-ADR O-ADR
times O-ADR O-ADR
the O-ADR O-ADR
upper O-ADR O-ADR
limit O-ADR O-ADR
of O-ADR O-ADR
normal O-ADR O-ADR
* O-ADR O-ADR
aminotransferase O-ADR B-ADR
elevations O-ADR I-ADR
are O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
five O-ADR O-ADR
times O-ADR O-ADR
the O-ADR O-ADR
upper O-ADR O-ADR
limit O-ADR O-ADR
of O-ADR O-ADR
normal O-ADR O-ADR
and O-ADR O-ADR
persist O-ADR O-ADR
beyond O-ADR O-ADR
two O-ADR O-ADR
weeks O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Drug O-ADR O-ADR
Interactions O-ADR O-ADR
CYP3A4 O-ADR O-ADR
inducers O-ADR O-ADR
/ O-ADR O-ADR
inhibitors O-ADR O-ADR
Bedaquiline O-ADR O-ADR
is O-ADR O-ADR
metabolized O-ADR O-ADR
by O-ADR O-ADR
CYP3A4 O-ADR O-ADR
and O-ADR O-ADR
its O-ADR O-ADR
systemic O-ADR O-ADR
exposure O-ADR O-ADR
and O-ADR O-ADR
therapeutic O-ADR O-ADR
effect O-ADR O-ADR
may O-ADR O-ADR
therefore O-ADR O-ADR
be O-ADR O-ADR
reduced O-ADR O-ADR
during O-ADR O-ADR
co O-ADR O-ADR
- O-ADR O-ADR
administration O-ADR O-ADR
with O-ADR O-ADR
inducers O-ADR O-ADR
of O-ADR O-ADR
CYP3A4 O-ADR O-ADR
. O-ADR O-ADR
New O-ADR O-ADR
Malignancies O-ADR O-ADR
New O-ADR O-ADR
malignancies B-ADR B-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
no O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
group O-ADR O-ADR
and O-ADR O-ADR
4 O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
prostate B-ADR B-ADR
cancers I-ADR I-ADR
, O-ADR O-ADR
1 O-ADR O-ADR
basal B-ADR B-ADR
cell I-ADR I-ADR
carcinoma I-ADR I-ADR
) O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Prolia O-ADR O-ADR
group O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
Prosthetic O-ADR O-ADR
Heart O-ADR O-ADR
Valves O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
and O-ADR O-ADR
efficacy O-ADR O-ADR
of O-ADR O-ADR
ELIQUIS O-ADR O-ADR
have O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
studied O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
prosthetic O-ADR O-ADR
heart O-ADR O-ADR
valves O-ADR O-ADR
. O-ADR O-ADR
Most O-ADR O-ADR
events O-ADR O-ADR
( O-ADR O-ADR
95 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
Grade O-ADR O-ADR
1 O-ADR O-ADR
or O-ADR O-ADR
Grade O-ADR O-ADR
2 O-ADR O-ADR
in O-ADR O-ADR
severity O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
hemodialysis O-ADR O-ADR
, O-ADR O-ADR
physicians O-ADR O-ADR
may O-ADR O-ADR
consider O-ADR O-ADR
the O-ADR O-ADR
prompt O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
hemodialysis O-ADR O-ADR
following O-ADR O-ADR
the O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
GBCA O-ADR O-ADR
in O-ADR O-ADR
order O-ADR O-ADR
to O-ADR O-ADR
enhance O-ADR O-ADR
the O-ADR O-ADR
contrast O-ADR O-ADR
agent O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
elimination O-ADR O-ADR
. O-ADR O-ADR
Features O-ADR O-ADR
of O-ADR O-ADR
acute O-ADR B-ADR
kidney O-ADR I-ADR
injury O-ADR I-ADR
consist O-ADR O-ADR
of O-ADR O-ADR
rapid O-ADR O-ADR
( O-ADR O-ADR
over O-ADR O-ADR
hours O-ADR O-ADR
to O-ADR O-ADR
days O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
usually O-ADR O-ADR
reversible O-ADR O-ADR
decrease O-ADR I-ADR
in O-ADR I-ADR
kidney O-ADR I-ADR
function O-ADR I-ADR
, O-ADR O-ADR
commonly O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
setting O-ADR O-ADR
of O-ADR O-ADR
surgery O-ADR O-ADR
, O-ADR O-ADR
severe O-ADR O-ADR
infection O-ADR O-ADR
, O-ADR O-ADR
injury O-ADR O-ADR
or O-ADR O-ADR
drug O-ADR O-ADR
- O-ADR O-ADR
induced O-ADR O-ADR
kidney O-ADR O-ADR
toxicity O-ADR O-ADR
. O-ADR O-ADR
After O-ADR O-ADR
resolution O-ADR O-ADR
, O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
ERWINAZE O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
resumed O-ADR O-ADR
. O-ADR O-ADR
Ensure O-ADR O-ADR
that O-ADR O-ADR
appropriate O-ADR O-ADR
medical O-ADR O-ADR
support O-ADR O-ADR
measures O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
cardiopulmonary O-ADR O-ADR
resuscitation O-ADR O-ADR
equipment O-ADR O-ADR
, O-ADR O-ADR
are O-ADR O-ADR
readily O-ADR O-ADR
available O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Radiation O-ADR O-ADR
Risk O-ADR O-ADR
Amyvid O-ADR O-ADR
, O-ADR O-ADR
similar O-ADR O-ADR
to O-ADR O-ADR
other O-ADR O-ADR
radiopharmaceuticals O-ADR O-ADR
, O-ADR O-ADR
contributes O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
patient O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
overall O-ADR O-ADR
long B-ADR B-ADR
- O-ADR O-ADR
term O-ADR O-ADR
cumulative I-ADR I-ADR
radiation I-ADR I-ADR
exposure I-ADR I-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Not O-ADR O-ADR
recommended O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
end O-ADR O-ADR
- O-ADR O-ADR
stage O-ADR O-ADR
renal O-ADR O-ADR
disease O-ADR O-ADR
. O-ADR O-ADR
Withhold O-ADR O-ADR
GILOTRIF O-ADR O-ADR
for O-ADR O-ADR
severe O-ADR O-ADR
and O-ADR O-ADR
prolonged O-ADR O-ADR
cutaneous O-ADR O-ADR
reactions O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
more O-ADR O-ADR
information O-ADR O-ADR
, O-ADR O-ADR
ask O-ADR O-ADR
your O-ADR O-ADR
healthcare O-ADR O-ADR
provider O-ADR O-ADR
or O-ADR O-ADR
pharmacist O-ADR O-ADR
. O-ADR O-ADR
program O-ADR O-ADR
may O-ADR O-ADR
use O-ADR O-ADR
ENTEREG O-ADR O-ADR
. O-ADR O-ADR
Hepatobiliary O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
Hepatitis B-ADR B-ADR
. O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
, O-ADR O-ADR
including O-ADR O-ADR
serious O-ADR O-ADR
reactions O-ADR O-ADR
, O-ADR O-ADR
has O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
have O-ADR O-ADR
previously O-ADR O-ADR
tolerated O-ADR O-ADR
infusions O-ADR O-ADR
of O-ADR O-ADR
BENLYSTA O-ADR O-ADR
. O-ADR O-ADR
Psychiatric O-ADR O-ADR
Disorders O-ADR O-ADR
Nervousness B-ADR B-ADR
. O-ADR O-ADR
These O-ADR O-ADR
women O-ADR O-ADR
should O-ADR O-ADR
have O-ADR O-ADR
their O-ADR O-ADR
thyroid O-ADR O-ADR
function O-ADR O-ADR
monitored O-ADR O-ADR
in O-ADR O-ADR
order O-ADR O-ADR
to O-ADR O-ADR
maintain O-ADR O-ADR
their O-ADR O-ADR
free O-ADR O-ADR
thyroid O-ADR O-ADR
hormone O-ADR O-ADR
levels O-ADR O-ADR
in O-ADR O-ADR
an O-ADR O-ADR
acceptable O-ADR O-ADR
range O-ADR O-ADR
. O-ADR O-ADR
Continue O-ADR O-ADR
hydration O-ADR O-ADR
and O-ADR O-ADR
alkalinization O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
urine O-ADR O-ADR
as O-ADR O-ADR
indicated O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Renal O-ADR O-ADR
Failure O-ADR O-ADR
Cases O-ADR O-ADR
of O-ADR O-ADR
renal B-ADR B-ADR
failure I-ADR I-ADR
( O-ADR O-ADR
including O-ADR O-ADR
acute B-ADR B-ADR
renal I-ADR I-ADR
failure I-ADR I-ADR
) O-ADR O-ADR
, O-ADR O-ADR
some O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
fatal B-ADR B-ADR
outcome O-ADR O-ADR
, O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
AFINITOR O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Laboratory O-ADR O-ADR
Tests O-ADR O-ADR
and O-ADR O-ADR
Monitoring O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Other O-ADR O-ADR
fatal B-ADR B-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
in O-ADR O-ADR
JEVTANA O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
included O-ADR O-ADR
ventricular B-ADR B-ADR
fibrillation I-ADR I-ADR
, O-ADR O-ADR
cerebral B-ADR B-ADR
hemorrhage I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
dyspnea B-ADR B-ADR
. O-ADR O-ADR
UTIs O-ADR O-ADR
in O-ADR O-ADR
AMPYRA O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
evaluated O-ADR O-ADR
and O-ADR O-ADR
treated O-ADR O-ADR
as O-ADR O-ADR
clinically O-ADR O-ADR
indicated O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
with O-ADR O-ADR
BENLYSTA O-ADR O-ADR
and O-ADR O-ADR
are O-ADR O-ADR
discussed O-ADR O-ADR
in O-ADR O-ADR
detail O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
section O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Mortality B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Serious O-ADR O-ADR
Infections B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Malignancy B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
Reactions I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
Anaphylaxis B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Infusion B-ADR B-ADR
Reactions I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Depression B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
Common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
were O-ADR O-ADR
: O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
pyrexia B-ADR B-ADR
, O-ADR O-ADR
nasopharyngitis B-ADR B-ADR
, O-ADR O-ADR
bronchitis B-ADR B-ADR
, O-ADR O-ADR
insomnia B-ADR B-ADR
, O-ADR O-ADR
pain B-ADR B-ADR
in I-ADR I-ADR
extremity I-ADR I-ADR
, O-ADR O-ADR
depression B-ADR B-ADR
, O-ADR O-ADR
migraine B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
pharyngitis B-ADR B-ADR
. O-ADR O-ADR
Consider O-ADR O-ADR
the O-ADR O-ADR
benefit O-ADR O-ADR
- O-ADR O-ADR
risk O-ADR O-ADR
profile O-ADR O-ADR
in O-ADR O-ADR
such O-ADR O-ADR
patients O-ADR O-ADR
before O-ADR O-ADR
treating O-ADR O-ADR
with O-ADR O-ADR
Prolia O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
is O-ADR O-ADR
discussed O-ADR O-ADR
in O-ADR O-ADR
more O-ADR O-ADR
detail O-ADR O-ADR
in O-ADR O-ADR
other O-ADR O-ADR
sections O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
labeling O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Seizure B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
are O-ADR O-ADR
asthenia O-ADR O-ADR
/ O-ADR O-ADR
fatigue O-ADR O-ADR
, O-ADR O-ADR
back B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
decreased B-ADR B-ADR
appetite I-ADR I-ADR
, O-ADR O-ADR
constipation B-ADR B-ADR
, O-ADR O-ADR
arthralgia B-ADR B-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
hot B-ADR B-ADR
flush I-ADR I-ADR
, O-ADR O-ADR
upper B-ADR B-ADR
respiratory I-ADR I-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
, O-ADR O-ADR
peripheral B-ADR B-ADR
edema I-ADR I-ADR
, O-ADR O-ADR
dyspnea B-ADR B-ADR
, O-ADR O-ADR
musculoskeletal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
weight B-ADR B-ADR
decreased I-ADR I-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
hypertension B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
dizziness O-ADR O-ADR
/ O-ADR O-ADR
vertigo O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
median O-ADR O-ADR
number O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
cycles O-ADR O-ADR
in O-ADR O-ADR
each O-ADR O-ADR
study O-ADR O-ADR
arm O-ADR O-ADR
was O-ADR O-ADR
15 O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
, O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
16 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
80 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
48 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
ADCETRIS O-ADR O-ADR
- O-ADR O-ADR
treatment O-ADR O-ADR
arm O-ADR O-ADR
received O-ADR O-ADR
16 O-ADR O-ADR
cycles O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
new O-ADR O-ADR
malignancies O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
therapy O-ADR O-ADR
, O-ADR O-ADR
while O-ADR O-ADR
on O-ADR O-ADR
therapy O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
following O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
TAFINLAR O-ADR O-ADR
or O-ADR O-ADR
the O-ADR O-ADR
combination O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
Cardiac O-ADR O-ADR
: O-ADR O-ADR
New O-ADR O-ADR
or O-ADR O-ADR
worsening O-ADR O-ADR
heart B-ADR O-ADR
failure I-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
Atrial B-ADR B-ADR
flutter I-ADR I-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
very O-ADR O-ADR
rarely O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
majority O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
developed O-ADR O-ADR
IgG O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
, O-ADR O-ADR
typically O-ADR O-ADR
within O-ADR O-ADR
3 O-ADR O-ADR
months O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
from O-ADR O-ADR
One O-ADR O-ADR
Open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
Trial O-ADR O-ADR
in O-ADR O-ADR
Adults O-ADR O-ADR
with O-ADR O-ADR
Severe O-ADR O-ADR
Aplastic O-ADR O-ADR
Anemia O-ADR O-ADR
Adverse O-ADR O-ADR
Reaction O-ADR O-ADR
PROMACTA O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
43 O-ADR O-ADR
) O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Nausea B-ADR B-ADR
33 O-ADR O-ADR
Fatigue B-ADR B-ADR
28 O-ADR O-ADR
Cough B-ADR B-ADR
23 O-ADR O-ADR
Diarrhea B-ADR B-ADR
21 O-ADR O-ADR
Headache B-ADR B-ADR
21 O-ADR O-ADR
Pain B-ADR B-ADR
in I-ADR I-ADR
extremity I-ADR I-ADR
19 O-ADR O-ADR
Dyspnea B-ADR B-ADR
14 O-ADR O-ADR
Pyrexia B-ADR B-ADR
14 O-ADR O-ADR
Dizziness B-ADR B-ADR
14 O-ADR O-ADR
Oropharyngeal B-ADR B-ADR
pain I-ADR I-ADR
14 O-ADR O-ADR
Febrile B-ADR B-ADR
neutropenia I-ADR I-ADR
14 O-ADR O-ADR
Abdominal B-ADR B-ADR
pain I-ADR I-ADR
12 O-ADR O-ADR
Ecchymosis B-ADR B-ADR
12 O-ADR O-ADR
Muscle B-ADR B-ADR
spasms I-ADR I-ADR
12 O-ADR O-ADR
Transaminases B-ADR B-ADR
increased I-ADR I-ADR
12 O-ADR O-ADR
Arthralgia B-ADR B-ADR
12 O-ADR O-ADR
Rhinorrhea B-ADR B-ADR
12 O-ADR O-ADR
In O-ADR O-ADR
this O-ADR O-ADR
trial O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
had O-ADR O-ADR
bone O-ADR O-ADR
marrow O-ADR O-ADR
aspirates O-ADR O-ADR
evaluated O-ADR O-ADR
for O-ADR O-ADR
cytogenetic O-ADR O-ADR
abnormalities O-ADR O-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
orthostatic O-ADR O-ADR
hypotension O-ADR O-ADR
with O-ADR O-ADR
SAPHRIS O-ADR O-ADR
, O-ADR O-ADR
caution O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
cardiac O-ADR O-ADR
patients O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
PROMACTA O-ADR O-ADR
was O-ADR O-ADR
administered O-ADR O-ADR
to O-ADR O-ADR
277 O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
6 O-ADR O-ADR
months O-ADR O-ADR
and O-ADR O-ADR
202 O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
1 O-ADR O-ADR
year O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
anemia O-ADR O-ADR
develops O-ADR O-ADR
during O-ADR O-ADR
or O-ADR O-ADR
after O-ADR O-ADR
therapy O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
diagnostic O-ADR O-ADR
workup O-ADR O-ADR
for O-ADR O-ADR
drug O-ADR O-ADR
- O-ADR O-ADR
induced O-ADR O-ADR
hemolytic O-ADR O-ADR
anemia O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
performed O-ADR O-ADR
and O-ADR O-ADR
consideration O-ADR O-ADR
given O-ADR O-ADR
to O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
Teflaro O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
reported O-ADR O-ADR
by O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
the O-ADR O-ADR
additional O-ADR O-ADR
30 O-ADR O-ADR
mg O-ADR O-ADR
subcutaneous O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
KALBITOR O-ADR O-ADR
were O-ADR O-ADR
consistent O-ADR O-ADR
with O-ADR O-ADR
those O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
a O-ADR O-ADR
single O-ADR O-ADR
dose O-ADR O-ADR
. O-ADR O-ADR
Serious O-ADR O-ADR
febrile B-ADR B-ADR
reactions I-ADR I-ADR
and O-ADR O-ADR
fever B-ADR B-ADR
of O-ADR O-ADR
any O-ADR O-ADR
severity O-ADR O-ADR
complicated O-ADR O-ADR
by O-ADR O-ADR
hypotension B-ADR B-ADR
, O-ADR O-ADR
rigors B-ADR B-ADR
or O-ADR O-ADR
chills B-ADR B-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
25 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
/ O-ADR O-ADR
55 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TAFINLAR O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
/ O-ADR O-ADR
53 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TAFINLAR O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
single O-ADR O-ADR
agent O-ADR O-ADR
. O-ADR O-ADR
GILENYA O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
discontinued O-ADR O-ADR
if O-ADR O-ADR
significant O-ADR O-ADR
liver O-ADR O-ADR
injury O-ADR O-ADR
is O-ADR O-ADR
confirmed O-ADR O-ADR
. O-ADR O-ADR
Causality O-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
established O-ADR O-ADR
as O-ADR O-ADR
these O-ADR O-ADR
fractures O-ADR B-ADR
also O-ADR O-ADR
occur O-ADR O-ADR
in O-ADR O-ADR
osteoporotic O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
have O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
resorptive O-ADR O-ADR
agents O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
ILARIS O-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
administered O-ADR O-ADR
concomitantly O-ADR O-ADR
with O-ADR O-ADR
tumor O-ADR O-ADR
necrosis O-ADR O-ADR
factor O-ADR O-ADR
( O-ADR O-ADR
TNF O-ADR O-ADR
) O-ADR O-ADR
inhibitors O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
second O-ADR O-ADR
most O-ADR O-ADR
commonly O-ADR O-ADR
reported O-ADR O-ADR
adverse O-ADR O-ADR
event O-ADR O-ADR
was O-ADR O-ADR
constipation B-ADR B-ADR
. O-ADR O-ADR
Discontinue O-ADR O-ADR
INLYTA O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
developing O-ADR O-ADR
RPLS O-ADR O-ADR
. O-ADR O-ADR
Dose O-ADR O-ADR
reductions O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
required O-ADR O-ADR
in O-ADR O-ADR
57 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
GILOTRIF O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Avoid O-ADR O-ADR
administering O-ADR O-ADR
STRIBILD O-ADR O-ADR
with O-ADR O-ADR
concurrent O-ADR O-ADR
or O-ADR O-ADR
recent O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
nephrotoxic O-ADR O-ADR
drugs O-ADR O-ADR
. O-ADR O-ADR
Only O-ADR O-ADR
hospitals O-ADR O-ADR
that O-ADR O-ADR
have O-ADR O-ADR
enrolled O-ADR O-ADR
in O-ADR O-ADR
and O-ADR O-ADR
met O-ADR O-ADR
all O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
requirements O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
E O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
. O-ADR O-ADR
S O-ADR O-ADR
. O-ADR O-ADR
E O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Immune O-ADR O-ADR
- O-ADR O-ADR
mediated O-ADR O-ADR
Endocrinopathies O-ADR O-ADR
In O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
severe O-ADR O-ADR
to O-ADR O-ADR
life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
immune B-ADR B-ADR
- O-ADR O-ADR
mediated O-ADR O-ADR
endocrinopathies I-ADR I-ADR
( O-ADR O-ADR
requiring O-ADR O-ADR
hospitalization O-ADR O-ADR
, O-ADR O-ADR
urgent O-ADR O-ADR
medical O-ADR O-ADR
intervention O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
interfering O-ADR O-ADR
with O-ADR O-ADR
activities O-ADR O-ADR
of O-ADR O-ADR
daily O-ADR O-ADR
living O-ADR O-ADR
; O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
9 O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
YERVOY O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Hypertensive B-ADR B-ADR
crisis I-ADR I-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
2 O-ADR O-ADR
/ O-ADR O-ADR
359 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
receiving O-ADR O-ADR
INLYTA O-ADR O-ADR
and O-ADR O-ADR
none O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
sorafenib O-ADR O-ADR
. O-ADR O-ADR
Before O-ADR O-ADR
you O-ADR O-ADR
take O-ADR O-ADR
DUAVEE O-ADR O-ADR
, O-ADR O-ADR
tell O-ADR O-ADR
your O-ADR O-ADR
healthcare O-ADR O-ADR
provider O-ADR O-ADR
if O-ADR O-ADR
you O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
have O-ADR O-ADR
any O-ADR O-ADR
unusual O-ADR O-ADR
vaginal O-ADR O-ADR
bleeding O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
case O-ADR O-ADR
of O-ADR O-ADR
persistent O-ADR O-ADR
hypertension O-ADR O-ADR
despite O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
hypertensive O-ADR O-ADR
medications O-ADR O-ADR
, O-ADR O-ADR
reduce O-ADR O-ADR
the O-ADR O-ADR
INLYTA O-ADR O-ADR
dose O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Glucose O-ADR O-ADR
Intolerance O-ADR O-ADR
Glucose O-ADR B-ADR
intolerance O-ADR I-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
ERWINAZE O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
5Includes O-ADR O-ADR
the O-ADR O-ADR
preferred O-ADR O-ADR
terms O-ADR O-ADR
hyperinsulinemia B-ADR B-ADR
and O-ADR O-ADR
blood B-ADR B-ADR
insulin I-ADR I-ADR
increased I-ADR I-ADR
. O-ADR O-ADR
Renal O-ADR O-ADR
replacement O-ADR O-ADR
therapy O-ADR O-ADR
was O-ADR O-ADR
not O-ADR O-ADR
required O-ADR O-ADR
for O-ADR O-ADR
these O-ADR O-ADR
subjects O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
pneumonia B-ADR B-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
COPD O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Postmarketing O-ADR O-ADR
Experience O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
during O-ADR O-ADR
post O-ADR O-ADR
- O-ADR O-ADR
approval O-ADR O-ADR
use O-ADR O-ADR
with O-ADR O-ADR
XEOMIN O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
patients O-ADR O-ADR
at O-ADR O-ADR
highest O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
NSF O-ADR O-ADR
, O-ADR O-ADR
do O-ADR O-ADR
not O-ADR O-ADR
exceed O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
DOTAREM O-ADR O-ADR
dose O-ADR O-ADR
and O-ADR O-ADR
allow O-ADR O-ADR
a O-ADR O-ADR
sufficient O-ADR O-ADR
period O-ADR O-ADR
of O-ADR O-ADR
time O-ADR O-ADR
for O-ADR O-ADR
elimination O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
drug O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
re O-ADR O-ADR
- O-ADR O-ADR
administration O-ADR O-ADR
. O-ADR O-ADR
Clinically O-ADR O-ADR
notable O-ADR O-ADR
decreases B-ADR B-ADR
in I-ADR I-ADR
serum I-ADR I-ADR
potassium I-ADR I-ADR
or O-ADR O-ADR
changes B-ADR B-ADR
in I-ADR I-ADR
blood I-ADR I-ADR
glucose I-ADR I-ADR
were O-ADR O-ADR
infrequent O-ADR O-ADR
during O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
with O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
ARCAPTA O-ADR O-ADR
NEOHALER O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
similar O-ADR O-ADR
to O-ADR O-ADR
those O-ADR O-ADR
for O-ADR O-ADR
placebo O-ADR O-ADR
controls O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
dispatch O-ADR O-ADR
: O-ADR O-ADR
unexpected O-ADR O-ADR
key O-ADR O-ADR
: O-ADR O-ADR
list O-ADR O-ADR
in O-ADR O-ADR
dispatch O-ADR O-ADR
table O-ADR O-ADR
: O-ADR O-ADR
{ O-ADR O-ADR
' O-ADR O-ADR
caption O-ADR O-ADR
' O-ADR O-ADR
: O-ADR O-ADR
< O-ADR O-ADR
function O-ADR O-ADR
print O-ADR O-ADR
_ O-ADR O-ADR
caption O-ADR O-ADR
at O-ADR O-ADR
0x1c6c8c0 O-ADR O-ADR
> O-ADR O-ADR
, O-ADR O-ADR
' O-ADR O-ADR
text O-ADR O-ADR
' O-ADR O-ADR
: O-ADR O-ADR
< O-ADR O-ADR
function O-ADR O-ADR
print O-ADR O-ADR
_ O-ADR O-ADR
text O-ADR O-ADR
at O-ADR O-ADR
0x1c6c500 O-ADR O-ADR
> O-ADR O-ADR
} O-ADR O-ADR
Metabolic B-ADR O-ADR
Changes I-ADR O-ADR
: O-ADR O-ADR
Atypical O-ADR O-ADR
antipsychotic O-ADR O-ADR
drugs O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
metabolic B-ADR O-ADR
changes I-ADR O-ADR
that O-ADR O-ADR
may O-ADR O-ADR
increase O-ADR O-ADR
cerebrovascular B-ADR B-ADR
risk I-ADR I-ADR
. O-ADR O-ADR
Withhold O-ADR O-ADR
, O-ADR O-ADR
dose O-ADR O-ADR
reduce O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
discontinue O-ADR O-ADR
BOSULIF O-ADR O-ADR
as O-ADR O-ADR
necessary O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
those O-ADR O-ADR
patients O-ADR O-ADR
continued O-ADR O-ADR
on O-ADR O-ADR
POTIGA O-ADR O-ADR
, O-ADR O-ADR
dizziness B-ADR B-ADR
and O-ADR O-ADR
somnolence B-ADR B-ADR
appeared O-ADR O-ADR
to O-ADR O-ADR
diminish O-ADR O-ADR
with O-ADR O-ADR
continued O-ADR O-ADR
use O-ADR O-ADR
. O-ADR O-ADR
Concurrent O-ADR O-ADR
hypochloremia B-ADR B-ADR
was O-ADR O-ADR
also O-ADR O-ADR
present O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
hyponatremia B-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
frequent O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
study O-ADR O-ADR
withdrawal O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
TREANDA O-ADR O-ADR
were O-ADR O-ADR
hypersensitivity B-ADR B-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
pyrexia B-ADR B-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
It O-ADR O-ADR
is O-ADR O-ADR
unknown O-ADR O-ADR
whether O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
pancreatitis O-ADR O-ADR
are O-ADR O-ADR
at O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
development O-ADR O-ADR
of O-ADR O-ADR
pancreatitis O-ADR B-ADR
while O-ADR O-ADR
using O-ADR O-ADR
NESINA O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
was O-ADR O-ADR
no O-ADR O-ADR
increased B-ADR O-ADR
incidence I-ADR O-ADR
of I-ADR O-ADR
serious I-ADR O-ADR
infections I-ADR B-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
lymphocyte O-ADR O-ADR
counts O-ADR O-ADR
< O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
8x10 O-ADR O-ADR
9 O-ADR O-ADR
/ O-ADR O-ADR
L O-ADR O-ADR
or O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5x10 O-ADR O-ADR
9 O-ADR O-ADR
/ O-ADR O-ADR
L O-ADR O-ADR
in O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
although O-ADR O-ADR
one O-ADR O-ADR
patient O-ADR O-ADR
in O-ADR O-ADR
an O-ADR O-ADR
extension O-ADR O-ADR
study O-ADR O-ADR
developed O-ADR O-ADR
PML B-ADR B-ADR
in O-ADR O-ADR
the O-ADR O-ADR
setting O-ADR O-ADR
of O-ADR O-ADR
prolonged B-ADR O-ADR
lymphopenia I-ADR B-ADR
( O-ADR O-ADR
lymphocyte O-ADR O-ADR
counts O-ADR O-ADR
predominantly O-ADR O-ADR
< O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5x10 O-ADR O-ADR
9 O-ADR O-ADR
/ O-ADR O-ADR
L O-ADR O-ADR
for O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
years O-ADR O-ADR
) O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Three O-ADR O-ADR
percent O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
discontinued O-ADR O-ADR
TECFIDERA O-ADR O-ADR
for O-ADR O-ADR
flushing B-ADR B-ADR
and O-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
had O-ADR O-ADR
serious O-ADR O-ADR
flushing B-ADR B-ADR
symptoms O-ADR I-ADR
that O-ADR O-ADR
were O-ADR O-ADR
not O-ADR O-ADR
life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
but O-ADR O-ADR
led O-ADR O-ADR
to O-ADR O-ADR
hospitalization O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
NHL O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
regardless O-ADR O-ADR
of O-ADR O-ADR
severity O-ADR O-ADR
, O-ADR O-ADR
are O-ADR O-ADR
shown O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
Remove O-ADR O-ADR
contact O-ADR O-ADR
lenses O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
instillation O-ADR O-ADR
of O-ADR O-ADR
DUREZOL O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Trial O-ADR O-ADR
Experience O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
drug O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
drug O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
Hypersensitivity O-ADR O-ADR
Reactions O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
angioedema B-ADR B-ADR
, O-ADR O-ADR
urticaria B-ADR B-ADR
, O-ADR O-ADR
hypersensitivity B-ADR B-ADR
) O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
FARXIGA O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
Experience O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
drug O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
drug O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
Two O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
5 O-ADR O-ADR
cases O-ADR O-ADR
presented O-ADR O-ADR
with O-ADR O-ADR
CNS O-ADR O-ADR
involvement O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
35 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
Hispanic O-ADR O-ADR
or O-ADR O-ADR
Latino O-ADR O-ADR
. O-ADR O-ADR
Additional O-ADR O-ADR
testing O-ADR O-ADR
may O-ADR O-ADR
include O-ADR O-ADR
fluorescein O-ADR O-ADR
angiograms O-ADR O-ADR
( O-ADR O-ADR
FA O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
optical O-ADR O-ADR
coherence O-ADR O-ADR
tomography O-ADR O-ADR
( O-ADR O-ADR
OCT O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
perimetry O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
electroretinograms O-ADR O-ADR
( O-ADR O-ADR
ERG O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Perform O-ADR O-ADR
an O-ADR O-ADR
evaluation O-ADR O-ADR
for O-ADR O-ADR
RPLS O-ADR O-ADR
in O-ADR O-ADR
any O-ADR O-ADR
patient O-ADR O-ADR
presenting O-ADR O-ADR
with O-ADR O-ADR
seizures O-ADR O-ADR
, O-ADR O-ADR
headache O-ADR O-ADR
, O-ADR O-ADR
visual O-ADR O-ADR
disturbances O-ADR O-ADR
, O-ADR O-ADR
confusion O-ADR O-ADR
or O-ADR O-ADR
altered O-ADR O-ADR
mental O-ADR O-ADR
function O-ADR O-ADR
. O-ADR O-ADR
Therefore O-ADR O-ADR
, O-ADR O-ADR
XIAFLEX O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
injected O-ADR O-ADR
only O-ADR O-ADR
into O-ADR O-ADR
the O-ADR O-ADR
Peyronie O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
plaque O-ADR O-ADR
and O-ADR O-ADR
care O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
taken O-ADR O-ADR
to O-ADR O-ADR
avoid O-ADR O-ADR
injecting O-ADR O-ADR
into O-ADR O-ADR
the O-ADR O-ADR
urethra O-ADR O-ADR
, O-ADR O-ADR
nerves O-ADR O-ADR
, O-ADR O-ADR
blood O-ADR O-ADR
vessels O-ADR O-ADR
, O-ADR O-ADR
corpora O-ADR O-ADR
cavernosa O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
collagen O-ADR O-ADR
- O-ADR O-ADR
containing O-ADR O-ADR
structures O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
penis O-ADR O-ADR
. O-ADR O-ADR
Both O-ADR O-ADR
GRANIX O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
US O-ADR O-ADR
- O-ADR O-ADR
approved O-ADR O-ADR
filgrastim O-ADR O-ADR
product O-ADR O-ADR
were O-ADR O-ADR
administered O-ADR O-ADR
at O-ADR O-ADR
5 O-ADR O-ADR
mcg O-ADR O-ADR
/ O-ADR O-ADR
kg O-ADR O-ADR
subcutaneously O-ADR O-ADR
once O-ADR O-ADR
daily O-ADR O-ADR
beginning O-ADR O-ADR
one O-ADR O-ADR
day O-ADR O-ADR
after O-ADR O-ADR
chemotherapy O-ADR O-ADR
for O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
five O-ADR O-ADR
days O-ADR O-ADR
and O-ADR O-ADR
continued O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
maximum O-ADR O-ADR
of O-ADR O-ADR
14 O-ADR O-ADR
days O-ADR O-ADR
or O-ADR O-ADR
until O-ADR O-ADR
an O-ADR O-ADR
ANC O-ADR O-ADR
of O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
10 O-ADR O-ADR
, O-ADR O-ADR
000 O-ADR O-ADR
x O-ADR O-ADR
10 O-ADR O-ADR
6 O-ADR O-ADR
/ O-ADR O-ADR
L O-ADR O-ADR
after O-ADR O-ADR
nadir O-ADR O-ADR
was O-ADR O-ADR
reached O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
Experience O-ADR O-ADR
: O-ADR O-ADR
Pediatric O-ADR O-ADR
Subjects O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
years O-ADR O-ADR
to O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
18 O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
age O-ADR O-ADR
) O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
assessment O-ADR O-ADR
in O-ADR O-ADR
children O-ADR O-ADR
and O-ADR O-ADR
adolescents O-ADR O-ADR
is O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
Week O-ADR O-ADR
24 O-ADR O-ADR
analysis O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
single O-ADR O-ADR
- O-ADR O-ADR
arm O-ADR O-ADR
, O-ADR O-ADR
Phase O-ADR O-ADR
2 O-ADR O-ADR
trial O-ADR O-ADR
TMC125 O-ADR O-ADR
- O-ADR O-ADR
C213 O-ADR O-ADR
in O-ADR O-ADR
which O-ADR O-ADR
101 O-ADR O-ADR
antiretroviral O-ADR O-ADR
treatment O-ADR O-ADR
- O-ADR O-ADR
experienced O-ADR O-ADR
HIV O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
infected O-ADR O-ADR
subjects O-ADR O-ADR
6 O-ADR O-ADR
years O-ADR O-ADR
to O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
18 O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
age O-ADR O-ADR
and O-ADR O-ADR
weighing O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
16 O-ADR O-ADR
kg O-ADR O-ADR
received O-ADR O-ADR
INTELENCE O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
other O-ADR O-ADR
antiretroviral O-ADR O-ADR
agents O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Treatment O-ADR O-ADR
discontinuation O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
liver B-ADR B-ADR
enzyme I-ADR I-ADR
increases I-ADR I-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
taking O-ADR O-ADR
ZYTIGA O-ADR O-ADR
. O-ADR O-ADR
Withhold O-ADR O-ADR
YERVOY O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
Grade O-ADR O-ADR
2 O-ADR O-ADR
hepatotoxicity O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
have O-ADR O-ADR
followed O-ADR O-ADR
AdreView O-ADR O-ADR
administration O-ADR O-ADR
. O-ADR O-ADR
Physicians O-ADR O-ADR
should O-ADR O-ADR
remain O-ADR O-ADR
vigilant O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
possible O-ADR O-ADR
development O-ADR O-ADR
of O-ADR O-ADR
pneumonia O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
COPD O-ADR O-ADR
as O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
features O-ADR O-ADR
of O-ADR O-ADR
such O-ADR O-ADR
infections O-ADR O-ADR
overlap O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
COPD O-ADR O-ADR
exacerbations O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Peripheral B-ADR B-ADR
neuropathy I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Twenty O-ADR O-ADR
- O-ADR O-ADR
two O-ADR O-ADR
percent O-ADR O-ADR
( O-ADR O-ADR
109 O-ADR O-ADR
/ O-ADR O-ADR
503 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
developed O-ADR O-ADR
a O-ADR O-ADR
new O-ADR O-ADR
or O-ADR O-ADR
worsening O-ADR O-ADR
neuropathy B-ADR B-ADR
that O-ADR O-ADR
had O-ADR O-ADR
not O-ADR O-ADR
recovered O-ADR O-ADR
within O-ADR O-ADR
a O-ADR O-ADR
median O-ADR O-ADR
follow O-ADR O-ADR
- O-ADR O-ADR
up O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
269 O-ADR O-ADR
days O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
25 O-ADR O-ADR
- O-ADR O-ADR
662 O-ADR O-ADR
days O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
16 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Asthma O-ADR O-ADR
- O-ADR O-ADR
Related O-ADR O-ADR
Death O-ADR O-ADR
LABA O-ADR O-ADR
, O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
vilanterol O-ADR O-ADR
, O-ADR O-ADR
one O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
active O-ADR O-ADR
ingredients O-ADR O-ADR
in O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
, O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
asthma O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
death B-ADR B-ADR
. O-ADR O-ADR
No O-ADR O-ADR
apparent O-ADR O-ADR
correlation O-ADR O-ADR
of O-ADR O-ADR
antibody O-ADR O-ADR
development O-ADR O-ADR
to O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
or O-ADR O-ADR
efficacy O-ADR O-ADR
was O-ADR O-ADR
observed O-ADR O-ADR
. O-ADR O-ADR
Healthcare O-ADR O-ADR
providers O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
prepared O-ADR O-ADR
to O-ADR O-ADR
address O-ADR O-ADR
severe O-ADR O-ADR
allergic O-ADR O-ADR
reactions O-ADR O-ADR
following O-ADR O-ADR
XIAFLEX O-ADR O-ADR
injections O-ADR O-ADR
. O-ADR O-ADR
Signs O-ADR O-ADR
or O-ADR O-ADR
symptoms O-ADR O-ADR
that O-ADR O-ADR
may O-ADR O-ADR
reflect O-ADR O-ADR
serious O-ADR O-ADR
injury O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
penis O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
promptly O-ADR O-ADR
evaluated O-ADR O-ADR
in O-ADR O-ADR
order O-ADR O-ADR
to O-ADR O-ADR
assess O-ADR O-ADR
for O-ADR O-ADR
corporal O-ADR O-ADR
rupture O-ADR O-ADR
or O-ADR O-ADR
severe O-ADR O-ADR
penile O-ADR O-ADR
hematoma O-ADR O-ADR
, O-ADR O-ADR
which O-ADR O-ADR
may O-ADR O-ADR
require O-ADR O-ADR
surgical O-ADR O-ADR
intervention O-ADR O-ADR
. O-ADR O-ADR
One O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
564 O-ADR O-ADR
Crohn O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
disease O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
CIMZIA O-ADR O-ADR
developed O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
lupus B-ADR B-ADR
- O-ADR O-ADR
like O-ADR O-ADR
syndrome I-ADR I-ADR
. O-ADR O-ADR
Placement O-ADR O-ADR
or O-ADR O-ADR
removal O-ADR O-ADR
of O-ADR O-ADR
an O-ADR O-ADR
epidural O-ADR O-ADR
catheter O-ADR O-ADR
or O-ADR O-ADR
lumbar O-ADR O-ADR
puncture O-ADR O-ADR
is O-ADR O-ADR
best O-ADR O-ADR
performed O-ADR O-ADR
when O-ADR O-ADR
the O-ADR O-ADR
anticoagulant O-ADR O-ADR
effect O-ADR O-ADR
of O-ADR O-ADR
dabigatran O-ADR O-ADR
is O-ADR O-ADR
low O-ADR O-ADR
; O-ADR O-ADR
however O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
exact O-ADR O-ADR
timing O-ADR O-ADR
to O-ADR O-ADR
reach O-ADR O-ADR
a O-ADR O-ADR
sufficiently O-ADR O-ADR
low O-ADR O-ADR
anticoagulant O-ADR O-ADR
effect O-ADR O-ADR
in O-ADR O-ADR
each O-ADR O-ADR
patient O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
known O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
are O-ADR O-ADR
insufficient O-ADR O-ADR
data O-ADR O-ADR
to O-ADR O-ADR
support O-ADR O-ADR
meaningful O-ADR O-ADR
analyses O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
by O-ADR O-ADR
age O-ADR O-ADR
or O-ADR O-ADR
race O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
these O-ADR O-ADR
reasons O-ADR O-ADR
, O-ADR O-ADR
comparison O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
blinatumomab O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
other O-ADR O-ADR
products O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
misleading O-ADR O-ADR
. O-ADR O-ADR
Progressive O-ADR O-ADR
Multifocal O-ADR O-ADR
Leukoencephalopathy O-ADR O-ADR
Two O-ADR O-ADR
fatal B-ADR B-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
progressive B-ADR B-ADR
multifocal I-ADR I-ADR
leukoencephalopathy I-ADR I-ADR
( O-ADR O-ADR
PML B-ADR B-ADR
) O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
among O-ADR O-ADR
1096 O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
NULOJIX O-ADR O-ADR
- O-ADR O-ADR
containing O-ADR O-ADR
regimen O-ADR O-ADR
: O-ADR O-ADR
one O-ADR O-ADR
patient O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
kidney O-ADR O-ADR
transplant O-ADR O-ADR
( O-ADR O-ADR
Studies O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
3 O-ADR O-ADR
described O-ADR O-ADR
above O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
one O-ADR O-ADR
patient O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
trial O-ADR O-ADR
of O-ADR O-ADR
liver O-ADR O-ADR
transplant O-ADR O-ADR
( O-ADR O-ADR
trial O-ADR O-ADR
of O-ADR O-ADR
250 O-ADR O-ADR
patients O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Other O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
included O-ADR O-ADR
pyrexia B-ADR B-ADR
, O-ADR O-ADR
transaminase B-ADR B-ADR
increase I-ADR I-ADR
, O-ADR O-ADR
dizziness B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
rash B-ADR B-ADR
. O-ADR O-ADR
These O-ADR O-ADR
reactions O-ADR O-ADR
include O-ADR O-ADR
anaphylaxis B-ADR B-ADR
, O-ADR O-ADR
angioedema B-ADR B-ADR
and O-ADR O-ADR
severe O-ADR O-ADR
cutaneous B-ADR B-ADR
adverse I-ADR I-ADR
reactions I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
Stevens B-ADR B-ADR
- O-ADR O-ADR
Johnson O-ADR O-ADR
syndrome I-ADR I-ADR
. O-ADR O-ADR
Clinically O-ADR O-ADR
significant O-ADR O-ADR
cardiovascular O-ADR O-ADR
effects O-ADR O-ADR
and O-ADR O-ADR
fatalities O-ADR B-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
association O-ADR O-ADR
with O-ADR O-ADR
excessive O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
inhaled O-ADR O-ADR
sympathomimetic O-ADR O-ADR
drugs O-ADR O-ADR
. O-ADR O-ADR
Summary O-ADR O-ADR
of O-ADR O-ADR
Treatment O-ADR O-ADR
- O-ADR O-ADR
Emergent O-ADR O-ADR
Laboratory O-ADR O-ADR
Abnormalities O-ADR O-ADR
with O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
or O-ADR O-ADR
4 O-ADR O-ADR
Incidence O-ADR O-ADR
of O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
XALKORI O-ADR O-ADR
- O-ADR O-ADR
Treated O-ADR O-ADR
Patients O-ADR O-ADR
in O-ADR O-ADR
Study O-ADR O-ADR
2 O-ADR O-ADR
Laboratory O-ADR O-ADR
Abnormality O-ADR O-ADR
XALKORI O-ADR O-ADR
Chemotherapy O-ADR O-ADR
Any O-ADR O-ADR
Grade O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
/ O-ADR O-ADR
4 O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Any O-ADR O-ADR
Grade O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
/ O-ADR O-ADR
4 O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Hematology O-ADR O-ADR
Neutropenia B-ADR B-ADR
49 O-ADR O-ADR
12 O-ADR O-ADR
28 O-ADR O-ADR
12 O-ADR O-ADR
Lymphopenia B-ADR B-ADR
51 O-ADR O-ADR
9 O-ADR O-ADR
60 O-ADR O-ADR
25 O-ADR O-ADR
Chemistry O-ADR O-ADR
ALT B-ADR B-ADR
elevation I-ADR I-ADR
76 O-ADR O-ADR
17 O-ADR O-ADR
38 O-ADR O-ADR
4 O-ADR O-ADR
AST B-ADR B-ADR
elevation I-ADR I-ADR
61 O-ADR O-ADR
9 O-ADR O-ADR
33 O-ADR O-ADR
0 O-ADR O-ADR
Hypokalemia B-ADR B-ADR
18 O-ADR O-ADR
4 O-ADR O-ADR
10 O-ADR O-ADR
1 O-ADR O-ADR
Hypophosphatemia B-ADR B-ADR
28 O-ADR O-ADR
5 O-ADR O-ADR
25 O-ADR O-ADR
6 O-ADR O-ADR
Description O-ADR O-ADR
of O-ADR O-ADR
Selected O-ADR O-ADR
Adverse O-ADR O-ADR
Drug O-ADR O-ADR
Reactions O-ADR O-ADR
Vision O-ADR O-ADR
disorders O-ADR O-ADR
Vision B-ADR B-ADR
disorders I-ADR O-ADR
, O-ADR O-ADR
most O-ADR O-ADR
commonly O-ADR O-ADR
visual B-ADR B-ADR
impairment I-ADR I-ADR
, O-ADR O-ADR
photopsia B-ADR B-ADR
, O-ADR O-ADR
blurred B-ADR B-ADR
vision I-ADR I-ADR
, O-ADR O-ADR
or O-ADR O-ADR
vitreous B-ADR B-ADR
floaters I-ADR I-ADR
, O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
1038 O-ADR O-ADR
( O-ADR O-ADR
62 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
1669 O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
Switching O-ADR O-ADR
Between O-ADR O-ADR
Biological O-ADR O-ADR
Disease O-ADR O-ADR
Modifying O-ADR O-ADR
Antirheumatic O-ADR O-ADR
Drugs O-ADR O-ADR
( O-ADR O-ADR
DMARDs O-ADR O-ADR
) O-ADR O-ADR
Care O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
taken O-ADR O-ADR
when O-ADR O-ADR
switching O-ADR O-ADR
from O-ADR O-ADR
one O-ADR O-ADR
biologic O-ADR O-ADR
product O-ADR O-ADR
to O-ADR O-ADR
another O-ADR O-ADR
biologic O-ADR O-ADR
product O-ADR O-ADR
since O-ADR O-ADR
overlapping O-ADR O-ADR
biological O-ADR O-ADR
activity O-ADR O-ADR
may O-ADR O-ADR
further O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
infection O-ADR B-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Nausea B-ADR B-ADR
* O-ADR O-ADR
Muscle B-ADR B-ADR
spasms I-ADR I-ADR
* O-ADR O-ADR
Rash B-ADR B-ADR
* O-ADR O-ADR
Pruritus B-ADR B-ADR
* O-ADR O-ADR
Angioedema B-ADR B-ADR
BOXED O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
FETAL B-ADR B-ADR
TOXICITY I-ADR I-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
FETAL B-ADR B-ADR
TOXICITY I-ADR I-ADR
* O-ADR O-ADR
When O-ADR O-ADR
pregnancy O-ADR O-ADR
is O-ADR O-ADR
detected O-ADR O-ADR
, O-ADR O-ADR
discontinue O-ADR O-ADR
Edarbi O-ADR O-ADR
as O-ADR O-ADR
soon O-ADR O-ADR
as O-ADR O-ADR
possible O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
safety O-ADR O-ADR
population O-ADR O-ADR
in O-ADR O-ADR
controlled O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
620 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
Crohn O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
disease O-ADR O-ADR
received O-ADR O-ADR
CIMZIA O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
400 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
614 O-ADR O-ADR
subjects O-ADR O-ADR
received O-ADR O-ADR
placebo O-ADR O-ADR
( O-ADR O-ADR
including O-ADR O-ADR
subjects O-ADR O-ADR
randomized O-ADR O-ADR
to O-ADR O-ADR
placebo O-ADR O-ADR
in O-ADR O-ADR
Study O-ADR O-ADR
CD2 O-ADR O-ADR
following O-ADR O-ADR
open O-ADR O-ADR
label O-ADR O-ADR
dosing O-ADR O-ADR
of O-ADR O-ADR
CIMZIA O-ADR O-ADR
at O-ADR O-ADR
Weeks O-ADR O-ADR
0 O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
STRIBILD O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
avoided O-ADR O-ADR
with O-ADR O-ADR
concurrent O-ADR O-ADR
or O-ADR O-ADR
recent O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
nephrotoxic O-ADR O-ADR
agent O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
of O-ADR O-ADR
any O-ADR O-ADR
cause O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
48 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
DYSPORT O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
33 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
frequent O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
in O-ADR O-ADR
XEOMIN O-ADR O-ADR
treated O-ADR O-ADR
subjects O-ADR O-ADR
were O-ADR O-ADR
: O-ADR O-ADR
headache B-ADR B-ADR
29 O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
facial B-ADR B-ADR
paresis I-ADR I-ADR
4 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
hematoma I-ADR I-ADR
3 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
eyelid B-ADR B-ADR
edema I-ADR I-ADR
2 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
Tumorigenic O-ADR O-ADR
Potential O-ADR O-ADR
In O-ADR O-ADR
an O-ADR O-ADR
oral O-ADR O-ADR
carcinogenicity O-ADR O-ADR
study O-ADR O-ADR
, O-ADR O-ADR
gabapentin O-ADR O-ADR
enacarbil O-ADR O-ADR
increased O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
pancreatic B-ADR B-ADR
acinar I-ADR I-ADR
cell I-ADR I-ADR
adenoma I-ADR I-ADR
in O-ADR O-ADR
male O-ADR O-ADR
and O-ADR O-ADR
female O-ADR O-ADR
rats O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Nonclinical O-ADR O-ADR
Toxicology O-ADR O-ADR
( O-ADR O-ADR
13 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Unless O-ADR O-ADR
an O-ADR O-ADR
alternate O-ADR O-ADR
etiology O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
identified O-ADR O-ADR
, O-ADR O-ADR
signs O-ADR O-ADR
or O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
dermatitis O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
immune O-ADR O-ADR
- O-ADR O-ADR
mediated O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
clinical O-ADR O-ADR
relevance O-ADR O-ADR
of O-ADR O-ADR
this O-ADR O-ADR
finding O-ADR O-ADR
is O-ADR O-ADR
unknown O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Patients O-ADR O-ADR
Coinfected O-ADR O-ADR
with O-ADR O-ADR
HIV O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
HBV O-ADR O-ADR
It O-ADR O-ADR
is O-ADR O-ADR
recommended O-ADR O-ADR
that O-ADR O-ADR
all O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
HIV O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
be O-ADR O-ADR
tested O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
presence O-ADR O-ADR
of O-ADR O-ADR
chronic O-ADR O-ADR
hepatitis O-ADR O-ADR
B O-ADR O-ADR
virus O-ADR O-ADR
( O-ADR O-ADR
HBV O-ADR O-ADR
) O-ADR O-ADR
before O-ADR O-ADR
initiating O-ADR O-ADR
antiretroviral O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
/ O-ADR O-ADR
4 O-ADR O-ADR
laboratory O-ADR O-ADR
abnormalities O-ADR O-ADR
( O-ADR O-ADR
incidence O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
lymphopenia B-ADR B-ADR
, O-ADR O-ADR
hyperglycemia B-ADR B-ADR
, O-ADR O-ADR
anemia B-ADR B-ADR
, O-ADR O-ADR
decreased B-ADR B-ADR
potassium I-ADR I-ADR
, O-ADR O-ADR
increased B-ADR B-ADR
AST I-ADR I-ADR
, O-ADR O-ADR
increased B-ADR B-ADR
ALT I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
thrombocytopenia B-ADR B-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
Wound O-ADR O-ADR
Healing O-ADR O-ADR
Complications O-ADR O-ADR
No O-ADR O-ADR
formal O-ADR O-ADR
studies O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
effect O-ADR O-ADR
of O-ADR O-ADR
INLYTA O-ADR O-ADR
on O-ADR O-ADR
wound O-ADR B-ADR
healing O-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
conducted O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
remaining O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
symptoms O-ADR O-ADR
resolved O-ADR O-ADR
within O-ADR O-ADR
4 O-ADR O-ADR
to O-ADR O-ADR
5 O-ADR O-ADR
weeks O-ADR O-ADR
. O-ADR O-ADR
Mild O-ADR O-ADR
to O-ADR O-ADR
severe O-ADR O-ADR
hypertension B-ADR B-ADR
may O-ADR O-ADR
be O-ADR O-ADR
present O-ADR O-ADR
. O-ADR O-ADR
Initiate O-ADR O-ADR
systemic O-ADR O-ADR
corticosteroids O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
1 O-ADR O-ADR
to O-ADR O-ADR
2 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
kg O-ADR O-ADR
/ O-ADR O-ADR
day O-ADR O-ADR
of O-ADR O-ADR
prednisone O-ADR O-ADR
or O-ADR O-ADR
equivalent O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
initiate O-ADR O-ADR
appropriate O-ADR O-ADR
hormone O-ADR O-ADR
replacement O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
multicenter O-ADR O-ADR
, O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
trial O-ADR O-ADR
( O-ADR O-ADR
FLAMINGO O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
243 O-ADR O-ADR
subjects O-ADR O-ADR
received O-ADR O-ADR
TIVICAY O-ADR O-ADR
50 O-ADR O-ADR
mg O-ADR O-ADR
once O-ADR O-ADR
daily O-ADR O-ADR
versus O-ADR O-ADR
242 O-ADR O-ADR
subjects O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
darunavir O-ADR O-ADR
800 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
ritonavir O-ADR O-ADR
100 O-ADR O-ADR
mg O-ADR O-ADR
once O-ADR O-ADR
daily O-ADR O-ADR
, O-ADR O-ADR
both O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
investigator O-ADR O-ADR
- O-ADR O-ADR
selected O-ADR O-ADR
NRTI O-ADR O-ADR
background O-ADR O-ADR
regimen O-ADR O-ADR
( O-ADR O-ADR
either O-ADR O-ADR
EPZICOM O-ADR O-ADR
or O-ADR O-ADR
TRUVADA O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
these O-ADR O-ADR
reasons O-ADR O-ADR
, O-ADR O-ADR
comparison O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
KALBITOR O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
other O-ADR O-ADR
products O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
misleading O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
10 O-ADR O-ADR
Hypothyroidism O-ADR O-ADR
Estrogen O-ADR O-ADR
administration O-ADR O-ADR
leads O-ADR O-ADR
to O-ADR O-ADR
increased B-ADR B-ADR
thyroid I-ADR I-ADR
- O-ADR O-ADR
binding O-ADR O-ADR
globulin I-ADR I-ADR
( I-ADR I-ADR
TBG I-ADR I-ADR
) I-ADR I-ADR
levels I-ADR I-ADR
. O-ADR O-ADR
Discontinue O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
ILARIS O-ADR O-ADR
if O-ADR O-ADR
a O-ADR O-ADR
patient O-ADR O-ADR
develops O-ADR O-ADR
a O-ADR O-ADR
serious O-ADR O-ADR
infection O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
of O-ADR O-ADR
resuming O-ADR O-ADR
TNF O-ADR O-ADR
blocker O-ADR O-ADR
therapy O-ADR O-ADR
after O-ADR O-ADR
HBV O-ADR O-ADR
reactivation O-ADR O-ADR
is O-ADR O-ADR
controlled O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
known O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
ARISTOTLE O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
mean O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
exposure O-ADR O-ADR
was O-ADR O-ADR
89 O-ADR O-ADR
weeks O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
15 O-ADR O-ADR
, O-ADR O-ADR
000 O-ADR O-ADR
patient O-ADR O-ADR
- O-ADR O-ADR
years O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Hemoglobin O-ADR O-ADR
Decreases O-ADR B-ADR
in O-ADR I-ADR
hemoglobin O-ADR I-ADR
may O-ADR O-ADR
require O-ADR O-ADR
a O-ADR O-ADR
decrease O-ADR O-ADR
in O-ADR O-ADR
dosage O-ADR O-ADR
or O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
ribavirin O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
prescribing O-ADR O-ADR
information O-ADR O-ADR
for O-ADR O-ADR
ribavirin O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Neoplasm O-ADR O-ADR
Benign O-ADR O-ADR
and O-ADR O-ADR
Malignant O-ADR O-ADR
: O-ADR O-ADR
Melanoma B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
Immune O-ADR O-ADR
System O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
Serious O-ADR O-ADR
systemic B-ADR B-ADR
hypersensitivity I-ADR I-ADR
reactions I-ADR I-ADR
( O-ADR O-ADR
including O-ADR O-ADR
anaphylactic B-ADR B-ADR
reaction I-ADR I-ADR
) O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
10 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
, O-ADR O-ADR
sarcoidosis B-ADR B-ADR
Respiratory O-ADR O-ADR
, O-ADR O-ADR
thoracic O-ADR O-ADR
and O-ADR O-ADR
mediastinal O-ADR O-ADR
disorders O-ADR O-ADR
: O-ADR O-ADR
Interstitial B-ADR B-ADR
lung I-ADR I-ADR
disease I-ADR I-ADR
Skin O-ADR O-ADR
and O-ADR O-ADR
subcutaneous O-ADR O-ADR
tissue O-ADR O-ADR
disorders O-ADR O-ADR
: O-ADR O-ADR
Skin B-ADR B-ADR
exfoliation I-ADR I-ADR
, O-ADR O-ADR
bullous B-ADR B-ADR
skin I-ADR I-ADR
reactions I-ADR I-ADR
BOXED O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
SERIOUS O-ADR O-ADR
INFECTIONS B-ADR B-ADR
AND O-ADR O-ADR
MALIGNANCY B-ADR B-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
SERIOUS O-ADR O-ADR
INFECTIONS B-ADR B-ADR
AND O-ADR O-ADR
MALIGNANCY B-ADR B-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
SERIOUS O-ADR O-ADR
INFECTIONS B-ADR B-ADR
AND O-ADR O-ADR
MALIGNANCY B-ADR B-ADR
See O-ADR O-ADR
full O-ADR O-ADR
prescribing O-ADR O-ADR
information O-ADR O-ADR
for O-ADR O-ADR
complete O-ADR O-ADR
boxed O-ADR O-ADR
warning O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Hypersensitivity O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
ILARIS O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
are O-ADR O-ADR
currently O-ADR O-ADR
no O-ADR O-ADR
marketed O-ADR O-ADR
tests O-ADR O-ADR
for O-ADR O-ADR
antibodies O-ADR O-ADR
against O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
; O-ADR O-ADR
however O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
testing O-ADR O-ADR
service O-ADR O-ADR
is O-ADR O-ADR
provided O-ADR O-ADR
by O-ADR O-ADR
Genzyme O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
EOVIST O-ADR O-ADR
is O-ADR O-ADR
used O-ADR O-ADR
in O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
complete O-ADR O-ADR
MRI O-ADR O-ADR
no O-ADR O-ADR
later O-ADR O-ADR
than O-ADR O-ADR
60 O-ADR O-ADR
minutes O-ADR O-ADR
after O-ADR O-ADR
EOVIST O-ADR O-ADR
administration O-ADR O-ADR
and O-ADR O-ADR
use O-ADR O-ADR
a O-ADR O-ADR
paired O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
contrast O-ADR O-ADR
and O-ADR O-ADR
contrast O-ADR O-ADR
MRI O-ADR O-ADR
set O-ADR O-ADR
for O-ADR O-ADR
diagnosis O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Heart O-ADR O-ADR
Failure O-ADR O-ADR
Cases O-ADR O-ADR
of O-ADR O-ADR
worsening B-ADR B-ADR
congestive I-ADR I-ADR
heart I-ADR I-ADR
failure I-ADR I-ADR
) O-ADR O-ADR
and O-ADR O-ADR
new B-ADR B-ADR
onset I-ADR I-ADR
CHF I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
TNF O-ADR O-ADR
blockers O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
CIMZIA O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
Experience O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
event O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
drug O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
any O-ADR O-ADR
other O-ADR O-ADR
drug O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Radiation O-ADR O-ADR
Risk O-ADR O-ADR
Vizamyl O-ADR O-ADR
, O-ADR O-ADR
similar O-ADR O-ADR
to O-ADR O-ADR
other O-ADR O-ADR
radiopharmaceuticals O-ADR O-ADR
, O-ADR O-ADR
contributes O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
patient O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
overall O-ADR O-ADR
long B-ADR B-ADR
- O-ADR O-ADR
term O-ADR O-ADR
cumulative I-ADR I-ADR
radiation I-ADR I-ADR
exposure I-ADR I-ADR
. O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Cubist O-ADR O-ADR
Pharmaceuticals O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
877 O-ADR O-ADR
- O-ADR O-ADR
CUBIST O-ADR O-ADR
- O-ADR O-ADR
6 O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
877 O-ADR O-ADR
- O-ADR O-ADR
282 O-ADR O-ADR
- O-ADR O-ADR
4786 O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
Infections O-ADR O-ADR
Serious O-ADR O-ADR
infections B-ADR B-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
included O-ADR O-ADR
sepsis B-ADR B-ADR
, O-ADR O-ADR
pneumonia B-ADR B-ADR
, O-ADR O-ADR
cellulitis B-ADR B-ADR
, O-ADR O-ADR
abscess B-ADR B-ADR
, O-ADR O-ADR
opportunistic B-ADR B-ADR
infections I-ADR I-ADR
, O-ADR O-ADR
tuberculosis B-ADR B-ADR
( O-ADR O-ADR
TB B-ADR B-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
invasive B-ADR B-ADR
fungal I-ADR I-ADR
infections I-ADR I-ADR
. O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
MULTAQ O-ADR O-ADR
is O-ADR O-ADR
contraindicated O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
symptomatic O-ADR O-ADR
heart O-ADR O-ADR
failure O-ADR O-ADR
with O-ADR O-ADR
recent O-ADR O-ADR
decompensation O-ADR O-ADR
requiring O-ADR O-ADR
hospitalization O-ADR O-ADR
or O-ADR O-ADR
NYHA O-ADR O-ADR
Class O-ADR O-ADR
IV O-ADR O-ADR
heart O-ADR O-ADR
failure O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Administer O-ADR O-ADR
EOVIST O-ADR O-ADR
only O-ADR O-ADR
in O-ADR O-ADR
situations O-ADR O-ADR
where O-ADR O-ADR
trained O-ADR O-ADR
personnel O-ADR O-ADR
and O-ADR O-ADR
therapies O-ADR O-ADR
are O-ADR O-ADR
promptly O-ADR O-ADR
available O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
hypersensitivity O-ADR O-ADR
reactions O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
personnel O-ADR O-ADR
trained O-ADR O-ADR
in O-ADR O-ADR
resuscitation O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Serious O-ADR O-ADR
Skin B-ADR B-ADR
Toxicity I-ADR I-ADR
: O-ADR O-ADR
Monitor O-ADR O-ADR
for O-ADR O-ADR
skin O-ADR O-ADR
toxicities O-ADR O-ADR
and O-ADR O-ADR
for O-ADR O-ADR
secondary O-ADR O-ADR
infections O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
collected O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
included O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
at O-ADR O-ADR
baseline O-ADR O-ADR
but O-ADR O-ADR
only O-ADR O-ADR
treatment O-ADR O-ADR
emergent O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
, O-ADR O-ADR
defined O-ADR O-ADR
as O-ADR O-ADR
events O-ADR O-ADR
that O-ADR O-ADR
appeared O-ADR O-ADR
or O-ADR O-ADR
worsened O-ADR O-ADR
after O-ADR O-ADR
the O-ADR O-ADR
start O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
, O-ADR O-ADR
are O-ADR O-ADR
presented O-ADR O-ADR
below O-ADR O-ADR
. O-ADR O-ADR
DUAVEE O-ADR O-ADR
contains O-ADR O-ADR
an O-ADR O-ADR
estrogen O-ADR O-ADR
agonist O-ADR O-ADR
/ O-ADR O-ADR
antagonist O-ADR O-ADR
. O-ADR O-ADR
When O-ADR O-ADR
feasible O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
decision O-ADR O-ADR
to O-ADR O-ADR
administer O-ADR O-ADR
empiric O-ADR O-ADR
antifungal O-ADR O-ADR
therapy O-ADR O-ADR
in O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
made O-ADR O-ADR
in O-ADR O-ADR
consultation O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
physician O-ADR O-ADR
with O-ADR O-ADR
expertise O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
diagnosis O-ADR O-ADR
and O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
invasive O-ADR O-ADR
fungal O-ADR O-ADR
infections O-ADR O-ADR
and O-ADR O-ADR
should O-ADR O-ADR
take O-ADR O-ADR
into O-ADR O-ADR
account O-ADR O-ADR
both O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
severe O-ADR O-ADR
fungal O-ADR O-ADR
infection O-ADR O-ADR
and O-ADR O-ADR
risks O-ADR O-ADR
of O-ADR O-ADR
antifungal O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
such O-ADR O-ADR
symptoms O-ADR O-ADR
occur O-ADR O-ADR
, O-ADR O-ADR
discontinue O-ADR O-ADR
PRISTIQ O-ADR O-ADR
and O-ADR O-ADR
initiate O-ADR O-ADR
supportive O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
Prophylaxis O-ADR O-ADR
for O-ADR O-ADR
cytomegalovirus O-ADR O-ADR
is O-ADR O-ADR
recommended O-ADR O-ADR
for O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
3 O-ADR O-ADR
months O-ADR O-ADR
after O-ADR O-ADR
transplantation O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
Dermatologic O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
large O-ADR O-ADR
clinical O-ADR O-ADR
trial O-ADR O-ADR
of O-ADR O-ADR
over O-ADR O-ADR
7800 O-ADR O-ADR
women O-ADR O-ADR
with O-ADR O-ADR
postmenopausal O-ADR O-ADR
osteoporosis O-ADR O-ADR
, O-ADR O-ADR
dermal B-ADR B-ADR
adverse I-ADR I-ADR
events I-ADR I-ADR
such O-ADR O-ADR
as O-ADR O-ADR
dermatitis B-ADR B-ADR
, O-ADR O-ADR
eczema B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
rashes B-ADR B-ADR
occurred O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
significantly O-ADR O-ADR
higher O-ADR O-ADR
rate O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Prolia O-ADR O-ADR
group O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
group O-ADR O-ADR
. O-ADR O-ADR
Common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
in O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
perioperative O-ADR O-ADR
studies O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
develop O-ADR O-ADR
HBV O-ADR O-ADR
reactivation O-ADR O-ADR
, O-ADR O-ADR
discontinue O-ADR O-ADR
CIMZIA O-ADR O-ADR
and O-ADR O-ADR
initiate O-ADR O-ADR
effective O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
viral O-ADR O-ADR
therapy O-ADR O-ADR
with O-ADR O-ADR
appropriate O-ADR O-ADR
supportive O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
2 O-ADR O-ADR
- O-ADR O-ADR
year O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
elevation B-ADR B-ADR
of I-ADR I-ADR
liver I-ADR I-ADR
transaminases I-ADR I-ADR
to O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
fold O-ADR O-ADR
the O-ADR O-ADR
upper O-ADR O-ADR
limit O-ADR O-ADR
of O-ADR O-ADR
normal O-ADR O-ADR
( O-ADR O-ADR
ULN O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
greater O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
14 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
GILENYA O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
and O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
on O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
such O-ADR O-ADR
cases O-ADR O-ADR
, O-ADR O-ADR
topical O-ADR O-ADR
treatments O-ADR O-ADR
are O-ADR O-ADR
recommended O-ADR O-ADR
, O-ADR O-ADR
but O-ADR O-ADR
alcohol O-ADR O-ADR
- O-ADR O-ADR
, O-ADR O-ADR
hydrogen O-ADR O-ADR
peroxide O-ADR O-ADR
- O-ADR O-ADR
, O-ADR O-ADR
iodine O-ADR O-ADR
- O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
thyme O-ADR O-ADR
- O-ADR O-ADR
containing O-ADR O-ADR
mouthwashes O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
avoided O-ADR O-ADR
as O-ADR O-ADR
they O-ADR O-ADR
may O-ADR O-ADR
exacerbate O-ADR O-ADR
the O-ADR O-ADR
condition O-ADR O-ADR
. O-ADR O-ADR
Women O-ADR O-ADR
with O-ADR O-ADR
normal O-ADR O-ADR
thyroid O-ADR O-ADR
function O-ADR O-ADR
can O-ADR O-ADR
compensate O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
increased B-ADR O-ADR
TBG I-ADR O-ADR
by O-ADR O-ADR
making O-ADR O-ADR
more O-ADR O-ADR
thyroid O-ADR O-ADR
hormone O-ADR O-ADR
, O-ADR O-ADR
thus O-ADR O-ADR
maintaining O-ADR O-ADR
free O-ADR O-ADR
T4 O-ADR O-ADR
and O-ADR O-ADR
T3 O-ADR O-ADR
serum O-ADR O-ADR
concentrations O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
normal O-ADR O-ADR
range O-ADR O-ADR
. O-ADR O-ADR
RPLS B-ADR O-ADR
is O-ADR O-ADR
a O-ADR O-ADR
neurological O-ADR O-ADR
disorder O-ADR O-ADR
which O-ADR O-ADR
can O-ADR O-ADR
present O-ADR O-ADR
with O-ADR O-ADR
headache B-ADR O-ADR
, O-ADR O-ADR
seizure B-ADR O-ADR
, O-ADR O-ADR
lethargy B-ADR O-ADR
, O-ADR O-ADR
confusion B-ADR O-ADR
, O-ADR O-ADR
blindness B-ADR O-ADR
and O-ADR O-ADR
other O-ADR O-ADR
neurologic B-ADR O-ADR
disturbances I-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
events O-ADR O-ADR
were O-ADR O-ADR
not O-ADR O-ADR
treatment O-ADR O-ADR
limiting O-ADR O-ADR
. O-ADR O-ADR
This O-ADR O-ADR
finding O-ADR O-ADR
with O-ADR O-ADR
salmeterol O-ADR O-ADR
is O-ADR O-ADR
considered O-ADR O-ADR
a O-ADR O-ADR
class O-ADR O-ADR
effect O-ADR O-ADR
of O-ADR O-ADR
all O-ADR O-ADR
LABA O-ADR O-ADR
. O-ADR O-ADR
Furthermore O-ADR O-ADR
, O-ADR O-ADR
CRIM O-ADR O-ADR
- O-ADR O-ADR
negative O-ADR O-ADR
infants O-ADR O-ADR
have O-ADR O-ADR
shown O-ADR O-ADR
reduced O-ADR O-ADR
clinical O-ADR O-ADR
effect O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
presence O-ADR O-ADR
of O-ADR O-ADR
high O-ADR O-ADR
sustained O-ADR O-ADR
IgG B-ADR O-ADR
antibody I-ADR O-ADR
titers I-ADR O-ADR
with I-ADR O-ADR
inhibitory I-ADR O-ADR
activity I-ADR O-ADR
. O-ADR O-ADR
Musculoskeletal O-ADR O-ADR
and O-ADR O-ADR
Connective O-ADR O-ADR
Tissue O-ADR O-ADR
Disorders O-ADR O-ADR
Muscle B-ADR B-ADR
spasms I-ADR I-ADR
. O-ADR O-ADR
Fatal B-ADR B-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
occurred O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
AFINITOR O-ADR O-ADR
plus O-ADR O-ADR
exemestane O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
patients O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
plus O-ADR O-ADR
exemestane O-ADR O-ADR
arm O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Drug O-ADR O-ADR
Interactions O-ADR O-ADR
Co O-ADR O-ADR
- O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
strong O-ADR O-ADR
cytochrome O-ADR O-ADR
P450 O-ADR O-ADR
enzyme O-ADR O-ADR
inducer O-ADR O-ADR
, O-ADR O-ADR
rifampin O-ADR O-ADR
, O-ADR O-ADR
resulted O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
reduction O-ADR O-ADR
of O-ADR O-ADR
systemic O-ADR O-ADR
exposure O-ADR O-ADR
of O-ADR O-ADR
apremilast O-ADR O-ADR
, O-ADR O-ADR
which O-ADR O-ADR
may O-ADR O-ADR
result O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
loss O-ADR O-ADR
of O-ADR O-ADR
efficacy O-ADR O-ADR
of O-ADR O-ADR
OTEZLA O-ADR O-ADR
. O-ADR O-ADR
BOXED O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
LACTIC B-ADR B-ADR
ACIDOSIS O-ADR O-ADR
/ O-ADR O-ADR
SEVERE O-ADR O-ADR
HEPATOMEGALY B-ADR B-ADR
WITH O-ADR O-ADR
STEATOSIS B-ADR O-ADR
and O-ADR O-ADR
POST O-ADR O-ADR
TREATMENT O-ADR O-ADR
ACUTE B-ADR B-ADR
EXACERBATION I-ADR I-ADR
OF I-ADR I-ADR
HEPATITIS I-ADR I-ADR
B I-ADR I-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
LACTIC B-ADR B-ADR
ACIDOSIS O-ADR O-ADR
/ O-ADR O-ADR
SEVERE O-ADR O-ADR
HEPATOMEGALY B-ADR B-ADR
WITH O-ADR O-ADR
STEATOSIS B-ADR O-ADR
and O-ADR O-ADR
POST O-ADR O-ADR
TREATMENT O-ADR O-ADR
ACUTE B-ADR O-ADR
EXACERBATION I-ADR O-ADR
OF I-ADR O-ADR
HEPATITIS I-ADR O-ADR
B I-ADR O-ADR
Lactic B-ADR B-ADR
acidosis I-ADR I-ADR
and O-ADR O-ADR
severe O-ADR O-ADR
hepatomegaly B-ADR B-ADR
with O-ADR O-ADR
steatosis B-ADR B-ADR
, O-ADR O-ADR
including O-ADR O-ADR
fatal B-ADR B-ADR
cases O-ADR O-ADR
, O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
nucleoside O-ADR O-ADR
analogs O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
tenofovir O-ADR O-ADR
disoproxil O-ADR O-ADR
fumarate O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
component O-ADR O-ADR
of O-ADR O-ADR
STRIBILD O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
other O-ADR O-ADR
antiretrovirals O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
At O-ADR O-ADR
48 O-ADR O-ADR
weeks O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
discontinuation O-ADR O-ADR
were O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
subjects O-ADR O-ADR
receiving O-ADR O-ADR
TIVICAY O-ADR O-ADR
50 O-ADR O-ADR
mg O-ADR O-ADR
once O-ADR O-ADR
daily O-ADR O-ADR
+ O-ADR O-ADR
background O-ADR O-ADR
regimen O-ADR O-ADR
and O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
subjects O-ADR O-ADR
receiving O-ADR O-ADR
raltegravir O-ADR O-ADR
400 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
+ O-ADR O-ADR
background O-ADR O-ADR
regimen O-ADR O-ADR
. O-ADR O-ADR
Some O-ADR O-ADR
patients O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
rechallenged O-ADR O-ADR
and O-ADR O-ADR
have O-ADR O-ADR
continued O-ADR O-ADR
to O-ADR O-ADR
receive O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
under O-ADR O-ADR
close O-ADR O-ADR
clinical O-ADR O-ADR
supervision O-ADR O-ADR
. O-ADR O-ADR
Tell O-ADR O-ADR
your O-ADR O-ADR
healthcare O-ADR O-ADR
provider O-ADR O-ADR
about O-ADR O-ADR
all O-ADR O-ADR
the O-ADR O-ADR
medicines O-ADR O-ADR
you O-ADR O-ADR
take O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
prescription O-ADR O-ADR
and O-ADR O-ADR
over O-ADR O-ADR
- O-ADR O-ADR
the O-ADR O-ADR
- O-ADR O-ADR
counter O-ADR O-ADR
medicines O-ADR O-ADR
, O-ADR O-ADR
vitamins O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
herbal O-ADR O-ADR
supplements O-ADR O-ADR
. O-ADR O-ADR
d O-ADR O-ADR
Hypertension B-ADR B-ADR
includes O-ADR O-ADR
the O-ADR O-ADR
preferred O-ADR O-ADR
terms O-ADR O-ADR
of O-ADR O-ADR
hypertension B-ADR B-ADR
, O-ADR O-ADR
hypertensive B-ADR B-ADR
crisis I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
hypertensive B-ADR B-ADR
emergency I-ADR I-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Immune B-ADR B-ADR
- O-ADR O-ADR
Mediated O-ADR O-ADR
Reactions I-ADR I-ADR
: O-ADR O-ADR
Monitor O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
development O-ADR O-ADR
of O-ADR O-ADR
systemic O-ADR O-ADR
immune O-ADR O-ADR
- O-ADR O-ADR
mediated O-ADR O-ADR
reactions O-ADR O-ADR
involving O-ADR O-ADR
skin O-ADR O-ADR
and O-ADR O-ADR
other O-ADR O-ADR
organs O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
pediatric O-ADR O-ADR
trial O-ADR O-ADR
with O-ADR O-ADR
bipolar O-ADR O-ADR
I O-ADR O-ADR
disorder O-ADR O-ADR
, O-ADR O-ADR
transient O-ADR O-ADR
elevations B-ADR B-ADR
in I-ADR I-ADR
serum I-ADR I-ADR
transaminases I-ADR I-ADR
) O-ADR O-ADR
were O-ADR O-ADR
more O-ADR O-ADR
common O-ADR O-ADR
in O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Impaired O-ADR O-ADR
Renal O-ADR O-ADR
Function O-ADR O-ADR
As O-ADR O-ADR
a O-ADR O-ADR
consequence O-ADR O-ADR
of O-ADR O-ADR
inhibiting O-ADR O-ADR
the O-ADR O-ADR
renin O-ADR O-ADR
- O-ADR O-ADR
angiotensin O-ADR O-ADR
system O-ADR O-ADR
, O-ADR O-ADR
changes B-ADR B-ADR
in I-ADR I-ADR
renal I-ADR I-ADR
function I-ADR I-ADR
may O-ADR O-ADR
be O-ADR O-ADR
anticipated O-ADR O-ADR
in O-ADR O-ADR
susceptible O-ADR O-ADR
individuals O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
Edarbi O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
these O-ADR O-ADR
reasons O-ADR O-ADR
, O-ADR O-ADR
comparison O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
antibodies O-ADR O-ADR
across O-ADR O-ADR
products O-ADR O-ADR
in O-ADR O-ADR
this O-ADR O-ADR
class O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
misleading O-ADR O-ADR
. O-ADR O-ADR
Controlled O-ADR O-ADR
Studies O-ADR O-ADR
with O-ADR O-ADR
Crohn O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
Disease O-ADR O-ADR
The O-ADR O-ADR
data O-ADR O-ADR
described O-ADR O-ADR
below O-ADR O-ADR
reflect O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
CIMZIA O-ADR O-ADR
at O-ADR O-ADR
400 O-ADR O-ADR
mg O-ADR O-ADR
subcutaneous O-ADR O-ADR
dosing O-ADR O-ADR
in O-ADR O-ADR
studies O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
Crohn O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
disease O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
patients O-ADR O-ADR
at O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
chronically O-ADR O-ADR
reduced O-ADR O-ADR
renal O-ADR O-ADR
function O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
age O-ADR O-ADR
> O-ADR O-ADR
60 O-ADR O-ADR
years O-ADR O-ADR
, O-ADR O-ADR
diabetes O-ADR O-ADR
mellitus O-ADR O-ADR
or O-ADR O-ADR
chronic O-ADR O-ADR
hypertension O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
estimate O-ADR O-ADR
the O-ADR O-ADR
GFR O-ADR O-ADR
through O-ADR O-ADR
laboratory O-ADR O-ADR
testing O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
shows O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
INVOKANA O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
majority O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
XALKORI O-ADR O-ADR
arms O-ADR O-ADR
in O-ADR O-ADR
Studies O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
50 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
reported O-ADR O-ADR
visual B-ADR B-ADR
disturbances I-ADR I-ADR
which O-ADR O-ADR
occurred O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
frequency O-ADR O-ADR
of O-ADR O-ADR
4 O-ADR O-ADR
- O-ADR O-ADR
7 O-ADR O-ADR
days O-ADR O-ADR
each O-ADR O-ADR
week O-ADR O-ADR
, O-ADR O-ADR
lasted O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
1 O-ADR O-ADR
minute O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
had O-ADR O-ADR
mild O-ADR O-ADR
or O-ADR O-ADR
no O-ADR O-ADR
impact O-ADR O-ADR
( O-ADR O-ADR
scores O-ADR O-ADR
0 O-ADR O-ADR
to O-ADR O-ADR
3 O-ADR O-ADR
out O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
maximum O-ADR O-ADR
score O-ADR O-ADR
of O-ADR O-ADR
10 O-ADR O-ADR
) O-ADR O-ADR
on O-ADR O-ADR
daily O-ADR O-ADR
activities O-ADR O-ADR
as O-ADR O-ADR
captured O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
VSAQ O-ADR O-ADR
- O-ADR O-ADR
ALK O-ADR O-ADR
questionnaire O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
Hypokalemia O-ADR O-ADR
and O-ADR O-ADR
Hyperglycemia O-ADR O-ADR
Beta2 O-ADR O-ADR
- O-ADR O-ADR
agonist O-ADR O-ADR
medications O-ADR O-ADR
may O-ADR O-ADR
produce O-ADR O-ADR
significant O-ADR O-ADR
hypokalemia B-ADR B-ADR
in O-ADR O-ADR
some O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
possibly O-ADR O-ADR
through O-ADR O-ADR
intracellular O-ADR O-ADR
shunting O-ADR O-ADR
, O-ADR O-ADR
which O-ADR O-ADR
has O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
to O-ADR O-ADR
produce O-ADR O-ADR
adverse B-ADR O-ADR
cardiovascular I-ADR O-ADR
effects I-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Pharmacology O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Twenty O-ADR O-ADR
percent O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
patients O-ADR O-ADR
experienced O-ADR O-ADR
an O-ADR O-ADR
increase B-ADR B-ADR
in I-ADR I-ADR
either I-ADR I-ADR
ALT I-ADR I-ADR
. O-ADR O-ADR
Other O-ADR O-ADR
ocular O-ADR B-ADR
adverse O-ADR I-ADR
reactions O-ADR I-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
included O-ADR O-ADR
reduced B-ADR B-ADR
visual I-ADR I-ADR
acuity I-ADR I-ADR
, O-ADR O-ADR
punctate B-ADR B-ADR
keratitis I-ADR I-ADR
, O-ADR O-ADR
eye B-ADR B-ADR
inflammation I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
iritis B-ADR B-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
Drug O-ADR O-ADR
Induced O-ADR O-ADR
Liver O-ADR O-ADR
Injury O-ADR O-ADR
Hepatic O-ADR B-ADR
effects O-ADR I-ADR
, O-ADR O-ADR
ranging O-ADR O-ADR
from O-ADR O-ADR
mild O-ADR O-ADR
to O-ADR O-ADR
moderate O-ADR O-ADR
elevations B-ADR B-ADR
in I-ADR I-ADR
transaminases I-ADR I-ADR
( O-ADR O-ADR
> O-ADR O-ADR
3 O-ADR O-ADR
times O-ADR O-ADR
the O-ADR O-ADR
upper O-ADR O-ADR
limit O-ADR O-ADR
of O-ADR O-ADR
normal O-ADR O-ADR
) O-ADR O-ADR
to O-ADR O-ADR
rare O-ADR O-ADR
cases O-ADR O-ADR
with O-ADR O-ADR
concomitant O-ADR O-ADR
elevations B-ADR B-ADR
of I-ADR I-ADR
total I-ADR I-ADR
bilirubin I-ADR I-ADR
( O-ADR O-ADR
> O-ADR O-ADR
2 O-ADR O-ADR
times O-ADR O-ADR
the O-ADR O-ADR
upper O-ADR O-ADR
limit O-ADR O-ADR
of O-ADR O-ADR
normal O-ADR O-ADR
) O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
APTIOM O-ADR O-ADR
use O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Bradycardia O-ADR O-ADR
Symptomatic B-ADR B-ADR
bradycardia I-ADR I-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
XALKORI O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
type O-ADR O-ADR
2 O-ADR O-ADR
diabetes O-ADR O-ADR
may O-ADR O-ADR
have O-ADR O-ADR
fatty O-ADR O-ADR
liver O-ADR O-ADR
disease O-ADR O-ADR
, O-ADR O-ADR
which O-ADR O-ADR
may O-ADR O-ADR
cause O-ADR O-ADR
liver O-ADR B-ADR
test O-ADR I-ADR
abnormalities O-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
they O-ADR O-ADR
may O-ADR O-ADR
also O-ADR O-ADR
have O-ADR O-ADR
other O-ADR O-ADR
forms O-ADR O-ADR
of O-ADR O-ADR
liver O-ADR O-ADR
disease O-ADR O-ADR
, O-ADR O-ADR
many O-ADR O-ADR
of O-ADR O-ADR
which O-ADR O-ADR
can O-ADR O-ADR
be O-ADR O-ADR
treated O-ADR O-ADR
or O-ADR O-ADR
managed O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
40 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
TECFIDERA O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
experienced O-ADR O-ADR
flushing B-ADR B-ADR
. O-ADR O-ADR
Cases O-ADR O-ADR
of O-ADR O-ADR
progressive B-ADR B-ADR
multifocal I-ADR I-ADR
leukoencephalopathy I-ADR I-ADR
( O-ADR O-ADR
PML B-ADR B-ADR
) O-ADR O-ADR
have O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
IMBRUVICA O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Second B-ADR B-ADR
Primary I-ADR I-ADR
Malignancies I-ADR I-ADR
: O-ADR O-ADR
Other O-ADR O-ADR
malignancies B-ADR B-ADR
have O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
skin B-ADR B-ADR
cancers I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
other O-ADR O-ADR
carcinomas B-ADR B-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Therefore O-ADR O-ADR
, O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
higher O-ADR O-ADR
than O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
doses O-ADR O-ADR
or O-ADR O-ADR
more O-ADR O-ADR
frequent O-ADR O-ADR
dosing O-ADR O-ADR
of O-ADR O-ADR
NULOJIX O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
recommended O-ADR O-ADR
. O-ADR O-ADR
Across O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
program O-ADR O-ADR
, O-ADR O-ADR
serious O-ADR O-ADR
anaphylactic B-ADR B-ADR
reactions I-ADR I-ADR
and O-ADR O-ADR
severe O-ADR O-ADR
cutaneous B-ADR B-ADR
adverse I-ADR I-ADR
reactions I-ADR I-ADR
and O-ADR O-ADR
angioedema B-ADR B-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
comparator O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
FARXIGA O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Comparison O-ADR O-ADR
of O-ADR O-ADR
Gender O-ADR O-ADR
, O-ADR O-ADR
Age O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
Race O-ADR O-ADR
The O-ADR O-ADR
overall O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
profile O-ADR O-ADR
of O-ADR O-ADR
POTIGA O-ADR O-ADR
was O-ADR O-ADR
similar O-ADR O-ADR
for O-ADR O-ADR
females O-ADR O-ADR
and O-ADR O-ADR
males O-ADR O-ADR
. O-ADR O-ADR
Discontinue O-ADR O-ADR
COMETRIQ O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
develop O-ADR O-ADR
RPLS O-ADR O-ADR
. O-ADR O-ADR
YERVOY O-ADR O-ADR
can O-ADR O-ADR
result O-ADR O-ADR
in O-ADR O-ADR
severe O-ADR O-ADR
and O-ADR O-ADR
fatal B-ADR B-ADR
immune B-ADR B-ADR
- O-ADR O-ADR
mediated O-ADR O-ADR
adverse I-ADR I-ADR
reactions I-ADR I-ADR
due O-ADR O-ADR
to O-ADR O-ADR
T O-ADR O-ADR
- O-ADR O-ADR
cell O-ADR O-ADR
activation O-ADR O-ADR
and O-ADR O-ADR
proliferation O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
Nutritional O-ADR O-ADR
Management O-ADR O-ADR
: O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
initial O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
NAGS O-ADR O-ADR
deficiency O-ADR O-ADR
, O-ADR O-ADR
protein O-ADR O-ADR
restriction O-ADR O-ADR
is O-ADR O-ADR
recommended O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
B O-ADR O-ADR
) O-ADR O-ADR
SPINAL O-ADR O-ADR
/ O-ADR O-ADR
EPIDURAL O-ADR O-ADR
HEMATOMAspinal O-ADR B-ADR
hematomas B-ADR I-ADR
may O-ADR O-ADR
occur O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
PRADAXA O-ADR O-ADR
who O-ADR O-ADR
are O-ADR O-ADR
receiving O-ADR O-ADR
neuraxial O-ADR O-ADR
anesthesia O-ADR O-ADR
or O-ADR O-ADR
undergoing O-ADR O-ADR
spinal O-ADR O-ADR
puncture O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
reported O-ADR O-ADR
most O-ADR O-ADR
frequently O-ADR O-ADR
as O-ADR O-ADR
the O-ADR O-ADR
reason O-ADR O-ADR
for O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
included O-ADR O-ADR
anemia B-ADR B-ADR
, O-ADR O-ADR
febrile B-ADR B-ADR
neutropenia I-ADR I-ADR
, O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
multi B-ADR B-ADR
- O-ADR O-ADR
organ O-ADR O-ADR
failure I-ADR I-ADR
. O-ADR O-ADR
Women O-ADR O-ADR
with O-ADR O-ADR
uncontrolled O-ADR O-ADR
hypertension O-ADR O-ADR
or O-ADR O-ADR
hypertension O-ADR O-ADR
with O-ADR O-ADR
vascular O-ADR O-ADR
disease O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
use O-ADR O-ADR
COCs O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
discussed O-ADR O-ADR
in O-ADR O-ADR
detail O-ADR O-ADR
in O-ADR O-ADR
other O-ADR O-ADR
sections O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
labeling O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Neutropenia B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
replicate O-ADR O-ADR
12 O-ADR O-ADR
- O-ADR O-ADR
month O-ADR O-ADR
trials O-ADR O-ADR
in O-ADR O-ADR
3 O-ADR O-ADR
, O-ADR O-ADR
255 O-ADR O-ADR
subjects O-ADR O-ADR
with O-ADR O-ADR
COPD O-ADR O-ADR
who O-ADR O-ADR
had O-ADR O-ADR
experienced O-ADR O-ADR
a O-ADR O-ADR
COPD O-ADR O-ADR
exacerbation O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
previous O-ADR O-ADR
year O-ADR O-ADR
, O-ADR O-ADR
there O-ADR O-ADR
was O-ADR O-ADR
a O-ADR O-ADR
higher O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
pneumonia B-ADR B-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
subjects O-ADR O-ADR
receiving O-ADR O-ADR
fluticasone O-ADR O-ADR
furoate O-ADR O-ADR
/ O-ADR O-ADR
vilanterol O-ADR O-ADR
50 O-ADR O-ADR
mcg O-ADR O-ADR
/ O-ADR O-ADR
25 O-ADR O-ADR
mcg O-ADR O-ADR
: O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
48 O-ADR O-ADR
of O-ADR O-ADR
820 O-ADR O-ADR
subjects O-ADR O-ADR
) O-ADR O-ADR
; O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
100 O-ADR O-ADR
/ O-ADR O-ADR
25 O-ADR O-ADR
: O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
51 O-ADR O-ADR
of O-ADR O-ADR
806 O-ADR O-ADR
subjects O-ADR O-ADR
) O-ADR O-ADR
; O-ADR O-ADR
or O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
200 O-ADR O-ADR
/ O-ADR O-ADR
25 O-ADR O-ADR
: O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
55 O-ADR O-ADR
of O-ADR O-ADR
811 O-ADR O-ADR
subjects O-ADR O-ADR
) O-ADR O-ADR
than O-ADR O-ADR
in O-ADR O-ADR
subjects O-ADR O-ADR
receiving O-ADR O-ADR
vilanterol O-ADR O-ADR
25 O-ADR O-ADR
mcg O-ADR O-ADR
: O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
27 O-ADR O-ADR
of O-ADR O-ADR
818 O-ADR O-ADR
subjects O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
of O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
Moderate O-ADR O-ADR
IntensityIntensities O-ADR O-ADR
are O-ADR O-ADR
defined O-ADR O-ADR
as O-ADR O-ADR
follows O-ADR O-ADR
: O-ADR O-ADR
Moderate O-ADR O-ADR
( O-ADR O-ADR
discomfort O-ADR O-ADR
enough O-ADR O-ADR
to O-ADR O-ADR
cause O-ADR O-ADR
interference O-ADR O-ADR
with O-ADR O-ADR
usual O-ADR O-ADR
activity O-ADR O-ADR
) O-ADR O-ADR
; O-ADR O-ADR
Severe O-ADR O-ADR
( O-ADR O-ADR
incapacitating O-ADR O-ADR
with O-ADR O-ADR
inability O-ADR O-ADR
to O-ADR O-ADR
work O-ADR O-ADR
or O-ADR O-ADR
do O-ADR O-ADR
usual O-ADR O-ADR
activity O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Errors O-ADR O-ADR
may O-ADR O-ADR
also O-ADR O-ADR
occur O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
motion O-ADR O-ADR
artifacts O-ADR O-ADR
that O-ADR O-ADR
result O-ADR O-ADR
in O-ADR O-ADR
image O-ADR O-ADR
distortion O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
addition O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
observed O-ADR O-ADR
for O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
adrenal O-ADR O-ADR
insufficiency O-ADR O-ADR
, O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
fatigue O-ADR O-ADR
, O-ADR O-ADR
lassitude O-ADR O-ADR
, O-ADR O-ADR
weakness O-ADR O-ADR
, O-ADR O-ADR
nausea O-ADR O-ADR
and O-ADR O-ADR
vomiting O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
hypotension O-ADR O-ADR
. O-ADR O-ADR
c O-ADR O-ADR
Includes O-ADR O-ADR
: O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
penile B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
discomfort I-ADR I-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Tumor O-ADR O-ADR
Lysis O-ADR O-ADR
Syndrome O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
rapidly O-ADR O-ADR
proliferating O-ADR O-ADR
tumor O-ADR O-ADR
and O-ADR O-ADR
high O-ADR O-ADR
tumor O-ADR O-ADR
burden O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
at O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
tumor B-ADR B-ADR
lysis I-ADR I-ADR
syndrome I-ADR I-ADR
. O-ADR O-ADR
Discontinue O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
if O-ADR O-ADR
such O-ADR O-ADR
reactions O-ADR O-ADR
occur O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
treatment O-ADR O-ADR
emergent O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
2 O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
AMPYRA O-ADR O-ADR
and O-ADR O-ADR
that O-ADR O-ADR
led O-ADR O-ADR
to O-ADR O-ADR
discontinuation O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
placebo O-ADR O-ADR
were O-ADR O-ADR
headache B-ADR B-ADR
( O-ADR O-ADR
AMPYRA O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
balance B-ADR B-ADR
disorder I-ADR I-ADR
( O-ADR O-ADR
AMPYRA O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
dizziness B-ADR B-ADR
( O-ADR O-ADR
AMPYRA O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
confusional B-ADR B-ADR
state I-ADR I-ADR
( O-ADR O-ADR
AMPYRA O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
described O-ADR O-ADR
in O-ADR O-ADR
greater O-ADR O-ADR
detail O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
section O-ADR O-ADR
* O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
Reactions I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Clostridium B-ADR B-ADR
difficile I-ADR I-ADR
- I-ADR O-ADR
Associated O-ADR O-ADR
diarrhea I-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Direct B-ADR B-ADR
Coombs I-ADR I-ADR
' I-ADR I-ADR
Test I-ADR I-ADR
Seroconversion I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
are O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
rash B-ADR B-ADR
. O-ADR O-ADR
Thirty O-ADR O-ADR
- O-ADR O-ADR
nine O-ADR O-ADR
subjects O-ADR O-ADR
( O-ADR O-ADR
35 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
had O-ADR O-ADR
dose O-ADR O-ADR
interruptions O-ADR O-ADR
and O-ADR O-ADR
sixteen O-ADR O-ADR
subjects O-ADR O-ADR
( O-ADR O-ADR
15 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
had O-ADR O-ADR
dose O-ADR O-ADR
reductions O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
or O-ADR O-ADR
laboratory O-ADR O-ADR
abnormalities O-ADR O-ADR
. O-ADR O-ADR
Across O-ADR O-ADR
these O-ADR O-ADR
13 O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
2360 O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
treated O-ADR O-ADR
once O-ADR O-ADR
daily O-ADR O-ADR
with O-ADR O-ADR
FARXIGA O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
for O-ADR O-ADR
a O-ADR O-ADR
mean O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
exposure O-ADR O-ADR
of O-ADR O-ADR
22 O-ADR O-ADR
weeks O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
these O-ADR O-ADR
reasons O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
dulaglutide O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
antibodies O-ADR O-ADR
of O-ADR O-ADR
other O-ADR O-ADR
products O-ADR O-ADR
. O-ADR O-ADR
nasopharyngitis B-ADR B-ADR
, O-ADR O-ADR
laryngitis B-ADR B-ADR
, O-ADR O-ADR
viral B-ADR B-ADR
infection I-ADR I-ADR
) O-ADR O-ADR
in O-ADR O-ADR
20 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
CIMZIA O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
13 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
urinary B-ADR B-ADR
tract I-ADR I-ADR
infections I-ADR I-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
and O-ADR O-ADR
laboratory O-ADR O-ADR
abnormalities O-ADR O-ADR
which O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
COMETRIQ O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
occurring O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
COMETRIQ O-ADR O-ADR
arm O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
between O-ADR O-ADR
- O-ADR O-ADR
arm O-ADR O-ADR
difference O-ADR O-ADR
of O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
included O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
order O-ADR O-ADR
of O-ADR O-ADR
decreasing O-ADR O-ADR
frequency O-ADR O-ADR
; O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
PPES B-ADR B-ADR
, O-ADR O-ADR
lymphopenia B-ADR B-ADR
, O-ADR O-ADR
hypocalcemia B-ADR B-ADR
, O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
hypertension B-ADR B-ADR
, O-ADR O-ADR
asthenia B-ADR B-ADR
, O-ADR O-ADR
increased B-ADR B-ADR
ALT I-ADR I-ADR
, O-ADR O-ADR
decreased B-ADR B-ADR
weight I-ADR I-ADR
, O-ADR O-ADR
stomatitis B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
decreased B-ADR B-ADR
appetite I-ADR I-ADR
( O-ADR O-ADR
see O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Suicidal O-ADR O-ADR
Behavior O-ADR O-ADR
and O-ADR O-ADR
Ideation O-ADR O-ADR
Antiepileptic O-ADR O-ADR
drugs O-ADR O-ADR
( O-ADR O-ADR
AEDs O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
APTIOM O-ADR O-ADR
, O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
suicidal B-ADR B-ADR
thoughts I-ADR I-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
taking O-ADR O-ADR
these O-ADR O-ADR
drugs O-ADR O-ADR
for O-ADR O-ADR
any O-ADR O-ADR
indication O-ADR O-ADR
. O-ADR O-ADR
Therefore O-ADR O-ADR
, O-ADR O-ADR
remove O-ADR O-ADR
Qutenza O-ADR O-ADR
patches O-ADR O-ADR
gently O-ADR O-ADR
and O-ADR O-ADR
slowly O-ADR O-ADR
by O-ADR O-ADR
rolling O-ADR O-ADR
the O-ADR O-ADR
adhesive O-ADR O-ADR
side O-ADR O-ADR
inward O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Of O-ADR O-ADR
this O-ADR O-ADR
total O-ADR O-ADR
, O-ADR O-ADR
782 O-ADR O-ADR
received O-ADR O-ADR
Toviaz O-ADR O-ADR
4 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
day O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
785 O-ADR O-ADR
received O-ADR O-ADR
Toviaz O-ADR O-ADR
8 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
day O-ADR O-ADR
in O-ADR O-ADR
Phase O-ADR O-ADR
2 O-ADR O-ADR
or O-ADR O-ADR
3 O-ADR O-ADR
studies O-ADR O-ADR
with O-ADR O-ADR
treatment O-ADR O-ADR
periods O-ADR O-ADR
of O-ADR O-ADR
8 O-ADR O-ADR
or O-ADR O-ADR
12 O-ADR O-ADR
weeks O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
skin O-ADR O-ADR
not O-ADR O-ADR
intended O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
treated O-ADR O-ADR
comes O-ADR O-ADR
into O-ADR O-ADR
contact O-ADR O-ADR
with O-ADR O-ADR
Qutenza O-ADR O-ADR
, O-ADR O-ADR
apply O-ADR O-ADR
Cleansing O-ADR O-ADR
Gel O-ADR O-ADR
and O-ADR O-ADR
then O-ADR O-ADR
wipe O-ADR O-ADR
off O-ADR O-ADR
with O-ADR O-ADR
dry O-ADR O-ADR
gauze O-ADR O-ADR
. O-ADR O-ADR
Among O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
Qutenza O-ADR O-ADR
, O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
discontinued O-ADR O-ADR
prematurely O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
an O-ADR O-ADR
adverse O-ADR O-ADR
event O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
Experience O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
drug O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
drug O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
rate O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
If O-ADR O-ADR
the O-ADR O-ADR
following O-ADR O-ADR
occur O-ADR O-ADR
, O-ADR O-ADR
discontinue O-ADR O-ADR
ERWINAZE O-ADR O-ADR
: O-ADR O-ADR
Serious O-ADR O-ADR
hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
anaphylaxis B-ADR B-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
Severe O-ADR O-ADR
or O-ADR O-ADR
pancreatitis B-ADR B-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Glucose B-ADR B-ADR
intolerance I-ADR I-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
and O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
some O-ADR O-ADR
cases O-ADR O-ADR
, O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
irreversible O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
persistent O-ADR O-ADR
hypertension O-ADR O-ADR
despite O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
hypertensive O-ADR O-ADR
medications O-ADR O-ADR
, O-ADR O-ADR
reduce O-ADR O-ADR
the O-ADR O-ADR
INLYTA O-ADR O-ADR
dose O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
diagnosis O-ADR O-ADR
of O-ADR O-ADR
probable O-ADR O-ADR
PML B-ADR O-ADR
was O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
MRI O-ADR O-ADR
findings O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
detection O-ADR O-ADR
of O-ADR O-ADR
JCV B-ADR O-ADR
DNA I-ADR O-ADR
in I-ADR O-ADR
the I-ADR O-ADR
CSF I-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
absence O-ADR O-ADR
of O-ADR O-ADR
clinical O-ADR O-ADR
signs O-ADR O-ADR
or O-ADR O-ADR
symptoms O-ADR O-ADR
specific O-ADR O-ADR
to O-ADR O-ADR
PML B-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Pulmonary B-ADR B-ADR
Toxicity I-ADR I-ADR
: O-ADR O-ADR
including O-ADR O-ADR
Acute B-ADR B-ADR
Respiratory I-ADR I-ADR
Distress I-ADR I-ADR
Syndrome I-ADR I-ADR
, O-ADR O-ADR
acute B-ADR B-ADR
respiratory I-ADR I-ADR
failure I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
acute B-ADR B-ADR
diffuse I-ADR I-ADR
infiltrative I-ADR I-ADR
pulmonary I-ADR I-ADR
disease I-ADR I-ADR
: O-ADR O-ADR
Withhold O-ADR O-ADR
Kyprolis O-ADR O-ADR
and O-ADR O-ADR
evaluate O-ADR O-ADR
promptly O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Pulmonary B-ADR B-ADR
Hypertension I-ADR I-ADR
: O-ADR O-ADR
Withhold O-ADR O-ADR
Kyprolis O-ADR O-ADR
and O-ADR O-ADR
evaluate O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Dyspnea B-ADR B-ADR
: O-ADR O-ADR
For O-ADR O-ADR
severe O-ADR O-ADR
or O-ADR O-ADR
life O-ADR O-ADR
threatening O-ADR O-ADR
dyspnea O-ADR O-ADR
, O-ADR O-ADR
withhold O-ADR O-ADR
Kyprolis O-ADR O-ADR
and O-ADR O-ADR
evaluate O-ADR O-ADR
. O-ADR O-ADR
breathing B-ADR B-ADR
difficulties I-ADR I-ADR
can O-ADR O-ADR
be O-ADR O-ADR
life O-ADR O-ADR
threatening O-ADR O-ADR
and O-ADR O-ADR
there O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reports O-ADR O-ADR
of O-ADR O-ADR
death B-ADR B-ADR
related O-ADR O-ADR
to O-ADR O-ADR
spread B-ADR B-ADR
of I-ADR I-ADR
toxin I-ADR I-ADR
effects I-ADR I-ADR
. O-ADR O-ADR
For O-ADR O-ADR
this O-ADR O-ADR
same O-ADR O-ADR
group O-ADR O-ADR
of O-ADR O-ADR
AFINITOR O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
females O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
following O-ADR O-ADR
menstrual B-ADR B-ADR
abnormalities I-ADR I-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
: O-ADR O-ADR
dysmenorrhea B-ADR B-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
menorrhagia B-ADR B-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
metrorrhagia B-ADR B-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
unspecified B-ADR O-ADR
menstrual I-ADR B-ADR
irregularity I-ADR I-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Immune O-ADR O-ADR
Reconstitution O-ADR O-ADR
Syndrome O-ADR O-ADR
Immune B-ADR B-ADR
reconstitution I-ADR I-ADR
syndrome I-ADR I-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
combination O-ADR O-ADR
antiretroviral O-ADR O-ADR
therapy O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
TIVICAY O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Pulmonary O-ADR O-ADR
Toxicity O-ADR O-ADR
Acute B-ADR B-ADR
Respiratory I-ADR I-ADR
Distress I-ADR I-ADR
Syndrome I-ADR I-ADR
( O-ADR O-ADR
ARDS B-ADR B-ADR
) O-ADR O-ADR
, O-ADR O-ADR
acute B-ADR B-ADR
respiratory I-ADR I-ADR
failure I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
acute B-ADR B-ADR
diffuse I-ADR I-ADR
infiltrative I-ADR I-ADR
pulmonary I-ADR I-ADR
disease I-ADR I-ADR
such O-ADR O-ADR
as O-ADR O-ADR
pneumonitis B-ADR B-ADR
and O-ADR O-ADR
interstitial B-ADR B-ADR
lung I-ADR I-ADR
disease I-ADR I-ADR
have O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
Kyprolis O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
this O-ADR O-ADR
product O-ADR O-ADR
is O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
given O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
patient O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
cephalosporin O-ADR O-ADR
, O-ADR O-ADR
penicillin O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
beta O-ADR O-ADR
- O-ADR O-ADR
lactam O-ADR O-ADR
allergy O-ADR O-ADR
, O-ADR O-ADR
exercise O-ADR O-ADR
caution O-ADR O-ADR
because O-ADR O-ADR
cross O-ADR O-ADR
sensitivity O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
established O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
13 O-ADR O-ADR
Posterior O-ADR O-ADR
Reversible O-ADR O-ADR
Encephalopathy O-ADR O-ADR
Syndrome O-ADR O-ADR
( O-ADR O-ADR
PRES O-ADR O-ADR
) O-ADR O-ADR
Cases O-ADR O-ADR
of O-ADR O-ADR
PRES B-ADR B-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
Kyprolis O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
data O-ADR O-ADR
described O-ADR O-ADR
below O-ADR O-ADR
are O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
confirmatory O-ADR O-ADR
6 O-ADR O-ADR
- O-ADR O-ADR
and O-ADR O-ADR
12 O-ADR O-ADR
- O-ADR O-ADR
month O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
B O-ADR O-ADR
) O-ADR O-ADR
SPINAL O-ADR O-ADR
/ O-ADR O-ADR
EPIDURAL O-ADR O-ADR
HEMATOMA O-ADR B-ADR
spinal B-ADR B-ADR
hematomas I-ADR I-ADR
may O-ADR O-ADR
occur O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
ELIQUIS O-ADR O-ADR
who O-ADR O-ADR
are O-ADR O-ADR
receiving O-ADR O-ADR
neuraxial O-ADR O-ADR
anesthesia O-ADR O-ADR
or O-ADR O-ADR
undergoing O-ADR O-ADR
spinal O-ADR O-ADR
puncture O-ADR O-ADR
. O-ADR O-ADR
Data O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
are O-ADR O-ADR
for O-ADR O-ADR
all O-ADR O-ADR
AEs O-ADR O-ADR
for O-ADR O-ADR
all O-ADR O-ADR
CAPS O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
canakinumab O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
Study O-ADR O-ADR
2 O-ADR O-ADR
only O-ADR O-ADR
VORAXAZE O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
collected O-ADR O-ADR
and O-ADR O-ADR
severity O-ADR O-ADR
was O-ADR O-ADR
graded O-ADR O-ADR
according O-ADR O-ADR
to O-ADR O-ADR
NCI O-ADR O-ADR
CTCAE O-ADR O-ADR
version O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
significance O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
findings O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
effect O-ADR O-ADR
of O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
Prolia O-ADR O-ADR
are O-ADR O-ADR
unknown O-ADR O-ADR
. O-ADR O-ADR
Localized O-ADR B-ADR
and O-ADR I-ADR
systemic O-ADR I-ADR
infections O-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
pneumonia B-ADR B-ADR
, O-ADR O-ADR
mycobacterial B-ADR B-ADR
infections I-ADR I-ADR
, O-ADR O-ADR
other O-ADR O-ADR
bacterial B-ADR B-ADR
infections I-ADR I-ADR
, O-ADR O-ADR
invasive B-ADR B-ADR
fungal I-ADR I-ADR
infections I-ADR I-ADR
, O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
aspergillosis B-ADR B-ADR
, O-ADR O-ADR
candidiasis B-ADR B-ADR
, O-ADR O-ADR
or O-ADR O-ADR
pneumocystis B-ADR B-ADR
jiroveci I-ADR I-ADR
pneumonia I-ADR I-ADR
( O-ADR O-ADR
PJP B-ADR B-ADR
) O-ADR O-ADR
and O-ADR O-ADR
viral B-ADR B-ADR
infections I-ADR I-ADR
including O-ADR O-ADR
reactivation B-ADR B-ADR
of I-ADR I-ADR
hepatitis I-ADR I-ADR
B I-ADR I-ADR
virus I-ADR I-ADR
have O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
taking O-ADR O-ADR
AFINITOR O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Postmarketing O-ADR O-ADR
Experience O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
identified O-ADR O-ADR
during O-ADR O-ADR
post O-ADR O-ADR
approval O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
Picato O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
( O-ADR O-ADR
ingenol O-ADR O-ADR
mebutate O-ADR O-ADR
) O-ADR O-ADR
gel O-ADR O-ADR
, O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
015 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
05 O-ADR O-ADR
% O-ADR O-ADR
: O-ADR O-ADR
hypersensitivity B-ADR B-ADR
, O-ADR O-ADR
allergic B-ADR B-ADR
contact I-ADR I-ADR
dermatitis I-ADR I-ADR
, O-ADR O-ADR
herpes B-ADR B-ADR
zoster I-ADR I-ADR
, O-ADR O-ADR
chemical B-ADR B-ADR
conjunctivitis I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
corneal B-ADR B-ADR
burn I-ADR I-ADR
. O-ADR O-ADR
Advise O-ADR O-ADR
patients O-ADR O-ADR
to O-ADR O-ADR
report O-ADR O-ADR
promptly O-ADR O-ADR
any O-ADR O-ADR
new O-ADR O-ADR
or O-ADR O-ADR
worsening O-ADR O-ADR
respiratory O-ADR O-ADR
symptoms O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Acute B-ADR B-ADR
hypersensitivity I-ADR I-ADR
reactions I-ADR I-ADR
( O-ADR O-ADR
angioedema B-ADR B-ADR
, O-ADR O-ADR
dyspnea B-ADR B-ADR
, O-ADR O-ADR
pruritus B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
rash B-ADR B-ADR
) O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
immunogenicity O-ADR O-ADR
of O-ADR O-ADR
EYLEA O-ADR O-ADR
was O-ADR O-ADR
evaluated O-ADR O-ADR
in O-ADR O-ADR
serum O-ADR O-ADR
samples O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
causal O-ADR O-ADR
relationship O-ADR O-ADR
with O-ADR O-ADR
ULORIC O-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
established O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Postmarketing O-ADR O-ADR
Experience O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
additional O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
postmarketing O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
EOVIST O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
58 O-ADR O-ADR
patient O-ADR O-ADR
samples O-ADR O-ADR
that O-ADR O-ADR
were O-ADR O-ADR
either O-ADR O-ADR
transiently O-ADR O-ADR
or O-ADR O-ADR
persistently O-ADR O-ADR
positive O-ADR O-ADR
for O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
brentuximab O-ADR O-ADR
vedotin O-ADR O-ADR
antibodies O-ADR O-ADR
were O-ADR O-ADR
tested O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
presence O-ADR O-ADR
of O-ADR O-ADR
neutralizing O-ADR O-ADR
antibodies O-ADR O-ADR
. O-ADR O-ADR
Should O-ADR O-ADR
any O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
occur O-ADR O-ADR
or O-ADR O-ADR
be O-ADR O-ADR
suspected O-ADR O-ADR
, O-ADR O-ADR
DUAVEE O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
discontinued O-ADR O-ADR
immediately O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
risks O-ADR O-ADR
and O-ADR O-ADR
benefits O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
initiating O-ADR O-ADR
therapy O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
with O-ADR O-ADR
chronic O-ADR O-ADR
or O-ADR O-ADR
recurrent O-ADR O-ADR
infection O-ADR O-ADR
* O-ADR O-ADR
who O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
exposed O-ADR O-ADR
to O-ADR O-ADR
tuberculosis O-ADR O-ADR
* O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
an O-ADR O-ADR
opportunistic O-ADR O-ADR
infection O-ADR O-ADR
* O-ADR O-ADR
who O-ADR O-ADR
have O-ADR O-ADR
resided O-ADR O-ADR
or O-ADR O-ADR
traveled O-ADR O-ADR
in O-ADR O-ADR
areas O-ADR O-ADR
of O-ADR O-ADR
endemic O-ADR O-ADR
tuberculosis O-ADR O-ADR
or O-ADR O-ADR
endemic O-ADR O-ADR
mycoses O-ADR O-ADR
, O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
histoplasmosis O-ADR O-ADR
, O-ADR O-ADR
coccidioidomycosis O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
blastomycosis O-ADR O-ADR
* O-ADR O-ADR
with O-ADR O-ADR
underlying O-ADR O-ADR
conditions O-ADR O-ADR
that O-ADR O-ADR
may O-ADR O-ADR
predispose O-ADR O-ADR
them O-ADR O-ADR
to O-ADR O-ADR
infection O-ADR O-ADR
Tuberculosis O-ADR O-ADR
Cases O-ADR O-ADR
of O-ADR O-ADR
reactivation B-ADR B-ADR
of I-ADR I-ADR
tuberculosis I-ADR I-ADR
or O-ADR O-ADR
new O-ADR B-ADR
tuberculosis B-ADR I-ADR
infections I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
CIMZIA O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
have O-ADR O-ADR
previously O-ADR O-ADR
received O-ADR O-ADR
treatment O-ADR O-ADR
for O-ADR O-ADR
latent O-ADR O-ADR
or O-ADR O-ADR
active O-ADR O-ADR
tuberculosis O-ADR O-ADR
. O-ADR O-ADR
CDAD O-ADR O-ADR
must O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
in O-ADR O-ADR
all O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
present O-ADR O-ADR
with O-ADR O-ADR
diarrhea O-ADR O-ADR
following O-ADR O-ADR
antibacterial O-ADR O-ADR
use O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Anemia O-ADR O-ADR
( O-ADR O-ADR
Use O-ADR O-ADR
with O-ADR O-ADR
Ribavirin O-ADR O-ADR
and O-ADR O-ADR
Peginterferon O-ADR O-ADR
Alfa O-ADR O-ADR
) O-ADR O-ADR
Anemia B-ADR B-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
peginterferon O-ADR O-ADR
alfa O-ADR O-ADR
and O-ADR O-ADR
ribavirin O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
addition O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
presented O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
dizziness B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
ULORIC O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
subjects O-ADR O-ADR
although O-ADR O-ADR
not O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
rate O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
values O-ADR O-ADR
did O-ADR O-ADR
not O-ADR O-ADR
exceed O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
3 O-ADR O-ADR
times O-ADR O-ADR
the O-ADR O-ADR
baseline O-ADR O-ADR
values O-ADR O-ADR
and O-ADR O-ADR
returned O-ADR O-ADR
to O-ADR O-ADR
baseline O-ADR O-ADR
within O-ADR O-ADR
1 O-ADR O-ADR
to O-ADR O-ADR
4 O-ADR O-ADR
days O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
portal B-ADR B-ADR
venous I-ADR I-ADR
thrombosis I-ADR I-ADR
was O-ADR O-ADR
increased O-ADR O-ADR
in O-ADR O-ADR
thrombocytopenic O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
chronic O-ADR O-ADR
liver O-ADR O-ADR
disease O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
75 O-ADR O-ADR
mg O-ADR O-ADR
of O-ADR O-ADR
PROMACTA O-ADR O-ADR
once O-ADR O-ADR
daily O-ADR O-ADR
for O-ADR O-ADR
2 O-ADR O-ADR
weeks O-ADR O-ADR
in O-ADR O-ADR
preparation O-ADR O-ADR
for O-ADR O-ADR
invasive O-ADR O-ADR
procedures O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
resulting O-ADR O-ADR
in O-ADR O-ADR
permanent O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
study O-ADR O-ADR
medication O-ADR O-ADR
in O-ADR O-ADR
Trial O-ADR O-ADR
1 O-ADR O-ADR
was O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TAFINLAR O-ADR O-ADR
and O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
dacarbazine O-ADR O-ADR
. O-ADR O-ADR
Serious O-ADR O-ADR
infections B-ADR B-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
pneumonia B-ADR B-ADR
, O-ADR O-ADR
varicella B-ADR B-ADR
, O-ADR O-ADR
gastroenteritis B-ADR B-ADR
, O-ADR O-ADR
measles B-ADR B-ADR
, O-ADR O-ADR
sepsis B-ADR B-ADR
, O-ADR O-ADR
otitis B-ADR B-ADR
media I-ADR I-ADR
, O-ADR O-ADR
sinusitis B-ADR B-ADR
, O-ADR O-ADR
adenovirus B-ADR B-ADR
, O-ADR O-ADR
lymph B-ADR B-ADR
node I-ADR I-ADR
abscess I-ADR I-ADR
, O-ADR O-ADR
pharyngitis B-ADR B-ADR
) O-ADR O-ADR
were O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
approximately O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
to O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
02 O-ADR O-ADR
to O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
17 O-ADR O-ADR
per O-ADR O-ADR
100 O-ADR O-ADR
patient O-ADR O-ADR
- O-ADR O-ADR
days O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
ILARIS O-ADR O-ADR
in O-ADR O-ADR
both O-ADR O-ADR
studies O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Children O-ADR O-ADR
ULESFIA O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
Lotion O-ADR O-ADR
should O-ADR O-ADR
only O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
on O-ADR O-ADR
children O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
months O-ADR O-ADR
of O-ADR O-ADR
age O-ADR O-ADR
and O-ADR O-ADR
older O-ADR O-ADR
) O-ADR O-ADR
under O-ADR O-ADR
the O-ADR O-ADR
direct O-ADR O-ADR
supervision O-ADR O-ADR
of O-ADR O-ADR
an O-ADR O-ADR
adult O-ADR O-ADR
. O-ADR O-ADR
Common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
in O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
MDD O-ADR O-ADR
studies O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
commonly O-ADR O-ADR
observed O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
in O-ADR O-ADR
PRISTIQ O-ADR O-ADR
treated O-ADR O-ADR
MDD O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
pre O-ADR O-ADR
- O-ADR O-ADR
marketing O-ADR O-ADR
pooled O-ADR O-ADR
8 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
, O-ADR O-ADR
fixed O-ADR O-ADR
- O-ADR O-ADR
dose O-ADR O-ADR
studies O-ADR O-ADR
( O-ADR O-ADR
incidence O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
twice O-ADR O-ADR
the O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
placebo O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
50 O-ADR O-ADR
or O-ADR O-ADR
100 O-ADR O-ADR
mg O-ADR O-ADR
dose O-ADR O-ADR
groups O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
: O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
dizziness B-ADR B-ADR
, O-ADR O-ADR
insomnia B-ADR B-ADR
, O-ADR O-ADR
hyperhidrosis B-ADR B-ADR
, O-ADR O-ADR
constipation B-ADR B-ADR
, O-ADR O-ADR
somnolence B-ADR B-ADR
, O-ADR O-ADR
decreased B-ADR B-ADR
appetite I-ADR I-ADR
, O-ADR O-ADR
anxiety B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
specific O-ADR B-ADR
male B-ADR I-ADR
sexual I-ADR I-ADR
function I-ADR I-ADR
disorders I-ADR I-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
DIFICID O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
for O-ADR O-ADR
systemic O-ADR O-ADR
infections O-ADR O-ADR
. O-ADR O-ADR
Opportunistic O-ADR O-ADR
infections O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
pneumocystis O-ADR O-ADR
jiroveci O-ADR O-ADR
pneumonia O-ADR O-ADR
( O-ADR O-ADR
PJP O-ADR O-ADR
) O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
differential O-ADR O-ADR
diagnosis O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Infections O-ADR O-ADR
AFINITOR O-ADR O-ADR
has O-ADR O-ADR
immunosuppressive O-ADR O-ADR
properties O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
predispose O-ADR O-ADR
patients O-ADR O-ADR
to O-ADR O-ADR
protozoal B-ADR B-ADR
infections I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
infections B-ADR B-ADR
with I-ADR I-ADR
opportunistic I-ADR I-ADR
pathogens I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
, O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
, O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
Experience O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
drug O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
drug O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
physician O-ADR O-ADR
responsible O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
maintenance O-ADR O-ADR
therapy O-ADR O-ADR
should O-ADR O-ADR
have O-ADR O-ADR
complete O-ADR O-ADR
information O-ADR O-ADR
requisite O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
follow O-ADR O-ADR
- O-ADR O-ADR
up O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Boxed O-ADR O-ADR
Warning O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
hematomas B-ADR B-ADR
may O-ADR O-ADR
result O-ADR O-ADR
in O-ADR O-ADR
permanent B-ADR B-ADR
paralysis I-ADR I-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Impairment O-ADR O-ADR
in O-ADR O-ADR
Renal O-ADR O-ADR
Function O-ADR O-ADR
JARDIANCE O-ADR O-ADR
increases B-ADR B-ADR
serum I-ADR I-ADR
creatinine I-ADR I-ADR
and O-ADR O-ADR
decreases B-ADR B-ADR
eGFR I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Macular B-ADR B-ADR
edema I-ADR I-ADR
generally O-ADR O-ADR
partially O-ADR O-ADR
or O-ADR O-ADR
completely O-ADR O-ADR
resolved O-ADR O-ADR
with O-ADR O-ADR
or O-ADR O-ADR
without O-ADR O-ADR
treatment O-ADR O-ADR
after O-ADR O-ADR
drug O-ADR O-ADR
discontinuation O-ADR O-ADR
. O-ADR O-ADR
Consider O-ADR O-ADR
whether O-ADR O-ADR
to O-ADR O-ADR
restart O-ADR O-ADR
Kyprolis O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
a O-ADR O-ADR
benefit O-ADR O-ADR
/ O-ADR O-ADR
risk O-ADR O-ADR
assessment O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Observe O-ADR O-ADR
patients O-ADR O-ADR
carefully O-ADR O-ADR
when O-ADR O-ADR
the O-ADR O-ADR
dosage O-ADR O-ADR
of O-ADR O-ADR
NORTHERA O-ADR O-ADR
is O-ADR O-ADR
changed O-ADR O-ADR
or O-ADR O-ADR
when O-ADR O-ADR
concomitant O-ADR O-ADR
levodopa O-ADR O-ADR
is O-ADR O-ADR
reduced O-ADR O-ADR
abruptly O-ADR O-ADR
or O-ADR O-ADR
discontinued O-ADR O-ADR
, O-ADR O-ADR
especially O-ADR O-ADR
if O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
is O-ADR O-ADR
receiving O-ADR O-ADR
neuroleptics O-ADR O-ADR
. O-ADR O-ADR
Periodic O-ADR O-ADR
skin O-ADR O-ADR
examination O-ADR O-ADR
is O-ADR O-ADR
recommended O-ADR O-ADR
for O-ADR O-ADR
all O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
particularly O-ADR O-ADR
those O-ADR O-ADR
with O-ADR O-ADR
risk O-ADR O-ADR
factors O-ADR O-ADR
for O-ADR O-ADR
skin O-ADR O-ADR
cancer O-ADR O-ADR
. O-ADR O-ADR
Other O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
involving O-ADR O-ADR
the O-ADR O-ADR
female O-ADR O-ADR
reproductive O-ADR O-ADR
system O-ADR O-ADR
were O-ADR O-ADR
menorrhagia B-ADR B-ADR
( O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
menstrual B-ADR B-ADR
irregularities I-ADR I-ADR
( O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
vaginal B-ADR B-ADR
hemorrhage I-ADR I-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
management O-ADR O-ADR
of O-ADR O-ADR
this O-ADR O-ADR
syndrome O-ADR O-ADR
should O-ADR O-ADR
include O-ADR O-ADR
: O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
immediate O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
antipsychotic O-ADR O-ADR
drugs O-ADR O-ADR
and O-ADR O-ADR
other O-ADR O-ADR
drugs O-ADR O-ADR
not O-ADR O-ADR
essential O-ADR O-ADR
to O-ADR O-ADR
concurrent O-ADR O-ADR
therapy O-ADR O-ADR
, O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
intensive O-ADR O-ADR
symptomatic O-ADR O-ADR
treatment O-ADR O-ADR
and O-ADR O-ADR
medical O-ADR O-ADR
monitoring O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
any O-ADR O-ADR
concomitant O-ADR O-ADR
serious O-ADR O-ADR
medical O-ADR O-ADR
problems O-ADR O-ADR
for O-ADR O-ADR
which O-ADR O-ADR
specific O-ADR O-ADR
treatments O-ADR O-ADR
are O-ADR O-ADR
available O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Thrombocytopenia B-ADR B-ADR
: O-ADR O-ADR
Monitor O-ADR O-ADR
platelet O-ADR O-ADR
counts O-ADR O-ADR
; O-ADR O-ADR
interrupt O-ADR O-ADR
or O-ADR O-ADR
reduce O-ADR O-ADR
Kyprolis O-ADR O-ADR
dosing O-ADR O-ADR
as O-ADR O-ADR
clinically O-ADR O-ADR
indicated O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
Increases O-ADR O-ADR
in O-ADR O-ADR
Low O-ADR O-ADR
- O-ADR O-ADR
Density O-ADR O-ADR
Lipoprotein O-ADR O-ADR
( O-ADR O-ADR
LDL O-ADR O-ADR
- O-ADR O-ADR
C O-ADR O-ADR
) O-ADR O-ADR
Dose O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
increases B-ADR B-ADR
in I-ADR I-ADR
LDL I-ADR I-ADR
- O-ADR O-ADR
C O-ADR O-ADR
occur O-ADR O-ADR
with O-ADR O-ADR
INVOKANA O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
stated O-ADR O-ADR
frequencies O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
represent O-ADR O-ADR
the O-ADR O-ADR
proportion O-ADR O-ADR
of O-ADR O-ADR
individuals O-ADR O-ADR
who O-ADR O-ADR
experienced O-ADR O-ADR
a O-ADR O-ADR
treatment O-ADR O-ADR
- O-ADR O-ADR
emergent O-ADR O-ADR
adverse O-ADR O-ADR
event O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
type O-ADR O-ADR
listed O-ADR O-ADR
. O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
Besivance O-ADR O-ADR
was O-ADR O-ADR
conjunctival B-ADR B-ADR
redness I-ADR I-ADR
. O-ADR O-ADR
All O-ADR O-ADR
women O-ADR O-ADR
were O-ADR O-ADR
instructed O-ADR O-ADR
to O-ADR O-ADR
take O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
1000 O-ADR O-ADR
mg O-ADR O-ADR
of O-ADR O-ADR
calcium O-ADR O-ADR
and O-ADR O-ADR
400 O-ADR O-ADR
IU O-ADR O-ADR
of O-ADR O-ADR
vitamin O-ADR O-ADR
D O-ADR O-ADR
supplementation O-ADR O-ADR
per O-ADR O-ADR
day O-ADR O-ADR
. O-ADR O-ADR
Pediatric O-ADR O-ADR
Patients O-ADR O-ADR
: O-ADR O-ADR
Data O-ADR O-ADR
from O-ADR O-ADR
the O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trial O-ADR O-ADR
in O-ADR O-ADR
pediatric O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
bipolar O-ADR O-ADR
I O-ADR O-ADR
disorder O-ADR O-ADR
are O-ADR O-ADR
shown O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
Given O-ADR O-ADR
these O-ADR O-ADR
confounders O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
relationship O-ADR O-ADR
between O-ADR O-ADR
atypical O-ADR O-ADR
antipsychotic O-ADR O-ADR
use O-ADR O-ADR
and O-ADR O-ADR
hyperglycemia O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
completely O-ADR O-ADR
understood O-ADR O-ADR
. O-ADR O-ADR
Therefore O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
RANKL O-ADR O-ADR
inhibitor O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
Prolia O-ADR O-ADR
may O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
infection B-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
irritation O-ADR O-ADR
of O-ADR O-ADR
eyes O-ADR O-ADR
or O-ADR O-ADR
airways O-ADR O-ADR
occurs O-ADR O-ADR
, O-ADR O-ADR
remove O-ADR O-ADR
the O-ADR O-ADR
affected O-ADR O-ADR
individual O-ADR O-ADR
from O-ADR O-ADR
the O-ADR O-ADR
vicinity O-ADR O-ADR
of O-ADR O-ADR
Qutenza O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
adverse O-ADR O-ADR
event O-ADR O-ADR
information O-ADR O-ADR
from O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
does O-ADR O-ADR
, O-ADR O-ADR
however O-ADR O-ADR
, O-ADR O-ADR
provide O-ADR O-ADR
a O-ADR O-ADR
basis O-ADR O-ADR
for O-ADR O-ADR
identifying O-ADR O-ADR
the O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
that O-ADR O-ADR
appear O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
related O-ADR O-ADR
to O-ADR O-ADR
drug O-ADR O-ADR
use O-ADR O-ADR
and O-ADR O-ADR
for O-ADR O-ADR
approximating O-ADR O-ADR
rates O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
two O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
1227 O-ADR O-ADR
subjects O-ADR O-ADR
were O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
JUBLIA O-ADR O-ADR
, O-ADR O-ADR
1161 O-ADR O-ADR
for O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
24 O-ADR O-ADR
weeks O-ADR O-ADR
and O-ADR O-ADR
780 O-ADR O-ADR
for O-ADR O-ADR
48 O-ADR O-ADR
weeks O-ADR O-ADR
. O-ADR O-ADR
Ask O-ADR O-ADR
patients O-ADR O-ADR
about O-ADR O-ADR
symptoms O-ADR O-ADR
suggestive O-ADR O-ADR
of O-ADR O-ADR
infusion O-ADR O-ADR
reactions O-ADR O-ADR
after O-ADR O-ADR
their O-ADR O-ADR
first O-ADR O-ADR
cycle O-ADR O-ADR
of O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Hepatic B-ADR B-ADR
effects I-ADR I-ADR
: O-ADR O-ADR
Postmarketing O-ADR O-ADR
reports O-ADR O-ADR
of O-ADR O-ADR
hepatic B-ADR B-ADR
failure I-ADR I-ADR
, O-ADR O-ADR
sometimes O-ADR O-ADR
fatal B-ADR B-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Risk O-ADR O-ADR
of O-ADR O-ADR
Thyroid O-ADR O-ADR
C O-ADR O-ADR
- O-ADR O-ADR
cell O-ADR O-ADR
Tumors O-ADR O-ADR
In O-ADR O-ADR
male O-ADR O-ADR
and O-ADR O-ADR
female O-ADR O-ADR
rats O-ADR O-ADR
, O-ADR O-ADR
dulaglutide O-ADR O-ADR
causes O-ADR O-ADR
a O-ADR O-ADR
dose O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
and O-ADR O-ADR
treatment O-ADR O-ADR
- O-ADR O-ADR
duration O-ADR O-ADR
- O-ADR O-ADR
dependent O-ADR O-ADR
increase O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
thyroid B-ADR B-ADR
C I-ADR I-ADR
- O-ADR O-ADR
cell O-ADR O-ADR
tumors I-ADR I-ADR
) O-ADR O-ADR
after O-ADR O-ADR
lifetime O-ADR O-ADR
exposure O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Nonclinical O-ADR O-ADR
Toxicology O-ADR O-ADR
( O-ADR O-ADR
13 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
double O-ADR O-ADR
- O-ADR O-ADR
blind O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
where O-ADR O-ADR
the O-ADR O-ADR
dose O-ADR O-ADR
was O-ADR O-ADR
increased O-ADR O-ADR
slowly O-ADR O-ADR
, O-ADR O-ADR
as O-ADR O-ADR
recommended O-ADR O-ADR
above O-ADR O-ADR
, O-ADR O-ADR
syncope B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
/ O-ADR O-ADR
1344 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
FANAPT O-ADR O-ADR
, O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
/ O-ADR O-ADR
587 O-ADR O-ADR
) O-ADR O-ADR
on O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
Data O-ADR O-ADR
from O-ADR O-ADR
a O-ADR O-ADR
4 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
, O-ADR O-ADR
fixed O-ADR O-ADR
- O-ADR O-ADR
dose O-ADR O-ADR
study O-ADR O-ADR
in O-ADR O-ADR
adult O-ADR O-ADR
subjects O-ADR O-ADR
with O-ADR O-ADR
schizophrenia O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
which O-ADR O-ADR
fasting O-ADR O-ADR
blood O-ADR O-ADR
samples O-ADR O-ADR
were O-ADR O-ADR
drawn O-ADR O-ADR
, O-ADR O-ADR
are O-ADR O-ADR
presented O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
This O-ADR O-ADR
pool O-ADR O-ADR
combined O-ADR O-ADR
13 O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
3 O-ADR O-ADR
monotherapy O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
9 O-ADR O-ADR
add O-ADR O-ADR
- O-ADR O-ADR
on O-ADR O-ADR
to O-ADR O-ADR
background O-ADR O-ADR
antidiabetic O-ADR O-ADR
therapy O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
an O-ADR O-ADR
initial O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
metformin O-ADR O-ADR
study O-ADR O-ADR
. O-ADR O-ADR
Infections B-ADR B-ADR
not O-ADR O-ADR
meeting O-ADR O-ADR
these O-ADR O-ADR
criteria O-ADR O-ADR
are O-ADR O-ADR
considered O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
serious O-ADR O-ADR
. O-ADR O-ADR
Hypersensitivity O-ADR O-ADR
Systemic B-ADR B-ADR
hypersensitivity I-ADR I-ADR
adverse O-ADR I-ADR
reactions O-ADR I-ADR
sometimes O-ADR O-ADR
severe O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
severe O-ADR O-ADR
urticaria B-ADR B-ADR
, O-ADR O-ADR
systemic B-ADR B-ADR
rash I-ADR I-ADR
, O-ADR O-ADR
facial B-ADR B-ADR
edema I-ADR I-ADR
, O-ADR O-ADR
lip B-ADR B-ADR
swelling I-ADR I-ADR
) O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
on O-ADR O-ADR
TRULICITY O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
four O-ADR O-ADR
Phase O-ADR O-ADR
2 O-ADR O-ADR
and O-ADR O-ADR
five O-ADR O-ADR
Phase O-ADR O-ADR
3 O-ADR O-ADR
studies O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
median O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
Zydelig O-ADR O-ADR
was O-ADR O-ADR
5 O-ADR O-ADR
months O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
that O-ADR O-ADR
led O-ADR O-ADR
to O-ADR O-ADR
treatment O-ADR O-ADR
discontinuations O-ADR O-ADR
were O-ADR O-ADR
hepatotoxicity B-ADR B-ADR
and O-ADR O-ADR
diarrhea O-ADR O-ADR
/ O-ADR O-ADR
colitis O-ADR O-ADR
. O-ADR O-ADR
Clevidipine O-ADR O-ADR
was O-ADR O-ADR
evaluated O-ADR O-ADR
in O-ADR O-ADR
15 O-ADR O-ADR
studies O-ADR O-ADR
in O-ADR O-ADR
hypertensive O-ADR O-ADR
patients O-ADR O-ADR
: O-ADR O-ADR
1099 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
perioperative O-ADR O-ADR
hypertension O-ADR O-ADR
, O-ADR O-ADR
126 O-ADR O-ADR
with O-ADR O-ADR
severe O-ADR O-ADR
hypertension O-ADR O-ADR
and O-ADR O-ADR
82 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
essential O-ADR O-ADR
hypertension O-ADR O-ADR
. O-ADR O-ADR
b O-ADR O-ADR
Includes O-ADR O-ADR
: O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
swelling I-ADR I-ADR
, O-ADR O-ADR
penile B-ADR B-ADR
edema I-ADR I-ADR
, O-ADR O-ADR
penile B-ADR B-ADR
swelling I-ADR I-ADR
, O-ADR O-ADR
local B-ADR B-ADR
swelling I-ADR I-ADR
, O-ADR O-ADR
scrotal B-ADR B-ADR
swelling I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
edema I-ADR I-ADR
. O-ADR O-ADR
Transfer O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
from O-ADR O-ADR
systemic O-ADR O-ADR
corticosteroid O-ADR O-ADR
therapy O-ADR O-ADR
to O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
may O-ADR O-ADR
unmask O-ADR O-ADR
allergic O-ADR O-ADR
conditions O-ADR O-ADR
previously O-ADR O-ADR
suppressed O-ADR O-ADR
by O-ADR O-ADR
the O-ADR O-ADR
systemic O-ADR O-ADR
corticosteroid O-ADR O-ADR
therapy O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
rhinitis O-ADR O-ADR
, O-ADR O-ADR
conjunctivitis O-ADR O-ADR
, O-ADR O-ADR
eczema O-ADR O-ADR
, O-ADR O-ADR
arthritis O-ADR O-ADR
, O-ADR O-ADR
eosinophilic O-ADR O-ADR
conditions O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
frequent O-ADR O-ADR
adverse O-ADR O-ADR
drug O-ADR O-ADR
reactions O-ADR O-ADR
that O-ADR O-ADR
led O-ADR O-ADR
to O-ADR O-ADR
discontinuation O-ADR O-ADR
in O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
or O-ADR O-ADR
more O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
were O-ADR O-ADR
pneumonia B-ADR B-ADR
, O-ADR O-ADR
ILD O-ADR O-ADR
/ O-ADR O-ADR
pneumonitis O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
decreased B-ADR B-ADR
appetite I-ADR I-ADR
. O-ADR O-ADR
Pool O-ADR O-ADR
of O-ADR O-ADR
12 O-ADR O-ADR
Placebo O-ADR O-ADR
- O-ADR O-ADR
Controlled O-ADR O-ADR
Studies O-ADR O-ADR
for O-ADR O-ADR
FARXIGA O-ADR O-ADR
5 O-ADR O-ADR
and O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
The O-ADR O-ADR
data O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
is O-ADR O-ADR
derived O-ADR O-ADR
from O-ADR O-ADR
12 O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
studies O-ADR O-ADR
ranging O-ADR O-ADR
from O-ADR O-ADR
12 O-ADR O-ADR
to O-ADR O-ADR
24 O-ADR O-ADR
weeks O-ADR O-ADR
. O-ADR O-ADR
At O-ADR O-ADR
three O-ADR O-ADR
years O-ADR O-ADR
after O-ADR O-ADR
transplantation O-ADR O-ADR
, O-ADR O-ADR
systolic O-ADR B-ADR
blood O-ADR I-ADR
pressures O-ADR I-ADR
were O-ADR I-ADR
6 O-ADR I-ADR
mmHg O-ADR I-ADR
lower O-ADR I-ADR
and O-ADR O-ADR
diastolic O-ADR B-ADR
blood O-ADR I-ADR
pressures O-ADR I-ADR
were O-ADR I-ADR
3 O-ADR I-ADR
mmHg O-ADR I-ADR
lower O-ADR I-ADR
in O-ADR O-ADR
NULOJIX O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
cyclosporine O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
of O-ADR O-ADR
ZYTIGA O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
LVEF O-ADR O-ADR
< O-ADR O-ADR
50 O-ADR O-ADR
% O-ADR O-ADR
or O-ADR O-ADR
NYHA O-ADR O-ADR
Class O-ADR O-ADR
III O-ADR O-ADR
or O-ADR O-ADR
IV O-ADR O-ADR
heart O-ADR O-ADR
failure O-ADR O-ADR
in O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
or O-ADR O-ADR
LVEF O-ADR O-ADR
< O-ADR O-ADR
50 O-ADR O-ADR
% O-ADR O-ADR
or O-ADR O-ADR
NYHA O-ADR O-ADR
Class O-ADR O-ADR
II O-ADR O-ADR
to O-ADR O-ADR
IV O-ADR O-ADR
heart O-ADR O-ADR
failure O-ADR O-ADR
in O-ADR O-ADR
Study O-ADR O-ADR
2 O-ADR O-ADR
was O-ADR O-ADR
not O-ADR O-ADR
established O-ADR O-ADR
. O-ADR O-ADR
Lung O-ADR O-ADR
function O-ADR O-ADR
( O-ADR O-ADR
FEV1or O-ADR O-ADR
peak O-ADR O-ADR
expiratory O-ADR O-ADR
flow O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
beta O-ADR O-ADR
- O-ADR O-ADR
agonist O-ADR O-ADR
use O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
COPD O-ADR O-ADR
or O-ADR O-ADR
asthma O-ADR O-ADR
symptoms O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
carefully O-ADR O-ADR
monitored O-ADR O-ADR
during O-ADR O-ADR
withdrawal O-ADR O-ADR
of O-ADR O-ADR
oral O-ADR O-ADR
corticosteroids O-ADR O-ADR
. O-ADR O-ADR
No O-ADR O-ADR
fractures B-ADR B-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
group O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
FARXIGA O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
group O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
8 O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
FARXIGA O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
group O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
4814 O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
evaluated O-ADR O-ADR
for O-ADR O-ADR
safety O-ADR O-ADR
when O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
Edarbi O-ADR O-ADR
at O-ADR O-ADR
doses O-ADR O-ADR
of O-ADR O-ADR
20 O-ADR O-ADR
, O-ADR O-ADR
40 O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
80 O-ADR O-ADR
mg O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Delayed O-ADR O-ADR
Healing O-ADR O-ADR
The O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
steroids O-ADR O-ADR
after O-ADR O-ADR
cataract O-ADR O-ADR
surgery O-ADR O-ADR
may O-ADR O-ADR
delay B-ADR B-ADR
healing I-ADR O-ADR
and O-ADR O-ADR
increase B-ADR O-ADR
the I-ADR O-ADR
incidence I-ADR O-ADR
of I-ADR O-ADR
bleb I-ADR B-ADR
formation I-ADR I-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
Discontinuations O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
elevated B-ADR B-ADR
hepatic I-ADR I-ADR
transaminases I-ADR I-ADR
were O-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
were O-ADR O-ADR
similar O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TECFIDERA O-ADR O-ADR
or O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
Approximately O-ADR O-ADR
five O-ADR O-ADR
percent O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
IMBRUVICA O-ADR O-ADR
in O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
Study O-ADR O-ADR
2 O-ADR O-ADR
discontinued O-ADR O-ADR
treatment O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Progressive O-ADR O-ADR
Multifocal O-ADR O-ADR
Leukoencephalopathy O-ADR O-ADR
A O-ADR O-ADR
fatal B-ADR B-ADR
case O-ADR O-ADR
of O-ADR O-ADR
progressive B-ADR B-ADR
multifocal I-ADR I-ADR
leukoencephalopathy I-ADR I-ADR
( O-ADR O-ADR
PML B-ADR B-ADR
) O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
patient O-ADR O-ADR
with O-ADR O-ADR
MS O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
TECFIDERA O-ADR O-ADR
for O-ADR O-ADR
4 O-ADR O-ADR
years O-ADR O-ADR
while O-ADR O-ADR
enrolled O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
clinical O-ADR O-ADR
trial O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
receiving O-ADR O-ADR
SAPHRIS O-ADR O-ADR
should O-ADR O-ADR
receive O-ADR O-ADR
regular O-ADR O-ADR
monitoring O-ADR O-ADR
of O-ADR O-ADR
weight O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Patient O-ADR O-ADR
Counseling O-ADR O-ADR
Information O-ADR O-ADR
( O-ADR O-ADR
17 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
majority O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
78 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
Hispanic O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
frequent O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
that O-ADR O-ADR
led O-ADR O-ADR
to O-ADR O-ADR
dose O-ADR O-ADR
reduction O-ADR O-ADR
in O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
nausea B-ADR B-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
elevated B-ADR B-ADR
transaminases I-ADR I-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Opioids O-ADR O-ADR
may O-ADR O-ADR
affect O-ADR O-ADR
the O-ADR O-ADR
ability O-ADR O-ADR
to O-ADR O-ADR
perform O-ADR O-ADR
potentially O-ADR O-ADR
hazardous O-ADR O-ADR
activities O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
driving O-ADR O-ADR
or O-ADR O-ADR
operating O-ADR O-ADR
machinery O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
Study O-ADR O-ADR
3 O-ADR O-ADR
, O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
16 O-ADR O-ADR
/ O-ADR O-ADR
233 O-ADR O-ADR
) O-ADR O-ADR
subjects O-ADR O-ADR
died B-ADR B-ADR
. O-ADR O-ADR
Among O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
moderate O-ADR O-ADR
renal O-ADR O-ADR
impairment O-ADR O-ADR
, O-ADR O-ADR
approximately O-ADR O-ADR
84 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
taking O-ADR O-ADR
medications O-ADR O-ADR
that O-ADR O-ADR
interfere O-ADR O-ADR
with O-ADR O-ADR
potassium O-ADR O-ADR
excretion O-ADR O-ADR
, O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
potassium O-ADR O-ADR
- O-ADR O-ADR
sparing O-ADR O-ADR
diuretics O-ADR O-ADR
, O-ADR O-ADR
angiotensin O-ADR O-ADR
- O-ADR O-ADR
converting O-ADR O-ADR
- O-ADR O-ADR
enzyme O-ADR O-ADR
inhibitors O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
angiotensin O-ADR O-ADR
- O-ADR O-ADR
receptor O-ADR O-ADR
blockers O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
and O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Precise O-ADR O-ADR
risk O-ADR O-ADR
estimates O-ADR O-ADR
for O-ADR O-ADR
hyperglycemia O-ADR B-ADR
- O-ADR O-ADR
related O-ADR O-ADR
adverse O-ADR I-ADR
events O-ADR I-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
atypical O-ADR O-ADR
antipsychotics O-ADR O-ADR
are O-ADR O-ADR
not O-ADR O-ADR
available O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Hypertension B-ADR B-ADR
including O-ADR O-ADR
hypertensive B-ADR B-ADR
crisis I-ADR I-ADR
: O-ADR O-ADR
Monitor O-ADR O-ADR
blood O-ADR O-ADR
pressure O-ADR O-ADR
regularly O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Hemorrhagic B-ADR B-ADR
events I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
fatal B-ADR B-ADR
events O-ADR O-ADR
, O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
. O-ADR O-ADR
Withhold O-ADR O-ADR
Kyprolis O-ADR O-ADR
if O-ADR O-ADR
suspected O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
additional O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
AFINITOR O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
: O-ADR O-ADR
nausea B-ADR B-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
pain B-ADR B-ADR
in I-ADR I-ADR
extremity I-ADR I-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
insomnia B-ADR B-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
pneumonia B-ADR B-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
epistaxis B-ADR B-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
hypersensitivity B-ADR B-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
increased B-ADR B-ADR
blood I-ADR I-ADR
luteinizing I-ADR I-ADR
hormone I-ADR I-ADR
( I-ADR I-ADR
LH I-ADR I-ADR
) I-ADR I-ADR
levels I-ADR I-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
pneumonitis B-ADR B-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
may O-ADR O-ADR
include O-ADR O-ADR
asthenia B-ADR B-ADR
, O-ADR O-ADR
generalized B-ADR B-ADR
muscle I-ADR I-ADR
weakness I-ADR I-ADR
, O-ADR O-ADR
diplopia B-ADR B-ADR
, O-ADR O-ADR
blurred B-ADR B-ADR
vision I-ADR I-ADR
, O-ADR O-ADR
ptosis B-ADR B-ADR
, O-ADR O-ADR
dysphagia B-ADR B-ADR
, O-ADR O-ADR
dysphonia B-ADR B-ADR
, O-ADR O-ADR
dysarthria B-ADR B-ADR
, O-ADR O-ADR
urinary B-ADR B-ADR
incontinence I-ADR I-ADR
and O-ADR O-ADR
breathing B-ADR B-ADR
difficulties I-ADR I-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
incidence O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
stomatitis B-ADR B-ADR
and O-ADR O-ADR
amenorrhea B-ADR B-ADR
. O-ADR O-ADR
Six O-ADR O-ADR
out O-ADR O-ADR
of O-ADR O-ADR
107 O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
200 O-ADR O-ADR
mg O-ADR O-ADR
of O-ADR O-ADR
HORIZANT O-ADR O-ADR
discontinued O-ADR O-ADR
treatment O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
12 O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
95 O-ADR O-ADR
( O-ADR O-ADR
13 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
FANAPT O-ADR O-ADR
should O-ADR O-ADR
also O-ADR O-ADR
be O-ADR O-ADR
avoided O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
congenital O-ADR O-ADR
long O-ADR O-ADR
QT O-ADR O-ADR
syndrome O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
cardiac O-ADR O-ADR
arrhythmias O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
these O-ADR O-ADR
three O-ADR O-ADR
12 O-ADR O-ADR
week O-ADR O-ADR
studies O-ADR O-ADR
in O-ADR O-ADR
< O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
600 O-ADR O-ADR
mg O-ADR O-ADR
of O-ADR O-ADR
HORIZANT O-ADR O-ADR
and O-ADR O-ADR
numerically O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
placebo O-ADR O-ADR
were O-ADR O-ADR
balance B-ADR B-ADR
disorder I-ADR I-ADR
, O-ADR O-ADR
blurred B-ADR B-ADR
vision I-ADR I-ADR
, O-ADR O-ADR
disorientation B-ADR B-ADR
, O-ADR O-ADR
feeling B-ADR B-ADR
drunk I-ADR I-ADR
, O-ADR O-ADR
lethargy B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
vertigo B-ADR B-ADR
. O-ADR O-ADR
Psoriasis O-ADR O-ADR
: O-ADR O-ADR
During O-ADR O-ADR
the O-ADR O-ADR
0 O-ADR O-ADR
to O-ADR O-ADR
16 O-ADR O-ADR
week O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
period O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
3 O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
/ O-ADR O-ADR
920 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
OTEZLA O-ADR O-ADR
reported O-ADR O-ADR
depression B-ADR B-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
/ O-ADR O-ADR
506 O-ADR O-ADR
) O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
GUERBET O-ADR O-ADR
LLC O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
877 O-ADR O-ADR
- O-ADR O-ADR
729 O-ADR O-ADR
- O-ADR O-ADR
6679 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
Experience O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
drug O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
drug O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Anaphylaxis O-ADR O-ADR
and O-ADR O-ADR
Infusion O-ADR O-ADR
Reactions O-ADR O-ADR
Infusion B-ADR B-ADR
- O-ADR O-ADR
related O-ADR O-ADR
reactions I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
anaphylaxis B-ADR B-ADR
, O-ADR O-ADR
have O-ADR O-ADR
occurred O-ADR O-ADR
with O-ADR O-ADR
ADCETRIS O-ADR O-ADR
. O-ADR O-ADR
P O-ADR O-ADR
- O-ADR O-ADR
gp O-ADR O-ADR
inhibition O-ADR O-ADR
and O-ADR O-ADR
impaired O-ADR O-ADR
renal O-ADR O-ADR
function O-ADR O-ADR
are O-ADR O-ADR
the O-ADR O-ADR
major O-ADR O-ADR
independent O-ADR O-ADR
factors O-ADR O-ADR
that O-ADR O-ADR
result O-ADR O-ADR
in O-ADR O-ADR
increased O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
dabigatran O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Pharmacology O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
discontinuation O-ADR O-ADR
in O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
rate O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
placebo O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
PRISTIQ O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
8 O-ADR O-ADR
weeks O-ADR O-ADR
, O-ADR O-ADR
were O-ADR O-ADR
: O-ADR O-ADR
nausea B-ADR B-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
; O-ADR O-ADR
dizziness B-ADR B-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
and O-ADR O-ADR
vomiting B-ADR B-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
each O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
Macrovascular O-ADR O-ADR
Outcomes O-ADR O-ADR
There O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
no O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
establishing O-ADR O-ADR
conclusive O-ADR O-ADR
evidence O-ADR O-ADR
of O-ADR O-ADR
macrovascular O-ADR O-ADR
risk O-ADR O-ADR
reduction O-ADR O-ADR
with O-ADR O-ADR
JARDIANCE O-ADR O-ADR
or O-ADR O-ADR
any O-ADR O-ADR
other O-ADR O-ADR
antidiabetic O-ADR O-ADR
drug O-ADR O-ADR
. O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
neutropenia B-ADR B-ADR
has O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
82 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
JEVTANA O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
randomized O-ADR O-ADR
trial O-ADR O-ADR
. O-ADR O-ADR
Complete O-ADR O-ADR
blood O-ADR O-ADR
count O-ADR O-ADR
( O-ADR O-ADR
with O-ADR O-ADR
white O-ADR O-ADR
blood O-ADR O-ADR
cell O-ADR O-ADR
differential O-ADR O-ADR
counts O-ADR O-ADR
) O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
obtained O-ADR O-ADR
at O-ADR O-ADR
pretreatment O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
at O-ADR O-ADR
Treatment O-ADR O-ADR
Weeks O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
4 O-ADR O-ADR
, O-ADR O-ADR
8 O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
12 O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
monitored O-ADR O-ADR
closely O-ADR O-ADR
at O-ADR O-ADR
other O-ADR O-ADR
time O-ADR O-ADR
points O-ADR O-ADR
, O-ADR O-ADR
as O-ADR O-ADR
clinically O-ADR O-ADR
appropriate O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
require O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
corticosteroids O-ADR O-ADR
for O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
infectious O-ADR O-ADR
pneumonitis O-ADR O-ADR
, O-ADR O-ADR
prophylaxis O-ADR O-ADR
for O-ADR O-ADR
PJP O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
. O-ADR O-ADR
However O-ADR O-ADR
, O-ADR O-ADR
relapsing O-ADR O-ADR
malaria O-ADR O-ADR
caused O-ADR O-ADR
by O-ADR O-ADR
P O-ADR O-ADR
. O-ADR O-ADR
vivax O-ADR O-ADR
requires O-ADR O-ADR
additional O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
other O-ADR O-ADR
antimalarial O-ADR O-ADR
agents O-ADR O-ADR
to O-ADR O-ADR
achieve O-ADR O-ADR
radical O-ADR O-ADR
cure O-ADR O-ADR
i O-ADR O-ADR
. O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
eradicate O-ADR O-ADR
any O-ADR O-ADR
hypnozoites O-ADR O-ADR
forms O-ADR O-ADR
that O-ADR O-ADR
may O-ADR O-ADR
remain O-ADR O-ADR
dormant O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
liver O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
median O-ADR O-ADR
time O-ADR O-ADR
to O-ADR O-ADR
onset O-ADR O-ADR
of O-ADR O-ADR
hemoglobin B-ADR B-ADR
less I-ADR I-ADR
than I-ADR I-ADR
10 I-ADR I-ADR
g I-ADR I-ADR
per I-ADR I-ADR
dL I-ADR I-ADR
from O-ADR O-ADR
the O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
therapy O-ADR O-ADR
was O-ADR O-ADR
similar O-ADR O-ADR
among O-ADR O-ADR
subjects O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
combination O-ADR O-ADR
of O-ADR O-ADR
VICTRELIS O-ADR O-ADR
and O-ADR O-ADR
PegIntron O-ADR O-ADR
/ O-ADR O-ADR
REBETOL O-ADR O-ADR
( O-ADR O-ADR
71 O-ADR O-ADR
days O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
range O-ADR O-ADR
of O-ADR O-ADR
15 O-ADR O-ADR
- O-ADR O-ADR
337 O-ADR O-ADR
days O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
those O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
PegIntron O-ADR O-ADR
/ O-ADR O-ADR
REBETOL O-ADR O-ADR
( O-ADR O-ADR
71 O-ADR O-ADR
days O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
range O-ADR O-ADR
of O-ADR O-ADR
8 O-ADR O-ADR
- O-ADR O-ADR
337 O-ADR O-ADR
days O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
liver O-ADR O-ADR
test O-ADR O-ADR
abnormalities O-ADR O-ADR
persist O-ADR O-ADR
, O-ADR O-ADR
worsen O-ADR O-ADR
or O-ADR O-ADR
recur O-ADR O-ADR
, O-ADR O-ADR
then O-ADR O-ADR
permanently O-ADR O-ADR
discontinue O-ADR O-ADR
PROMACTA O-ADR O-ADR
. O-ADR O-ADR
Therefore O-ADR O-ADR
, O-ADR O-ADR
treatments O-ADR O-ADR
for O-ADR O-ADR
ED O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
STENDRA O-ADR O-ADR
, O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
in O-ADR O-ADR
men O-ADR O-ADR
for O-ADR O-ADR
whom O-ADR O-ADR
sexual O-ADR O-ADR
activity O-ADR O-ADR
is O-ADR O-ADR
inadvisable O-ADR O-ADR
because O-ADR O-ADR
of O-ADR O-ADR
their O-ADR O-ADR
underlying O-ADR O-ADR
cardiovascular O-ADR O-ADR
status O-ADR O-ADR
. O-ADR O-ADR
Complete O-ADR O-ADR
blood O-ADR O-ADR
counts O-ADR O-ADR
( O-ADR O-ADR
with O-ADR O-ADR
white O-ADR O-ADR
blood O-ADR O-ADR
cell O-ADR O-ADR
differential O-ADR O-ADR
counts O-ADR O-ADR
) O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
obtained O-ADR O-ADR
pretreatment O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
at O-ADR O-ADR
Treatment O-ADR O-ADR
Weeks O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
4 O-ADR O-ADR
, O-ADR O-ADR
8 O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
12 O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
monitored O-ADR O-ADR
closely O-ADR O-ADR
at O-ADR O-ADR
other O-ADR O-ADR
time O-ADR O-ADR
points O-ADR O-ADR
, O-ADR O-ADR
as O-ADR O-ADR
clinically O-ADR O-ADR
appropriate O-ADR O-ADR
. O-ADR O-ADR
No O-ADR O-ADR
new O-ADR O-ADR
safety O-ADR O-ADR
findings O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
` O-ADR O-ADR
` O-ADR O-ADR
crowded O-ADR O-ADR
' O-ADR O-ADR
' O-ADR O-ADR
optic O-ADR O-ADR
disc O-ADR O-ADR
may O-ADR O-ADR
also O-ADR O-ADR
be O-ADR O-ADR
at O-ADR O-ADR
an O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
NAION O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
, O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Patients O-ADR O-ADR
should O-ADR O-ADR
stop O-ADR O-ADR
taking O-ADR O-ADR
STENDRA O-ADR O-ADR
and O-ADR O-ADR
seek O-ADR O-ADR
prompt O-ADR O-ADR
medical O-ADR O-ADR
attention O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
event O-ADR O-ADR
of O-ADR O-ADR
sudden O-ADR O-ADR
decrease O-ADR O-ADR
or O-ADR O-ADR
loss O-ADR O-ADR
of O-ADR O-ADR
hearing O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Cardiovascular O-ADR O-ADR
Risks O-ADR O-ADR
There O-ADR O-ADR
is O-ADR O-ADR
a O-ADR O-ADR
potential O-ADR O-ADR
for O-ADR O-ADR
cardiac B-ADR B-ADR
risk I-ADR O-ADR
during O-ADR O-ADR
sexual O-ADR O-ADR
activity O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
pre O-ADR O-ADR
- O-ADR O-ADR
existing O-ADR O-ADR
cardiovascular O-ADR O-ADR
disease O-ADR O-ADR
. O-ADR O-ADR
What O-ADR O-ADR
are O-ADR O-ADR
the O-ADR O-ADR
ingredients O-ADR O-ADR
in O-ADR O-ADR
DUAVEE O-ADR O-ADR
? O-ADR O-ADR
Approximately O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
these O-ADR O-ADR
trials O-ADR O-ADR
developed O-ADR O-ADR
persistently O-ADR O-ADR
positive O-ADR O-ADR
antibodies O-ADR O-ADR
( O-ADR O-ADR
positive O-ADR O-ADR
test O-ADR O-ADR
at O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
2 O-ADR O-ADR
timepoints O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
30 O-ADR O-ADR
% O-ADR O-ADR
developed O-ADR O-ADR
transiently O-ADR O-ADR
positive O-ADR O-ADR
antibodies O-ADR O-ADR
( O-ADR O-ADR
positive O-ADR O-ADR
in O-ADR O-ADR
1 O-ADR O-ADR
or O-ADR O-ADR
2 O-ADR O-ADR
post O-ADR O-ADR
- O-ADR O-ADR
baseline O-ADR O-ADR
timepoints O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
tuberculosis B-ADR O-ADR
disease O-ADR O-ADR
. O-ADR O-ADR
Agranulocytosis B-ADR B-ADR
( O-ADR O-ADR
including O-ADR O-ADR
fatal B-ADR B-ADR
cases O-ADR O-ADR
) O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
other O-ADR O-ADR
agents O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
class O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
all O-ADR O-ADR
mild O-ADR O-ADR
to O-ADR O-ADR
moderate O-ADR O-ADR
in O-ADR O-ADR
severity O-ADR O-ADR
and O-ADR O-ADR
were O-ADR O-ADR
predominantly O-ADR O-ADR
isolated O-ADR O-ADR
occurrences O-ADR O-ADR
( O-ADR O-ADR
< O-ADR O-ADR
= O-ADR O-ADR
2 O-ADR O-ADR
patients O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
one O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
following O-ADR O-ADR
reactions O-ADR O-ADR
: O-ADR O-ADR
dizziness B-ADR B-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
, O-ADR O-ADR
pruritus B-ADR B-ADR
, O-ADR O-ADR
flushing B-ADR B-ADR
or O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
hemorrhage I-ADR I-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
were O-ADR O-ADR
treated O-ADR O-ADR
and O-ADR O-ADR
followed O-ADR O-ADR
for O-ADR O-ADR
3 O-ADR O-ADR
years O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
: O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Reaction O-ADR O-ADR
Rate O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
6330 O-ADR O-ADR
Headache B-ADR B-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Nausea B-ADR B-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Dizziness B-ADR B-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Dysgeusia B-ADR B-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Feeling B-ADR B-ADR
Hot I-ADR I-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Injection B-ADR B-ADR
site I-ADR I-ADR
reactions I-ADR I-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Vomiting B-ADR B-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Rash B-ADR B-ADR
) O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Pruritus B-ADR B-ADR
) O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Erythema B-ADR B-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Hypersensitivity O-ADR O-ADR
/ O-ADR O-ADR
Anaphylactoid O-ADR O-ADR
* O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Dyspnea B-ADR B-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Paresthesia B-ADR B-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
* O-ADR O-ADR
Hypersensitivity O-ADR O-ADR
/ O-ADR O-ADR
anaphylactoid O-ADR O-ADR
reaction B-ADR I-ADR
may O-ADR O-ADR
occur O-ADR O-ADR
with O-ADR O-ADR
one O-ADR O-ADR
or O-ADR O-ADR
more O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
: O-ADR O-ADR
for O-ADR O-ADR
example O-ADR O-ADR
, O-ADR O-ADR
hypotension B-ADR B-ADR
, O-ADR O-ADR
urticaria B-ADR B-ADR
, O-ADR O-ADR
face B-ADR B-ADR
edema I-ADR I-ADR
, O-ADR O-ADR
eyelid B-ADR B-ADR
edema I-ADR I-ADR
, O-ADR O-ADR
flushing B-ADR B-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
that O-ADR O-ADR
occurred O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
frequency O-ADR O-ADR
of O-ADR O-ADR
< O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
subjects O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
Gadavist O-ADR O-ADR
include O-ADR O-ADR
: O-ADR O-ADR
loss B-ADR B-ADR
of I-ADR I-ADR
consciousness I-ADR I-ADR
, O-ADR O-ADR
convulsion B-ADR B-ADR
, O-ADR O-ADR
parosmia B-ADR B-ADR
, O-ADR O-ADR
tachycardia B-ADR B-ADR
, O-ADR O-ADR
palpitation B-ADR B-ADR
, O-ADR O-ADR
dry B-ADR B-ADR
mouth I-ADR I-ADR
, O-ADR O-ADR
malaise B-ADR B-ADR
and O-ADR O-ADR
feeling B-ADR B-ADR
cold I-ADR I-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
7 O-ADR O-ADR
: O-ADR O-ADR
Change O-ADR O-ADR
in O-ADR O-ADR
Body O-ADR O-ADR
Weight O-ADR O-ADR
in O-ADR O-ADR
Pediatric O-ADR O-ADR
Subjects O-ADR O-ADR
from O-ADR O-ADR
Baseline O-ADR O-ADR
N O-ADR O-ADR
* O-ADR O-ADR
= O-ADR O-ADR
Number O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
who O-ADR O-ADR
had O-ADR O-ADR
assessments O-ADR O-ADR
at O-ADR O-ADR
both O-ADR O-ADR
Baseline O-ADR O-ADR
and O-ADR O-ADR
Endpoint O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
c O-ADR O-ADR
Plasma B-ADR B-ADR
glucose I-ADR I-ADR
concentration I-ADR I-ADR
< I-ADR I-ADR
= I-ADR I-ADR
70 O-ADR I-ADR
mg I-ADR I-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
and O-ADR O-ADR
presence O-ADR O-ADR
of O-ADR O-ADR
hypoglycemic B-ADR B-ADR
symptoms I-ADR I-ADR
. O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
longer O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
study O-ADR O-ADR
, O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
9 O-ADR O-ADR
months O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
was O-ADR O-ADR
vomiting B-ADR B-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Contact O-ADR O-ADR
Dermatitis O-ADR O-ADR
ULESFIA O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
Lotion O-ADR O-ADR
may O-ADR O-ADR
cause O-ADR O-ADR
irritant B-ADR B-ADR
dermatitis I-ADR I-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
patients O-ADR O-ADR
during O-ADR O-ADR
infusion O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
patients O-ADR O-ADR
of O-ADR O-ADR
all O-ADR O-ADR
ages O-ADR O-ADR
who O-ADR O-ADR
are O-ADR O-ADR
started O-ADR O-ADR
on O-ADR O-ADR
antidepressant O-ADR O-ADR
therapy O-ADR O-ADR
, O-ADR O-ADR
monitor O-ADR O-ADR
closely O-ADR O-ADR
for O-ADR O-ADR
worsening O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
for O-ADR O-ADR
emergence O-ADR O-ADR
of O-ADR O-ADR
suicidal O-ADR O-ADR
thoughts O-ADR O-ADR
and O-ADR O-ADR
behaviors O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
these O-ADR O-ADR
consequences O-ADR O-ADR
. O-ADR O-ADR
Baseline O-ADR O-ADR
and O-ADR O-ADR
follow O-ADR O-ADR
- O-ADR O-ADR
up O-ADR O-ADR
ophthalmological O-ADR O-ADR
examinations O-ADR O-ADR
are O-ADR O-ADR
recommended O-ADR O-ADR
in O-ADR O-ADR
pediatric O-ADR O-ADR
patients O-ADR O-ADR
initiating O-ADR O-ADR
KALYDECO O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
in O-ADR O-ADR
Late O-ADR O-ADR
- O-ADR O-ADR
Onset O-ADR O-ADR
Pompe O-ADR O-ADR
Disease O-ADR O-ADR
Assessment O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
late O-ADR O-ADR
- O-ADR O-ADR
onset O-ADR O-ADR
Pompe O-ADR O-ADR
disease O-ADR O-ADR
is O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
exposure O-ADR O-ADR
of O-ADR O-ADR
90 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
45 O-ADR O-ADR
male O-ADR O-ADR
, O-ADR O-ADR
45 O-ADR O-ADR
female O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
aged O-ADR O-ADR
10 O-ADR O-ADR
to O-ADR O-ADR
70 O-ADR O-ADR
years O-ADR O-ADR
, O-ADR O-ADR
to O-ADR O-ADR
20 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
kg O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
or O-ADR O-ADR
placebo O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
randomized O-ADR O-ADR
, O-ADR O-ADR
double O-ADR O-ADR
- O-ADR O-ADR
blind O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trial O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
cobicistat O-ADR O-ADR
component O-ADR O-ADR
of O-ADR O-ADR
STRIBILD O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
shown O-ADR O-ADR
to O-ADR O-ADR
increase B-ADR B-ADR
serum I-ADR I-ADR
creatinine I-ADR I-ADR
and O-ADR O-ADR
decrease B-ADR B-ADR
estimated I-ADR I-ADR
creatinine I-ADR I-ADR
clearance I-ADR I-ADR
due O-ADR O-ADR
to O-ADR O-ADR
inhibition O-ADR O-ADR
of O-ADR O-ADR
tubular O-ADR O-ADR
secretion O-ADR O-ADR
of O-ADR O-ADR
creatinine O-ADR O-ADR
without O-ADR O-ADR
affecting B-ADR O-ADR
renal I-ADR O-ADR
glomerular I-ADR O-ADR
function I-ADR O-ADR
. O-ADR O-ADR
Certain O-ADR O-ADR
circumstances O-ADR O-ADR
may O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
torsade O-ADR B-ADR
de O-ADR I-ADR
pointes O-ADR I-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
sudden O-ADR B-ADR
death O-ADR I-ADR
in O-ADR O-ADR
association O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
drugs O-ADR O-ADR
that O-ADR O-ADR
prolong O-ADR O-ADR
the O-ADR O-ADR
QTc O-ADR O-ADR
interval O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
bradycardia O-ADR O-ADR
; O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
hypokalemia O-ADR O-ADR
or O-ADR O-ADR
hypomagnesemia O-ADR O-ADR
; O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
concomitant O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
other O-ADR O-ADR
drugs O-ADR O-ADR
that O-ADR O-ADR
prolong O-ADR O-ADR
the O-ADR O-ADR
QTc O-ADR O-ADR
interval O-ADR O-ADR
; O-ADR O-ADR
and O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
presence O-ADR O-ADR
of O-ADR O-ADR
congenital O-ADR O-ADR
prolongation O-ADR O-ADR
of O-ADR I-ADR
the O-ADR I-ADR
QT O-ADR I-ADR
interval O-ADR I-ADR
; O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
recent O-ADR O-ADR
acute O-ADR O-ADR
myocardial O-ADR O-ADR
infarction O-ADR O-ADR
; O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
uncompensated O-ADR O-ADR
heart O-ADR O-ADR
failure O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
dose O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
: O-ADR O-ADR
somnolence O-ADR O-ADR
/ O-ADR O-ADR
sedation O-ADR O-ADR
, O-ADR O-ADR
dizziness B-ADR B-ADR
, O-ADR O-ADR
feeling B-ADR B-ADR
drunk I-ADR I-ADR
, O-ADR O-ADR
libido B-ADR B-ADR
decreased I-ADR I-ADR
, O-ADR O-ADR
depression B-ADR B-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
peripheral B-ADR B-ADR
edema I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
vertigo B-ADR B-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Driving B-ADR B-ADR
impairment I-ADR I-ADR
: O-ADR O-ADR
Warn O-ADR O-ADR
patients O-ADR O-ADR
not O-ADR O-ADR
to O-ADR O-ADR
drive O-ADR O-ADR
until O-ADR O-ADR
they O-ADR O-ADR
have O-ADR O-ADR
gained O-ADR O-ADR
sufficient O-ADR O-ADR
experience O-ADR O-ADR
with O-ADR O-ADR
HORIZANT O-ADR O-ADR
to O-ADR O-ADR
assess O-ADR O-ADR
whether O-ADR O-ADR
it O-ADR O-ADR
will O-ADR O-ADR
impair O-ADR O-ADR
their O-ADR O-ADR
ability O-ADR O-ADR
to O-ADR O-ADR
drive O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
median O-ADR O-ADR
age O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
was O-ADR O-ADR
9 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
years O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
to O-ADR O-ADR
26 O-ADR O-ADR
years O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
93 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
Caucasian O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
57 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
male O-ADR O-ADR
. O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
DISTANT B-ADR B-ADR
SPREAD I-ADR I-ADR
OF I-ADR I-ADR
TOXIN I-ADR I-ADR
EFFECT I-ADR I-ADR
See O-ADR O-ADR
full O-ADR O-ADR
prescribing O-ADR O-ADR
information O-ADR O-ADR
for O-ADR O-ADR
complete O-ADR O-ADR
boxed O-ADR O-ADR
warning O-ADR O-ADR
. O-ADR O-ADR
Autoimmune B-ADR B-ADR
disorders I-ADR I-ADR
( O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
Graves B-ADR B-ADR
' I-ADR I-ADR
disease I-ADR I-ADR
, O-ADR O-ADR
polymyositis B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
Guillain B-ADR B-ADR
- O-ADR O-ADR
Barre O-ADR O-ADR
syndrome I-ADR I-ADR
) O-ADR O-ADR
have O-ADR O-ADR
also O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
to O-ADR O-ADR
occur O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
setting O-ADR O-ADR
of O-ADR O-ADR
immune O-ADR O-ADR
reconstitution O-ADR O-ADR
; O-ADR O-ADR
however O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
time O-ADR O-ADR
to O-ADR O-ADR
onset O-ADR O-ADR
is O-ADR O-ADR
more O-ADR O-ADR
variable O-ADR O-ADR
and O-ADR O-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
many O-ADR O-ADR
months O-ADR O-ADR
after O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
reaction O-ADR O-ADR
was O-ADR O-ADR
considered O-ADR O-ADR
treatment O-ADR O-ADR
emergent O-ADR O-ADR
if O-ADR O-ADR
it O-ADR O-ADR
occurred O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
time O-ADR O-ADR
or O-ADR O-ADR
worsened O-ADR O-ADR
while O-ADR O-ADR
receiving O-ADR O-ADR
therapy O-ADR O-ADR
following O-ADR O-ADR
baseline O-ADR O-ADR
evaluation O-ADR O-ADR
. O-ADR O-ADR
None O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
4 O-ADR O-ADR
patients O-ADR O-ADR
had O-ADR O-ADR
neutralizing O-ADR O-ADR
antibodies O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
presence O-ADR O-ADR
of O-ADR O-ADR
ADA O-ADR O-ADR
to O-ADR O-ADR
ERWINAZE O-ADR O-ADR
is O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
higher O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
ERWINAZE O-ADR O-ADR
through O-ADR O-ADR
intravenous O-ADR O-ADR
infusion O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
intramuscular O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
ERWINAZE O-ADR O-ADR
. O-ADR O-ADR
Immunogenicity O-ADR O-ADR
assay O-ADR O-ADR
are O-ADR O-ADR
highly O-ADR O-ADR
dependent O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
sensitivity O-ADR O-ADR
and O-ADR O-ADR
specificity O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
assay O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
influenced O-ADR O-ADR
by O-ADR O-ADR
several O-ADR O-ADR
factors O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
: O-ADR O-ADR
assay O-ADR O-ADR
methodology O-ADR O-ADR
, O-ADR O-ADR
sample O-ADR O-ADR
handling O-ADR O-ADR
, O-ADR O-ADR
timing O-ADR O-ADR
of O-ADR O-ADR
sample O-ADR O-ADR
collection O-ADR O-ADR
, O-ADR O-ADR
concomitant O-ADR O-ADR
medications O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
underlying O-ADR O-ADR
disease O-ADR O-ADR
. O-ADR O-ADR
Overall O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
in O-ADR O-ADR
255 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
HAE O-ADR O-ADR
were O-ADR O-ADR
headache B-ADR B-ADR
( O-ADR O-ADR
16 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
( O-ADR O-ADR
13 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
fatigue B-ADR B-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
( O-ADR O-ADR
11 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
upper B-ADR B-ADR
respiratory I-ADR I-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
reactions I-ADR I-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
nasopharyngitis B-ADR B-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
vomiting B-ADR B-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
pruritus B-ADR B-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
upper B-ADR B-ADR
abdominal I-ADR I-ADR
pain I-ADR I-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
pyrexia B-ADR B-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
Increased O-ADR O-ADR
Mortality O-ADR O-ADR
* O-ADR O-ADR
An O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
death B-ADR B-ADR
was O-ADR O-ADR
seen O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
SIRTURO O-ADR O-ADR
treatment O-ADR O-ADR
group O-ADR O-ADR
( O-ADR O-ADR
9 O-ADR O-ADR
/ O-ADR O-ADR
79 O-ADR O-ADR
, O-ADR O-ADR
11 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
treatment O-ADR O-ADR
group O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
/ O-ADR O-ADR
81 O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
one O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trial O-ADR O-ADR
. O-ADR O-ADR
Increased O-ADR O-ADR
Mortality O-ADR O-ADR
* O-ADR O-ADR
An O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
death B-ADR B-ADR
was O-ADR O-ADR
seen O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
SIRTURO O-ADR O-ADR
treatment O-ADR O-ADR
group O-ADR O-ADR
( O-ADR O-ADR
9 O-ADR O-ADR
/ O-ADR O-ADR
79 O-ADR O-ADR
, O-ADR O-ADR
11 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
treatment O-ADR O-ADR
group O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
/ O-ADR O-ADR
81 O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
one O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trial O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
presented O-ADR O-ADR
by O-ADR O-ADR
system O-ADR O-ADR
organ O-ADR O-ADR
class O-ADR O-ADR
and O-ADR O-ADR
are O-ADR O-ADR
ranked O-ADR O-ADR
by O-ADR O-ADR
frequency O-ADR O-ADR
. O-ADR O-ADR
Overall O-ADR O-ADR
, O-ADR O-ADR
approximately O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
reported O-ADR O-ADR
one O-ADR O-ADR
or O-ADR O-ADR
more O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
during O-ADR O-ADR
a O-ADR O-ADR
follow O-ADR O-ADR
- O-ADR O-ADR
up O-ADR O-ADR
period O-ADR O-ADR
that O-ADR O-ADR
ranged O-ADR O-ADR
from O-ADR O-ADR
24 O-ADR O-ADR
hours O-ADR O-ADR
to O-ADR O-ADR
7 O-ADR O-ADR
days O-ADR O-ADR
after O-ADR O-ADR
Gadavist O-ADR O-ADR
administration O-ADR O-ADR
. O-ADR O-ADR
Prepare O-ADR O-ADR
to O-ADR O-ADR
treat O-ADR O-ADR
acute O-ADR O-ADR
pain O-ADR O-ADR
during O-ADR O-ADR
and O-ADR O-ADR
following O-ADR O-ADR
the O-ADR O-ADR
application O-ADR O-ADR
procedure O-ADR O-ADR
with O-ADR O-ADR
local O-ADR O-ADR
cooling O-ADR O-ADR
( O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
an O-ADR O-ADR
ice O-ADR O-ADR
pack O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
appropriate O-ADR O-ADR
analgesic O-ADR O-ADR
medication O-ADR O-ADR
, O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
opioids O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
and O-ADR O-ADR
laboratory O-ADR O-ADR
abnormalities O-ADR O-ADR
described O-ADR O-ADR
below O-ADR O-ADR
in O-ADR O-ADR
Tables O-ADR O-ADR
7 O-ADR O-ADR
and O-ADR O-ADR
8 O-ADR O-ADR
reflect O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
IMBRUVICA O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
median O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
11 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
months O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
WM O-ADR O-ADR
trial O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
acute O-ADR O-ADR
respiratory O-ADR O-ADR
illness O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
at O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
serious O-ADR O-ADR
acute O-ADR O-ADR
exacerbation O-ADR O-ADR
of O-ADR O-ADR
their O-ADR O-ADR
respiratory O-ADR O-ADR
compromise O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
hypersensitivity O-ADR O-ADR
reactions O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
require O-ADR O-ADR
additional O-ADR O-ADR
monitoring O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Incidence O-ADR O-ADR
and O-ADR O-ADR
Rate O-ADR O-ADR
of O-ADR O-ADR
HypoglycemiaAdverse O-ADR O-ADR
reactions O-ADR O-ADR
of O-ADR O-ADR
hypoglycemia B-ADR B-ADR
were O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
all O-ADR O-ADR
reports O-ADR O-ADR
of O-ADR O-ADR
symptomatic O-ADR O-ADR
and O-ADR O-ADR
asymptomatic O-ADR O-ADR
hypoglycemia B-ADR B-ADR
; O-ADR O-ADR
a O-ADR O-ADR
concurrent O-ADR O-ADR
glucose O-ADR O-ADR
measurement O-ADR O-ADR
was O-ADR O-ADR
not O-ADR O-ADR
required O-ADR O-ADR
; O-ADR O-ADR
intent O-ADR O-ADR
- O-ADR O-ADR
to O-ADR O-ADR
- O-ADR O-ADR
treat O-ADR O-ADR
population O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
this O-ADR O-ADR
analysis O-ADR O-ADR
, O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
58 O-ADR O-ADR
evaluable O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
who O-ADR O-ADR
were O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
kg O-ADR O-ADR
dose O-ADR O-ADR
, O-ADR O-ADR
tested O-ADR O-ADR
positive O-ADR O-ADR
for O-ADR O-ADR
binding O-ADR O-ADR
antibodies O-ADR O-ADR
against O-ADR O-ADR
ipilimumab O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
alanine O-ADR O-ADR
aminotransferase O-ADR O-ADR
( O-ADR O-ADR
ALT O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
aspartate O-ADR O-ADR
aminotransferase O-ADR O-ADR
( O-ADR O-ADR
AST O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
gamma O-ADR O-ADR
- O-ADR O-ADR
glutamyl O-ADR O-ADR
transferase O-ADR O-ADR
( O-ADR O-ADR
GGT O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
total O-ADR O-ADR
blood O-ADR O-ADR
bilirubin O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
start O-ADR O-ADR
of O-ADR O-ADR
and O-ADR O-ADR
during O-ADR O-ADR
BLINCYTO O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
Fatal B-ADR B-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
placebo O-ADR O-ADR
and O-ADR O-ADR
resulted O-ADR O-ADR
from O-ADR O-ADR
septicemia B-ADR B-ADR
, O-ADR O-ADR
pneumonia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
general B-ADR B-ADR
deterioration I-ADR I-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Elevated O-ADR O-ADR
Blood O-ADR O-ADR
Pressure O-ADR O-ADR
Patients O-ADR O-ADR
receiving O-ADR O-ADR
PRISTIQ O-ADR O-ADR
should O-ADR O-ADR
have O-ADR O-ADR
regular O-ADR O-ADR
monitoring O-ADR O-ADR
of O-ADR O-ADR
blood O-ADR O-ADR
pressure O-ADR O-ADR
since O-ADR O-ADR
increases B-ADR O-ADR
in I-ADR O-ADR
blood I-ADR O-ADR
pressure I-ADR O-ADR
were O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
This O-ADR O-ADR
includes O-ADR O-ADR
1704 O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
for O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
six O-ADR O-ADR
months O-ADR O-ADR
; O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
, O-ADR O-ADR
588 O-ADR O-ADR
were O-ADR O-ADR
treated O-ADR O-ADR
for O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
one O-ADR O-ADR
year O-ADR O-ADR
. O-ADR O-ADR
Eight O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
13 O-ADR O-ADR
fractures B-ADR B-ADR
were O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
had O-ADR O-ADR
a O-ADR O-ADR
baseline O-ADR O-ADR
eGFR O-ADR O-ADR
of O-ADR O-ADR
30 O-ADR O-ADR
to O-ADR O-ADR
45 O-ADR O-ADR
mL O-ADR O-ADR
/ O-ADR O-ADR
min O-ADR O-ADR
/ O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
73 O-ADR O-ADR
m O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
FANAPT O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
with O-ADR O-ADR
caution O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
known O-ADR O-ADR
cardiovascular O-ADR O-ADR
disease O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
heart O-ADR O-ADR
failure O-ADR O-ADR
, O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
myocardial O-ADR O-ADR
infarction O-ADR O-ADR
, O-ADR O-ADR
ischemia O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
conduction O-ADR O-ADR
abnormalities O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
cerebrovascular O-ADR O-ADR
disease O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
conditions O-ADR O-ADR
that O-ADR O-ADR
predispose O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
to O-ADR O-ADR
hypotension O-ADR O-ADR
( O-ADR O-ADR
dehydration O-ADR O-ADR
, O-ADR O-ADR
hypovolemia O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
antihypertensive O-ADR O-ADR
medications O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Manage O-ADR O-ADR
with O-ADR O-ADR
dose O-ADR O-ADR
delay O-ADR O-ADR
and O-ADR O-ADR
adjustment O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Embryo B-ADR B-ADR
- O-ADR O-ADR
Fetal O-ADR O-ADR
Toxicity I-ADR I-ADR
: O-ADR O-ADR
Fetal B-ADR B-ADR
harm I-ADR I-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
when O-ADR O-ADR
administered O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
pregnant O-ADR O-ADR
woman O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
QT B-ADR B-ADR
Prolongation I-ADR I-ADR
: O-ADR O-ADR
Monitor O-ADR O-ADR
for O-ADR O-ADR
prolonged O-ADR O-ADR
QT O-ADR O-ADR
intervals O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
congestive O-ADR O-ADR
heart O-ADR O-ADR
failure O-ADR O-ADR
, O-ADR O-ADR
bradyarrhythmias O-ADR O-ADR
, O-ADR O-ADR
drugs O-ADR O-ADR
known O-ADR O-ADR
to O-ADR O-ADR
prolong O-ADR O-ADR
the O-ADR O-ADR
QT O-ADR O-ADR
interval O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
electrolyte O-ADR B-ADR
abnormalities O-ADR I-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
CYP3A4 O-ADR O-ADR
induction O-ADR O-ADR
: O-ADR O-ADR
Women O-ADR O-ADR
taking O-ADR O-ADR
strong O-ADR O-ADR
CYP3A4 O-ADR O-ADR
inducers O-ADR O-ADR
( O-ADR O-ADR
for O-ADR O-ADR
example O-ADR O-ADR
, O-ADR O-ADR
carbamazepine O-ADR O-ADR
, O-ADR O-ADR
phenytoin O-ADR O-ADR
, O-ADR O-ADR
rifampicin O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
St O-ADR O-ADR
. O-ADR O-ADR
John O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
wort O-ADR O-ADR
) O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
choose O-ADR O-ADR
Natazia O-ADR O-ADR
as O-ADR O-ADR
their O-ADR O-ADR
oral O-ADR O-ADR
contraceptive O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
possibility O-ADR O-ADR
of O-ADR O-ADR
decreased O-ADR O-ADR
contraceptive O-ADR O-ADR
efficacy O-ADR O-ADR
. O-ADR O-ADR
Febrile B-ADR B-ADR
neutropenia I-ADR I-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
23 O-ADR O-ADR
/ O-ADR O-ADR
503 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
; O-ADR O-ADR
two O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
died B-ADR B-ADR
from O-ADR O-ADR
complications O-ADR O-ADR
of O-ADR O-ADR
febrile B-ADR B-ADR
neutropenia I-ADR I-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Pancreatitis O-ADR O-ADR
In O-ADR O-ADR
Phase O-ADR O-ADR
2 O-ADR O-ADR
and O-ADR O-ADR
Phase O-ADR O-ADR
3 O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
12 O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
cases O-ADR O-ADR
per O-ADR O-ADR
1000 O-ADR O-ADR
patient O-ADR O-ADR
years O-ADR O-ADR
) O-ADR O-ADR
pancreatitis B-ADR B-ADR
related O-ADR I-ADR
adverse O-ADR I-ADR
reactions O-ADR I-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
exposed O-ADR O-ADR
to O-ADR O-ADR
TRULICITY O-ADR O-ADR
versus O-ADR O-ADR
3 O-ADR O-ADR
in O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
incretin O-ADR O-ADR
comparators O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
cases O-ADR O-ADR
per O-ADR O-ADR
1000 O-ADR O-ADR
patient O-ADR O-ADR
years O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
fever O-ADR O-ADR
. O-ADR O-ADR
Hypertension B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
as O-ADR O-ADR
an O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
in O-ADR O-ADR
32 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
NULOJIX O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
37 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
cyclosporine O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
see O-ADR O-ADR
Table O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
this O-ADR O-ADR
reason O-ADR O-ADR
, O-ADR O-ADR
COCs O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
by O-ADR O-ADR
women O-ADR O-ADR
who O-ADR O-ADR
are O-ADR O-ADR
over O-ADR O-ADR
35 O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
age O-ADR O-ADR
and O-ADR O-ADR
smoke O-ADR O-ADR
. O-ADR O-ADR
G O-ADR O-ADR
- O-ADR O-ADR
CSF O-ADR O-ADR
( O-ADR O-ADR
granulocyte O-ADR O-ADR
colony O-ADR O-ADR
- O-ADR O-ADR
stimulating O-ADR O-ADR
factor O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
GM O-ADR O-ADR
- O-ADR O-ADR
CSF O-ADR O-ADR
( O-ADR O-ADR
granulocyte O-ADR O-ADR
- O-ADR O-ADR
macrophage O-ADR O-ADR
colony O-ADR O-ADR
- O-ADR O-ADR
stimulating O-ADR O-ADR
factor O-ADR O-ADR
) O-ADR O-ADR
was O-ADR O-ADR
used O-ADR O-ADR
in O-ADR O-ADR
19 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
HALAVEN O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
Experience O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
drug O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
compared O-ADR O-ADR
directly O-ADR O-ADR
to O-ADR O-ADR
rates O-ADR O-ADR
from O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
drug O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Postmarketing O-ADR O-ADR
Experience O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
identified O-ADR O-ADR
during O-ADR O-ADR
post O-ADR O-ADR
- O-ADR O-ADR
approval O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
Natazia O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
clinical O-ADR O-ADR
significance O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
imaging O-ADR O-ADR
changes O-ADR O-ADR
is O-ADR O-ADR
unknown O-ADR O-ADR
. O-ADR O-ADR
b O-ADR O-ADR
Including O-ADR O-ADR
intestinal B-ADR B-ADR
perforation I-ADR I-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
cautioned O-ADR O-ADR
about O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
bleeding O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
concomitant O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
PRISTIQ O-ADR O-ADR
and O-ADR O-ADR
NSAIDs O-ADR O-ADR
, O-ADR O-ADR
aspirin O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
drugs O-ADR O-ADR
that O-ADR O-ADR
affect O-ADR O-ADR
coagulation O-ADR O-ADR
or O-ADR O-ADR
bleeding O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
overall O-ADR O-ADR
number O-ADR O-ADR
of O-ADR O-ADR
infections B-ADR B-ADR
, O-ADR O-ADR
serious O-ADR O-ADR
infections B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
select O-ADR O-ADR
infections B-ADR B-ADR
with O-ADR O-ADR
identified O-ADR O-ADR
etiology O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
NULOJIX O-ADR O-ADR
recommended O-ADR O-ADR
regimen O-ADR O-ADR
or O-ADR O-ADR
the O-ADR O-ADR
cyclosporine O-ADR O-ADR
control O-ADR O-ADR
in O-ADR O-ADR
Studies O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
are O-ADR O-ADR
shown O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
Such O-ADR O-ADR
patients O-ADR O-ADR
should O-ADR O-ADR
undergo O-ADR O-ADR
a O-ADR O-ADR
prompt O-ADR O-ADR
medical O-ADR O-ADR
evaluation O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
PRISTIQ O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
. O-ADR O-ADR
Closer O-ADR O-ADR
monitoring O-ADR O-ADR
is O-ADR O-ADR
recommended O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
have O-ADR O-ADR
other O-ADR O-ADR
risk O-ADR O-ADR
factors O-ADR O-ADR
for O-ADR O-ADR
urinary O-ADR O-ADR
retention O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
benign O-ADR O-ADR
prostatic O-ADR O-ADR
hyperplasia O-ADR O-ADR
[ O-ADR O-ADR
BPH O-ADR O-ADR
] O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
are O-ADR O-ADR
unable O-ADR O-ADR
to O-ADR O-ADR
communicate O-ADR O-ADR
clinical O-ADR O-ADR
symptoms O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
cognitively O-ADR O-ADR
impaired O-ADR O-ADR
patients O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
use O-ADR O-ADR
concomitant O-ADR O-ADR
medications O-ADR O-ADR
that O-ADR O-ADR
may O-ADR O-ADR
affect O-ADR O-ADR
voiding O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
anticholinergics O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
other O-ADR O-ADR
XIAFLEX O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
9 O-ADR O-ADR
of O-ADR O-ADR
1044 O-ADR O-ADR
; O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
combination O-ADR O-ADR
of O-ADR O-ADR
penile B-ADR B-ADR
ecchymoses I-ADR I-ADR
, O-ADR O-ADR
sudden O-ADR O-ADR
penile B-ADR B-ADR
detumescence I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
a O-ADR O-ADR
penile B-ADR B-ADR
` O-ADR O-ADR
` O-ADR O-ADR
popping B-ADR B-ADR
' O-ADR O-ADR
' O-ADR O-ADR
sound B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
these O-ADR O-ADR
cases O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
diagnosis O-ADR O-ADR
of O-ADR O-ADR
corporal B-ADR B-ADR
rupture I-ADR I-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
excluded O-ADR O-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
these O-ADR O-ADR
studies O-ADR O-ADR
did O-ADR O-ADR
not O-ADR O-ADR
include O-ADR O-ADR
a O-ADR O-ADR
placebo O-ADR O-ADR
control O-ADR O-ADR
group O-ADR O-ADR
, O-ADR O-ADR
causality O-ADR O-ADR
could O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
established O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
discussed O-ADR O-ADR
elsewhere O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
labeling O-ADR O-ADR
: O-ADR O-ADR
Application B-ADR B-ADR
- O-ADR O-ADR
Associated O-ADR O-ADR
Pain I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
Increase B-ADR O-ADR
in I-ADR O-ADR
Blood I-ADR O-ADR
Pressure I-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
control O-ADR O-ADR
) O-ADR O-ADR
are O-ADR O-ADR
application B-ADR B-ADR
site I-ADR I-ADR
erythema I-ADR I-ADR
, O-ADR O-ADR
application B-ADR B-ADR
site I-ADR I-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
application B-ADR B-ADR
site I-ADR I-ADR
pruritus I-ADR I-ADR
and O-ADR O-ADR
application B-ADR B-ADR
site I-ADR I-ADR
papules I-ADR I-ADR
. O-ADR O-ADR
Increases B-ADR B-ADR
in I-ADR I-ADR
blood I-ADR I-ADR
pressure I-ADR I-ADR
were O-ADR O-ADR
unrelated O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
pretreatment O-ADR O-ADR
blood O-ADR O-ADR
pressure O-ADR O-ADR
but O-ADR O-ADR
were O-ADR O-ADR
related O-ADR O-ADR
to O-ADR O-ADR
treatment O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
increases B-ADR B-ADR
in I-ADR O-ADR
pain I-ADR B-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Pfizer O-ADR O-ADR
Inc O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
438 O-ADR O-ADR
- O-ADR O-ADR
1985 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
Females O-ADR O-ADR
of O-ADR O-ADR
reproductive O-ADR O-ADR
potential O-ADR O-ADR
should O-ADR O-ADR
avoid O-ADR O-ADR
becoming O-ADR O-ADR
pregnant O-ADR O-ADR
while O-ADR O-ADR
being O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
BOSULIF O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
mean O-ADR O-ADR
baseline O-ADR O-ADR
LDL O-ADR O-ADR
- O-ADR O-ADR
C O-ADR O-ADR
levels O-ADR O-ADR
were O-ADR O-ADR
104 O-ADR O-ADR
to O-ADR O-ADR
110 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
across O-ADR O-ADR
treatment O-ADR O-ADR
groups O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
incidence O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
are O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
dizziness B-ADR B-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Bayer O-ADR O-ADR
HealthCare O-ADR O-ADR
Pharmaceuticals O-ADR O-ADR
Inc O-ADR O-ADR
. O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
888 O-ADR O-ADR
- O-ADR O-ADR
842 O-ADR O-ADR
- O-ADR O-ADR
2937 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
Experience O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
drug O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
drug O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Myelosuppression B-ADR B-ADR
: O-ADR O-ADR
Monitor O-ADR O-ADR
blood O-ADR O-ADR
counts O-ADR O-ADR
and O-ADR O-ADR
manage O-ADR O-ADR
as O-ADR O-ADR
necessary O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
1314 O-ADR O-ADR
SAPHRIS O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
treated O-ADR O-ADR
for O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
24 O-ADR O-ADR
weeks O-ADR O-ADR
and O-ADR O-ADR
785 O-ADR O-ADR
SAPHRIS O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
had O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
52 O-ADR O-ADR
weeks O-ADR O-ADR
of O-ADR O-ADR
exposure O-ADR O-ADR
at O-ADR O-ADR
therapeutic O-ADR O-ADR
doses O-ADR O-ADR
. O-ADR O-ADR
Cervical O-ADR O-ADR
Dystonia O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
smaller O-ADR O-ADR
neck O-ADR O-ADR
muscle O-ADR O-ADR
mass O-ADR O-ADR
and O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
require O-ADR O-ADR
bilateral O-ADR O-ADR
injections O-ADR O-ADR
into O-ADR O-ADR
the O-ADR O-ADR
sternocleidomastoid O-ADR O-ADR
muscles O-ADR O-ADR
are O-ADR O-ADR
at O-ADR O-ADR
greater O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
dysphagia B-ADR B-ADR
. O-ADR O-ADR
In O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
first B-ADR B-ADR
- O-ADR O-ADR
degree O-ADR O-ADR
AV I-ADR I-ADR
block I-ADR I-ADR
after O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
dose O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
GILENYA O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
on O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
Under O-ADR O-ADR
conditions O-ADR O-ADR
of O-ADR O-ADR
metabolic O-ADR O-ADR
inhibition O-ADR O-ADR
for O-ADR O-ADR
both O-ADR O-ADR
2D6 O-ADR O-ADR
and O-ADR O-ADR
3A4 O-ADR O-ADR
, O-ADR O-ADR
FANAPT O-ADR O-ADR
12 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
was O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
mean O-ADR O-ADR
QTcF B-ADR B-ADR
increase I-ADR I-ADR
from O-ADR O-ADR
baseline O-ADR O-ADR
of O-ADR O-ADR
about O-ADR O-ADR
19 O-ADR O-ADR
msec O-ADR O-ADR
. O-ADR O-ADR
Depression B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
as O-ADR O-ADR
serious O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
/ O-ADR O-ADR
1441 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
exposed O-ADR O-ADR
to O-ADR O-ADR
OTEZLA O-ADR O-ADR
, O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
none O-ADR O-ADR
in O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
subjects O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
/ O-ADR O-ADR
495 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
mean O-ADR O-ADR
age O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
population O-ADR O-ADR
was O-ADR O-ADR
56 O-ADR O-ADR
years O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
older O-ADR O-ADR
than O-ADR O-ADR
75 O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
age O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Immunogenicity O-ADR O-ADR
As O-ADR O-ADR
with O-ADR O-ADR
all O-ADR O-ADR
therapeutic O-ADR O-ADR
proteins O-ADR O-ADR
, O-ADR O-ADR
there O-ADR O-ADR
is O-ADR O-ADR
potential O-ADR O-ADR
for O-ADR O-ADR
immunogenicity O-ADR O-ADR
. O-ADR O-ADR
All O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
naive O-ADR O-ADR
to O-ADR O-ADR
enzyme O-ADR O-ADR
replacement O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
AEDs O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
suicidal B-ADR B-ADR
thoughts I-ADR I-ADR
. O-ADR O-ADR
Imaging O-ADR O-ADR
appears O-ADR O-ADR
to O-ADR O-ADR
overestimate O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
clinical O-ADR O-ADR
pneumonitis O-ADR B-ADR
. O-ADR O-ADR
Therapeutic O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
G O-ADR O-ADR
- O-ADR O-ADR
CSF O-ADR O-ADR
and O-ADR O-ADR
secondary O-ADR O-ADR
prophylaxis O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
in O-ADR O-ADR
all O-ADR O-ADR
patients O-ADR O-ADR
considered O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
at O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
neutropenia O-ADR O-ADR
complications O-ADR O-ADR
. O-ADR O-ADR
Please O-ADR O-ADR
refer O-ADR O-ADR
to O-ADR O-ADR
Table O-ADR O-ADR
5 O-ADR O-ADR
for O-ADR O-ADR
established O-ADR O-ADR
and O-ADR O-ADR
other O-ADR O-ADR
potentially O-ADR O-ADR
significant O-ADR O-ADR
drug O-ADR O-ADR
interactions O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Drug O-ADR O-ADR
Interactions O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Injection O-ADR O-ADR
Site O-ADR O-ADR
Reactions O-ADR O-ADR
In O-ADR O-ADR
CAPS O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
subcutaneous B-ADR B-ADR
injection I-ADR I-ADR
site I-ADR I-ADR
reactions I-ADR I-ADR
were O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
Part O-ADR O-ADR
1 O-ADR O-ADR
with O-ADR O-ADR
mild O-ADR O-ADR
tolerability O-ADR O-ADR
reactions O-ADR O-ADR
; O-ADR O-ADR
in O-ADR O-ADR
Part O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
one O-ADR O-ADR
patient O-ADR O-ADR
each O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
had O-ADR O-ADR
a O-ADR O-ADR
mild O-ADR O-ADR
or O-ADR O-ADR
a O-ADR O-ADR
moderate O-ADR O-ADR
tolerability O-ADR O-ADR
reaction O-ADR O-ADR
and O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
Part O-ADR O-ADR
3 O-ADR O-ADR
, O-ADR O-ADR
one O-ADR O-ADR
patient O-ADR O-ADR
had O-ADR O-ADR
a O-ADR O-ADR
mild O-ADR O-ADR
local B-ADR B-ADR
tolerability I-ADR I-ADR
reaction I-ADR I-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
similar O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
doses O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
250 O-ADR O-ADR
mg O-ADR O-ADR
daily O-ADR O-ADR
. O-ADR O-ADR
To O-ADR O-ADR
reduce O-ADR O-ADR
this O-ADR O-ADR
risk O-ADR O-ADR
, O-ADR O-ADR
consider O-ADR O-ADR
coverage O-ADR O-ADR
with O-ADR O-ADR
another O-ADR O-ADR
anticoagulant O-ADR O-ADR
if O-ADR O-ADR
ELIQUIS O-ADR O-ADR
is O-ADR O-ADR
discontinued O-ADR O-ADR
for O-ADR O-ADR
a O-ADR O-ADR
reason O-ADR O-ADR
other O-ADR O-ADR
than O-ADR O-ADR
pathological O-ADR O-ADR
bleeding O-ADR O-ADR
or O-ADR O-ADR
completion O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
course O-ADR O-ADR
of O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
Since O-ADR O-ADR
CMV O-ADR O-ADR
seronegative O-ADR O-ADR
patients O-ADR O-ADR
are O-ADR O-ADR
at O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
CMV O-ADR O-ADR
disease O-ADR O-ADR
( O-ADR O-ADR
a O-ADR O-ADR
known O-ADR O-ADR
risk O-ADR O-ADR
factor O-ADR O-ADR
for O-ADR O-ADR
PTLD O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
significance O-ADR O-ADR
of O-ADR O-ADR
CMV O-ADR O-ADR
serology O-ADR O-ADR
for O-ADR O-ADR
PTLD O-ADR O-ADR
remains O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
determined O-ADR O-ADR
; O-ADR O-ADR
however O-ADR O-ADR
, O-ADR O-ADR
these O-ADR O-ADR
findings O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
when O-ADR O-ADR
prescribing O-ADR O-ADR
NULOJIX O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Thromboembolic O-ADR O-ADR
and O-ADR O-ADR
Bleeding O-ADR O-ADR
Events O-ADR O-ADR
in O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
thromboembolic B-ADR B-ADR
events I-ADR I-ADR
, O-ADR O-ADR
transient B-ADR B-ADR
ischemic I-ADR I-ADR
attack I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
myocardial B-ADR B-ADR
infarction I-ADR I-ADR
) O-ADR O-ADR
and O-ADR O-ADR
an O-ADR O-ADR
excess O-ADR O-ADR
of O-ADR O-ADR
major O-ADR O-ADR
bleeding B-ADR B-ADR
( O-ADR O-ADR
predominantly O-ADR O-ADR
post O-ADR O-ADR
- O-ADR O-ADR
operative O-ADR O-ADR
pericardial B-ADR B-ADR
effusions I-ADR I-ADR
requiring O-ADR O-ADR
intervention O-ADR O-ADR
for O-ADR O-ADR
hemodynamic O-ADR O-ADR
compromise O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
PRADAXA O-ADR O-ADR
treatment O-ADR O-ADR
arm O-ADR O-ADR
as O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
warfarin O-ADR O-ADR
treatment O-ADR O-ADR
arm O-ADR O-ADR
. O-ADR O-ADR
Epstein O-ADR O-ADR
- O-ADR O-ADR
Barr O-ADR O-ADR
virus O-ADR O-ADR
serology O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
ascertained O-ADR O-ADR
before O-ADR O-ADR
starting O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
NULOJIX O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
only O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
are O-ADR O-ADR
EBV O-ADR O-ADR
seropositive O-ADR O-ADR
should O-ADR O-ADR
receive O-ADR O-ADR
NULOJIX O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
of O-ADR O-ADR
XALKORI O-ADR O-ADR
is O-ADR O-ADR
based O-ADR O-ADR
primarily O-ADR O-ADR
on O-ADR O-ADR
343 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
ALK O-ADR O-ADR
- O-ADR O-ADR
positive O-ADR O-ADR
metastatic O-ADR O-ADR
NSCLC O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
XALKORI O-ADR O-ADR
250 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
in O-ADR O-ADR
two O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
, O-ADR O-ADR
randomized O-ADR O-ADR
, O-ADR O-ADR
active O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
( O-ADR O-ADR
Studies O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Pancreatitis B-ADR B-ADR
: O-ADR O-ADR
Discontinue O-ADR O-ADR
promptly O-ADR O-ADR
if O-ADR O-ADR
suspected O-ADR O-ADR
. O-ADR O-ADR
To O-ADR O-ADR
minimize O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
thrombotic O-ADR O-ADR
/ O-ADR O-ADR
thromboembolic O-ADR O-ADR
complications O-ADR O-ADR
, O-ADR O-ADR
do O-ADR O-ADR
not O-ADR O-ADR
use O-ADR O-ADR
PROMACTA O-ADR O-ADR
in O-ADR O-ADR
an O-ADR O-ADR
attempt O-ADR O-ADR
to O-ADR O-ADR
normalize O-ADR O-ADR
platelet O-ADR O-ADR
counts O-ADR O-ADR
. O-ADR O-ADR
Therefore O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
may O-ADR O-ADR
require O-ADR O-ADR
a O-ADR O-ADR
lower O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
sulfonylurea O-ADR O-ADR
or O-ADR O-ADR
insulin O-ADR O-ADR
to O-ADR O-ADR
reduce O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
hypoglycemia B-ADR O-ADR
in O-ADR O-ADR
this O-ADR O-ADR
setting O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
( O-ADR O-ADR
anaphylacticshock B-ADR B-ADR
, O-ADR O-ADR
hypotension B-ADR B-ADR
, O-ADR O-ADR
pharyngolaryngeal B-ADR B-ADR
edema I-ADR I-ADR
, O-ADR O-ADR
urticaria B-ADR B-ADR
, O-ADR O-ADR
face B-ADR B-ADR
edema I-ADR I-ADR
, O-ADR O-ADR
rhinitis B-ADR B-ADR
, O-ADR O-ADR
conjunctivitis B-ADR B-ADR
, O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
hypoesthesia B-ADR B-ADR
, O-ADR O-ADR
sneezing B-ADR B-ADR
, O-ADR O-ADR
cough B-ADR B-ADR
and O-ADR O-ADR
pallor B-ADR B-ADR
) O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Tachycardia B-ADR B-ADR
* O-ADR O-ADR
Restlessness B-ADR B-ADR
BOXED O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
NEPHROGENIC B-ADR B-ADR
SYSTEMIC I-ADR I-ADR
FIBROSIS I-ADR I-ADR
( O-ADR O-ADR
NSF B-ADR B-ADR
) O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
NEPHROGENIC B-ADR O-ADR
SYSTEMIC I-ADR O-ADR
FIBROSIS I-ADR O-ADR
( O-ADR O-ADR
NSF B-ADR O-ADR
) O-ADR O-ADR
Gadolinium O-ADR O-ADR
- O-ADR O-ADR
based O-ADR O-ADR
contrast O-ADR O-ADR
agents O-ADR O-ADR
( O-ADR O-ADR
GBCAs O-ADR O-ADR
) O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
NSF B-ADR B-ADR
among O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
impaired O-ADR O-ADR
elimination O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
drugs O-ADR O-ADR
. O-ADR O-ADR
This O-ADR O-ADR
Patient O-ADR O-ADR
Information O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
approved O-ADR O-ADR
by O-ADR O-ADR
the O-ADR O-ADR
U O-ADR O-ADR
. O-ADR O-ADR
S O-ADR O-ADR
. O-ADR O-ADR
Food O-ADR O-ADR
and O-ADR O-ADR
Drug O-ADR O-ADR
Administration O-ADR O-ADR
. O-ADR O-ADR
MALIGNANCY O-ADR O-ADR
Lymphoma B-ADR B-ADR
and O-ADR O-ADR
other O-ADR O-ADR
malignancies B-ADR B-ADR
, O-ADR O-ADR
some O-ADR O-ADR
fatal B-ADR B-ADR
, O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
children O-ADR O-ADR
and O-ADR O-ADR
adolescent O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TNF O-ADR O-ADR
blockers O-ADR O-ADR
, O-ADR O-ADR
of O-ADR O-ADR
which O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
is O-ADR O-ADR
a O-ADR O-ADR
member O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Two O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
trials O-ADR O-ADR
were O-ADR O-ADR
extensions O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
month O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
one O-ADR O-ADR
was O-ADR O-ADR
a O-ADR O-ADR
dedicated O-ADR O-ADR
long O-ADR O-ADR
term O-ADR O-ADR
safety O-ADR O-ADR
trial O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
median O-ADR O-ADR
duration O-ADR O-ADR
on O-ADR O-ADR
treatment O-ADR O-ADR
was O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
months O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TAFINLAR O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
months O-ADR O-ADR
for O-ADR O-ADR
dacarbazine O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Amgen O-ADR O-ADR
Medical O-ADR O-ADR
Information O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
77 O-ADR O-ADR
- O-ADR O-ADR
AMGEN O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
772 O-ADR O-ADR
- O-ADR O-ADR
6436 O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
Two O-ADR O-ADR
randomized O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
, O-ADR O-ADR
multicenter O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
enrolled O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
had O-ADR O-ADR
metastatic O-ADR O-ADR
castration O-ADR O-ADR
- O-ADR O-ADR
resistant O-ADR O-ADR
prostate O-ADR O-ADR
cancer O-ADR O-ADR
who O-ADR O-ADR
were O-ADR O-ADR
using O-ADR O-ADR
a O-ADR O-ADR
gonadotropin O-ADR O-ADR
- O-ADR O-ADR
releasing O-ADR O-ADR
hormone O-ADR O-ADR
( O-ADR O-ADR
GnRH O-ADR O-ADR
) O-ADR O-ADR
agonist O-ADR O-ADR
or O-ADR O-ADR
were O-ADR O-ADR
previously O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
orchiectomy O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
both O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
Study O-ADR O-ADR
2 O-ADR O-ADR
ZYTIGA O-ADR O-ADR
was O-ADR O-ADR
administered O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
000 O-ADR O-ADR
mg O-ADR O-ADR
daily O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
prednisone O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
active O-ADR O-ADR
treatment O-ADR O-ADR
arms O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
: O-ADR O-ADR
Serious O-ADR O-ADR
systemic B-ADR B-ADR
hypersensitivity I-ADR I-ADR
reactions I-ADR I-ADR
including O-ADR O-ADR
anaphylaxis B-ADR B-ADR
may O-ADR O-ADR
occur O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
10 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Hypersensitivity O-ADR O-ADR
Reactions O-ADR O-ADR
Serious O-ADR O-ADR
skin B-ADR B-ADR
reactions I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
DALVANCE O-ADR O-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
these O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
reported O-ADR O-ADR
voluntarily O-ADR O-ADR
from O-ADR O-ADR
a O-ADR O-ADR
population O-ADR O-ADR
of O-ADR O-ADR
uncertain O-ADR O-ADR
size O-ADR O-ADR
, O-ADR O-ADR
it O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
possible O-ADR O-ADR
to O-ADR O-ADR
reliably O-ADR O-ADR
estimate O-ADR O-ADR
their O-ADR O-ADR
frequency O-ADR O-ADR
or O-ADR O-ADR
establish O-ADR O-ADR
a O-ADR O-ADR
causal O-ADR O-ADR
relationship O-ADR O-ADR
to O-ADR O-ADR
drug O-ADR O-ADR
exposure O-ADR O-ADR
. O-ADR O-ADR
STENDRA O-ADR O-ADR
200 O-ADR O-ADR
mg O-ADR O-ADR
resulted O-ADR O-ADR
in O-ADR O-ADR
transient B-ADR O-ADR
decreases I-ADR B-ADR
in I-ADR I-ADR
sitting I-ADR I-ADR
blood I-ADR I-ADR
pressure I-ADR I-ADR
in O-ADR O-ADR
healthy O-ADR O-ADR
volunteers O-ADR O-ADR
of O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
mmHg O-ADR O-ADR
systolic O-ADR O-ADR
and O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
mmHg O-ADR O-ADR
diastolic O-ADR O-ADR
[ O-ADR O-ADR
seeClinical O-ADR O-ADR
Pharmacology O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
, O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
maximum O-ADR O-ADR
decrease O-ADR O-ADR
observed O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
hour O-ADR O-ADR
after O-ADR O-ADR
dosing O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Cardiovascular O-ADR O-ADR
Disorders O-ADR O-ADR
Estrogen O-ADR O-ADR
agonist O-ADR O-ADR
/ O-ADR O-ADR
antagonists O-ADR O-ADR
( O-ADR O-ADR
including O-ADR O-ADR
bazedoxifene O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
component O-ADR O-ADR
of O-ADR O-ADR
DUAVEE O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
estrogens O-ADR O-ADR
individually O-ADR O-ADR
are O-ADR O-ADR
known O-ADR O-ADR
to O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
VTE B-ADR B-ADR
. O-ADR O-ADR
The O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
erythropoiesis O-ADR O-ADR
stimulating O-ADR O-ADR
agents O-ADR O-ADR
( O-ADR O-ADR
ESAs O-ADR O-ADR
) O-ADR O-ADR
was O-ADR O-ADR
permitted O-ADR O-ADR
for O-ADR O-ADR
management O-ADR O-ADR
of O-ADR O-ADR
anemia O-ADR O-ADR
, O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
investigator O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
discretion O-ADR O-ADR
, O-ADR O-ADR
with O-ADR O-ADR
or O-ADR O-ADR
without O-ADR O-ADR
ribavirin O-ADR O-ADR
dose O-ADR O-ADR
reduction O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Phase O-ADR O-ADR
2 O-ADR O-ADR
and O-ADR O-ADR
3 O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
Resume O-ADR O-ADR
TAFINLAR O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
same O-ADR O-ADR
dose O-ADR O-ADR
level O-ADR O-ADR
upon O-ADR O-ADR
recovery O-ADR O-ADR
of O-ADR O-ADR
cardiac O-ADR O-ADR
function O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
bleeding B-ADR B-ADR
and O-ADR O-ADR
thromboembolic B-ADR B-ADR
events I-ADR I-ADR
were O-ADR O-ADR
seen O-ADR O-ADR
both O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
were O-ADR O-ADR
initiated O-ADR O-ADR
on O-ADR O-ADR
PRADAXA O-ADR O-ADR
post O-ADR O-ADR
- O-ADR O-ADR
operatively O-ADR O-ADR
within O-ADR O-ADR
three O-ADR O-ADR
days O-ADR O-ADR
of O-ADR O-ADR
mechanical O-ADR O-ADR
bileaflet O-ADR O-ADR
valve O-ADR O-ADR
implantation O-ADR O-ADR
, O-ADR O-ADR
as O-ADR O-ADR
well O-ADR O-ADR
as O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
whose O-ADR O-ADR
valves O-ADR O-ADR
had O-ADR O-ADR
been O-ADR O-ADR
implanted O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
three O-ADR O-ADR
months O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
enrollment O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Angioedema B-ADR B-ADR
with O-ADR O-ADR
concomitant O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
ACE O-ADR O-ADR
inhibitors O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Results O-ADR O-ADR
from O-ADR O-ADR
these O-ADR O-ADR
studies O-ADR O-ADR
did O-ADR O-ADR
not O-ADR O-ADR
change O-ADR O-ADR
the O-ADR O-ADR
safety O-ADR O-ADR
profile O-ADR O-ADR
of O-ADR O-ADR
Picato O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
gel O-ADR O-ADR
. O-ADR O-ADR
No O-ADR O-ADR
severe O-ADR O-ADR
injection B-ADR B-ADR
- O-ADR O-ADR
site O-ADR O-ADR
reactions I-ADR I-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
and O-ADR O-ADR
none O-ADR O-ADR
led O-ADR O-ADR
to O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
Antibodies O-ADR O-ADR
against O-ADR O-ADR
ILARIS O-ADR O-ADR
were O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
approximately O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
ILARIS O-ADR O-ADR
for O-ADR O-ADR
CAPS O-ADR O-ADR
and O-ADR O-ADR
SJIA O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
platelet O-ADR O-ADR
counts O-ADR O-ADR
frequently O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
Kyprolis O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
event O-ADR O-ADR
of O-ADR O-ADR
drug O-ADR O-ADR
- O-ADR O-ADR
induced O-ADR O-ADR
pulmonary O-ADR O-ADR
toxicity O-ADR O-ADR
, O-ADR O-ADR
discontinue O-ADR O-ADR
Kyprolis O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
14 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
See O-ADR O-ADR
Full O-ADR O-ADR
Prescribing O-ADR O-ADR
Information O-ADR O-ADR
for O-ADR O-ADR
additional O-ADR O-ADR
WARNINGS O-ADR O-ADR
and O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
. O-ADR O-ADR
Hepatitis O-ADR O-ADR
B O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
Hepatitis O-ADR O-ADR
C O-ADR O-ADR
Virus O-ADR O-ADR
Co O-ADR O-ADR
- O-ADR O-ADR
infection O-ADR O-ADR
: O-ADR O-ADR
In O-ADR O-ADR
Phase O-ADR O-ADR
3 O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
subjects O-ADR O-ADR
with O-ADR O-ADR
hepatitis O-ADR O-ADR
B O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
C O-ADR O-ADR
virus O-ADR O-ADR
co O-ADR O-ADR
- O-ADR O-ADR
infection O-ADR O-ADR
were O-ADR O-ADR
permitted O-ADR O-ADR
to O-ADR O-ADR
enroll O-ADR O-ADR
provided O-ADR O-ADR
that O-ADR O-ADR
baseline O-ADR O-ADR
liver O-ADR O-ADR
chemistry O-ADR O-ADR
tests O-ADR O-ADR
did O-ADR O-ADR
not O-ADR O-ADR
exceed O-ADR O-ADR
5 O-ADR O-ADR
times O-ADR O-ADR
the O-ADR O-ADR
upper O-ADR O-ADR
limit O-ADR O-ADR
of O-ADR O-ADR
normal O-ADR O-ADR
. O-ADR O-ADR
Skin O-ADR O-ADR
, O-ADR O-ADR
scalp O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
ocular O-ADR O-ADR
irritation O-ADR O-ADR
were O-ADR O-ADR
monitored O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Weight B-ADR B-ADR
Decrease I-ADR I-ADR
: O-ADR O-ADR
Monitor O-ADR O-ADR
weight O-ADR O-ADR
regularly O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
laboratory O-ADR O-ADR
abnormalities O-ADR O-ADR
( O-ADR O-ADR
incidence O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
50 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
anemia B-ADR B-ADR
, O-ADR O-ADR
hypercholesterolemia B-ADR B-ADR
, O-ADR O-ADR
hypertriglyceridemia O-ADR B-ADR
, O-ADR O-ADR
hyperglycemia B-ADR B-ADR
, O-ADR O-ADR
lymphopenia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
increased B-ADR B-ADR
creatinine I-ADR I-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
from O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
Components O-ADR O-ADR
of O-ADR O-ADR
STRIBILD O-ADR O-ADR
Emtricitabine O-ADR O-ADR
and O-ADR O-ADR
Tenofovir O-ADR O-ADR
Disoproxil O-ADR O-ADR
Fumarate O-ADR O-ADR
: O-ADR O-ADR
In O-ADR O-ADR
addition O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
observed O-ADR O-ADR
with O-ADR O-ADR
STRIBILD O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
- O-ADR O-ADR
experienced O-ADR O-ADR
or O-ADR O-ADR
treatment O-ADR O-ADR
- O-ADR O-ADR
naive O-ADR O-ADR
subjects O-ADR O-ADR
receiving O-ADR O-ADR
emtricitabine O-ADR O-ADR
or O-ADR O-ADR
tenofovir O-ADR O-ADR
DF O-ADR O-ADR
with O-ADR O-ADR
other O-ADR O-ADR
antiretroviral O-ADR O-ADR
agents O-ADR O-ADR
in O-ADR O-ADR
other O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
: O-ADR O-ADR
depression B-ADR B-ADR
, O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
dyspepsia B-ADR B-ADR
, O-ADR O-ADR
vomiting B-ADR B-ADR
, O-ADR O-ADR
fever B-ADR B-ADR
, O-ADR O-ADR
pain B-ADR B-ADR
, O-ADR O-ADR
nasopharyngitis B-ADR B-ADR
, O-ADR O-ADR
pneumonia B-ADR B-ADR
, O-ADR O-ADR
sinusitis B-ADR B-ADR
, O-ADR O-ADR
upper B-ADR B-ADR
respiratory I-ADR I-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
, O-ADR O-ADR
arthralgia B-ADR B-ADR
, O-ADR O-ADR
back B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
myalgia B-ADR B-ADR
, O-ADR O-ADR
paresthesia B-ADR B-ADR
, O-ADR O-ADR
peripheral B-ADR B-ADR
neuropathy I-ADR I-ADR
( O-ADR O-ADR
including O-ADR O-ADR
peripheral B-ADR B-ADR
neuritis I-ADR I-ADR
) O-ADR O-ADR
, O-ADR O-ADR
anxiety B-ADR B-ADR
, O-ADR O-ADR
increased B-ADR B-ADR
cough I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
rhinitis B-ADR B-ADR
. O-ADR O-ADR
While O-ADR O-ADR
subjects O-ADR O-ADR
aged O-ADR O-ADR
12 O-ADR O-ADR
to O-ADR O-ADR
17 O-ADR O-ADR
years O-ADR O-ADR
were O-ADR O-ADR
included O-ADR O-ADR
in O-ADR O-ADR
these O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
approved O-ADR O-ADR
for O-ADR O-ADR
use O-ADR O-ADR
in O-ADR O-ADR
this O-ADR O-ADR
age O-ADR O-ADR
- O-ADR O-ADR
group O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
breathing B-ADR B-ADR
difficulties I-ADR I-ADR
can O-ADR O-ADR
be O-ADR O-ADR
life O-ADR O-ADR
threatening O-ADR O-ADR
and O-ADR O-ADR
there O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reports O-ADR O-ADR
of O-ADR O-ADR
death B-ADR B-ADR
. O-ADR O-ADR
These O-ADR O-ADR
reactions O-ADR O-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
within O-ADR O-ADR
hours O-ADR O-ADR
to O-ADR O-ADR
weeks O-ADR O-ADR
after O-ADR O-ADR
injection O-ADR O-ADR
with O-ADR O-ADR
botulinum O-ADR O-ADR
toxin O-ADR O-ADR
[ O-ADR O-ADR
See O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Permanently O-ADR O-ADR
discontinue O-ADR O-ADR
INLYTA O-ADR O-ADR
if O-ADR O-ADR
signs O-ADR O-ADR
or O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
RPLS O-ADR O-ADR
occur O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
incidence O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
stomatitis B-ADR B-ADR
, O-ADR O-ADR
pyrexia B-ADR B-ADR
, O-ADR O-ADR
pneumonia B-ADR B-ADR
, O-ADR O-ADR
gastroenteritis B-ADR B-ADR
, O-ADR O-ADR
aggression B-ADR B-ADR
, O-ADR O-ADR
agitation B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
amenorrhea B-ADR B-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
active O-ADR O-ADR
acute O-ADR O-ADR
or O-ADR O-ADR
chronic O-ADR O-ADR
infections O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
start O-ADR O-ADR
treatment O-ADR O-ADR
until O-ADR O-ADR
the O-ADR O-ADR
infection O-ADR O-ADR
( O-ADR O-ADR
s O-ADR O-ADR
) O-ADR O-ADR
is O-ADR O-ADR
resolved O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
study O-ADR O-ADR
of O-ADR O-ADR
697 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
available O-ADR O-ADR
24 O-ADR O-ADR
- O-ADR O-ADR
hour O-ADR O-ADR
Holter O-ADR O-ADR
monitoring O-ADR O-ADR
data O-ADR O-ADR
after O-ADR O-ADR
their O-ADR O-ADR
first O-ADR O-ADR
dose O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
351 O-ADR O-ADR
receiving O-ADR O-ADR
GILENYA O-ADR O-ADR
and O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
346 O-ADR O-ADR
on O-ADR O-ADR
placebo O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
second B-ADR O-ADR
- O-ADR O-ADR
degree O-ADR O-ADR
AV I-ADR O-ADR
blocks I-ADR O-ADR
] O-ADR O-ADR
or O-ADR O-ADR
2 B-ADR O-ADR
: O-ADR O-ADR
1 O-ADR O-ADR
AV I-ADR I-ADR
blocks I-ADR I-ADR
) O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
14 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
GILENYA O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
on O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Renal B-ADR B-ADR
Toxicity I-ADR I-ADR
Monitor O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
renal O-ADR O-ADR
function O-ADR O-ADR
at O-ADR O-ADR
baseline O-ADR O-ADR
and O-ADR O-ADR
during O-ADR O-ADR
therapy O-ADR O-ADR
with O-ADR O-ADR
BOSULIF O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Embryofetal B-ADR B-ADR
Toxicity I-ADR I-ADR
: O-ADR O-ADR
May O-ADR O-ADR
cause O-ADR O-ADR
fetal B-ADR B-ADR
harm I-ADR I-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
Experience O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
of O-ADR O-ADR
Toviaz O-ADR O-ADR
was O-ADR O-ADR
evaluated O-ADR O-ADR
in O-ADR O-ADR
Phase O-ADR O-ADR
2 O-ADR O-ADR
and O-ADR O-ADR
3 O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
2859 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
overactive O-ADR O-ADR
bladder O-ADR O-ADR
, O-ADR O-ADR
of O-ADR O-ADR
which O-ADR O-ADR
2288 O-ADR O-ADR
were O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
fesoterodine O-ADR O-ADR
. O-ADR O-ADR
SAPHRIS O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
or O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
with O-ADR O-ADR
flexible O-ADR O-ADR
dosing O-ADR O-ADR
. O-ADR O-ADR
Treatment O-ADR O-ADR
of O-ADR O-ADR
Postmenopausal O-ADR O-ADR
Women O-ADR O-ADR
with O-ADR O-ADR
Osteoporosis O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
of O-ADR O-ADR
Prolia O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
postmenopausal O-ADR O-ADR
osteoporosis O-ADR O-ADR
was O-ADR O-ADR
assessed O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
year O-ADR O-ADR
, O-ADR O-ADR
randomized O-ADR O-ADR
, O-ADR O-ADR
double O-ADR O-ADR
- O-ADR O-ADR
blind O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
, O-ADR O-ADR
multinational O-ADR O-ADR
study O-ADR O-ADR
of O-ADR O-ADR
7808 O-ADR O-ADR
postmenopausal O-ADR O-ADR
women O-ADR O-ADR
aged O-ADR O-ADR
60 O-ADR O-ADR
to O-ADR O-ADR
91 O-ADR O-ADR
years O-ADR O-ADR
. O-ADR O-ADR
Severe O-ADR O-ADR
elevations O-ADR B-ADR
( O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
or O-ADR O-ADR
equal O-ADR O-ADR
to O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mEq O-ADR O-ADR
/ O-ADR O-ADR
L O-ADR O-ADR
) O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
no O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
INVOKANA O-ADR O-ADR
100 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
INVOKANA O-ADR O-ADR
300 O-ADR O-ADR
mg O-ADR O-ADR
. O-ADR O-ADR
Discontinue O-ADR O-ADR
SIRTURO O-ADR O-ADR
if O-ADR O-ADR
significant O-ADR O-ADR
ventricular O-ADR O-ADR
arrhythmia O-ADR O-ADR
or O-ADR O-ADR
if O-ADR O-ADR
QTcF O-ADR O-ADR
interval O-ADR O-ADR
prolongation O-ADR O-ADR
of O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
500 O-ADR O-ADR
ms O-ADR O-ADR
develops O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
frequently O-ADR O-ADR
reported O-ADR O-ADR
ocular B-ADR B-ADR
adverse I-ADR I-ADR
reaction I-ADR I-ADR
was O-ADR O-ADR
conjunctival B-ADR B-ADR
redness I-ADR I-ADR
, O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
approximately O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Fatal B-ADR B-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
in O-ADR O-ADR
XALKORI O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
consisting O-ADR O-ADR
of O-ADR O-ADR
septic B-ADR B-ADR
shock I-ADR I-ADR
, O-ADR O-ADR
acute B-ADR B-ADR
respiratory I-ADR I-ADR
failure I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
diabetic B-ADR B-ADR
ketoacidosis I-ADR I-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
: O-ADR O-ADR
There O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
postmarketing O-ADR O-ADR
reports O-ADR O-ADR
of O-ADR O-ADR
serious O-ADR O-ADR
hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
NESINA O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
anaphylaxis B-ADR B-ADR
, O-ADR O-ADR
angioedema B-ADR B-ADR
and O-ADR O-ADR
severe O-ADR O-ADR
cutaneous B-ADR B-ADR
adverse I-ADR I-ADR
reactions I-ADR I-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
events O-ADR O-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
dose O-ADR O-ADR
reduction O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
approximately O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
: O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Reported O-ADR O-ADR
by O-ADR O-ADR
at O-ADR O-ADR
Least O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
Subjects O-ADR O-ADR
Treated O-ADR O-ADR
for O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
48 O-ADR O-ADR
Weeks O-ADR O-ADR
Adverse O-ADR O-ADR
Event O-ADR O-ADR
, O-ADR O-ADR
n O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
JUBLIAN O-ADR O-ADR
= O-ADR O-ADR
1227 O-ADR O-ADR
VehicleN O-ADR O-ADR
= O-ADR O-ADR
413 O-ADR O-ADR
Ingrown B-ADR B-ADR
toenail I-ADR I-ADR
28 O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
3 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Application B-ADR B-ADR
site I-ADR I-ADR
dermatitis I-ADR I-ADR
27 O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
1 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Application B-ADR B-ADR
site I-ADR I-ADR
vesicles I-ADR I-ADR
20 O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
0 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Application B-ADR B-ADR
site I-ADR I-ADR
pain I-ADR I-ADR
13 O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
1 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
20 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
hypertension B-ADR B-ADR
, O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
decreased B-ADR B-ADR
appetite I-ADR I-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
dysphonia B-ADR B-ADR
, O-ADR O-ADR
hand B-ADR B-ADR
- O-ADR O-ADR
foot O-ADR O-ADR
) I-ADR I-ADR
syndrome I-ADR I-ADR
, O-ADR O-ADR
weight B-ADR B-ADR
decreased I-ADR I-ADR
, O-ADR O-ADR
vomiting B-ADR B-ADR
, O-ADR O-ADR
asthenia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
constipation B-ADR B-ADR
. O-ADR O-ADR
The O-ADR O-ADR
possibility O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
PRISTIQ O-ADR O-ADR
who O-ADR O-ADR
present O-ADR O-ADR
with O-ADR O-ADR
progressive O-ADR O-ADR
dyspnea O-ADR O-ADR
, O-ADR O-ADR
cough O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
chest O-ADR O-ADR
discomfort O-ADR O-ADR
. O-ADR O-ADR
Discontinue O-ADR O-ADR
promptly O-ADR O-ADR
if O-ADR O-ADR
pancreatitis O-ADR O-ADR
is O-ADR O-ADR
suspected O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Hypersensitivity O-ADR O-ADR
Reactions O-ADR O-ADR
Systemic B-ADR B-ADR
hypersensitivity I-ADR I-ADR
reactions O-ADR I-ADR
were O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
TRULICITY O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
such O-ADR O-ADR
effects O-ADR O-ADR
occur O-ADR O-ADR
, O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
reduced O-ADR O-ADR
slowly O-ADR O-ADR
, O-ADR O-ADR
consistent O-ADR O-ADR
with O-ADR O-ADR
accepted O-ADR O-ADR
procedures O-ADR O-ADR
for O-ADR O-ADR
reducing O-ADR O-ADR
systemic O-ADR O-ADR
corticosteroids O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
other O-ADR O-ADR
treatments O-ADR O-ADR
for O-ADR O-ADR
management O-ADR O-ADR
of O-ADR O-ADR
COPD O-ADR O-ADR
or O-ADR O-ADR
asthma O-ADR O-ADR
symptoms O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
. O-ADR O-ADR
Immunogenicity O-ADR O-ADR
assay O-ADR O-ADR
results O-ADR O-ADR
are O-ADR O-ADR
highly O-ADR O-ADR
dependent O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
sensitivity O-ADR O-ADR
and O-ADR O-ADR
specificity O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
assay O-ADR O-ADR
used O-ADR O-ADR
in O-ADR O-ADR
detection O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
influenced O-ADR O-ADR
by O-ADR O-ADR
several O-ADR O-ADR
factors O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
sample O-ADR O-ADR
handling O-ADR O-ADR
, O-ADR O-ADR
timing O-ADR O-ADR
of O-ADR O-ADR
sample O-ADR O-ADR
collection O-ADR O-ADR
, O-ADR O-ADR
concomitant O-ADR O-ADR
medications O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
underlying O-ADR O-ADR
disease O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Blood O-ADR O-ADR
and O-ADR O-ADR
Lymphatic O-ADR O-ADR
System O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
lymphopenia B-ADR B-ADR
* O-ADR O-ADR
Gastrointestinal O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
pancreatitis B-ADR B-ADR
* O-ADR O-ADR
Hepatobiliary O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
hepatotoxicity B-ADR B-ADR
* O-ADR O-ADR
Immune O-ADR O-ADR
System O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
drug O-ADR B-ADR
hypersensitivity B-ADR I-ADR
* O-ADR O-ADR
Infections O-ADR O-ADR
and O-ADR O-ADR
Infestations O-ADR O-ADR
: O-ADR O-ADR
pneumonia B-ADR B-ADR
, O-ADR O-ADR
sepsis O-ADR O-ADR
/ O-ADR O-ADR
neutropenic O-ADR O-ADR
sepsis B-ADR B-ADR
* O-ADR O-ADR
Metabolism O-ADR O-ADR
and O-ADR O-ADR
Nutrition O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
hypomagnesemia B-ADR B-ADR
, O-ADR O-ADR
dehydration B-ADR B-ADR
* O-ADR O-ADR
Respiratory O-ADR O-ADR
, O-ADR O-ADR
thoracic O-ADR O-ADR
and O-ADR O-ADR
mediastinal O-ADR O-ADR
disorders O-ADR O-ADR
: O-ADR O-ADR
interstitial B-ADR B-ADR
lung I-ADR I-ADR
disease I-ADR I-ADR
* O-ADR O-ADR
Skin O-ADR O-ADR
and O-ADR O-ADR
Subcutaneous O-ADR O-ADR
Tissue O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
pruritus B-ADR B-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Neutropenia B-ADR B-ADR
: O-ADR O-ADR
Monitor O-ADR O-ADR
peripheral O-ADR O-ADR
blood O-ADR O-ADR
cell O-ADR O-ADR
counts O-ADR O-ADR
and O-ADR O-ADR
adjust O-ADR O-ADR
dose O-ADR O-ADR
as O-ADR O-ADR
appropriate O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Peripheral B-ADR B-ADR
Neuropathy I-ADR I-ADR
: O-ADR O-ADR
Monitor O-ADR O-ADR
for O-ADR O-ADR
signs O-ADR O-ADR
of O-ADR O-ADR
neuropathy O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
Teflaro O-ADR O-ADR
were O-ADR O-ADR
predominantly O-ADR O-ADR
male O-ADR O-ADR
( O-ADR O-ADR
63 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Caucasian O-ADR O-ADR
( O-ADR O-ADR
82 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
Commonly O-ADR O-ADR
observed O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
incidence O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
- O-ADR O-ADR
fold O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
placebo O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
: O-ADR O-ADR
dizziness B-ADR B-ADR
, O-ADR O-ADR
dry B-ADR B-ADR
mouth I-ADR I-ADR
, O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
nasal B-ADR B-ADR
congestion I-ADR I-ADR
, O-ADR O-ADR
orthostatic B-ADR B-ADR
hypotension I-ADR I-ADR
, O-ADR O-ADR
somnolence B-ADR B-ADR
, O-ADR O-ADR
tachycardia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
weight B-ADR B-ADR
increased I-ADR I-ADR
. O-ADR O-ADR
However O-ADR O-ADR
, O-ADR O-ADR
exceeding O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
dosage O-ADR O-ADR
or O-ADR O-ADR
coadministration O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
strong O-ADR O-ADR
cytochrome O-ADR O-ADR
P450 O-ADR O-ADR
3A4 O-ADR O-ADR
( O-ADR O-ADR
CYP3A4 O-ADR O-ADR
) O-ADR O-ADR
inhibitor O-ADR O-ADR
may O-ADR O-ADR
result O-ADR O-ADR
in O-ADR O-ADR
HPA B-ADR B-ADR
dysfunction I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
Drug O-ADR O-ADR
Interactions O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
finding O-ADR O-ADR
of O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
with O-ADR O-ADR
AEDs O-ADR O-ADR
of O-ADR O-ADR
varying O-ADR O-ADR
mechanisms O-ADR O-ADR
of O-ADR O-ADR
action O-ADR O-ADR
and O-ADR O-ADR
across O-ADR O-ADR
a O-ADR O-ADR
range O-ADR O-ADR
of O-ADR O-ADR
indications O-ADR O-ADR
suggests O-ADR O-ADR
that O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
applies O-ADR O-ADR
to O-ADR O-ADR
all O-ADR O-ADR
AEDs O-ADR O-ADR
used O-ADR O-ADR
for O-ADR O-ADR
any O-ADR O-ADR
indication O-ADR O-ADR
. O-ADR O-ADR
Due O-ADR O-ADR
to O-ADR O-ADR
higher O-ADR O-ADR
MMAE O-ADR O-ADR
exposure O-ADR O-ADR
, O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
more O-ADR O-ADR
frequent O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
severe O-ADR O-ADR
renal O-ADR O-ADR
impairment O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
normal O-ADR O-ADR
renal O-ADR O-ADR
function O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Angle O-ADR O-ADR
Closure O-ADR O-ADR
Glaucoma O-ADR O-ADR
Angle B-ADR O-ADR
- O-ADR O-ADR
Closure O-ADR O-ADR
Glaucoma I-ADR O-ADR
: O-ADR O-ADR
The O-ADR O-ADR
pupillary O-ADR B-ADR
dilation O-ADR I-ADR
that O-ADR O-ADR
occurs O-ADR O-ADR
following O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
many O-ADR O-ADR
antidepressant O-ADR O-ADR
drugs O-ADR O-ADR
including O-ADR O-ADR
Pristiq O-ADR O-ADR
may O-ADR O-ADR
trigger O-ADR O-ADR
an O-ADR O-ADR
angle B-ADR B-ADR
closure I-ADR I-ADR
attack I-ADR I-ADR
in O-ADR O-ADR
a O-ADR O-ADR
patient O-ADR O-ADR
with O-ADR O-ADR
anatomically O-ADR O-ADR
narrow O-ADR O-ADR
angles O-ADR O-ADR
who O-ADR O-ADR
does O-ADR O-ADR
not O-ADR O-ADR
have O-ADR O-ADR
a O-ADR O-ADR
patent O-ADR O-ADR
iridectomy O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
controlled O-ADR O-ADR
and O-ADR O-ADR
uncontrolled O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
564 O-ADR O-ADR
patients O-ADR O-ADR
received O-ADR O-ADR
CIMZIA O-ADR O-ADR
at O-ADR O-ADR
some O-ADR O-ADR
dose O-ADR O-ADR
level O-ADR O-ADR
, O-ADR O-ADR
of O-ADR O-ADR
whom O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
350 O-ADR O-ADR
patients O-ADR O-ADR
received O-ADR O-ADR
400 O-ADR O-ADR
mg O-ADR O-ADR
CIMZIA O-ADR O-ADR
. O-ADR O-ADR
At O-ADR O-ADR
baseline O-ADR O-ADR
, O-ADR O-ADR
17 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
population O-ADR O-ADR
in O-ADR O-ADR
these O-ADR O-ADR
studies O-ADR O-ADR
reported O-ADR O-ADR
peripheral O-ADR O-ADR
neuropathy O-ADR O-ADR
and O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
reported O-ADR O-ADR
retinopathy O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Thyroid B-ADR B-ADR
C I-ADR I-ADR
- O-ADR O-ADR
cell O-ADR O-ADR
Tumors I-ADR I-ADR
: O-ADR O-ADR
See O-ADR O-ADR
Boxed O-ADR O-ADR
Warning O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
dose O-ADR O-ADR
was O-ADR O-ADR
reduced O-ADR O-ADR
in O-ADR O-ADR
79 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
COMETRIQ O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
Fungus O-ADR O-ADR
invasion O-ADR O-ADR
must O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
in O-ADR O-ADR
any O-ADR O-ADR
persistent O-ADR O-ADR
corneal O-ADR O-ADR
ulceration O-ADR O-ADR
where O-ADR O-ADR
a O-ADR O-ADR
steroid O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
used O-ADR O-ADR
or O-ADR O-ADR
is O-ADR O-ADR
in O-ADR O-ADR
use O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
closely O-ADR O-ADR
monitored O-ADR O-ADR
for O-ADR O-ADR
signs O-ADR O-ADR
or O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
events O-ADR O-ADR
. O-ADR O-ADR
At O-ADR O-ADR
baseline O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
population O-ADR O-ADR
had O-ADR O-ADR
diabetes O-ADR O-ADR
for O-ADR O-ADR
an O-ADR O-ADR
average O-ADR O-ADR
of O-ADR O-ADR
9 O-ADR O-ADR
years O-ADR O-ADR
, O-ADR O-ADR
had O-ADR O-ADR
a O-ADR O-ADR
mean O-ADR O-ADR
HbA1c O-ADR O-ADR
of O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
30 O-ADR O-ADR
% O-ADR O-ADR
had O-ADR O-ADR
established O-ADR O-ADR
microvascular O-ADR O-ADR
disease O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
normal O-ADR O-ADR
or O-ADR O-ADR
mildly O-ADR O-ADR
impaired O-ADR O-ADR
renal O-ADR O-ADR
function O-ADR O-ADR
at O-ADR O-ADR
baseline O-ADR O-ADR
, O-ADR O-ADR
serum O-ADR O-ADR
creatinine O-ADR O-ADR
and O-ADR O-ADR
eGFR O-ADR O-ADR
returned O-ADR O-ADR
to O-ADR O-ADR
baseline O-ADR O-ADR
values O-ADR O-ADR
at O-ADR O-ADR
Week O-ADR O-ADR
24 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Hemorrhage B-ADR B-ADR
: O-ADR O-ADR
Monitor O-ADR O-ADR
for O-ADR O-ADR
bleeding O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
or O-ADR O-ADR
4 O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
hematological O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
pneumonia B-ADR B-ADR
, O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
atrial B-ADR B-ADR
fibrillation I-ADR I-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
skin B-ADR B-ADR
infections I-ADR I-ADR
. O-ADR O-ADR
These O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
included O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
clinical O-ADR O-ADR
relevance O-ADR O-ADR
and O-ADR O-ADR
ranked O-ADR O-ADR
in O-ADR O-ADR
order O-ADR O-ADR
of O-ADR O-ADR
decreasing O-ADR O-ADR
seriousness O-ADR O-ADR
within O-ADR O-ADR
each O-ADR O-ADR
category O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Postmarketing O-ADR O-ADR
Experience O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
identified O-ADR O-ADR
during O-ADR O-ADR
worldwide O-ADR O-ADR
post O-ADR O-ADR
- O-ADR O-ADR
approval O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
indacaterol O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
active O-ADR O-ADR
ingredient O-ADR O-ADR
in O-ADR O-ADR
ARCAPTA O-ADR O-ADR
NEOHALER O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
mean O-ADR O-ADR
baseline O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
HDL O-ADR O-ADR
- O-ADR O-ADR
C O-ADR O-ADR
levels O-ADR O-ADR
were O-ADR O-ADR
140 O-ADR O-ADR
to O-ADR O-ADR
147 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
across O-ADR O-ADR
treatment O-ADR O-ADR
groups O-ADR O-ADR
. O-ADR O-ADR
Dose O-ADR O-ADR
adjustments O-ADR O-ADR
( O-ADR O-ADR
interruptions O-ADR O-ADR
or O-ADR O-ADR
reductions O-ADR O-ADR
) O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
55 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
AFINITOR O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
symptoms O-ADR O-ADR
and O-ADR O-ADR
signs O-ADR O-ADR
consistent O-ADR O-ADR
with O-ADR O-ADR
cryptococcal O-ADR O-ADR
meningitis O-ADR O-ADR
should O-ADR O-ADR
undergo O-ADR O-ADR
prompt O-ADR O-ADR
diagnostic O-ADR O-ADR
evaluation O-ADR O-ADR
and O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Hypersensitivity O-ADR O-ADR
Reactions O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
generalized B-ADR B-ADR
urticaria I-ADR I-ADR
) O-ADR O-ADR
, O-ADR O-ADR
some O-ADR O-ADR
serious O-ADR O-ADR
, O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
INVOKANA O-ADR O-ADR
treatment O-ADR O-ADR
; O-ADR O-ADR
these O-ADR O-ADR
reactions O-ADR O-ADR
generally O-ADR O-ADR
occurred O-ADR O-ADR
within O-ADR O-ADR
hours O-ADR O-ADR
to O-ADR O-ADR
days O-ADR O-ADR
after O-ADR O-ADR
initiating O-ADR O-ADR
INVOKANA O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
decision O-ADR O-ADR
on O-ADR O-ADR
whether O-ADR O-ADR
or O-ADR O-ADR
not O-ADR O-ADR
to O-ADR O-ADR
discontinue O-ADR O-ADR
GILENYA O-ADR O-ADR
therapy O-ADR O-ADR
should O-ADR O-ADR
include O-ADR O-ADR
an O-ADR O-ADR
assessment O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
benefits O-ADR O-ADR
and O-ADR O-ADR
risks O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
individual O-ADR O-ADR
patient O-ADR O-ADR
. O-ADR O-ADR
No O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
torsade B-ADR B-ADR
de I-ADR I-ADR
pointes I-ADR I-ADR
or O-ADR O-ADR
other O-ADR O-ADR
severe O-ADR O-ADR
cardiac B-ADR B-ADR
arrhythmias I-ADR I-ADR
were O-ADR O-ADR
observed O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
pre O-ADR O-ADR
- O-ADR O-ADR
marketing O-ADR O-ADR
clinical O-ADR O-ADR
program O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
receiving O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
3 O-ADR O-ADR
doses O-ADR O-ADR
of O-ADR O-ADR
an O-ADR O-ADR
opioid O-ADR O-ADR
within O-ADR O-ADR
the O-ADR O-ADR
week O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
surgery O-ADR O-ADR
were O-ADR O-ADR
not O-ADR O-ADR
studied O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
postoperative O-ADR O-ADR
ileus O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Immunization O-ADR B-ADR
: O-ADR O-ADR
Live O-ADR O-ADR
vaccines O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
given O-ADR O-ADR
concurrently O-ADR O-ADR
with O-ADR O-ADR
BENLYSTA O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Depression B-ADR B-ADR
: O-ADR O-ADR
Advise O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
their O-ADR O-ADR
caregivers O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
families O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
alert O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
emergence O-ADR O-ADR
or O-ADR O-ADR
worsening O-ADR O-ADR
of O-ADR O-ADR
depression O-ADR O-ADR
, O-ADR O-ADR
suicidal O-ADR O-ADR
thoughts O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
mood O-ADR O-ADR
changes O-ADR O-ADR
and O-ADR O-ADR
if O-ADR O-ADR
such O-ADR O-ADR
changes O-ADR O-ADR
occur O-ADR O-ADR
to O-ADR O-ADR
contact O-ADR O-ADR
their O-ADR O-ADR
healthcare O-ADR O-ADR
provider O-ADR O-ADR
. O-ADR O-ADR
Deaths B-ADR B-ADR
due O-ADR O-ADR
to O-ADR O-ADR
acute B-ADR B-ADR
respiratory I-ADR I-ADR
failure I-ADR I-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
infection B-ADR B-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
acute B-ADR B-ADR
renal I-ADR I-ADR
failure I-ADR I-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
observed O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
AFINITOR O-ADR O-ADR
arm O-ADR O-ADR
but O-ADR O-ADR
none O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
arm O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
blood O-ADR O-ADR
pressure O-ADR O-ADR
, O-ADR O-ADR
both O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
supine O-ADR O-ADR
position O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
head O-ADR O-ADR
- O-ADR O-ADR
elevated O-ADR O-ADR
sleeping O-ADR O-ADR
position O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
Experience O-ADR O-ADR
in O-ADR O-ADR
Asthma O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
6 O-ADR O-ADR
- O-ADR O-ADR
month O-ADR O-ADR
randomized O-ADR O-ADR
, O-ADR O-ADR
active O-ADR O-ADR
controlled O-ADR O-ADR
asthma O-ADR O-ADR
safety O-ADR O-ADR
trial O-ADR O-ADR
, O-ADR O-ADR
805 O-ADR O-ADR
adult O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
moderate O-ADR O-ADR
to O-ADR O-ADR
severe O-ADR O-ADR
persistent O-ADR O-ADR
asthma O-ADR O-ADR
were O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
ARCAPTA O-ADR O-ADR
NEOHALER O-ADR O-ADR
300 O-ADR O-ADR
mcg O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
268 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
ARCAPTA O-ADR O-ADR
NEOHALER O-ADR O-ADR
600 O-ADR O-ADR
mcg O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
268 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
salmeterol O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
269 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
all O-ADR O-ADR
concomitant O-ADR O-ADR
with O-ADR O-ADR
inhaled O-ADR O-ADR
corticosteroids O-ADR O-ADR
, O-ADR O-ADR
which O-ADR O-ADR
were O-ADR O-ADR
not O-ADR O-ADR
co O-ADR O-ADR
- O-ADR O-ADR
randomized O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
data O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
percentage O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
whose O-ADR O-ADR
test O-ADR O-ADR
results O-ADR O-ADR
were O-ADR O-ADR
considered O-ADR O-ADR
positive O-ADR O-ADR
for O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
using O-ADR O-ADR
an O-ADR O-ADR
enzyme O-ADR O-ADR
- O-ADR O-ADR
linked O-ADR O-ADR
immunosorbent O-ADR O-ADR
assay O-ADR O-ADR
( O-ADR O-ADR
ELISA O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
confirmed O-ADR O-ADR
by O-ADR O-ADR
a O-ADR O-ADR
radioimmunoprecipitation O-ADR O-ADR
( O-ADR O-ADR
RIP O-ADR O-ADR
) O-ADR O-ADR
assay O-ADR O-ADR
for O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
- O-ADR O-ADR
specific O-ADR O-ADR
IgG O-ADR O-ADR
antibodies O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
of O-ADR O-ADR
HORIZANT O-ADR O-ADR
in O-ADR O-ADR
doses O-ADR O-ADR
ranging O-ADR O-ADR
from O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
200 O-ADR O-ADR
to O-ADR O-ADR
3 O-ADR O-ADR
, O-ADR O-ADR
600 O-ADR O-ADR
mg O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
evaluated O-ADR O-ADR
in O-ADR O-ADR
417 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
PHN O-ADR O-ADR
in O-ADR O-ADR
3 O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
. O-ADR O-ADR
Manage O-ADR O-ADR
fluid O-ADR O-ADR
and O-ADR O-ADR
electrolyte O-ADR O-ADR
levels O-ADR O-ADR
as O-ADR O-ADR
appropriate O-ADR O-ADR
, O-ADR O-ADR
supplement O-ADR O-ADR
protein O-ADR O-ADR
intake O-ADR O-ADR
, O-ADR O-ADR
monitor O-ADR O-ADR
antibacterial O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
C O-ADR O-ADR
. O-ADR O-ADR
difficile O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
institute O-ADR O-ADR
surgical O-ADR O-ADR
evaluation O-ADR O-ADR
as O-ADR O-ADR
clinically O-ADR O-ADR
indicated O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Graft B-ADR B-ADR
Loss I-ADR I-ADR
with O-ADR I-ADR
Corticosteroid O-ADR I-ADR
Minimization O-ADR I-ADR
: O-ADR O-ADR
corticosteroid O-ADR O-ADR
utilization O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
consistent O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
NULOJIX O-ADR O-ADR
clinical O-ADR O-ADR
trial O-ADR O-ADR
experience O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
ULESFIA O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
Lotion O-ADR O-ADR
comes O-ADR O-ADR
in O-ADR O-ADR
contact O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
eyes O-ADR O-ADR
, O-ADR O-ADR
flush O-ADR O-ADR
them O-ADR O-ADR
immediately O-ADR O-ADR
with O-ADR O-ADR
water O-ADR O-ADR
. O-ADR O-ADR
Consistent O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
high O-ADR O-ADR
homology O-ADR O-ADR
of O-ADR O-ADR
albiglutide O-ADR O-ADR
with O-ADR O-ADR
human O-ADR O-ADR
GLP O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
majority O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
approximately O-ADR O-ADR
79 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
with O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
albiglutide O-ADR O-ADR
antibodies O-ADR O-ADR
also O-ADR O-ADR
tested O-ADR O-ADR
positive O-ADR O-ADR
for O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
GLP O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
antibodies O-ADR O-ADR
; O-ADR O-ADR
none O-ADR O-ADR
were O-ADR O-ADR
neutralizing O-ADR O-ADR
. O-ADR O-ADR
Previously O-ADR O-ADR
Untreated O-ADR O-ADR
ALK O-ADR O-ADR
- O-ADR O-ADR
Positive O-ADR O-ADR
Metastatic O-ADR O-ADR
NSCLC O-ADR O-ADR
- O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
The O-ADR O-ADR
data O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
3 O-ADR O-ADR
are O-ADR O-ADR
derived O-ADR O-ADR
from O-ADR O-ADR
340 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
ALK O-ADR O-ADR
- O-ADR O-ADR
positive O-ADR O-ADR
metastatic O-ADR O-ADR
NSCLC O-ADR O-ADR
who O-ADR O-ADR
had O-ADR O-ADR
not O-ADR O-ADR
received O-ADR O-ADR
previous O-ADR O-ADR
systemic O-ADR O-ADR
treatment O-ADR O-ADR
for O-ADR O-ADR
advanced O-ADR O-ADR
disease O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
treatment O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
randomized O-ADR O-ADR
, O-ADR O-ADR
multicenter O-ADR O-ADR
, O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
, O-ADR O-ADR
active O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trial O-ADR O-ADR
( O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Consider O-ADR O-ADR
the O-ADR O-ADR
benefits O-ADR O-ADR
and O-ADR O-ADR
risks O-ADR O-ADR
before O-ADR O-ADR
neuraxial O-ADR O-ADR
intervention O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
anticoagulated O-ADR O-ADR
or O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
anticoagulated O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
time O-ADR O-ADR
to O-ADR O-ADR
onset O-ADR O-ADR
of O-ADR O-ADR
symptoms O-ADR O-ADR
varied O-ADR O-ADR
from O-ADR O-ADR
one O-ADR O-ADR
day O-ADR O-ADR
to O-ADR O-ADR
several O-ADR O-ADR
months O-ADR O-ADR
after O-ADR O-ADR
starting O-ADR O-ADR
Prolia O-ADR O-ADR
. O-ADR O-ADR
Seven O-ADR O-ADR
thrombotic B-ADR B-ADR
complications I-ADR I-ADR
( O-ADR O-ADR
six O-ADR O-ADR
patients O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
group O-ADR O-ADR
that O-ADR O-ADR
received O-ADR O-ADR
PROMACTA O-ADR O-ADR
and O-ADR O-ADR
three O-ADR O-ADR
thrombotic B-ADR B-ADR
complications I-ADR I-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
group O-ADR O-ADR
( O-ADR O-ADR
two O-ADR O-ADR
patients O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Active O-ADR O-ADR
Ingredients O-ADR O-ADR
: O-ADR O-ADR
conjugated O-ADR O-ADR
estrogens O-ADR O-ADR
and O-ADR O-ADR
bazedoxifene O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
groups O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
not O-ADR O-ADR
included O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
safety O-ADR O-ADR
and O-ADR O-ADR
efficacy O-ADR O-ADR
trials O-ADR O-ADR
for O-ADR O-ADR
STENDRA O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
therefore O-ADR O-ADR
until O-ADR O-ADR
further O-ADR O-ADR
information O-ADR O-ADR
is O-ADR O-ADR
available O-ADR O-ADR
, O-ADR O-ADR
STENDRA O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
recommended O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
following O-ADR O-ADR
groups O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Patients O-ADR O-ADR
who O-ADR O-ADR
have O-ADR O-ADR
suffered O-ADR O-ADR
a O-ADR O-ADR
myocardial O-ADR O-ADR
infarction O-ADR O-ADR
, O-ADR O-ADR
stroke O-ADR O-ADR
, O-ADR O-ADR
life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
arrhythmia O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
coronary O-ADR O-ADR
revascularization O-ADR O-ADR
within O-ADR O-ADR
the O-ADR O-ADR
last O-ADR O-ADR
6 O-ADR O-ADR
months O-ADR O-ADR
; O-ADR O-ADR
* O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
resting O-ADR B-ADR
hypotension O-ADR I-ADR
( O-ADR O-ADR
blood O-ADR O-ADR
pressure O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
90 O-ADR O-ADR
/ O-ADR O-ADR
50 O-ADR O-ADR
mmHg O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
hypertension O-ADR B-ADR
( O-ADR O-ADR
blood O-ADR O-ADR
pressure O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
170 O-ADR O-ADR
/ O-ADR O-ADR
100 O-ADR O-ADR
mmHg O-ADR O-ADR
) O-ADR O-ADR
; O-ADR O-ADR
* O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
unstable O-ADR O-ADR
angina O-ADR O-ADR
, O-ADR O-ADR
angina O-ADR O-ADR
with O-ADR O-ADR
sexual O-ADR O-ADR
intercourse O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
New O-ADR O-ADR
York O-ADR O-ADR
Heart O-ADR O-ADR
Association O-ADR O-ADR
Class O-ADR O-ADR
2 O-ADR O-ADR
or O-ADR O-ADR
greater O-ADR O-ADR
congestive O-ADR O-ADR
heart O-ADR O-ADR
failure O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
next O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
ELIQUIS O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
administered O-ADR O-ADR
earlier O-ADR O-ADR
than O-ADR O-ADR
5 O-ADR O-ADR
hours O-ADR O-ADR
after O-ADR O-ADR
the O-ADR O-ADR
removal O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
catheter O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
patient O-ADR O-ADR
who O-ADR O-ADR
develops O-ADR O-ADR
a O-ADR O-ADR
new O-ADR O-ADR
infection O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
CIMZIA O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
closely O-ADR O-ADR
monitored O-ADR O-ADR
, O-ADR O-ADR
undergo O-ADR O-ADR
a O-ADR O-ADR
prompt O-ADR O-ADR
and O-ADR O-ADR
complete O-ADR O-ADR
diagnostic O-ADR O-ADR
workup O-ADR O-ADR
appropriate O-ADR O-ADR
for O-ADR O-ADR
an O-ADR O-ADR
immunocompromised O-ADR O-ADR
patient O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
appropriate O-ADR O-ADR
antimicrobial O-ADR O-ADR
therapy O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
initiated O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Clostridium O-ADR O-ADR
difficile O-ADR O-ADR
- O-ADR O-ADR
Associated O-ADR O-ADR
Diarrhea O-ADR O-ADR
Clostridium B-ADR B-ADR
difficile I-ADR I-ADR
- I-ADR I-ADR
associated O-ADR O-ADR
diarrhea I-ADR I-ADR
( O-ADR O-ADR
CDAD B-ADR B-ADR
) O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
users O-ADR O-ADR
of O-ADR O-ADR
nearly O-ADR O-ADR
all O-ADR O-ADR
systemic O-ADR O-ADR
antibacterial O-ADR O-ADR
drugs O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
DALVANCE O-ADR O-ADR
, O-ADR O-ADR
with O-ADR O-ADR
severity O-ADR O-ADR
ranging O-ADR O-ADR
from O-ADR O-ADR
mild O-ADR O-ADR
diarrhea B-ADR B-ADR
to O-ADR O-ADR
fatal B-ADR B-ADR
colitis B-ADR B-ADR
. O-ADR O-ADR
During O-ADR O-ADR
adult O-ADR O-ADR
pre O-ADR O-ADR
- O-ADR O-ADR
marketing O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
with O-ADR O-ADR
SAPHRIS O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
trials O-ADR O-ADR
without O-ADR O-ADR
comparison O-ADR O-ADR
to O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
syncope B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
11 O-ADR O-ADR
/ O-ADR O-ADR
1953 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
SAPHRIS O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
The O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
NSF B-ADR B-ADR
appears O-ADR O-ADR
highest O-ADR O-ADR
among O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
: O-ADR O-ADR
Chronic O-ADR O-ADR
, O-ADR O-ADR
severe O-ADR O-ADR
kidney O-ADR O-ADR
disease O-ADR O-ADR
( O-ADR O-ADR
GFR O-ADR O-ADR
< O-ADR O-ADR
30 O-ADR O-ADR
mL O-ADR O-ADR
/ O-ADR O-ADR
min O-ADR O-ADR
/ O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
73m2 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
orAcute O-ADR O-ADR
kidney O-ADR O-ADR
injury O-ADR O-ADR
. O-ADR O-ADR
Trial O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
multicenter O-ADR O-ADR
, O-ADR O-ADR
international O-ADR O-ADR
, O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
, O-ADR O-ADR
randomized O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
: O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
controlled O-ADR O-ADR
trial O-ADR O-ADR
allocated O-ADR O-ADR
250 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
unresectable O-ADR O-ADR
or O-ADR O-ADR
metastatic O-ADR O-ADR
BRAF O-ADR O-ADR
V600E O-ADR O-ADR
mutation O-ADR O-ADR
- O-ADR O-ADR
positive O-ADR O-ADR
melanoma O-ADR O-ADR
to O-ADR O-ADR
receive O-ADR O-ADR
TAFINLAR O-ADR O-ADR
150 O-ADR O-ADR
mg O-ADR O-ADR
orally O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
187 O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
dacarbazine O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
000 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
m O-ADR O-ADR
2 O-ADR O-ADR
intravenously O-ADR O-ADR
every O-ADR O-ADR
3 O-ADR O-ADR
weeks O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
63 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
QT O-ADR O-ADR
Interval O-ADR O-ADR
Prolongation O-ADR O-ADR
Dronedarone O-ADR O-ADR
induces O-ADR O-ADR
a O-ADR O-ADR
moderate O-ADR O-ADR
( O-ADR O-ADR
average O-ADR O-ADR
of O-ADR O-ADR
about O-ADR O-ADR
10 O-ADR O-ADR
ms O-ADR O-ADR
but O-ADR O-ADR
much O-ADR O-ADR
greater O-ADR O-ADR
effects O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
) O-ADR O-ADR
QTc B-ADR B-ADR
( I-ADR I-ADR
Bazett I-ADR I-ADR
) I-ADR I-ADR
prolongation I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Pharmacology O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
left O-ADR O-ADR
ventricular O-ADR O-ADR
outflow O-ADR O-ADR
obstruction O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
aortic O-ADR O-ADR
stenosis O-ADR O-ADR
, O-ADR O-ADR
idiopathic O-ADR O-ADR
hypertrophic O-ADR O-ADR
subaortic O-ADR O-ADR
stenosis O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
those O-ADR O-ADR
with O-ADR O-ADR
severely O-ADR O-ADR
impaired O-ADR O-ADR
autonomic O-ADR O-ADR
control O-ADR O-ADR
of O-ADR O-ADR
blood O-ADR O-ADR
pressure O-ADR O-ADR
can O-ADR O-ADR
be O-ADR O-ADR
particularly O-ADR O-ADR
sensitive O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
actions O-ADR O-ADR
of O-ADR O-ADR
vasodilators O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
STENDRA O-ADR O-ADR
. O-ADR O-ADR
All O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
thrombotic B-ADR B-ADR
complications I-ADR I-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
group O-ADR O-ADR
that O-ADR O-ADR
received O-ADR O-ADR
PROMACTA O-ADR O-ADR
were O-ADR O-ADR
portal B-ADR B-ADR
vein I-ADR I-ADR
thrombosis I-ADR I-ADR
( O-ADR O-ADR
PVT B-ADR B-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Metabolism O-ADR O-ADR
and O-ADR O-ADR
nutrition O-ADR O-ADR
disorders O-ADR O-ADR
: O-ADR O-ADR
hyperglycemia B-ADR B-ADR
. O-ADR O-ADR
In O-ADR O-ADR
Trial O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
ophthalmologic O-ADR O-ADR
examinations O-ADR O-ADR
including O-ADR O-ADR
retinal O-ADR O-ADR
evaluation O-ADR O-ADR
were O-ADR O-ADR
performed O-ADR O-ADR
pretreatment O-ADR O-ADR
and O-ADR O-ADR
at O-ADR O-ADR
regular O-ADR O-ADR
intervals O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
neurological O-ADR O-ADR
compromise O-ADR O-ADR
is O-ADR O-ADR
noted O-ADR O-ADR
, O-ADR O-ADR
urgent O-ADR O-ADR
treatment O-ADR O-ADR
is O-ADR O-ADR
necessary O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Instruct O-ADR O-ADR
patients O-ADR O-ADR
to O-ADR O-ADR
immediately O-ADR O-ADR
report O-ADR O-ADR
if O-ADR O-ADR
they O-ADR O-ADR
experience O-ADR O-ADR
any O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
above O-ADR O-ADR
signs O-ADR O-ADR
or O-ADR O-ADR
symptoms O-ADR O-ADR
. O-ADR O-ADR
Musculoskeletal O-ADR O-ADR
and O-ADR O-ADR
connective O-ADR O-ADR
tissue O-ADR O-ADR
disorders O-ADR O-ADR
- O-ADR O-ADR
Musculoskeletal B-ADR B-ADR
stiffness I-ADR I-ADR
. O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
Deaths B-ADR B-ADR
have O-ADR O-ADR
occurred O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
gastrointestinal B-ADR B-ADR
hemorrhage I-ADR I-ADR
and O-ADR O-ADR
neutropenic B-ADR B-ADR
enterocolitis I-ADR I-ADR
. O-ADR O-ADR
In O-ADR O-ADR
CAPS O-ADR O-ADR
trials O-ADR O-ADR
one O-ADR O-ADR
patient O-ADR O-ADR
discontinued O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
SJIA O-ADR O-ADR
trials O-ADR O-ADR
no O-ADR O-ADR
patients O-ADR O-ADR
discontinued O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
that O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
Picato O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
gel O-ADR O-ADR
and O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
higher O-ADR O-ADR
frequency O-ADR O-ADR
than O-ADR O-ADR
the O-ADR O-ADR
vehicle O-ADR O-ADR
are O-ADR O-ADR
presented O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
3 O-ADR O-ADR
and O-ADR O-ADR
Table O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Liver O-ADR O-ADR
transplant O-ADR O-ADR
: O-ADR O-ADR
use O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
recommended O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Pulmonary O-ADR O-ADR
Hypertension O-ADR O-ADR
Pulmonary B-ADR B-ADR
arterial I-ADR I-ADR
hypertension I-ADR I-ADR
( O-ADR O-ADR
PAH B-ADR B-ADR
) O-ADR O-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
approximately O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
Kyprolis O-ADR O-ADR
and O-ADR O-ADR
was O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
or O-ADR O-ADR
greater O-ADR O-ADR
in O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
data O-ADR O-ADR
reflect O-ADR O-ADR
exposure O-ADR O-ADR
of O-ADR O-ADR
1667 O-ADR O-ADR
patients O-ADR O-ADR
to O-ADR O-ADR
INVOKANA O-ADR O-ADR
and O-ADR O-ADR
a O-ADR O-ADR
mean O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
INVOKANA O-ADR O-ADR
of O-ADR O-ADR
24 O-ADR O-ADR
weeks O-ADR O-ADR
. O-ADR O-ADR
With O-ADR O-ADR
Kyprolis O-ADR O-ADR
monotherapy O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
venous B-ADR B-ADR
thromboembolic I-ADR I-ADR
events I-ADR I-ADR
was O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
. O-ADR O-ADR
Treatment O-ADR O-ADR
- O-ADR O-ADR
experienced O-ADR O-ADR
, O-ADR O-ADR
Integrase O-ADR O-ADR
Strand O-ADR O-ADR
Transfer O-ADR O-ADR
Inhibitor O-ADR O-ADR
- O-ADR O-ADR
naive O-ADR O-ADR
Subjects O-ADR O-ADR
: O-ADR O-ADR
Laboratory O-ADR O-ADR
abnormalities O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
SAILING O-ADR O-ADR
were O-ADR O-ADR
generally O-ADR O-ADR
similar O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
observations O-ADR O-ADR
seen O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
- O-ADR O-ADR
naive O-ADR O-ADR
( O-ADR O-ADR
SPRING O-ADR O-ADR
- O-ADR O-ADR
2 O-ADR O-ADR
and O-ADR O-ADR
SINGLE O-ADR O-ADR
) O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
FANAPT O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
avoided O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
other O-ADR O-ADR
drugs O-ADR O-ADR
that O-ADR O-ADR
are O-ADR O-ADR
known O-ADR O-ADR
to O-ADR O-ADR
prolong O-ADR O-ADR
QTc O-ADR O-ADR
including O-ADR O-ADR
Class O-ADR O-ADR
1A O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
quinidine O-ADR O-ADR
, O-ADR O-ADR
procainamide O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
Class O-ADR O-ADR
III O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
amiodarone O-ADR O-ADR
, O-ADR O-ADR
sotalol O-ADR O-ADR
) O-ADR O-ADR
antiarrhythmic O-ADR O-ADR
medications O-ADR O-ADR
, O-ADR O-ADR
antipsychotic O-ADR O-ADR
medications O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
chlorpromazine O-ADR O-ADR
, O-ADR O-ADR
thioridazine O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
antibiotics O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
gatifloxacin O-ADR O-ADR
, O-ADR O-ADR
moxifloxacin O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
any O-ADR O-ADR
other O-ADR O-ADR
class O-ADR O-ADR
of O-ADR O-ADR
medications O-ADR O-ADR
known O-ADR O-ADR
to O-ADR O-ADR
prolong O-ADR O-ADR
the O-ADR O-ADR
QTc O-ADR O-ADR
interval O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
pentamidine O-ADR O-ADR
, O-ADR O-ADR
levomethadyl O-ADR O-ADR
acetate O-ADR O-ADR
, O-ADR O-ADR
methadone O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
recurrence O-ADR O-ADR
after O-ADR O-ADR
rechallenge O-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
evaluated O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Cataracts O-ADR O-ADR
Cases O-ADR O-ADR
of O-ADR O-ADR
non B-ADR B-ADR
- O-ADR O-ADR
congenital O-ADR O-ADR
lens I-ADR I-ADR
opacities I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
pediatric O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
KALYDECO O-ADR O-ADR
. O-ADR O-ADR
NSF B-ADR B-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
clear O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
DOTAREM O-ADR O-ADR
alone O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Postmarketing O-ADR O-ADR
Experience O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
additional O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
identified O-ADR O-ADR
during O-ADR O-ADR
postmarketing O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
DOTAREM O-ADR O-ADR
. O-ADR O-ADR
Cryptococcal O-ADR O-ADR
infections O-ADR O-ADR
Cryptococcal B-ADR B-ADR
infections I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
cryptococcal B-ADR B-ADR
meningitis I-ADR I-ADR
, O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
GILENYA O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
postmarketing O-ADR O-ADR
setting O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
hypersensitivity O-ADR O-ADR
reactions O-ADR O-ADR
occur O-ADR O-ADR
, O-ADR O-ADR
discontinue O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
INVOKANA O-ADR O-ADR
; O-ADR O-ADR
treat O-ADR O-ADR
and O-ADR O-ADR
monitor O-ADR O-ADR
until O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
resolve O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Contraindications O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
With O-ADR O-ADR
continued O-ADR O-ADR
dosing O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
heart O-ADR O-ADR
rate O-ADR O-ADR
returns O-ADR O-ADR
to O-ADR O-ADR
baseline O-ADR O-ADR
within O-ADR O-ADR
1 O-ADR O-ADR
month O-ADR O-ADR
of O-ADR O-ADR
chronic O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
NEPHROGENIC B-ADR B-ADR
SYSTEMIC I-ADR I-ADR
FIBROSIS I-ADR I-ADR
( O-ADR O-ADR
NSF B-ADR B-ADR
) O-ADR O-ADR
See O-ADR O-ADR
full O-ADR O-ADR
prescribing O-ADR O-ADR
information O-ADR O-ADR
for O-ADR O-ADR
complete O-ADR O-ADR
boxed O-ADR O-ADR
warning O-ADR O-ADR
Gadolinium O-ADR O-ADR
- O-ADR O-ADR
based O-ADR O-ADR
contrast O-ADR O-ADR
agents O-ADR O-ADR
( O-ADR O-ADR
GBCAs O-ADR O-ADR
) O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
NSF B-ADR B-ADR
among O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
impaired O-ADR O-ADR
elimination O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
drugs O-ADR O-ADR
. O-ADR O-ADR
Blood O-ADR O-ADR
pressure O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
well O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
initiating O-ADR O-ADR
INLYTA O-ADR O-ADR
. O-ADR O-ADR
Therefore O-ADR O-ADR
, O-ADR O-ADR
Units O-ADR O-ADR
of O-ADR O-ADR
biological O-ADR O-ADR
activity O-ADR O-ADR
of O-ADR O-ADR
XEOMIN O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
or O-ADR O-ADR
converted O-ADR O-ADR
into O-ADR O-ADR
Units O-ADR O-ADR
of O-ADR O-ADR
any O-ADR O-ADR
other O-ADR O-ADR
botulinum O-ADR O-ADR
toxin O-ADR O-ADR
products O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
S O-ADR O-ADR
Also O-ADR O-ADR
includes O-ADR O-ADR
the O-ADR O-ADR
Flexible O-ADR O-ADR
- O-ADR O-ADR
dose O-ADR O-ADR
trial O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
90 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Summary O-ADR O-ADR
of O-ADR O-ADR
Treatment O-ADR O-ADR
- O-ADR O-ADR
Emergent O-ADR O-ADR
Laboratory O-ADR O-ADR
Abnormalities O-ADR O-ADR
with O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
or O-ADR O-ADR
4 O-ADR O-ADR
Incidence O-ADR O-ADR
of O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
XALKORI O-ADR O-ADR
- O-ADR O-ADR
Treated O-ADR O-ADR
Patients O-ADR O-ADR
in O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
Laboratory O-ADR O-ADR
Abnormality O-ADR O-ADR
XALKORI O-ADR O-ADR
Chemotherapy O-ADR O-ADR
Any O-ADR O-ADR
Grade O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
/ O-ADR O-ADR
4 O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Any O-ADR O-ADR
Grade O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
/ O-ADR O-ADR
4 O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Hematology O-ADR O-ADR
Neutropenia B-ADR B-ADR
52 O-ADR O-ADR
11 O-ADR O-ADR
59 O-ADR O-ADR
16 O-ADR O-ADR
Lymphopenia B-ADR B-ADR
48 O-ADR O-ADR
7 O-ADR O-ADR
53 O-ADR O-ADR
13 O-ADR O-ADR
Chemistry O-ADR O-ADR
ALT B-ADR B-ADR
elevation I-ADR I-ADR
79 O-ADR O-ADR
15 O-ADR O-ADR
33 O-ADR O-ADR
2 O-ADR O-ADR
AST B-ADR B-ADR
elevation I-ADR I-ADR
66 O-ADR O-ADR
8 O-ADR O-ADR
28 O-ADR O-ADR
1 O-ADR O-ADR
Hypophosphatemia B-ADR B-ADR
32 O-ADR O-ADR
10 O-ADR O-ADR
21 O-ADR O-ADR
6 O-ADR O-ADR
Previously O-ADR O-ADR
Treated O-ADR O-ADR
ALK O-ADR O-ADR
- O-ADR O-ADR
Positive O-ADR O-ADR
Metastatic O-ADR O-ADR
NSCLC O-ADR O-ADR
- O-ADR O-ADR
Study O-ADR O-ADR
2 O-ADR O-ADR
The O-ADR O-ADR
data O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
5 O-ADR O-ADR
are O-ADR O-ADR
derived O-ADR O-ADR
from O-ADR O-ADR
343 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
ALK O-ADR O-ADR
- O-ADR O-ADR
positive O-ADR O-ADR
metastatic O-ADR O-ADR
NSCLC O-ADR O-ADR
enrolled O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
randomized O-ADR O-ADR
, O-ADR O-ADR
multicenter O-ADR O-ADR
, O-ADR O-ADR
active O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
, O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
trial O-ADR O-ADR
( O-ADR O-ADR
Study O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Increase O-ADR O-ADR
in O-ADR O-ADR
Blood O-ADR O-ADR
Pressure O-ADR O-ADR
In O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
increases B-ADR B-ADR
in I-ADR I-ADR
blood I-ADR I-ADR
pressure I-ADR I-ADR
occurred O-ADR O-ADR
during O-ADR O-ADR
or O-ADR O-ADR
shortly O-ADR O-ADR
after O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
Qutenza O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
( O-ADR O-ADR
incidence O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
occurring O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
higher O-ADR O-ADR
frequency O-ADR O-ADR
than O-ADR O-ADR
placebo O-ADR O-ADR
among O-ADR O-ADR
ENTEREG O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
undergoing O-ADR O-ADR
surgeries O-ADR O-ADR
that O-ADR O-ADR
included O-ADR O-ADR
a O-ADR O-ADR
bowel O-ADR O-ADR
resection O-ADR O-ADR
was O-ADR O-ADR
dyspepsia B-ADR B-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
pool O-ADR O-ADR
of O-ADR O-ADR
four O-ADR O-ADR
placebo O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
mean O-ADR O-ADR
percent O-ADR O-ADR
change B-ADR B-ADR
in I-ADR I-ADR
serum I-ADR I-ADR
phosphate I-ADR I-ADR
levels I-ADR I-ADR
were O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
with O-ADR O-ADR
INVOKANA O-ADR O-ADR
100 O-ADR O-ADR
mg O-ADR O-ADR
and O-ADR O-ADR
INVOKANA O-ADR O-ADR
300 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
, O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
While O-ADR O-ADR
all O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
drugs O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
class O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
shown O-ADR O-ADR
to O-ADR O-ADR
produce O-ADR O-ADR
some O-ADR O-ADR
metabolic B-ADR O-ADR
changes I-ADR O-ADR
, O-ADR O-ADR
each O-ADR O-ADR
drug O-ADR O-ADR
has O-ADR O-ADR
its O-ADR O-ADR
own O-ADR O-ADR
specific O-ADR O-ADR
risk O-ADR O-ADR
profile O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
monotherapy O-ADR O-ADR
study O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
hypoglycemia B-ADR B-ADR
was O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
NESINA O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
Discontinue O-ADR O-ADR
COMETRIQ O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
perforation O-ADR O-ADR
or O-ADR O-ADR
fistula O-ADR O-ADR
. O-ADR O-ADR
Management O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
events O-ADR O-ADR
may O-ADR O-ADR
require O-ADR O-ADR
either O-ADR O-ADR
temporary O-ADR O-ADR
interruption O-ADR O-ADR
or O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
BLINCYTO O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
4 O-ADR O-ADR
: O-ADR O-ADR
Change O-ADR O-ADR
in O-ADR O-ADR
Cholesterol O-ADR O-ADR
Mean O-ADR O-ADR
Change O-ADR O-ADR
from O-ADR O-ADR
Baseline O-ADR O-ADR
( O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
) O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
6 O-ADR O-ADR
months O-ADR O-ADR
6 O-ADR O-ADR
- O-ADR O-ADR
12 O-ADR O-ADR
months O-ADR O-ADR
> O-ADR O-ADR
12 O-ADR O-ADR
months O-ADR O-ADR
FANAPT O-ADR O-ADR
10 O-ADR O-ADR
- O-ADR O-ADR
16 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
day O-ADR O-ADR
- O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
783 O-ADR O-ADR
) O-ADR O-ADR
- O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
726 O-ADR O-ADR
) O-ADR O-ADR
- O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
428 O-ADR O-ADR
) O-ADR O-ADR
FANAPT O-ADR O-ADR
20 O-ADR O-ADR
- O-ADR O-ADR
24 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
day O-ADR O-ADR
- O-ADR O-ADR
19 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
34 O-ADR O-ADR
) O-ADR O-ADR
- O-ADR O-ADR
23 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
31 O-ADR O-ADR
) O-ADR O-ADR
- O-ADR O-ADR
19 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
20 O-ADR O-ADR
) O-ADR O-ADR
Table O-ADR O-ADR
5 O-ADR O-ADR
: O-ADR O-ADR
Change O-ADR O-ADR
in O-ADR O-ADR
Triglycerides O-ADR O-ADR
Mean O-ADR O-ADR
Change O-ADR O-ADR
from O-ADR O-ADR
Baseline O-ADR O-ADR
( O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
) O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
6 O-ADR O-ADR
months O-ADR O-ADR
6 O-ADR O-ADR
- O-ADR O-ADR
12 O-ADR O-ADR
months O-ADR O-ADR
> O-ADR O-ADR
12 O-ADR O-ADR
months O-ADR O-ADR
FANAPT O-ADR O-ADR
10 O-ADR O-ADR
- O-ADR O-ADR
16 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
day O-ADR O-ADR
- O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
783 O-ADR O-ADR
) O-ADR O-ADR
- O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
726 O-ADR O-ADR
) O-ADR O-ADR
- O-ADR O-ADR
17 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
428 O-ADR O-ADR
) O-ADR O-ADR
FANAPT O-ADR O-ADR
20 O-ADR O-ADR
- O-ADR O-ADR
24 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
day O-ADR O-ADR
- O-ADR O-ADR
26 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
34 O-ADR O-ADR
) O-ADR O-ADR
- O-ADR O-ADR
35 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
31 O-ADR O-ADR
) O-ADR O-ADR
- O-ADR O-ADR
17 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
20 O-ADR O-ADR
) O-ADR O-ADR
Weight O-ADR O-ADR
Gain O-ADR O-ADR
Weight B-ADR B-ADR
gain I-ADR I-ADR
has O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
with O-ADR O-ADR
atypical O-ADR O-ADR
antipsychotic O-ADR O-ADR
use O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
epilepsy O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
` O-ADR O-ADR
` O-ADR O-ADR
urinary B-ADR B-ADR
retention I-ADR I-ADR
, O-ADR O-ADR
' O-ADR O-ADR
' O-ADR O-ADR
` O-ADR O-ADR
` O-ADR O-ADR
urinary B-ADR B-ADR
hesitation B-ADR I-ADR
, O-ADR O-ADR
' O-ADR O-ADR
' O-ADR O-ADR
and O-ADR O-ADR
` O-ADR O-ADR
` O-ADR O-ADR
dysuria B-ADR B-ADR
' O-ADR O-ADR
' O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
on O-ADR O-ADR
POTIGA O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
on O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
At O-ADR O-ADR
baseline O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
population O-ADR O-ADR
had O-ADR O-ADR
type O-ADR O-ADR
2 O-ADR O-ADR
diabetes O-ADR O-ADR
for O-ADR O-ADR
an O-ADR O-ADR
average O-ADR O-ADR
of O-ADR O-ADR
7 O-ADR O-ADR
years O-ADR O-ADR
and O-ADR O-ADR
had O-ADR O-ADR
a O-ADR O-ADR
mean O-ADR O-ADR
HbA1c O-ADR O-ADR
of O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Hypoglycemia B-ADR B-ADR
: O-ADR O-ADR
When O-ADR O-ADR
TRULICITY O-ADR O-ADR
is O-ADR O-ADR
used O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
insulin O-ADR O-ADR
secretagogue O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
sulfonylurea O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
insulin O-ADR O-ADR
, O-ADR O-ADR
consider O-ADR O-ADR
lowering O-ADR O-ADR
the O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
sulfonylurea O-ADR O-ADR
or O-ADR O-ADR
insulin O-ADR O-ADR
to O-ADR O-ADR
reduce O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
hypoglycemia O-ADR B-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Approximately O-ADR O-ADR
55 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
were O-ADR O-ADR
female O-ADR O-ADR
, O-ADR O-ADR
45 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
male O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
94 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
Caucasian O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
some O-ADR O-ADR
cases O-ADR O-ADR
, O-ADR O-ADR
hyperglycemia O-ADR O-ADR
has O-ADR O-ADR
resolved O-ADR O-ADR
when O-ADR O-ADR
the O-ADR O-ADR
atypical O-ADR O-ADR
antipsychotic O-ADR O-ADR
was O-ADR O-ADR
discontinued O-ADR O-ADR
; O-ADR O-ADR
however O-ADR O-ADR
, O-ADR O-ADR
some O-ADR O-ADR
patients O-ADR O-ADR
required O-ADR O-ADR
continuation O-ADR O-ADR
of O-ADR O-ADR
antidiabetic O-ADR O-ADR
treatment O-ADR O-ADR
despite O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
suspect O-ADR O-ADR
drug O-ADR O-ADR
. O-ADR O-ADR
At O-ADR O-ADR
one O-ADR O-ADR
year O-ADR O-ADR
after O-ADR O-ADR
transplantation O-ADR O-ADR
, O-ADR O-ADR
systolic O-ADR B-ADR
blood O-ADR I-ADR
pressures O-ADR I-ADR
were O-ADR I-ADR
8 O-ADR I-ADR
mmHg O-ADR I-ADR
lower O-ADR I-ADR
and O-ADR O-ADR
diastolic O-ADR B-ADR
blood O-ADR I-ADR
pressures O-ADR I-ADR
were O-ADR I-ADR
3 O-ADR I-ADR
mmHg O-ADR I-ADR
lower O-ADR I-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
NULOJIX O-ADR O-ADR
recommended O-ADR O-ADR
regimen O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
cyclosporine O-ADR O-ADR
control O-ADR O-ADR
regimen O-ADR O-ADR
. O-ADR O-ADR
Avoid O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
ADCETRIS O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
severe O-ADR O-ADR
renal O-ADR O-ADR
impairment O-ADR O-ADR
[ O-ADR O-ADR
creatinine O-ADR O-ADR
clearance O-ADR O-ADR
( O-ADR O-ADR
CLcr O-ADR O-ADR
) O-ADR O-ADR
< O-ADR O-ADR
30 O-ADR O-ADR
mL O-ADR O-ADR
/ O-ADR O-ADR
min O-ADR O-ADR
] O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Vascular O-ADR O-ADR
disorders O-ADR O-ADR
: O-ADR O-ADR
arterial B-ADR B-ADR
thromboembolic I-ADR I-ADR
events I-ADR I-ADR
( O-ADR O-ADR
including O-ADR O-ADR
pulmonary B-ADR B-ADR
emboli I-ADR I-ADR
, O-ADR O-ADR
deep B-ADR B-ADR
vein I-ADR I-ADR
thrombosis I-ADR I-ADR
, O-ADR O-ADR
cerebral B-ADR B-ADR
thrombosis I-ADR I-ADR
, O-ADR O-ADR
myocardial B-ADR B-ADR
infarction I-ADR I-ADR
and O-ADR O-ADR
stroke B-ADR B-ADR
) O-ADR O-ADR
, O-ADR O-ADR
hypertension B-ADR B-ADR
Hepatobiliary O-ADR O-ADR
disorders O-ADR O-ADR
: O-ADR O-ADR
Gallbladder B-ADR B-ADR
disease I-ADR I-ADR
, O-ADR O-ADR
hepatitis B-ADR B-ADR
Immune O-ADR O-ADR
system O-ADR O-ADR
disorders O-ADR O-ADR
: O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
Metabolism O-ADR O-ADR
and O-ADR O-ADR
nutrition O-ADR O-ADR
disorders O-ADR O-ADR
: O-ADR O-ADR
Fluid B-ADR B-ADR
retention I-ADR I-ADR
, O-ADR O-ADR
hypertriglyceridemia B-ADR B-ADR
Nervous O-ADR O-ADR
system O-ADR O-ADR
disorders O-ADR O-ADR
: O-ADR O-ADR
Dizziness B-ADR B-ADR
Skin O-ADR O-ADR
and O-ADR O-ADR
subcutaneous O-ADR O-ADR
tissue O-ADR O-ADR
disorders O-ADR O-ADR
: O-ADR O-ADR
Chloasma B-ADR B-ADR
, O-ADR O-ADR
angioedema B-ADR B-ADR
, O-ADR O-ADR
erythema B-ADR B-ADR
nodosum I-ADR I-ADR
, O-ADR O-ADR
erythema B-ADR B-ADR
multiforme I-ADR I-ADR
Gastrointestinal O-ADR O-ADR
disorders O-ADR O-ADR
: O-ADR O-ADR
Gastrointestinal B-ADR B-ADR
symptoms I-ADR I-ADR
( O-ADR O-ADR
for O-ADR O-ADR
example O-ADR O-ADR
, O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
) O-ADR O-ADR
Infections O-ADR O-ADR
and O-ADR O-ADR
infestations O-ADR O-ADR
: O-ADR O-ADR
Vulvovaginal B-ADR B-ADR
candidiasis I-ADR I-ADR
BOXED O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
CIGARETTE O-ADR B-ADR
SMOKING O-ADR I-ADR
AND O-ADR O-ADR
SERIOUS O-ADR O-ADR
CARDIOVASCULAR B-ADR B-ADR
EVENTS I-ADR I-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
CIGARETTE O-ADR B-ADR
SMOKING O-ADR I-ADR
AND O-ADR O-ADR
SERIOUS O-ADR O-ADR
CARDIOVASCULAR B-ADR B-ADR
EVENTS I-ADR I-ADR
Cigarette O-ADR O-ADR
smoking O-ADR O-ADR
increases O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
serious O-ADR O-ADR
cardiovascular B-ADR B-ADR
events I-ADR I-ADR
from O-ADR O-ADR
combination O-ADR O-ADR
oral O-ADR O-ADR
contraceptives O-ADR O-ADR
( O-ADR O-ADR
COC O-ADR O-ADR
) O-ADR O-ADR
use O-ADR O-ADR
. O-ADR O-ADR
Neutralizing O-ADR O-ADR
antibodies O-ADR O-ADR
were O-ADR O-ADR
assayed O-ADR O-ADR
for O-ADR O-ADR
all O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
204 O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
Eye O-ADR O-ADR
disorders O-ADR O-ADR
: O-ADR O-ADR
diplopia B-ADR B-ADR
, O-ADR O-ADR
papilledema B-ADR B-ADR
, O-ADR O-ADR
retinal B-ADR B-ADR
toxicity I-ADR I-ADR
. O-ADR O-ADR
Rash B-ADR B-ADR
occurred O-ADR O-ADR
most O-ADR O-ADR
commonly O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
6 O-ADR O-ADR
weeks O-ADR O-ADR
of O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Bradycardia B-ADR B-ADR
: O-ADR O-ADR
ZYKADIA O-ADR O-ADR
can O-ADR O-ADR
cause O-ADR O-ADR
bradycardia B-ADR B-ADR
. O-ADR O-ADR
